https://lipidbank.jp/mediawiki/api.php?action=feedcontributions&user=Editor&feedformat=atom
lipidbank_wiki - User contributions [en]
2024-03-19T07:40:12Z
User contributions
MediaWiki 1.39.0
https://lipidbank.jp/mediawiki/index.php?title=Category:LBSG&diff=117194
Category:LBSG
2023-12-02T12:31:05Z
<p>Editor: /* Svennerholm Notation スヴェンネルホルム表記 */</p>
<hr />
<div><font size="+2">Acidic Glycosphingolipid</font><br />
{{LB/Header}}<br />
{{Hierarchy|{{PAGENAME}}}}<br />
<br />
<br />
<br />
==Ganglioside ガングリオシド==<br />
<br />
{{Twocolumn|<br />
Ganglioside is a glycosphingolipid with one or more sialic acid. It was named by Klenk E. in 1942 as the major sphingolipid in ganglion, a nerve cell cluster.<ref>Sweeley CC, Siddiqui B. "Chemistry of Mammalian Glycolipids" Chapter 6 in ''The Glycoconjugates Volume I: Mammalian Glycoproteins and Glycolipids'' (Ed. Horowitz MI, Pigman W) 1977 Elsevier Inc. ISBN 978-0-12-356101-5</ref><br />
In vertebrate, close to 190 gangliosides have been identified.<ref>Yu RK, Tsai YT, Ariga T, Yanagisawa M. (2011) Structures, biosynthesis, and functions of gangliosides--an overview" J Oleo Sci. 60(10):537-44. PMID 21937853</ref><br />
They reside on lipid rafts of cell membranes, and involve in many cellular functions.<br />
Major structures with sialic acids include ganglio, lacto, and neolacto series. <br />
|<br />
酸性糖であるシアル酸を含む糖脂質をガングリオシドと呼びます。神経細胞の集まりである神経核 (ganglion) に多いことから Klenk E.により1942年に命名されました。<br />
脊椎動物では現在およそ190種のガングリオシドが見出されています。ガングリオシドは細胞膜の脂質ラフトに存在し、多くの生理機能に関わっています。シアル酸の結合する主要系列はガングリオ、ラクト、ネオラクト等です。<br />
}}<br />
<br />
<references/><br />
<br />
===Svennerholm Notation スヴェンネルホルム表記===<br />
<br />
{{Twocolumn|<br />
The often-used notation for ganglioside was proposed by the Swedish scientist, Lars Svennerholm. Each alpha-numeric digit stands for the number of sialic acids or sugars.<br />
|<br />
ガングリオシドの略称には、スウェーデンの科学者 Lars Svennerholm が導入した記法がよく使われます。各桁の数字やアルファベットはシアル酸の数や糖の数を意味します。<br />
}}<br />
<br />
{| class="wikitable" style="text-align:center; width:300px;"<br />
! Abbreviation <br />
| GM || GD || GT || GQ || GP<br />
|-<br />
! Number of Sialic Acid <br />
| 1 || 2 || 3 || 4 || 5<br />
|}<br />
<br />
{| class="wikitable" style="text-align:center; width:350px;"<br />
! Suffix Number <br />
| 1 || 2 || 3 || 4<br />
|-<br />
! Core <br />
| Gg4Cer || Gg3Cer || LacCer || GalCer<br />
|}<br />
{| class="wikitable" style="text-align:center;width:350px;"<br />
! Suffix Alphabet (only for Gg4Cer core)<br />
| a || b || c<br />
|-<br />
| Number of Sialic Acid Attached to IIGal<br />
| 1 || 2 || 3<br />
|}<br />
<br />
;Examples<br />
: GQ1b ... 4 sialic acids (GQ), 4 sugars (GQ1), 2 sialic acids attached to the 2nd galactose (GQ1b)<br />
: GM2 ... 1 sialic acids (GM), 3 sugars (GM2).<br />
<br />
<br />
{{:Category:LBS/Biosynthesis/Ganglioside}}<br />
<br />
==Sulfatide スルファチド==<br />
<br />
{{Twocolumn|<br />
<br />
More than ten compounds of sulfoglycolipids (glycosphingolipid sulfate, sulfatide, SM4) are identified by differences in sulfonated sugar chains. Among them 3-O-Sulfated galactosylceramide(GalCer) is called galactosylsulfatide, and is present in myelin sheath like GalCer. <ref>Ishizuka, I. “Chemistry and functional distribution of sulfoglycolipids” Prog. Lipid Res.1997; 36:245-319 PMID 9640458 </ref><br />
The existence of glucosylsufatide, 3-O-sulfated glucosylceramide was reported in rat kidney.<ref>Iida N, Toida T, Kushi Y, Handa S, Fredman P, Svennerholm L, Ishizuka I. A sulfated glucosylceramide from rat kidney. J Biol Chem. 1989 5;264:5974-80.PMID 2925645 </ref><br />
<br />
Sulfatides are present in various organs, such as nervous system, kidney, respiratory organ and digestive tract. The physiological functions of sulfatides are related to myelinogenesis, diabetes, immune system, thrombosis, bacterial and virus infection. <ref> Takahashi T, Suzuki T. “Role of sulfatide in normal and pathological cells and tissues” J Lipid Res. 2012; 53: 1437–1450, PMID 22619219 Takahashi T, Suzuki T. “Role of sulfatide in influenza A virus replication” Biol Pharm Bull. 2015; 38:809-16.PMID 26027821 </ref><br />
<br />
Lysosomal storage disease, metachromatic leukodystrophy, is a congenital metabolic disorder, and is caused by deficiency of lysosomal enzyme arylsulfatase A or its activator.<ref>Mirzaian M, Kramer G, Poorthuis BJ. “Quantification of sulfatides and lysosulfatides in tissues and body fluids by liquid chromatography-tandem mass spectrometry”J Lipid Res. 2015; 56:936-43. PMID 25632048 </ref><br />
|<br />
硫酸化糖脂質には硫酸化される糖鎖の違いにより十数種類が同定されています。その中でもガラクトシルセラミド(GalCer)のガラクトース3位の水酸基に硫酸基を導入したものをガラクトシルスルファチドと呼び、GalCerと同様にミエリンに多く存在します。ラット腎臓にはグルコシルセラミドに硫酸基が結合したグルコシルスルファチドも報告があります。<br />
<br />
スルファチドは神経系、腎臓、呼吸器、消化器などさまざまな組織に存在する糖脂質で、ミエリン形成に関わるほか、糖尿病、免疫系、血栓形成、細菌感染、ウィルス感染など生理作用は多岐にわたります。<br />
<br />
<br />
リソソーム病である異染性白質ジストロフィー(metachromatic leukodystrophy)という先天性代謝異常症は、スルファチド分解酵素(ASA)あるいは活性化因子の欠損か低下により起こります。<br />
}}<br />
<br />
<br />
===Metabolic pathway<ref>Honke K. Biosynthesis and biological function of sulfoglycolipids. Proc Jpn Acad Ser B Phys Biol Sci. 2013 89:129-38. PMID 23574804</ref>===<br />
<br />
;Biosynthesis<br />
;Cerebroside sulfotransferase (CST) + 3’-phosphoadenosine-5’-phosphosulfate(PAPS)<br />
:Galactosylceramide &rarr; galactosylsulfatide<br />
<br />
;Degradation<br />
;Arylsulfatase A (ASA) + Saposin B (activator)<br />
:Galctoslsulfatide &rarr; Galactosylceramide<br />
<br />
<br />
<references/><br />
<br />
==Acidic Modifiers 酸性基==<br />
<br />
<br />
===Sialic acid シアル酸===<br />
{{Twocolumn|<br />
Sialic acid is a collective noun and comprises a family of derivatives of neuraminic acid (5-amino- 3,5-dideoxy- D-glycero- D-galacto- nonulosonic acid)<ref>Schauer R "Sialic Acids - Chemistry, Metabolism and Function" Springer-Verlag, 1982.ISBN 978-3-7091-8680-0 </ref>.<br />
Nowadays, there are over 30 derivatives of neuraminic acid, including the followings.<br />
* N-acetyl neuraminic acid (NeuAc)<br />
* N-glycolyl neuraminic acid (NeuGc)<br />
* deamino neuraminic acid (Kdn: 3-deoxy-D-glycero-D-galacto-nonulosonic acid)<br />
<br />
NeuGc is different from NecAc only by a single oxygen. After NeuAc is bound to cytidine monophosphate (CMP), CMP-NeuAc is converted by N-acetylneuraminic acid hydroxylase (CMAH) to CMP-NeuGc. This gene is generally conserved among mammals but human, sauropsids (birds and reptiles), and monotreme lack this gene <ref>Irie A, Koyama S, Kozutsumi Y, et al. "The molecular basis for the absence of N-glycolylneuraminic acid in humans" J Biol Chem 273:15866–15871, 1998 PMID 9624188</ref><ref>Schauer R, Srinivasan GV, Coddeville B, et al. "Low incidence of N-glycolylneuraminic acid in birds and reptiles and its absence in the platypus" Carbohydr Res 344:1494–1500, 2009 PMID 19541293</ref> (therefore no NeuGc). Kdn is prominent in some fish but not in mammals.<br />
|<br />
シアル酸は、ノイラミン酸(5-アミノ-3,5-ジデオキシ-D-グリセロ-D-ガラクト-ノヌロン酸)に由来する物質の総称です。<br />
現在、ノイラミン酸には以下を含む30 種以上の誘導体が知られています。<br />
* N-アセチルノイラミン酸 (NeuAc)<br />
* N-グリコリルノイラミン酸 (NeuGc)<br />
* デアミノノイラミン酸 (Kdn)<br />
<br />
NeuGcはNeuAcは酸素原子一つしか違いません。シチジンモノホスホ-Neu5Acを基質として、シチジンN-アセチルノイラミン酸ヒドロキシラーゼ(CMAH)によりCMP-NeuGcが生成されます。この遺伝子は哺乳類に保存されていますが、ヒト、鳥類、爬虫類、単孔類は欠損しています(つまりNeuGcを持たない)。Kdnは魚類に知られていますが哺乳類には殆どありません。<br />
}}<br />
<br />
<center><br />
<table cellspacing="15"><br />
<tr><br />
<td> N-acetyl neuraminic acid (Neu5Ac) </td><br />
<td> N-glycolyl neuraminic acid (Neu5Gc) </td><br />
<td> deamino neuraminic acid (Kdn)</td><br />
</tr><br />
<tr><br />
<td style="position: relative">[[File:NeuAc.png]] <div style="position:absolute; top:25px; left:10px">[[File:circle10.png|20px]]</div> </td><br />
<td style="position: relative">[[File:NeuGc.png]] <div style="position:absolute; top:30px; left:0px">[[File:circle10.png|20px]]</div> </td><br />
<td style="position: relative">[[File:Kdn.png]] <div style="position:absolute; top:22px; left:35px">[[File:circle10.png|20px]]</div> </td><br />
</tr><br />
</table><br />
</center><br />
<br />
{{Twocolumn|<br />
Derivatives include the followings for the above three types.<ref>Angata T, Varki A "Chemical diversity in the sialic acids and related alpha-keto acids: an evolutionary perspective" Chem Rev 102(2):439-469, 2002 PMID 11841250</ref><br />
Such modifications are tissue- and organelle-specific.<ref>Butor C, Diaz S, Varki A "High level O-acetylation of sialic acids on N-linked oligosaccharides of rat liver membranes. Differential subcellular distribution of 7- and 9-O-acetyl groups and of enzymes involved in their regulation" J Biol Chem 268(14):10197-10206, 1993 PMID 8486687</ref><br />
* 8-O-methylation, 9-O-methylation<br />
* 4-O-sulfation, 8-O-sulfation<br />
* O-acetylation on the hydroxyl groups at C4, C7, and C9<br />
|<br />
誘導体には、上記の 3 構造全てにおいて以下が挙げられます。修飾は臓器や細胞小器官特異的におこなわれます。<br />
* 8-O-メチル化、9-O-メチル化<br />
* 4-O-硫酸化、8-O-硫酸化<br />
* C4, C7 または C9 における O-アセチル化<br />
}}<br />
<br />
====History====<br />
{{Twocolumn|<br />
* Gunnar Blix found a novel acidic aminosugars from salivary gland mucin in 1936 and later named it sialic acid (1938)<ref> Lundblad A "Gunnar Blix and his discovery of sialic acids. Fascinating molecules in glycobiology" Ups J Med Sci. 2015; 120:104–112 PMID 25921326</ref>. (Dried salivary mucin contains 2% sialic acid.)<br />
* Ernst Klenk identified "Substanz X" from the brain (neuro) of Tay-Sach's disease patient (1935) and later identified a polyhydroxyamino carboxylic acid, and called it neuraminic acid (1941).<br />
* Both substances are found identical, and the correct structure was postulated by Alfred Gottshalk in 1955 <ref>Gottschalk A. "Structural Relationship between Sialic Acid, Neuraminic Acid and 2-Carboxy-Pyrrole" Nature 1955; 176, 881 - 882 doi:10.1038/176881a0 </ref><br />
* In the same period, Tamio Yamakawa and Sakaru Suzuki identified a novel ganglioside from horse erythrocyte stroma and named it hematoside (1951), now called GM3<ref>Kanfer JN and Hakomori S "Sphingolipid biochemistry (Handbook of Lipid Research 3)" Chapter 1, Springer Science & Business Media, 2012 ISBN 978-1475703986</ref>.<br />
|<br />
* Gunnar Blixが1936年に唾液(sialo)のムチンから新規の酸性アミノ糖を見つけ、後にこれをシアル酸と名づけました(1938)。<br />
* Ernst Klenkはテイサックス病患者の脳から「物質X」を見つけ (1935)、後に加水分解によって水酸化アミノカルボン酸であるノイラミン酸を抽出しました(1941)。<br />
* 両者は同一物質であることがわかり、Alfred Gottshalkが1955年に正しい構造を提出しました。<br />
* Klenkとほぼ同時代に山川民夫と鈴木旺は馬の赤血球からヘキソースアミンを含まないガングリオシドを抽出し、1951年ヘマトシドと名付けました(現在のGM3)。<br />
}}<br />
<br />
<references/><br />
<br />
===ウロン酸===<br />
<br />
under construction<br />
<br />
===リン酸===<br />
<br />
under construction</div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Category:LBSG&diff=117193
Category:LBSG
2023-12-01T06:13:19Z
<p>Editor: /* Acidic Modifiers 酸性基 */</p>
<hr />
<div><font size="+2">Acidic Glycosphingolipid</font><br />
{{LB/Header}}<br />
{{Hierarchy|{{PAGENAME}}}}<br />
<br />
<br />
<br />
==Ganglioside ガングリオシド==<br />
<br />
{{Twocolumn|<br />
Ganglioside is a glycosphingolipid with one or more sialic acid. It was named by Klenk E. in 1942 as the major sphingolipid in ganglion, a nerve cell cluster.<ref>Sweeley CC, Siddiqui B. "Chemistry of Mammalian Glycolipids" Chapter 6 in ''The Glycoconjugates Volume I: Mammalian Glycoproteins and Glycolipids'' (Ed. Horowitz MI, Pigman W) 1977 Elsevier Inc. ISBN 978-0-12-356101-5</ref><br />
In vertebrate, close to 190 gangliosides have been identified.<ref>Yu RK, Tsai YT, Ariga T, Yanagisawa M. (2011) Structures, biosynthesis, and functions of gangliosides--an overview" J Oleo Sci. 60(10):537-44. PMID 21937853</ref><br />
They reside on lipid rafts of cell membranes, and involve in many cellular functions.<br />
Major structures with sialic acids include ganglio, lacto, and neolacto series. <br />
|<br />
酸性糖であるシアル酸を含む糖脂質をガングリオシドと呼びます。神経細胞の集まりである神経核 (ganglion) に多いことから Klenk E.により1942年に命名されました。<br />
脊椎動物では現在およそ190種のガングリオシドが見出されています。ガングリオシドは細胞膜の脂質ラフトに存在し、多くの生理機能に関わっています。シアル酸の結合する主要系列はガングリオ、ラクト、ネオラクト等です。<br />
}}<br />
<br />
<references/><br />
<br />
===Svennerholm Notation スヴェンネルホルム表記===<br />
<br />
{{Twocolumn|<br />
The notation was proposed by the Swedish scientist, Lars Svennerholm. Each alpha-numeric digit stands for the number of sialic acids or sugars.<br />
|<br />
スウェーデンの科学者 Lars Svennerholm が導入した記法です。各桁の数字やアルファベットはシアル酸の数や糖の数を意味します。<br />
}}<br />
<br />
{| class="wikitable" style="text-align:center; width:300px;"<br />
! Abbreviation <br />
| GM || GD || GT || GQ || GP<br />
|-<br />
! Number of Sialic Acid <br />
| 1 || 2 || 3 || 4 || 5<br />
|}<br />
<br />
{| class="wikitable" style="text-align:center; width:350px;"<br />
! Suffix Number <br />
| 1 || 2 || 3 || 4<br />
|-<br />
! Core <br />
| Gg4Cer || Gg3Cer || LacCer || GalCer<br />
|}<br />
{| class="wikitable" style="text-align:center;width:350px;"<br />
! Suffix Alphabet (only for Gg4Cer core)<br />
| a || b || c<br />
|-<br />
| Number of Sialic Acid Attached to IIGal<br />
| 1 || 2 || 3<br />
|}<br />
<br />
;Examples<br />
: GQ1b ... 4 sialic acids (GQ), 4 sugars (GQ1), 2 sialic acids attached to the 2nd galactose (GQ1b)<br />
: GM2 ... 1 sialic acids (GM), 3 sugars (GM2).<br />
<br />
<br />
{{:Category:LBS/Biosynthesis/Ganglioside}}<br />
<br />
==Sulfatide スルファチド==<br />
<br />
{{Twocolumn|<br />
<br />
More than ten compounds of sulfoglycolipids (glycosphingolipid sulfate, sulfatide, SM4) are identified by differences in sulfonated sugar chains. Among them 3-O-Sulfated galactosylceramide(GalCer) is called galactosylsulfatide, and is present in myelin sheath like GalCer. <ref>Ishizuka, I. “Chemistry and functional distribution of sulfoglycolipids” Prog. Lipid Res.1997; 36:245-319 PMID 9640458 </ref><br />
The existence of glucosylsufatide, 3-O-sulfated glucosylceramide was reported in rat kidney.<ref>Iida N, Toida T, Kushi Y, Handa S, Fredman P, Svennerholm L, Ishizuka I. A sulfated glucosylceramide from rat kidney. J Biol Chem. 1989 5;264:5974-80.PMID 2925645 </ref><br />
<br />
Sulfatides are present in various organs, such as nervous system, kidney, respiratory organ and digestive tract. The physiological functions of sulfatides are related to myelinogenesis, diabetes, immune system, thrombosis, bacterial and virus infection. <ref> Takahashi T, Suzuki T. “Role of sulfatide in normal and pathological cells and tissues” J Lipid Res. 2012; 53: 1437–1450, PMID 22619219 Takahashi T, Suzuki T. “Role of sulfatide in influenza A virus replication” Biol Pharm Bull. 2015; 38:809-16.PMID 26027821 </ref><br />
<br />
Lysosomal storage disease, metachromatic leukodystrophy, is a congenital metabolic disorder, and is caused by deficiency of lysosomal enzyme arylsulfatase A or its activator.<ref>Mirzaian M, Kramer G, Poorthuis BJ. “Quantification of sulfatides and lysosulfatides in tissues and body fluids by liquid chromatography-tandem mass spectrometry”J Lipid Res. 2015; 56:936-43. PMID 25632048 </ref><br />
|<br />
硫酸化糖脂質には硫酸化される糖鎖の違いにより十数種類が同定されています。その中でもガラクトシルセラミド(GalCer)のガラクトース3位の水酸基に硫酸基を導入したものをガラクトシルスルファチドと呼び、GalCerと同様にミエリンに多く存在します。ラット腎臓にはグルコシルセラミドに硫酸基が結合したグルコシルスルファチドも報告があります。<br />
<br />
スルファチドは神経系、腎臓、呼吸器、消化器などさまざまな組織に存在する糖脂質で、ミエリン形成に関わるほか、糖尿病、免疫系、血栓形成、細菌感染、ウィルス感染など生理作用は多岐にわたります。<br />
<br />
<br />
リソソーム病である異染性白質ジストロフィー(metachromatic leukodystrophy)という先天性代謝異常症は、スルファチド分解酵素(ASA)あるいは活性化因子の欠損か低下により起こります。<br />
}}<br />
<br />
<br />
===Metabolic pathway<ref>Honke K. Biosynthesis and biological function of sulfoglycolipids. Proc Jpn Acad Ser B Phys Biol Sci. 2013 89:129-38. PMID 23574804</ref>===<br />
<br />
;Biosynthesis<br />
;Cerebroside sulfotransferase (CST) + 3’-phosphoadenosine-5’-phosphosulfate(PAPS)<br />
:Galactosylceramide &rarr; galactosylsulfatide<br />
<br />
;Degradation<br />
;Arylsulfatase A (ASA) + Saposin B (activator)<br />
:Galctoslsulfatide &rarr; Galactosylceramide<br />
<br />
<br />
<references/><br />
<br />
==Acidic Modifiers 酸性基==<br />
<br />
<br />
===Sialic acid シアル酸===<br />
{{Twocolumn|<br />
Sialic acid is a collective noun and comprises a family of derivatives of neuraminic acid (5-amino- 3,5-dideoxy- D-glycero- D-galacto- nonulosonic acid)<ref>Schauer R "Sialic Acids - Chemistry, Metabolism and Function" Springer-Verlag, 1982.ISBN 978-3-7091-8680-0 </ref>.<br />
Nowadays, there are over 30 derivatives of neuraminic acid, including the followings.<br />
* N-acetyl neuraminic acid (NeuAc)<br />
* N-glycolyl neuraminic acid (NeuGc)<br />
* deamino neuraminic acid (Kdn: 3-deoxy-D-glycero-D-galacto-nonulosonic acid)<br />
<br />
NeuGc is different from NecAc only by a single oxygen. After NeuAc is bound to cytidine monophosphate (CMP), CMP-NeuAc is converted by N-acetylneuraminic acid hydroxylase (CMAH) to CMP-NeuGc. This gene is generally conserved among mammals but human, sauropsids (birds and reptiles), and monotreme lack this gene <ref>Irie A, Koyama S, Kozutsumi Y, et al. "The molecular basis for the absence of N-glycolylneuraminic acid in humans" J Biol Chem 273:15866–15871, 1998 PMID 9624188</ref><ref>Schauer R, Srinivasan GV, Coddeville B, et al. "Low incidence of N-glycolylneuraminic acid in birds and reptiles and its absence in the platypus" Carbohydr Res 344:1494–1500, 2009 PMID 19541293</ref> (therefore no NeuGc). Kdn is prominent in some fish but not in mammals.<br />
|<br />
シアル酸は、ノイラミン酸(5-アミノ-3,5-ジデオキシ-D-グリセロ-D-ガラクト-ノヌロン酸)に由来する物質の総称です。<br />
現在、ノイラミン酸には以下を含む30 種以上の誘導体が知られています。<br />
* N-アセチルノイラミン酸 (NeuAc)<br />
* N-グリコリルノイラミン酸 (NeuGc)<br />
* デアミノノイラミン酸 (Kdn)<br />
<br />
NeuGcはNeuAcは酸素原子一つしか違いません。シチジンモノホスホ-Neu5Acを基質として、シチジンN-アセチルノイラミン酸ヒドロキシラーゼ(CMAH)によりCMP-NeuGcが生成されます。この遺伝子は哺乳類に保存されていますが、ヒト、鳥類、爬虫類、単孔類は欠損しています(つまりNeuGcを持たない)。Kdnは魚類に知られていますが哺乳類には殆どありません。<br />
}}<br />
<br />
<center><br />
<table cellspacing="15"><br />
<tr><br />
<td> N-acetyl neuraminic acid (Neu5Ac) </td><br />
<td> N-glycolyl neuraminic acid (Neu5Gc) </td><br />
<td> deamino neuraminic acid (Kdn)</td><br />
</tr><br />
<tr><br />
<td style="position: relative">[[File:NeuAc.png]] <div style="position:absolute; top:25px; left:10px">[[File:circle10.png|20px]]</div> </td><br />
<td style="position: relative">[[File:NeuGc.png]] <div style="position:absolute; top:30px; left:0px">[[File:circle10.png|20px]]</div> </td><br />
<td style="position: relative">[[File:Kdn.png]] <div style="position:absolute; top:22px; left:35px">[[File:circle10.png|20px]]</div> </td><br />
</tr><br />
</table><br />
</center><br />
<br />
{{Twocolumn|<br />
Derivatives include the followings for the above three types.<ref>Angata T, Varki A "Chemical diversity in the sialic acids and related alpha-keto acids: an evolutionary perspective" Chem Rev 102(2):439-469, 2002 PMID 11841250</ref><br />
Such modifications are tissue- and organelle-specific.<ref>Butor C, Diaz S, Varki A "High level O-acetylation of sialic acids on N-linked oligosaccharides of rat liver membranes. Differential subcellular distribution of 7- and 9-O-acetyl groups and of enzymes involved in their regulation" J Biol Chem 268(14):10197-10206, 1993 PMID 8486687</ref><br />
* 8-O-methylation, 9-O-methylation<br />
* 4-O-sulfation, 8-O-sulfation<br />
* O-acetylation on the hydroxyl groups at C4, C7, and C9<br />
|<br />
誘導体には、上記の 3 構造全てにおいて以下が挙げられます。修飾は臓器や細胞小器官特異的におこなわれます。<br />
* 8-O-メチル化、9-O-メチル化<br />
* 4-O-硫酸化、8-O-硫酸化<br />
* C4, C7 または C9 における O-アセチル化<br />
}}<br />
<br />
====History====<br />
{{Twocolumn|<br />
* Gunnar Blix found a novel acidic aminosugars from salivary gland mucin in 1936 and later named it sialic acid (1938)<ref> Lundblad A "Gunnar Blix and his discovery of sialic acids. Fascinating molecules in glycobiology" Ups J Med Sci. 2015; 120:104–112 PMID 25921326</ref>. (Dried salivary mucin contains 2% sialic acid.)<br />
* Ernst Klenk identified "Substanz X" from the brain (neuro) of Tay-Sach's disease patient (1935) and later identified a polyhydroxyamino carboxylic acid, and called it neuraminic acid (1941).<br />
* Both substances are found identical, and the correct structure was postulated by Alfred Gottshalk in 1955 <ref>Gottschalk A. "Structural Relationship between Sialic Acid, Neuraminic Acid and 2-Carboxy-Pyrrole" Nature 1955; 176, 881 - 882 doi:10.1038/176881a0 </ref><br />
* In the same period, Tamio Yamakawa and Sakaru Suzuki identified a novel ganglioside from horse erythrocyte stroma and named it hematoside (1951), now called GM3<ref>Kanfer JN and Hakomori S "Sphingolipid biochemistry (Handbook of Lipid Research 3)" Chapter 1, Springer Science & Business Media, 2012 ISBN 978-1475703986</ref>.<br />
|<br />
* Gunnar Blixが1936年に唾液(sialo)のムチンから新規の酸性アミノ糖を見つけ、後にこれをシアル酸と名づけました(1938)。<br />
* Ernst Klenkはテイサックス病患者の脳から「物質X」を見つけ (1935)、後に加水分解によって水酸化アミノカルボン酸であるノイラミン酸を抽出しました(1941)。<br />
* 両者は同一物質であることがわかり、Alfred Gottshalkが1955年に正しい構造を提出しました。<br />
* Klenkとほぼ同時代に山川民夫と鈴木旺は馬の赤血球からヘキソースアミンを含まないガングリオシドを抽出し、1951年ヘマトシドと名付けました(現在のGM3)。<br />
}}<br />
<br />
<references/><br />
<br />
===ウロン酸===<br />
<br />
under construction<br />
<br />
===リン酸===<br />
<br />
under construction</div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=JCBL:DBmeeting&diff=117192
JCBL:DBmeeting
2023-12-01T05:03:43Z
<p>Editor: /* History (歴史) */</p>
<hr />
<div>==About LipidBank==<br />
<br />
{{Twocolumn|<br />
"LipidBank" is an open, publicly free database of natural lipids including fatty acids, glycerolipids, sphingolipids, steroids, and various vitamins.<br />
<br />
The database contains more than 6000 unique molecular structures (ChemDraw cdx format, MDL MOL format), their lipid names (common name, IUPAC), spectral information (mass, UV, IR, NMR and others), and most importantly, literature information.<br />
<br />
The database lists natural lipids only, and all molecular information is manually curated and approved by experts in lipid research (see Informant in each record).<br />
<br />
LipidBank is the official database of the Japanese Conference on the Biochemistry of Lipids (JCBL).<br />
<br />
<br/>'''Reference:'''<br/><br />
Watanabe K., Yasugi E. and Oshima M. "How to search the glycolipid data in LIPIDBANK for Web: the newly developed lipid database in Japan" Trend Glycosci. and Glycotechnol. 12, 175-184, 2000. ([https://www.jstage.jst.go.jp/article/tigg1989/12/65/12_65_175/_article/-char/ja/ PDF])<br />
|<br />
LipidBankは、脂肪酸、グリセロ脂質、スフィンゴ脂質、ステロイド、各種ビタミンを含む天然脂質の公開データベースです。<br/><br />
<br />
現在6000以上の天然物構造(ChemDraw cdx形式、MDL MOL形式)について、物質名(慣用名とIUPAC)、スペクトル情報(質量、UV, IR, NMRほか)に加えて、文献情報も掲載しています。<br/><br />
<br />
このデータベースは天然物を対象としており、全データについて監修者がチェックしています。LipidBankは日本脂質生化学会の公式データベースです。<br/><br />
<br/><br />
<br />
文献:<br/><br />
渡辺清博、八杉悦子、大島美恵子「糖脂質データを日本で新しく作成された生理活性脂質データベース[LIPIDBANK for Web]で検索してみよう」Trend Glycosci. and Glycotechnol. 12, 175-184, 2000.([https://www.jstage.jst.go.jp/article/tigg1989/12/65/12_65_175/_article/-char/ja/ PDF])<br />
}}<br />
<br />
==Bylaws==<br />
<pre><br />
日本脂質生化学会脂質データベース構築委員会 規約<br />
<br />
(名称)<br />
第1条 本会を日本脂質生化学会脂質データベース構築委員会(以下、委員会という。)と称する。<br />
(設置)<br />
第2条 委員会は、日本脂質生化学会が設置する。<br />
(目的)<br />
第3条 委員会は、脂質データベース“LipidBank”の構築・維持・更新を目的とし、脂質データの集積・更新、データベースシステムの構築・維持、<br />
ならびにこれらに関連する業務をおこなう。<br />
(委員会)<br />
第4条 委員会の委員は、脂質・バイオインフォマティクスに造詣の深い日本脂質生化学会会員で構成され、日本脂質生化学会会長が任命する。<br />
2 委員会には委員長を置くこととし、原則として日本脂質生化学会会長が兼務するが、委員の中から任命することができる。<br />
3 委員会に副委員長を置くことができ、日本脂質生化学会会長が任命する。<br />
4 委員会に顧問を置くことができ、日本脂質生化学会会長が任命する。<br />
5 顧問は委員会に出席し、意見を述べることができる。<br />
(事務局)<br />
第5条 委員会に、会務に関する事務をおこなうために事務局を置く。事務局長は委員長が指名する。<br />
(雑則)<br />
第6条 この規約に定めるもののほか、必要な事項は別に定める。<br />
<br />
附則<br />
本規約は、総会の承認を経て変更することができる。<br />
<br />
(平成17年10月1日制定)<br />
(平成29年6月15日改訂)<br />
</pre><br />
<br />
<br />
==History (歴史)==<br />
{{Twocolumn|<br />
===LIPID INFORMATION SERVICE (LIPIDBANK) (1984? - 1997)===<br />
The project was started as a database in Japanese around 1984 with Grant-in-Aid for scientific research publication (Akira Hayashi). This database was succeeded in 1989 under the <br />
committee of lipid information (President: Yoshitaka Nagai), organized by the members of The Japanese Conference on the Biochemistry of Lipids (JCBL). The actual construction of the database was managed by the JCBL committee of database construction (President: Akira Hayashi, Vice-president: Nobuo Ueta, Secretary: Kiyohiro Watanabe).<br />
<br />
The database included 16 lipid classes: fatty acid, long chain aldehyde, long chain alcohol, long chain base, bile acid, glyceride, phospholipid, glycolipid, lipoprotein, lipopolysaccharide, steroid, prostanoid, ether type lipid, mycolic acid and wax.<br />
<br />
Each record contained lipid name, biological activity, source, references, structure and spectra. About 2,700 records were collected and saved on floppy discs.<br />
|<br />
===脂質情報データベース (1984? - 1997)===<br />
LipidBankの淵源は、1984年頃に獲得された科学研究費補助金(研究成果刊行費、代表者:林 陽)により構築が開始された日本語のデータベース「脂質情報データベース」である。1989年に、このデータベースは日本脂質生化学会(JCBL)により構成された脂質情報作成委員会(委員長:永井克孝)が立ち上げたプロジェクトに引き継がれ、構築が本格化した。実務は脂質情報データベース構築委員会(委員長:林 陽、副委員長:植田伸夫、システム構築と入力:渡邊清博)が担った。<br/><br />
<br />
このデータベースは、脂質を16種類に分類して集積された(脂肪酸、長鎖アルデヒド、長鎖アルコール、長鎖塩基、胆汁酸、グリセリド、リン脂質、糖脂質、リポタンパク質、リポ多糖、ステロイド、プロスタノイド、エーテル型脂質、ミコール酸、ワックスなど)。<br/><br />
<br />
各脂質の名称、生理活性、分布、文献、化学構造、スペクトルデータなどの情報が記載された。約2,700件のデータが集積され、フロッピーディスクで配布された。<br />
}}<br />
<br />
{{Twocolumn|<br />
===LIPIDBANK for Web (1996 - 1999)===<br />
The initial three-year project started as a joint research between the International Medical Center of Japan (current National Center for Global Health and Medicine) ([http://www.ncgm.go.jp/ NCGM]) and the Japan Science and Technology Corporation ([http://www.jst.go.jp/ JST]).<br />
<br />
A new executive committee was organized (President: Shoshichi Nojima, Vice-president: Mieko Oshima, Secretary: Kiyohiro Watanabe and Etsuko Yasugi).<br />
<br />
The committee decided to collect the data on 27 lipid classes in English. Molecules in each class were collected independently under 27 team leaders and 122 data informants. <br />
<br />
The database became publicly available from October 1999. The database server was placed at the University of Tokyo where the office of JCBL was located. The total number of molecules was about 5400.<br />
<br />
|<br />
===生理活性脂質データベース (1996 - 1999)===<br />
<br />
3年間の本プロジェクトは、国立国際医療センター(現:国立国際医療研究センター)([http://www.ncgm.go.jp/ NCGM]) と科学技術振興機構 ([http://www.jst.go.jp/ JST]) との共同研究として発足した。<br />
<br />
新たに生理活性脂質データベース構築検討会(委員長:野島庄七、副委員長:大島美恵子、データ入力:渡邊清博、八杉悦子)が結成された。<br />
<br />
脂質を27種類に分類して、それぞれの脂質化合物データを英語で集積した。脂質分野ごとに、各脂質を専門とする27名のデータベース構築責任者をおき、122名のデータ提供者によりデータが収載された。<br />
<br />
1999年秋にJCBLの事務局があった東京大学にサーバーを設置し、インターネット上に公開された。5,400件の脂質化合物データが収録された。<br />
}}<br />
<br />
{{Twocolumn|<br />
===Updating LIPIDBANK for Web (1999 - 2005)===<br />
After adding one lipid class (lipid peroxides), 28 lipid classes were reorganized into 17 lipid groups. <br />
<br />
The DERIVED LIPIDS group now includes fatty acid, long chain alcohol, long chain aldehyde, and long chain base and ceramide. The FAT-SOLUBLE VITAMIN group includes carotenoid, coenzyme Q, vitamin A, vitamin D, vitamin E, and vitamin K. The GLYCOLIPID group includes glycosphingolipid, glycoglycerolipid and others. The PHOSPHOLIPID group includes glycerophospholipid, PAF, and sphingophospholipid. <br />
<br />
In 2004, JCBL officially established an executive committee (President: Yousuke Seyama, Secretary: Etsuko Yasugi) for updating the database.<br />
<br />
|<br />
===生理活性脂質データベースの維持・更新(1999 - 2005)===<br />
新たに過酸化脂質の項目を加えて、17種類の脂質グループに分類して、28種類の脂質化合物について、データ集積をおこなった。<br />
<br />
誘導脂質には、脂肪酸、長鎖アルコール、長鎖アルデヒド、長鎖塩基とセラミドが含まれる。脂溶性ビタミンは、カロテノイド、コエンザイムQ、ビタミンA、D、E、Kから構成されている。糖脂質にはスフィンゴ糖脂質とグリセロ糖脂質が、リン脂質にはグリセロリン脂質、PAF、スフィンゴリン脂質が含まれる。<br />
<br />
2004年には、脂質データベース構築委員会(委員長:脊山洋右、データ入力:八杉悦子)がJCBLから公認された。<br />
}}<br />
<br />
{{Twocolumn|<br />
===Renovating LIPIDBANK for Web (2006-2007)===<br />
LIPIDBANK for Web became the official database of JCBL, to which all rights were delegated from NCGM and JST. The name of database changed to "LipidBank". <br />
<br />
The Hopanoid group was removed and the number of category is now 16. The database system and its contents were updated and reorganized by the JCBL committee members (President: Masahiro Nishijima).<br />
<br />
|<br />
===生理活性脂質データベースの刷新(2006 - 2007)===<br />
生理活性脂質データベースは2006年にNCGMとJSTから譲渡され、JCBL公認のデータベースとなった。データベースの名称を"LipidBank"と改めた。<br/><br />
<br />
脂質項目のうちホパノイドを削除し、16種類の脂質グループとした。脂質データベース構築委員会(委員長:西島正弘)が、データベースのシステムと内容の維持・更新を担当。<br />
<br />
}}<br />
<br />
{{Twocolumn|<br />
=== Linking with the Wiki version (2017-2022)===<br />
With financial support from the AMED program "Studies on Specific Activities and Functions of Lipid Molecules to Develop Innovative Medical Technologies" (PS: YOKOYAMA Shinji), wiki-based database was updated for glycosphingolipid and others.<br />
<br />
Categories in the original LipidBank were translated into static HTML pages due to security issues.<br />
|<br />
=== LipidBank Wiki との連携 (2017-2022)===<br />
AMED革新的先端研究開発支援事業 「画期的医薬品等の創出をめざす脂質の生理活性と機能の解明」(総括:横山信治)より支援を受け、スフィンゴ糖脂質を中心に情報を整理、更新。<br />
<br />
旧LipidBankの各カテゴリーはセキュリティ脆弱性のためにコンテンツをHTML固定ページに変換。<br />
}}<br />
<br />
<br />
===Contact Address===<br />
{{Twocolumn|<br />
If you have questions or suggestions, please contact with:<br />
<br />
::Masanori Arita<br />
:::arita@nig.ac.jp<br />
::National Institute of Genetics<br />
|<br />
ご意見やご質問は、下記へお寄せください。<br />
<br/><br />
::有田正規<br />
:::arita@nig.ac.jp<br />
::国立遺伝学研究所<br />
}}<br />
<br />
==Members of Executive Committee of Lipid Database (脂質データベース構築委員会メンバー)==<br />
2019年 2月 27日<br />
<center><br />
{| class="wikitable"<br />
|-<br />
! colspan="3" style="text-align:center"| 委員長: 和泉 孝志 (Takashi Izumi)<br />
|-<br />
! colspan="3" style="text-align:center"| 委員<br />
|-<br />
| 青木 淳賢 (Junken Aoki) || 有田 誠 (Makoto Arita) || 有田 正規 (Masanori Arita)<br />
|-<br />
| 糸乗 前 (Saki Itonori) || 今井 博之 (Hiroyuki Imai) || 笠間 健嗣 (Takeshi Kasama)<br />
|-<br />
| 北 芳博 (Yoshihiro Kita) || 小林 哲幸 (Tetsuyuki Kobayashi) || 酒井 祥太 (Shota Sakai)<br />
|-<br />
| 清水 孝雄 (Takao Shimizu) || 中村 和生 (Kazuo Nakamura) || 八杉 悦子 (Etsuko Yasugi)<br />
|-<br />
| 横山 和明 (Kazuaki Yokoyama) || ||<br />
|-<br />
! colspan="3" style="text-align:center"| Advisors<br />
|-<br />
| 大島 美恵子(Mieko Oshima) || 脊山 洋右(Yousuke Seyama) || 西島 正弘(Masahiro Nishijima)<br />
|}<br />
</center><br />
<br />
==Funding (資金)==<br />
{|<br />
|-<br />
|colspan="2"| <big>'''1989 - 1997'''</big><br />
|-<br />
|LIPID INFORMATION SERVICE was funded by a Grant-in-Aid for Scientific Research (Grant-in-Aid for Publication of Scientific Research Results) from the Japan Society for the Promotion of Science.<br />
|LIPID INFORMATION SERVICEが日本学術振興会([http://www.jsps.go.jp/ JSPS])科学研究費に採択される。<br />
|-<br />
|colspan="2"| <big>'''1996 - 2002'''</big><br />
|-<br />
|LIPIDBANK for Web was funded by the Database Development Program of the Japan Science and Technology Agency (JST).<br />
|LIPIDBANK for Webが科学技術振興機構([http://www.jst.go.jp/ JST])に採択される。<br />
|-<br />
|colspan="2"| <big>'''2003 - 2006''', '''2009 - 2016'''</big><br />
|-<br />
|LIPIDBANK for Web was funded by a Grant-in-Aid for Scientific Research (Grant-in-Aid for Publication of Scientific Research Results) from the Japan Society for the Promotion of Science.<br />
|日本学術振興会([http://www.jsps.go.jp/ JSPS])科学研究費の研究成果公開促進費データベース事業による更新。<br />
|-<br />
|colspan="2"| <big>'''2017 - 2022'''</big><br />
|-<br />
|LIPIDBANK was funded by AMED-CREST in "Studies on Specific Activities and Functions of Lipid Molecules to Develop Innovative Medical Technologies".<br />
|AMED革新的先端研究開発支援事業 「画期的医薬品等の創出をめざす脂質の生理活性と機能の解明」(総括:横山信治)による更新。<br />
|}<br />
<br />
==構築委員会の歴史==<br />
{| class="wikitable"<br />
|-<br />
| 第1回 || 1997年1月8日 || 国立国際医療センター研究所 || 生理活性脂質データベース構築委員会<br />
|-<br />
| 第10回 || 2004年3月25日 ||学士会分館 || 脂質情報データベース推進委員会<br />
|-<br />
| 第20回 || 2007年3月8日 || 東京大学 医学部 || 脂質データベース構築委員会<br />
|-<br />
| 第30回 || 2015年5月29日 || 東京大学 薬学部 || 脂質データベース構築委員会<br />
|-<br />
| 第34回 || 2019年7月5日 || 北海道大学 || 脂質データベース構築委員会<br />
|-<br />
|colspan="4"| 2020-2022 年はCOVID-19のために中止。JCBLホームページを2010-2021年まで本サーバで維持管理してきたが、2021年より新サイト (jcbl.jp) に移行。<br />
|-<br />
| <br />
|}</div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Category:LBG&diff=117191
Category:LBG
2023-11-30T01:05:16Z
<p>Editor: /* Glycerophospholipid */</p>
<hr />
<div>{{Huge|{{Bilingual|グリセロ脂質|Glycerolipid}} }}<br />
{{LB/Header}}<br />
{{Hierarchy|{{PAGENAME}}}}<br />
{| style="float:right"<br />
|__TOC__<br />
|}<br />
==Class Overview==<br />
<br />
{{Twocolumn|<br />
Complex lipid is the major structural component of biological membranes (lipid bilayer), and is broadly classified into glycerolipid containing glycerol and sphingolipid containing sphingoid. The glycerolipid category (LBG) includes glycoglycerolipid and phosphoglycerolipid.<br />
|<br />
リン酸や糖などを含む脂質は複合脂質と呼ばれ、細胞膜の脂質二重層の主要な構成要素です。複合脂質は、一般的にグリセロールを含む脂質 (グリセロ脂質) とスフィンゴイドを含む脂質 (スフィンゴ脂質) に大別されます。グリセロ脂質 (LBG) には、グリセロ糖脂質 (glycoglycerolipid) とグリセロリン脂質 (glycerophospholipid) が含まれます。<br />
}}<br />
<br />
={{Bilingual|略称の記載法|Common Nomenclature}}=<br />
{{Twocolumn|<br />
[https://lipidmaps.org LipidMaps Consortium] in the US defines the standard way of structure description (nomenclature). Please follow this standard especially when exact structure is not determined due to experimental procedures.<br />
|<br />
米国の[https://lipidmaps.org LipidMaps コンソーシアム]では、構造の標準的な表記法を定めています(命名系)。とりわけ分析法により構造に曖昧な部分が残る場合は、以下の表記法を踏襲してください。<br />
}}<br />
Reference: "Update on LIPID MAPS classification, nomenclature, and shorthand notation for MS-derived lipid structures" [https://www.jlr.org/article/S0022-2275(20)60017-7/fulltext <i>J Lipid Res</i> 61(12), 1539-1555, 2020]<br />
<br />
==GlyceroLipid==<br />
<br />
{{Twocolumn|<br />
Glycerolipid is referred to as mono-, di-, and triglycerides depending on the number of acyl chains (fatty acids). When sugars are attached, the modification comes before the backbone name; SQ, MG, and DG indicate Sulfoquinovose, single hexose, and double hexoses, respectively.Hexose is commonly galactose, and MG and DG may refer to mono- and digalactose.<br />
|<br />
配位するアシル基(脂肪酸)の数により、モノ・ジ・トリアシルグリセロール(それぞれ MG, DG, TG)と呼ばれます。グリセロール骨格に糖鎖が付く場合は MG や DG の前に SQ (Sulfoquinovosyl)、MG (Monoglycosyl)、DG (Diglycosyl) をつけます。MGやDGの略称はガラクトースの意味で使われる場合もあります。<br />
}}<br />
<br />
{| class="wikitable" cellpadding="4"<br />
|-<br />
! || || Monoglycosyl (単糖) || Diglycosyl (二糖) || Sulfoquinovosyl (スルホキノボース)<br />
|-<br />
| MG : || Monoacylglycerol <br/>(モノアシルグリセロール) || MGMG || DGMG || SQMG<br />
|-<br />
| DG : || Diacylglycerol <br/>(ジアシルグリセロール) || MGDG || DGDG || SQDG<br />
|-<br />
| TG : || Triacylglycerol <br/>(トリアシルグリセロール) <br />
|colspan="3" align="center"| n.a. (該当なし) <br />
|}<br />
<br />
==Glycerophospholipid==<br />
{{Twocolmn|<br />
<br />
|<br />
グリセロリン脂質は生体膜の主要成分であり、グリセロールに2つの脂肪酸とリン酸を含む極性基が結合しています。<br />
<br />
}}<br />
{| class="wikitable"<br />
|-<br />
| Phosphatidic acid<br/>ホスファチジン酸 || PA, Ptd <br />
|-<br />
| Phosphatidylcholine<br/>ホスファチジルコリン || PC, PtdCho<br />
|-<br />
| Phosphatidylethanolamine<br/>ホスファチジルエタノールアミン || PE, PtdEtn<br />
|-<br />
| Phosphatidylserine<br/>ホスファチジルセリン || PS, PtdSer<br />
|-<br />
| Phosphatidylinositol<br/>ホスファチジルイノシトール || PI, PtdIns<br />
|-<br />
| Phosphatidylinositol-mannoside<br/>ホスファチジルイノシトールマンノシド || PIM<br />
|-<br />
| Phosphatidylglycerol<br/>ホスファチジルグリセロール || PG, PtdGro<br />
|-<br />
| Phosphatidylglycerolphosphate<br/>ホスファチジルグリセロールリン酸 || PGP<br />
|-<br />
| Cardiolipin<br/>カルジオリピン || CL, Ptd2Gro<br />
|-<br />
| Bis[monoacylglycero]phosphates<br/>ビス(モノアシルグリセロ)リン酸 || BMP<br />
|}<br />
<br />
<br />
<!----<br />
=={{Bilingual|分類|Classification}}==<br />
==={{Bilingual|糖の個数もしくは極性基|By the Number of Sugars or the Head Group}}===<br />
<br />
<br />
{{Twocolumn|<br />
For glycoglycerolipid, 2 digits indicate the number of sugars. For phosphoglycerolipid, common abbreviations such as PS (phosphatidylserine)or PE (phosphatidylethanolamine). <br />
|<br />
グリセロ糖脂質は結合している糖の総数を、グリセロリン脂質の場合はPS(ホスファチジルセリン)やPE(ホスファチジルエタノールアミン)等の記号を2桁で示しています。<br />
}}<br />
<br />
<br />
<br />
{| class="wikitable"<br />
|-<br />
! colspan="3" | Glycerolipid Overview<br />
|-<br />
| align="center" style="vertical-align:top" width=33%|<br />
Glycoglycerolipid<br><small>グリセロ糖脂質</small>: LBGnn<br />
<br>[[Image:LBGnn.png]]<br><br />
| align="center" style="vertical-align:top" width=33%|<br />
Phosphoglycerolipid<br><small>グリセロリン脂質</small>: LBGPn<br />
<br>[[Image:LBGPn.png]]<br><br />
|}<br />
</center><br />
<br />
<center><br />
{| class="wikitable" border="1" cellpadding="2" cellspacing="1" margin: 1em 1em 1em 1em"<br />
|+ Table 1. Classification by number of sugars or polar head group<br />
|- valign="top"<br />
|align="center"| {{MapLink|ListMol|LBGPA|LBGPA: <br>Ptd acid <br>ホスファチジン酸<br>}}<br>[[Image:LBGPA.png|90px]]<br />
|align="center"| {{MapLink|ListMol|LBGPC|LBGPC: <br>Ptd-choline<br>ホスファチジルコリン<br>}}<br>[[Image:LBGPC.png|155px]]<br />
|align="center"| {{MapLink|ListMol|LBGPE|LBGPE: <br>Ptd-ethanolamine<br>ホスファチジルエタノールアミン<br>}}<br>[[Image:LBGPE.png|135px]]<br />
|align="center"| {{MapLink|ListMol|LBGPG|LBGPG: <br>Ptd-glycerol <br>ホスファチジルグリセロール<br>}}<br>[[Image:LBGPG.png|130px]]<br />
<br />
|- valign="top"<br />
|align="center"| {{MapLink|ListMol|LBGPI|LBGPI: <br>Ptd-inositol<br>ホスファチジルイノシトール<br>}}<br>[[Image:LBGPI.png|110px]]<br />
|align="center"| {{MapLink|ListMol|LBGPS|LBGPS: <br>Ptd-serine<br>ホスファチジルセリン<br>}}<br>[[Image:LBGPS.png|150px]]<br />
|align="center"| {{MapLink|ListMol|LBGPx|LBGPx: <br>other <br>その他リン脂質<br>}}<br>[[Image:LBGPx.png|95px]]<br />
|- valign="top"<br />
|align="center"| {{MapLink|ListMol|LBGMG|LBGMG: <br>Monoacyl G<br>モノグリセリド<br>}}<br>[[Image:LBGMG.png]]<br />
|align="center"| {{MapLink|ListMol|LBGDG|LBGDG: <br>Diacyl G<br>ジグリセリド<br>}}<br>[[Image:LBGDG.png]]<br />
|align="center"| {{MapLink|ListMol|LBGTG|LBGTG: <br>Triacyl G<br>トリグリセリド<br>}}<br>[[Image:LBGTG.png]]<br />
|align="center"| {{MapLink|ListMol|LBG00|LBG00: <br>Alkyl-type G<br>含アルキル, アルケニル型<br>}}<br />
|-<br />
|align="center"| {{MapLink|ListMol|LBG01|LBG01: <br>1 sugar<br>糖の数1<br>}}<br />
|align="center"| {{MapLink|ListMol|LBG02|LBG02: <br>2 sugars<br>糖の数2<br>}}<br />
|align="center"| {{MapLink|ListMol|LBG03|LBG03: <br>3 sugars<br>糖の数3<br>}}<br />
|align="center"| {{MapLink|ListMol|LBG04|LBG04: <br>4 sugars<br>糖の数4<br>}}<br />
<br />
|}<br />
</center><br />
<br />
==={{Bilingual|その他の分類|Other Classification Charts}}===<br />
<br />
* {{#volatile:ClassMatrix|Head Group v.s. Length:Unsaturation of R1 <br>(極性基 対 R1の脂肪酸長:不飽和度)|LBG.....:.........:.........|10|12|4|5|Head_Group|Fatty_Acid_Length(R1)}}<br />
* {{#volatile:ClassMatrix|Head Group v.s. Length:Unsaturation of R2 <br>(極性基 対 R2の脂肪酸長:不飽和度)|LBG.....:.........:.........|20|22|4|5|Head_Group|Fatty_Acid_Length(R2)}}<br />
* {{#volatile:ClassMatrix|Length:Unsaturation of R1 v.s. Length:Unsaturation of R2 <br>(R2の脂肪酸長:不飽和度 対 R2の脂肪酸長:不飽和度)|LBG.....:.........:.........|10|12|20|22|Fatty_Acid_Length(R1)|Fatty_Acid_Length(R2)}}<br />
<br />
=={{Bilingual|ID番号の設計|Design of Glycerolipid Identifiers}}==<br />
<center><br />
28-DIGIT(8+9+9+2)<br />
<table border=1><br />
<tr><br />
<td style="background-color:yellowgreen;" width=15px align="center"><big>L</big><br />
<td style="background-color:yellowgreen;" width=15px align="center"><big>B</big><br />
<td style="background-color:darkseagreen;" width=15px align="center"><big>G</big><br />
<td style="background-color:Blue; color:white" width=15px align="center"><big>''a''</big><br />
<td style="background-color:Blue; color:white" width=15px align="center"><big>''a''</big><br />
<td style="background-color:aqua" width=15px align="center"><big>''b1''</big><br />
<td style="background-color:aqua" width=15px align="center"><big>''b2''</big><br />
<td style="background-color:aqua" width=15px align="center"><big>''b3''</big><br />
<td style="background-color:gray;" width=15px align="center"><big>:</big><br />
<td style="background-color:tomato; color:white" width=15px align="center"><big>''x1''</big><br />
<td style="background-color:tomato; color:white" width=15px align="center"><big>''x1''</big><br />
<td style="background-color:purple; color:white" width=15px align="center"><big>''y1''</big><br />
<td style="background-color:firebrick; color:white" width=15px align="center"><big>''z1''</big><br />
<td style="background-color:firebrick; color:white" width=15px align="center"><big>''z1''</big><br />
<td style="background-color:green; color:white" width=15px align="center"><big>''w1''</big><br />
<td style="background-color:green; color:white" width=15px align="center"><big>''w1''</big><br />
<td style="background-color:white;" width=15px align="center"><big>''c1''</big><br />
<td style="background-color:white;" width=15px align="center"><big>''c1''</big><br />
<td style="background-color:gray;" width=15px align="center"><big>:</big><br />
<td style="background-color:tomato; color:white" width=15px align="center"><big>''x2''</big><br />
<td style="background-color:tomato; color:white" width=15px align="center"><big>''x2''</big><br />
<td style="background-color:purple; color:white" width=15px align="center"><big>''y2''</big><br />
<td style="background-color:firebrick; color:white" width=15px align="center"><big>''z2''</big><br />
<td style="background-color:firebrick; color:white" width=15px align="center"><big>''z2''</big><br />
<td style="background-color:green; color:white" width=15px align="center"><big>''w2''</big><br />
<td style="background-color:green; color:white" width=15px align="center"><big>''w2''</big><br />
<td style="background-color:white;" width=15px align="center"><big>''c2''</big><br />
<td style="background-color:white;" width=15px align="center"><big>''c2''</big><br />
<td> (R3 if exists) </td><br />
</tr><br />
</table><br />
</center><br />
{{Twocolumn|<br />
* ''a'' ... the number of attached sugars (glycoglycerolipid) or the code of polar head group(phosphoglycerolipid)<br />
* ''b'' ... type of binding to fatty acid-1 through 3<br />
<br />
* ''x'' ... carbon chain length (fatty acid-1 through 3)<br />
* ''y'' ... degree of unsaturation (fatty acid-1 through 3)<br />
* ''z'' ... position of n-''z'' (n minus z; also ω-z or omega-z) nomenclature (fatty acid-1 through 3)<br />
* ''w'' ... structure type (fatty acid-1 through 3)<br />
* ''c'' ... serial number (fatty acid-1 through 3)<br />
|<br />
* ''a'' ... 修飾する糖の個数 (グリセロ糖脂質) もしくは極性基を示す略号 (グリセロリン脂質)<br />
* ''b'' ... 脂肪酸1および2の結合のタイプ<br />
<br />
* ''x'' ... 炭素鎖長 (脂肪酸1から3)<br />
* ''y'' ... 不飽和度 (脂肪酸1から3)<br />
* ''z'' ... n-''z'' (またはω-zやomega-z) における数 (脂肪酸1から3)<br />
* ''w'' ... 骨格のタイプ (脂肪酸1から3)<br />
* ''c'' ... 通し番号 (脂肪酸1から3)<br />
}}<br />
<br />
----></div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Category:LBSB&diff=117190
Category:LBSB
2023-11-29T06:25:01Z
<p>Editor: </p>
<hr />
<div>{{LB/Header}}<br />
{{Hierarchy|{{PAGENAME}}}}<br />
<br />
{{Twocolumn|<br />
Long-chain base (LCB or sphingoid base) is a 2-aminoalkane (or alkene) 1,3-diol. In cells, it constitutes sphingolipids and little exists as a free form.<br />
When LCB is linked with a long-chain fatty acid via an amide bond, it is called a ceramide (Cer).<ref>Yamaji T, Hanada K "Sphingolipid metabolism and interorganellar localization of sphingolipid enzymes and lipid transfer proteins" Traffic 2015 16:101-122. PMID 25382749</ref><br />
|<br />
長鎖塩基 LCB(またはスフィンゴイド塩基)は 2-アミノアルカン(またはアルケン) 1,3-ジオールを指し、生体内ではスフィンゴ脂質の構成成分です。遊離のLCBは微量しか存在しません。長鎖塩基に長鎖脂肪酸がアミド結合したものを、セラミドと呼びます。<br />
}}<br />
<references/><br />
<br />
* [[PathwayMap:CeramideBiosynthesis]]<br />
* [https://lipidbank.jp/DLB.html Link to the original LipidBank]<br />
<br />
<br />
==Notation 表記法 ==<br />
{|<br />
|style="background:lightgray" width="200px"| <font size="+2">Sph<br/>d18:1</font>&nbsp;<br />
|Sph is an abbreviation of LCB.<br/>''d'' or ''t'' stands for double or triple hydroxy groups, respectively. (We count the terminal alcohol.)<br/>18 is the carbon chain length.<br/>1 after the colon is the number of unsaturated bonds (double bonds).<br />
|width="30%"|<br />
長鎖塩基 LCB は Sph と表します。 ''d'', ''t'' はそれぞれ 2, 3 個の水酸基 (アルコールの水酸基含む)を意味し、18は炭素鎖長です。コロンの次にくる1は不飽和結合(二重結合)の数を表します。<br />
|}<br />
<br />
{|<br />
|style="background:lightgray" width="200px"| <font size="+2">Cer&nbsp;<br/>d18:1<sup>&Delta;8E</sup>/20:0</font>&nbsp;<br />
| Cer is an abbreviations of ceramide. The first part indicates the sphingoid base and the second, after the slash, fatty acid.<br/>In this website we do not use superscripts or subscripts for readability.<br/>Also we do not italicize E (or trans) and Z (or cis) for the same reason.<br />
|width="30%"| セラミドは Cer と表します。左側が長鎖塩基、スラッシュを挟んで右側は脂肪酸を表しています。このサイトでは上付き/下付きは使用せず(見づらいため)、 E (トランス), Z (シス)もイタリックにしていません。<br />
|}<br />
<br />
{| style="border-spacing: 20px;"<br />
|-<br />
! '''Common Name'''<br />
| sphingosine <br/>(= (4E)-sphingenine)<br/> スフィンゴシン<br />
| sphinganine <br/>(= dihydrosphingosine)<br/> スフィンガニン<br />
| phytosphingosine<br/>(= 4-hydroxydihydrosphingosine)<br/> フィトスフィンゴシン<br />
| 6-hydroxysphingosine<br/><br/> 6-ヒドロキシスフィンゴシン<br />
|-<br />
! '''Abbreviation'''<br />
| d18:1 or So<br />
| d18:0 or Sa (DHSo)<br />
| t18:0 or Phyto<br />
| t18:1 or 6-t18:1<br />
|-<br />
! '''Structure 構造'''<br />
| <small>{{LBS/Sph|OH}}</small><br />
| <small>{{LBS/DHSph|OH}}</small><br />
| <small>{{LBS/PhytoSph|OH}}</small><br />
| <small>{{LBS/6HSph|OH}}</small><br />
|-<br />
! '''Source 分布'''<br />
| Major in mammals<br />
| Major in mammals<br />
| Major in fungi and plant<br />
| Found in skin<br />
|}<br />
<br />
==Long-chain base 長鎖塩基==<br />
<br />
{{Twocolumn|<br />
The structural variation of LCB depends on biological species.<ref>Merrill AH "Sphingolipid and Glycosphingolipid Metabolic Pathways in the Era of Sphingolipidomics" Chem. Rev. 2011 111:6387–6422. PMID 21942574</ref><br />
|生物種によってLCBの構造は大きく異なります。<br />
}}<br />
<br />
{| class="wikitable"<br />
! Classification || Long-chain base<br />
|-<br />
| Mammalia || sphingosine (= (4E)-d18:1)<br/> (4E)-d20:1 (nerve tissue), t18:0 (intestine)<br />
|-<br />
| Arthropoda || short-chain sphingosine (d14:1, d16:1) <ref>Guan XL, Cestra G, Shui G, Kuhrs A, Schittenhelm RB, Hafen E, van der Goot FG, Robinett CC, Gatti M, Gonzalez-Gaitan M, Wenk MR "Biochemical membrane lipidomics during Drosophila development" Dev Cell 2013 24:98-111. PMID 23260625</ref><br />
|-<br />
| Plantae || (8E/Z)-d18:1, (8E/Z)-t18:1, (4E,8E/Z)-d18:2<br />
|-<br />
| Fungi || 9-methyl (4E,8E)-d18:2, t18:0<br />
|}<br />
<br />
<br />
===Bioactivity===<br />
{{Twocolumn|<br />
* Free LCB induces apoptosis.<ref>Hung WC, Chang HC, Chuang LY "Activation of caspase-3-like proteases in apoptosis induced by sphingosine and other long-chain bases in Hep3B hepatoma cells" Biochem J. 1999 338:161-166. PMID 9931312</ref><br />
* Sphingosine 1-phosphate is a lipid mediator of cell proliferation and motility control.<ref>Takabe K, Spiegel S."Export of sphingosine-1-phosphate and cancer progression"J Lipid Res. 2014 55:1839-46. PMID 24474820</ref><br />
|<br />
* 遊離のLCBはアポトーシスを惹起します。<br />
* スフィンゴシン 1リン酸 (Sph-1-P) は脂質メディエータとして細胞増殖や運動制御に働きます。<br />
}}<br />
<br />
<references/><br />
<br />
==Ceramide セラミド==<br />
<br />
{{Twocolumn|<br />
The conjugated fatty acids are often length 16 to 26. In normal tissues, little ceramide exists as an intermediate of phospho- and glycosphingolipid, whereas in the skin (corneocyte), ceramides and fatty-acid conjugated acyl-ceramides dominates and exhibit the barrier function.<br />
| セラミドに結合する脂肪酸の炭素鎖長は16から26が多く、通常組織ではスフィンゴリン脂質やスフィンゴ糖脂質の中間体として少量存在します。皮膚の角質層にはセラミドに更に脂肪酸が結合したアシルセラミドがあり、皮膚のバリア機能を担います。<br />
}}<br />
<br />
===Composition===<br />
{| class="wikitable"<br />
|-<br />
!rowspan="2"| Species<br />
!colspan="3"| Glycosylceramide<br />
!colspan="3"| Glycosyl inositol phosphoceramide (GIPC)<br />
|-<br />
! Fatty acid<br />
! Long chain base<br />
! References<br />
! Fatty acid<br />
! Long chain base<br />
! References<br />
|-<br />
!Plants<br />
| 16:0 - 26:0<br/>16:1 - 26:1<br/>16:0<br/>VLCFA<br />
| d18:2&Delta;4E8E/Z<br/>d18:2&Delta;4E8E/Z<br/>d18:1&Delta;8E/Z<br/>t18:1&Delta;8E/Z<br />
| <ref name=Mark>Markham JE, Lynch DV, Napier JA, Dunn TM, Cahoon EB. "Plant sphingolipids: function follows form" Curr Opin Plant Biol. 2013 16: 350-7. PMID 23499054</ref><ref name="War">Warnecke D, Heinz E."Recently discovered functions of glucosylceramides in plants and fungi" Cell Mol Life Sci. 2003 60:919-41.PMID 12827281</ref><br/><ref name="Mark"/><ref name="War"/><br/><ref name="Mark"/><br/><ref name="Mark"/><ref name="War"/><br />
| VLCFA<br/>14:0 - 26:0<br/>20:1 - 26:1<br />
| t18:1&Delta;8E/Z<br/>t18:1&Delta;8E/Z, t18:0<br/>t18:1&Delta;8E/Z, t18:0<br />
| <ref name="Mark"/><br/><ref name="Bure">Buré C, Cacas JL, Mongrand S, Schmitter JM. "Characterization of glycosyl inositol phosphoryl ceramides from plants and fungi by mass spectrometry" Anal Bioanal Chem. 2013 406:995-1010 PMID 23887274</ref><br/><ref name="Mark"/><ref name="Bure"/><br />
|-<br />
!Fungi<br />
| 16:0 - 18:0<br/>16:1 - 18:1<br />
| 9-methyl d18:2&Delta;4E,8E<br/>9-methyl d18:2&Delta;4E,8E<br />
| <ref name="Nim">Nimrichter L, Rodrigues ML. "Fungal glucosylceramides: from structural components to biologically active targets of new antimicrobials" Front Microbiol. 2011 2:212.PMID 22025918</ref><ref name="War"/><br/><ref name="Nim"/><ref name="War"/><br />
| 24:0 - 26:0<br/>24:1 - 26:1<br/>16:0 - 26:0<br />
| t18:0<br/>t18:0<br/>t18:0, t20:0<br />
| <ref name="Nim"/><br/><ref name="War"/><br/><ref name="War"/><ref name="Bure"/><br />
|}<br />
<br />
===Bioactivity===<br />
<br />
{{Twocolumn|<br />
* Atopic dermatitis (and dry skin) is associated with a decrease and compositional change of ceramides.<ref>Macheleidt O, Kaiser HW, Sandhoff K "Deficiency of epidermal protein-bound omega-hydroxyceramides in atopic dermatitis" J Invest Dermatol. 2002 119:166-173. PMID 12164940</ref><br />
* Ceramides involve in cell proliferation and autophagy, and ceramide 1-phosphate functions as a lipid mediator.<ref>Young MM, Kester M, Wang HG "Sphingolipids: regulators of crosstalk between apoptosis and autophagy" J Lipid Res.2013 54:5-19. PMID 23152582</ref><br />
|<br />
* アトピー性皮膚炎や乾燥肌ではセラミド量が減少し、組成も変化しています。<br />
* 通常細胞内ではLCBと同様に細胞増殖やオートファジーに関与し、セラミド末端にリン酸が結合した Cer-1-P も脂質メディエータとして働きます。<br />
}}<br />
<br />
<br />
<references/><br />
<br />
===Metabolism===<br />
<br />
[[:Category:LBS/Biosynthesis|Metabolism, Glycosphingolipid in Plant and Fungi]]</div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Category:LBSB&diff=117189
Category:LBSB
2023-11-29T06:24:42Z
<p>Editor: </p>
<hr />
<div>{{LB/Header}}<br />
{{Hierarchy|{{PAGENAME}}}}<br />
<br />
{{Twocolumn|<br />
Long-chain base (LCB or sphingoid base) is a 2-aminoalkane (or alkene) 1,3-diol. In cells, it constitutes sphingolipids and little exists as a free form.<br />
When LCB is linked with a long-chain fatty acid via an amide bond, it is called a ceramide (Cer).<ref>Yamaji T, Hanada K "Sphingolipid metabolism and interorganellar localization of sphingolipid enzymes and lipid transfer proteins" Traffic 2015 16:101-122. PMID 25382749</ref><br />
|<br />
長鎖塩基 LCB(またはスフィンゴイド塩基)は 2-アミノアルカン(またはアルケン) 1,3-ジオールを指し、生体内ではスフィンゴ脂質の構成成分です。遊離のLCBは微量しか存在しません。長鎖塩基に長鎖脂肪酸がアミド結合したものを、セラミドと呼びます。<br />
}}<br />
<references/><br />
<br />
* Pathway map for biosynthesis [[PathwayMap:CeramideBiosynthesis]]<br />
* [https://lipidbank.jp/DLB.html Link to the original LipidBank]<br />
<br />
<br />
==Notation 表記法 ==<br />
{|<br />
|style="background:lightgray" width="200px"| <font size="+2">Sph<br/>d18:1</font>&nbsp;<br />
|Sph is an abbreviation of LCB.<br/>''d'' or ''t'' stands for double or triple hydroxy groups, respectively. (We count the terminal alcohol.)<br/>18 is the carbon chain length.<br/>1 after the colon is the number of unsaturated bonds (double bonds).<br />
|width="30%"|<br />
長鎖塩基 LCB は Sph と表します。 ''d'', ''t'' はそれぞれ 2, 3 個の水酸基 (アルコールの水酸基含む)を意味し、18は炭素鎖長です。コロンの次にくる1は不飽和結合(二重結合)の数を表します。<br />
|}<br />
<br />
{|<br />
|style="background:lightgray" width="200px"| <font size="+2">Cer&nbsp;<br/>d18:1<sup>&Delta;8E</sup>/20:0</font>&nbsp;<br />
| Cer is an abbreviations of ceramide. The first part indicates the sphingoid base and the second, after the slash, fatty acid.<br/>In this website we do not use superscripts or subscripts for readability.<br/>Also we do not italicize E (or trans) and Z (or cis) for the same reason.<br />
|width="30%"| セラミドは Cer と表します。左側が長鎖塩基、スラッシュを挟んで右側は脂肪酸を表しています。このサイトでは上付き/下付きは使用せず(見づらいため)、 E (トランス), Z (シス)もイタリックにしていません。<br />
|}<br />
<br />
{| style="border-spacing: 20px;"<br />
|-<br />
! '''Common Name'''<br />
| sphingosine <br/>(= (4E)-sphingenine)<br/> スフィンゴシン<br />
| sphinganine <br/>(= dihydrosphingosine)<br/> スフィンガニン<br />
| phytosphingosine<br/>(= 4-hydroxydihydrosphingosine)<br/> フィトスフィンゴシン<br />
| 6-hydroxysphingosine<br/><br/> 6-ヒドロキシスフィンゴシン<br />
|-<br />
! '''Abbreviation'''<br />
| d18:1 or So<br />
| d18:0 or Sa (DHSo)<br />
| t18:0 or Phyto<br />
| t18:1 or 6-t18:1<br />
|-<br />
! '''Structure 構造'''<br />
| <small>{{LBS/Sph|OH}}</small><br />
| <small>{{LBS/DHSph|OH}}</small><br />
| <small>{{LBS/PhytoSph|OH}}</small><br />
| <small>{{LBS/6HSph|OH}}</small><br />
|-<br />
! '''Source 分布'''<br />
| Major in mammals<br />
| Major in mammals<br />
| Major in fungi and plant<br />
| Found in skin<br />
|}<br />
<br />
==Long-chain base 長鎖塩基==<br />
<br />
{{Twocolumn|<br />
The structural variation of LCB depends on biological species.<ref>Merrill AH "Sphingolipid and Glycosphingolipid Metabolic Pathways in the Era of Sphingolipidomics" Chem. Rev. 2011 111:6387–6422. PMID 21942574</ref><br />
|生物種によってLCBの構造は大きく異なります。<br />
}}<br />
<br />
{| class="wikitable"<br />
! Classification || Long-chain base<br />
|-<br />
| Mammalia || sphingosine (= (4E)-d18:1)<br/> (4E)-d20:1 (nerve tissue), t18:0 (intestine)<br />
|-<br />
| Arthropoda || short-chain sphingosine (d14:1, d16:1) <ref>Guan XL, Cestra G, Shui G, Kuhrs A, Schittenhelm RB, Hafen E, van der Goot FG, Robinett CC, Gatti M, Gonzalez-Gaitan M, Wenk MR "Biochemical membrane lipidomics during Drosophila development" Dev Cell 2013 24:98-111. PMID 23260625</ref><br />
|-<br />
| Plantae || (8E/Z)-d18:1, (8E/Z)-t18:1, (4E,8E/Z)-d18:2<br />
|-<br />
| Fungi || 9-methyl (4E,8E)-d18:2, t18:0<br />
|}<br />
<br />
<br />
===Bioactivity===<br />
{{Twocolumn|<br />
* Free LCB induces apoptosis.<ref>Hung WC, Chang HC, Chuang LY "Activation of caspase-3-like proteases in apoptosis induced by sphingosine and other long-chain bases in Hep3B hepatoma cells" Biochem J. 1999 338:161-166. PMID 9931312</ref><br />
* Sphingosine 1-phosphate is a lipid mediator of cell proliferation and motility control.<ref>Takabe K, Spiegel S."Export of sphingosine-1-phosphate and cancer progression"J Lipid Res. 2014 55:1839-46. PMID 24474820</ref><br />
|<br />
* 遊離のLCBはアポトーシスを惹起します。<br />
* スフィンゴシン 1リン酸 (Sph-1-P) は脂質メディエータとして細胞増殖や運動制御に働きます。<br />
}}<br />
<br />
<references/><br />
<br />
==Ceramide セラミド==<br />
<br />
{{Twocolumn|<br />
The conjugated fatty acids are often length 16 to 26. In normal tissues, little ceramide exists as an intermediate of phospho- and glycosphingolipid, whereas in the skin (corneocyte), ceramides and fatty-acid conjugated acyl-ceramides dominates and exhibit the barrier function.<br />
| セラミドに結合する脂肪酸の炭素鎖長は16から26が多く、通常組織ではスフィンゴリン脂質やスフィンゴ糖脂質の中間体として少量存在します。皮膚の角質層にはセラミドに更に脂肪酸が結合したアシルセラミドがあり、皮膚のバリア機能を担います。<br />
}}<br />
<br />
===Composition===<br />
{| class="wikitable"<br />
|-<br />
!rowspan="2"| Species<br />
!colspan="3"| Glycosylceramide<br />
!colspan="3"| Glycosyl inositol phosphoceramide (GIPC)<br />
|-<br />
! Fatty acid<br />
! Long chain base<br />
! References<br />
! Fatty acid<br />
! Long chain base<br />
! References<br />
|-<br />
!Plants<br />
| 16:0 - 26:0<br/>16:1 - 26:1<br/>16:0<br/>VLCFA<br />
| d18:2&Delta;4E8E/Z<br/>d18:2&Delta;4E8E/Z<br/>d18:1&Delta;8E/Z<br/>t18:1&Delta;8E/Z<br />
| <ref name=Mark>Markham JE, Lynch DV, Napier JA, Dunn TM, Cahoon EB. "Plant sphingolipids: function follows form" Curr Opin Plant Biol. 2013 16: 350-7. PMID 23499054</ref><ref name="War">Warnecke D, Heinz E."Recently discovered functions of glucosylceramides in plants and fungi" Cell Mol Life Sci. 2003 60:919-41.PMID 12827281</ref><br/><ref name="Mark"/><ref name="War"/><br/><ref name="Mark"/><br/><ref name="Mark"/><ref name="War"/><br />
| VLCFA<br/>14:0 - 26:0<br/>20:1 - 26:1<br />
| t18:1&Delta;8E/Z<br/>t18:1&Delta;8E/Z, t18:0<br/>t18:1&Delta;8E/Z, t18:0<br />
| <ref name="Mark"/><br/><ref name="Bure">Buré C, Cacas JL, Mongrand S, Schmitter JM. "Characterization of glycosyl inositol phosphoryl ceramides from plants and fungi by mass spectrometry" Anal Bioanal Chem. 2013 406:995-1010 PMID 23887274</ref><br/><ref name="Mark"/><ref name="Bure"/><br />
|-<br />
!Fungi<br />
| 16:0 - 18:0<br/>16:1 - 18:1<br />
| 9-methyl d18:2&Delta;4E,8E<br/>9-methyl d18:2&Delta;4E,8E<br />
| <ref name="Nim">Nimrichter L, Rodrigues ML. "Fungal glucosylceramides: from structural components to biologically active targets of new antimicrobials" Front Microbiol. 2011 2:212.PMID 22025918</ref><ref name="War"/><br/><ref name="Nim"/><ref name="War"/><br />
| 24:0 - 26:0<br/>24:1 - 26:1<br/>16:0 - 26:0<br />
| t18:0<br/>t18:0<br/>t18:0, t20:0<br />
| <ref name="Nim"/><br/><ref name="War"/><br/><ref name="War"/><ref name="Bure"/><br />
|}<br />
<br />
===Bioactivity===<br />
<br />
{{Twocolumn|<br />
* Atopic dermatitis (and dry skin) is associated with a decrease and compositional change of ceramides.<ref>Macheleidt O, Kaiser HW, Sandhoff K "Deficiency of epidermal protein-bound omega-hydroxyceramides in atopic dermatitis" J Invest Dermatol. 2002 119:166-173. PMID 12164940</ref><br />
* Ceramides involve in cell proliferation and autophagy, and ceramide 1-phosphate functions as a lipid mediator.<ref>Young MM, Kester M, Wang HG "Sphingolipids: regulators of crosstalk between apoptosis and autophagy" J Lipid Res.2013 54:5-19. PMID 23152582</ref><br />
|<br />
* アトピー性皮膚炎や乾燥肌ではセラミド量が減少し、組成も変化しています。<br />
* 通常細胞内ではLCBと同様に細胞増殖やオートファジーに関与し、セラミド末端にリン酸が結合した Cer-1-P も脂質メディエータとして働きます。<br />
}}<br />
<br />
<br />
<references/><br />
<br />
===Metabolism===<br />
<br />
[[:Category:LBS/Biosynthesis|Metabolism, Glycosphingolipid in Plant and Fungi]]</div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Category:LB&diff=117188
Category:LB
2023-11-29T06:04:18Z
<p>Editor: </p>
<hr />
<div>{{Huge|LipidBank Database}}<br />
{{LB/Header}}<br />
{{Twocolumn|<br />
LipidBank Database is an official data resource of [https://web.jcbl.jp/ JCBL] (Japanese Conference of Biochemistry of Lipids).<br />
Database contents are curated by [[JCBL:DBmeeting|a committee under JCBL]]. For citing this resource, please use the following information.<br />
|<br />
LipidBankデータベースは [https://web.jcbl.jp/ 日本脂質生化学会] の公式データベースです。内容はJCBLの[[JCBL:DBmeeting|構築委員会]]によって管理されています。<br />
引用される場合は以下の文献を利用してください。<br />
}}<br />
; References<br />
* History: Yasugi E, Seyama Y "Lipid database "LipidBank" and international collaboration" Tanpakushitsu Kakusan Koso. 52(11), 1357-1362, 2007 (in Japanese; 日本語)<br />
* Usage: Yasugi E, Watanabe K "LIPIDBANK for Web, the newly developed lipid database" Tanpakushitsu Kakusan Koso. 47(7), 837-841, 2002 (in Japanese; 日本語)<br />
* Glycolipid: Watanabe K., Yasugi E. and Oshima M. "How to search the glycolipid data in LIPIDBANK for Web: the newly developed lipid database" Japan Trend Glycosci. and Glycotechnol. 12, 175-184, 2000<br />
* LipidBank History & Committee page [[JCBL:DBmeeting]]<br />
<br />
; Related projects<br />
* [https://lipidbank.jp/ Original LipidBank classification]<br />
* [[Lipoquality:Database|LipoQuality Database]]<br />
<br />
<center><br />
{| class="wikitable"<br />
|-<br />
! colspan="3" | LipidBank Class Overview<br />
|-<br />
| align="left" style="vertical-align:top" width=33%|<br />
[[:Category:LBF|LBF: Fatty acyls <br><small>脂肪酸アシル</small>]] <br />
<br>[[Image:LBF.png|100px]]<br><br />
<br />
;Links to the original LipidBank<br />
:[https://lipidbank.jp/DFA.html fatty acids]<br />
:[https://lipidbank.jp/DLL.html long-chain alcohol]<br />
:[https://lipidbank.jp/DLD.html long-chain aldehyde]<br />
:[https://lipidbank.jp/XPR.html eicosanoids]<br />
:[https://lipidbank.jp/OPO.html lipid peroxide]<br />
:[https://lipidbank.jp/WWA.html wax]<br />
:[https://lipidbank.jp/MMA.html mycolic acid]<br />
<br />
<br />
| align="left" style="vertical-align:top" width=33%|<br />
[[:Category:LBG|LBG: Glycerolipids<br><small>グリセロ脂質</small>]]<br />
<br>[[Image:LBG.png|100px]]<br><br />
<br />
;Links to the original LipidBank<br />
:[https://lipidbank.jp/NAG.html acylglycerols]<br />
:[https://lipidbank.jp/PGP.html glycerophospholipid]<br />
:[https://lipidbank.jp/EEA.html ether-type lipid]<br />
:[https://lipidbank.jp/GGG.html glycoglycerolipid]<br />
* [[:Category:LBGA|LBGA: Archaeal Lipid (Ether-type)<br/><small>古細菌の脂質</small>]] <br />
<br />
| align="left" style="vertical-align:top" width=33%|<br />
[[:Category:LBS|LBS: Sphingolipids<br><small>スフィンゴ脂質</small>]] (new)<br />
<br>[[Image:LBS.png|110px]]<br><br />
<br />
* [[:Category:LBSB|LBSB: long-chain base and ceramide]]<br />
* [[:Category:LBSC|LBSC: cerebroside]]<br />
* [[:Category:LBSG|LBSG: acidic glycosphingolipid]]<br />
* [[:Category:LBSP|LBSP: phospho-sphingolipid]]<br />
<br />
|-<br />
| style="vertical-align:top"| Sterol Lipids<br />
<br/>[[File:Cholestane.png]]<br/><br />
;Links to the original LipidBank<br />
:[https://lipidbank.jp/SST.html steroid]<br />
:[https://lipidbank.jp/BBA.html bile acid]<br />
:[https://lipidbank.jp/VVD.html vitamin D]<br />
<br />
<br />
| style="vertical-align:top"| Prenol Lipids<br />
<br/><BIG>(</BIG> [[File:Isoprene.png]]<BIG>)</BIG><sub>n</sub><br/><br />
;Links to the original LipidBank<br />
:[https://lipidbank.jp/IIP.html isoprenoid]<br />
:[https://lipidbank.jp/VCA.html carotenoid]<br />
:[https://lipidbank.jp/VVA.html vitamin A]<br />
:[https://lipidbank.jp/VVK.html vitamin K]<br />
:[https://lipidbank.jp/VCQ.html coenzyme Q]<br />
<br />
<br />
| style="vertical-align:top"| Others<br />
<br />
;Links to the original LipidBank<br />
:[https://lipidbank.jp/CLS.html lipopolysaccharide]<br />
:[https://lipidbank.jp/ALA.html lipoamino acid]<br />
:[https://lipidbank.jp/TLP.html lipoprotein]<br />
:[https://lipidbank.jp/VVE.html vitamin E]<br />
:[https://lipidbank.jp/NAG.html acylglycerols]<br />
<br />
|}<br />
</center><br />
<br />
{{Twocolumn|<br />
Biogenic substances insoluble to water are collectively called as '''lipid'''. Lipid is generally classified into the following three types.<br />
* '''Simple lipid''' ... fatty acid esters of alchohol such as glycerol and sphingoid base.<br />
* '''Complex lipid''' ... glycosylated or phosphorylated version of the simple lipid.<br />
* '''Derived lipid''' ... alcohols and fatty acids derived by hydrolyzing the simple lipid. Also includes sterols and polyketides.<br />
|<br />
水に溶けない生体成分を一般に脂質と呼び、以下の3つに分けられます。<br />
* '''単純脂質''' ... アルコールと脂肪酸のエステルで、スフィンゴ骨格とグリセロ骨格のものに大別されます。<br />
* '''複合脂質''' ... 単純脂質にリン酸や糖がついたものです。<br />
* '''誘導脂質''' ... 単純脂質を分解して得られるアルコール、脂肪酸。ステロールやポリケチドもここに含めます。<br />
}}<br />
<br />
<br />
<!---- Class Information (Do not delete)<br />
&&LB&&Lipid<br />
&&LBS&&Sphingolipid<br />
&&LBSB&&Sphingoid base<br />
&&LBSR&&Ceramide<br />
&&LBSG&&Glycosphingolipid<br />
&&LBSP&&Phosphosphingolipid<br />
&&LBG&&Glycerolipid<br />
&&LBGG&&Glycoglycerolipid<br />
&&LBGP&&Phosphoglycerolipid<br />
<br />
&&LBF&&Fatty Acyl<br />
<br />
&&LBFA&&Fatty Acyl<br />
&&LBFA01&&Fatty Acids and Conjugates<br />
&&LBFA0101&&Straight chain fatty acids<br />
&&LBFA0102&&Methyl branched fatty acids<br />
&&LBFA0103&&Unsaturated fatty acids<br />
&&LBFA0104&&Hydroperoxy fatty acids<br />
&&LBFA0105&&Hydroxy fatty acids<br />
&&LBFA0106&&Oxo fatty acids<br />
&&LBFA0107&&Epoxy fatty acids<br />
&&LBFA0108&&Methoxy fatty acids<br />
&&LBFA0109&&Halogenated fatty acids<br />
&&LBFA0110&&Amino fatty acids<br />
&&LBFA0111&&Cyano fatty acids<br />
&&LBFA0112&&Nitro fatty acids<br />
&&LBFA0113&&Thia fatty acids<br />
&&LBFA0114&&Carbocyclic fatty acids<br />
&&LBFA0115&&Heterocyclic fatty acids<br />
&&LBFA0116&&Mycolic acids<br />
&&LBFA0117&&Dicarboxylic acids<br />
&&LBFA02&&Octadecanoids<br />
&&LBFA0201&&12-oxophytodienoic acid metabolites<br />
&&LBFA0202&&jasmonic acids<br />
&&LBFA03&&Eicosanoids<br />
&&LBFA0301&&Prostaglandins<br />
&&LBFA0302&&Leukotrienes<br />
&&LBFA0303&&Thromboxanes<br />
&&LBFA0304&&Lipoxins<br />
&&LBFA0305&&Hydroxyeicosatrienoic acids<br />
&&LBFA0306&&Hydroxyeicosatetraenoic acids<br />
&&LBFA0307&&Hydroxyeicosapentaenoic acids<br />
&&LBFA0308&&Epoxyeicosatetraenoic acids<br />
&&LBFA0309&&Hepoxilins<br />
&&LBFA0310&&Levuglandins<br />
&&LBFA0311&&Isoprostanes<br />
&&LBFA0312&&Clavulones<br />
&&LBFA04&&Docosanoids<br />
&&LBFA05&&Fatty alcohols<br />
&&LBFA06&&Fatty aldehydes<br />
&&LBFA07&&Fatty esters<br />
&&LBFA0701&&Wax monoesters<br />
&&LBFA0702&&Wax diesters<br />
&&LBFA0703&&Cyano esters<br />
&&LBFA0704&&Lactones<br />
&&LBFA0705&&Fatty acyl CoAs<br />
&&LBFA0706&&Fatty acyl ACPs<br />
&&LBFA0707&&Fatty acyl carnitines<br />
&&LBFA0708&&Fatty acyl adenylates<br />
&&LBFA08&&Fatty amides<br />
&&LBFA0801&&Primary amides<br />
&&LBFA0802&&N-acyl amides<br />
&&LBFA0803&&Fatty acyl homoserine lactones<br />
&&LBFA0804&&N-acyl ethanolamides (endocannabinoids)<br />
&&LBFA09&&Fatty nitriles<br />
&&LBFA10&&Fatty ethers<br />
&&LBFA11&&Hydrocarbons<br />
&&LBFA12&&Oxygenated hydrocarbons<br />
&&LBFA00&&Other<br />
&&LBGL&&Glycerolipids<br />
&&LBGL01&&Monoradylglycerols<br />
&&LBGL0101&&Monoacylglycerols<br />
&&LBGL0102&&Monoalkylglycerols<br />
&&LBGL0103&&Mono-(1Z-alkenyl)-glycerols<br />
&&LBGL0104&&Monoacylglycerolglycosides<br />
&&LBGL0105&&Monoalkylglycerolglycosides<br />
&&LBGL02&&Diradylglycerols<br />
&&LBGL0201&&Diacylglycerols<br />
&&LBGL0202&&Alkylacylglycerols<br />
&&LBGL0203&&Dialkylglycerols<br />
&&LBGL0204&&1Z-alkenylacylglycerols<br />
&&LBGL0205&&Diacylglycerolglycosides<br />
&&LBGL0206&&Alkylacylglycerolglycosides<br />
&&LBGL0207&&Dialkylglycerolglycosides<br />
&&LBGL0208&&Di-glycerol tetraethers<br />
&&LBGL0209&&Di-glycerol tetraether glycans<br />
&&LBGL03&&Triradylglycerols<br />
&&LBGL0301&&Triacylglycerols<br />
&&LBGL0302&&Alkyldiacylglycerols<br />
&&LBGL0303&&Dialkylmonoacylglycerols<br />
&&LBGL0304&&1Z-alkenyldiacylglycerols<br />
&&LBGL0305&&Estolides<br />
&&LBGL00&&Other<br />
&&LBGP&&Glycerophospholipids<br />
&&LBGP01&&Glycerophosphocholines<br />
&&LBGP0101&&Diacylglycerophosphocholines<br />
&&LBGP0102&&1-alkyl,2-acylglycerophosphocholines<br />
&&LBGP0103&&1Z-alkenyl,2-acylglycerophosphocholines<br />
&&LBGP0104&&Dialkylglycerophosphocholines<br />
&&LBGP0105&&Monoacylglycerophosphocholines<br />
&&LBGP0106&&1-alkyl glycerophosphocholines<br />
&&LBGP0107&&1Z-alkenylglycerophosphocholines<br />
&&LBGP02&&Glycerophosphoethanolamines<br />
&&LBGP0201&&Diacylglycerophosphoethanolamines<br />
&&LBGP0202&&1-alkyl,2-acylglycerophosphoethanolamines<br />
&&LBGP0203&&1Z-alkenyl,2-acylglycerophosphoethanolamines<br />
&&LBGP0204&&Dialkylglycerophosphoethanolamines<br />
&&LBGP0205&&Monoacylglycerophosphoethanolamines<br />
&&LBGP0206&&1-alkyl glycerophosphoethanolamines<br />
&&LBGP0207&&1Z-alkenylglycerophosphoethanolamines<br />
&&LBGP03&&Glycerophosphoserines<br />
&&LBGP0301&&Diacylglycerophosphoserines<br />
&&LBGP0302&&1-alkyl,2-acylglycerophosphoserines<br />
&&LBGP0303&&1Z-alkenyl,2-acylglycerophosphoserines<br />
&&LBGP0304&&Dialkylglycerophosphoserines<br />
&&LBGP0305&&Monoacylglycerophosphoserines<br />
&&LBGP0306&&1-alkyl glycerophosphoserines<br />
&&LBGP0307&&1Z-alkenylglycerophosphoserines<br />
&&LBGP04&&Glycerophosphoglycerols<br />
&&LBGP0401&&Diacylglycerophosphoglycerols<br />
&&LBGP0402&&1-alkyl,2-acylglycerophosphoglycerols<br />
&&LBGP0403&&1Z-alkenyl,2-acylglycerophosphoglycerols<br />
&&LBGP0404&&Dialkylglycerophosphoglycerols<br />
&&LBGP0405&&Monoacylglycerophosphoglycerols<br />
&&LBGP0406&&1-alkyl glycerophosphoglycerols<br />
&&LBGP0407&&1Z-alkenylglycerophosphoglycerols<br />
&&LBGP0408&&Diacylglycerophosphodiradylglycerols<br />
&&LBGP0409&&Diacylglycerophosphomonoradylglycerols<br />
&&LBGP0410&&Monoacylglycerophosphomonoradylglycerols<br />
&&LBGP05&&Glycerophosphoglycerophosphates<br />
&&LBGP0501&&Diacylglycerophosphoglycerophosphates<br />
&&LBGP0502&&1-alkyl,2-acylglycerophosphoglycerophosphates<br />
&&LBGP0503&&1Z-alkenyl,2-acylglycerophosphoglycerophosphates<br />
&&LBGP0504&&Dialkylglycerophosphoglycerophosphates<br />
&&LBGP0505&&Monoacylglycerophosphoglycerophosphates<br />
&&LBGP0506&&1-alkyl glycerophosphoglycerophosphates<br />
&&LBGP0507&&1Z-alkenylglycerophosphoglycerophosphates<br />
&&LBGP06&&Glycerophosphoinositols<br />
&&LBGP0601&&Diacylglycerophosphoinositols<br />
&&LBGP0602&&1-alkyl,2-acylglycerophosphoinositols<br />
&&LBGP0603&&1Z-alkenyl,2-acylglycerophosphoinositols<br />
&&LBGP0604&&Dialkylglycerophosphoinositols<br />
&&LBGP0605&&Monoacylglycerophosphoinositols<br />
&&LBGP0606&&1-alkyl glycerophosphoinositols<br />
&&LBGP0607&&1Z-alkenylglycerophosphoinositols<br />
&&LBGP07&&Glycerophosphoinositol monophosphates<br />
&&LBGP0701&&Diacylglycerophosphoinositol monophosphates<br />
&&LBGP0702&&1-alkyl,2-acylglycerophosphoinositol monophosphates<br />
&&LBGP0703&&1Z-alkenyl,2-acylglycerophosphoinositol monophosphates<br />
&&LBGP0704&&Dialkylglycerophosphoinositol monophosphates<br />
&&LBGP0705&&Monoacylglycerophosphoinositol monophosphates<br />
&&LBGP0706&&1-alkyl glycerophosphoinositol monophosphates<br />
&&LBGP0707&&1Z-alkenylglycerophosphoinositol monophosphates<br />
&&LBGP08&&Glycerophosphoinositol bisphosphates<br />
&&LBGP0801&&Diacylglycerophosphoinositol bisphosphates<br />
&&LBGP0802&&1-alkyl,2-acylglycerophosphoinositol bisphosphates<br />
&&LBGP0803&&1Z-alkenyl,2-acylglycerophosphoinositol bisphosphates<br />
&&LBGP0804&&Monoacylglycerophosphoinositol bisphosphates<br />
&&LBGP0805&&1-alkyl glycerophosphoinositol bisphosphates<br />
&&LBGP0806&&1Z-alkenylglycerophosphoinositol bisphosphates<br />
&&LBGP09&&Glycerophosphoinositol trisphosphates<br />
&&LBGP0901&&Diacylglycerophosphoinositol trisphosphates<br />
&&LBGP0902&&1-alkyl,2-acylglycerophosphoinositol trisphosphates<br />
&&LBGP0903&&1Z-alkenyl,2-acylglycerophosphoinositol trisphosphates<br />
&&LBGP0904&&Monoacylglycerophosphoinositol trisphosphates<br />
&&LBGP0905&&1-alkyl glycerophosphoinositol trisphosphates<br />
&&LBGP0906&&1Z-alkenylglycerophosphoinositol trisphosphates<br />
&&LBGP10&&Glycerophosphates<br />
&&LBGP1001&&Diacylglycerophosphates<br />
&&LBGP1002&&1-alkyl,2-acylglycerophosphates<br />
&&LBGP1003&&1Z-alkenyl,2-acylglycerophosphates<br />
&&LBGP1004&&Dialkylglycerophosphates<br />
&&LBGP1005&&Monoacylglycerophosphates<br />
&&LBGP1006&&1-alkyl glycerophosphates<br />
&&LBGP1007&&1Z-alkenylglycerophosphates<br />
&&LBGP11&&Glyceropyrophosphates<br />
&&LBGP1101&&Diacylglyceropyrophosphates<br />
&&LBGP1102&&Monoacylglyceropyrophosphates<br />
&&LBGP12&&Glycerophosphoglycerophosphoglycerols (Cardiolipins)<br />
&&LBGP1201&&Diacylglycerophosphoglycerophosphodiradylglycerols<br />
&&LBGP1202&&Diacylglycerophosphoglycerophosphomonoradylglycerols<br />
&&LBGP1203&&1-alkyl,2-acylglycerophosphoglycerophosphodiradylglycerols<br />
&&LBGP1204&&1-alkyl,2-acylglycerophosphoglycerophosphomonoradylglycerols<br />
&&LBGP1205&&1Z-alkenyl,2-acylglycerophosphoglycerophosphodiradylglycerols<br />
&&LBGP1206&&1Z-alkenyl,2-acylglycerophosphoglycerophosphomonoradylglycerols<br />
&&LBGP1207&&Monoacylglycerophosphoglycerophosphomonoradylglycerols<br />
&&LBGP1208&&1-alkyl glycerophosphoglycerophosphodiradylglycerols<br />
&&LBGP1209&&1-alkyl glycerophosphoglycerophosphomonoradylglycerols<br />
&&LBGP1210&&1Z-alkenylglycerophosphoglycerophosphodiradylglycerols<br />
&&LBGP1211&&1Z-alkenylglycerophosphoglycerophosphomonoradylglycerols<br />
&&LBGP13&&CDP-Glycerols<br />
&&LBGP1301&&CDP-diacylglycerols<br />
&&LBGP1302&&CDP-1-alkyl,2-acylglycerols<br />
&&LBGP1303&&CDP-1Z-alkenyl,2-acylglycerols<br />
&&LBGP1304&&CDP-Dialkylglycerols<br />
&&LBGP1305&&CDP-Monoacylglycerols<br />
&&LBGP1306&&CDP-1-alkyl glycerols<br />
&&LBGP1307&&CDP-1Z-alkenylglycerols<br />
&&LBGP14&&Glycerophosphoglucose lipids<br />
&&LBGP1401&&Diacylglycerophosphoglucose lipids<br />
&&LBGP1402&&1-alkyl,2-acylglycerophosphoglucose lipids<br />
&&LBGP1403&&1Z-alkenyl,2-acylglycerophosphoglucose lipids<br />
&&LBGP1404&&Monoacylglycerophosphoglucose lipids<br />
&&LBGP1405&&1-alkyl glycerophosphoglucose lipids<br />
&&LBGP1406&&1Z-alkenylglycerophosphoglucose lipids<br />
&&LBGP15&&Glycerophosphoinositolglycans<br />
&&LBGP1501&&Diacylglycerophosphoinositolglycans<br />
&&LBGP1502&&1-alkyl,2-acylglycerophosphoinositolglycans<br />
&&LBGP1503&&1Z-alkenyl,2-acylglycerophosphoinositolglycans<br />
&&LBGP1504&&Monoacylglycerophosphoinositolglycans<br />
&&LBGP1505&&1-alkyl glycerophosphoinositolglycans<br />
&&LBGP1506&&1Z-alkenylglycerophosphoinositolglycans<br />
&&LBGP16&&Glycerophosphonocholines<br />
&&LBGP1601&&Diacylglycerophosphonocholines<br />
&&LBGP1602&&1-alkyl,2-acylglycerophosphonocholines<br />
&&LBGP1603&&1Z-alkenyl,2-acylglycerophosphonocholines<br />
&&LBGP1604&&Dialkylglycerophosphonocholines<br />
&&LBGP1605&&Monoacylglycerophosphonocholines<br />
&&LBGP1606&&1-alkyl glycerophosphonocholines<br />
&&LBGP1607&&1Z-alkenylglycerophosphonocholines<br />
&&LBGP17&&Glycerophosphonoethanolamines<br />
&&LBGP1701&&Diacylglycerophosphonoethanolamines<br />
&&LBGP1702&&1-alkyl,2-acylglycerophosphonoethanolamines<br />
&&LBGP1703&&1Z-alkenyl,2-acylglycerophosphonoethanolamines<br />
&&LBGP1704&&Dialkylglycerophosphonoethanolamines<br />
&&LBGP1705&&Monoacylglycerophosphonoethanolamines<br />
&&LBGP1706&&1-alkyl glycerophosphonoethanolamines<br />
&&LBGP1707&&1Z-alkenylglycerophosphonoethanolamines<br />
&&LBGP18&&Di-glycerol tetraether phospholipids (caldarchaeols)<br />
&&LBGP19&&Glycerol-nonitol tetraether phospholipids<br />
&&LBGP20&&Oxidized glycerophospholipids<br />
&&LBGP00&&Other<br />
&&LBSP&&Sphingolipids<br />
&&LBSP01&&Sphingoid bases<br />
&&LBSP0101&&Sphing-4-enines (Sphingosines)<br />
&&LBSP0102&&Sphinganines<br />
&&LBSP0103&&4-Hydroxysphinganines (Phytosphingosines)<br />
&&LBSP0104&&Sphingoid base homologs and variants<br />
&&LBSP0105&&Sphingoid base 1-phosphates<br />
&&LBSP0106&&Lysosphingomyelins and lysoglycosphingolipids<br />
&&LBSP0107&&N-methylated sphingoid bases<br />
&&LBSP0108&&Sphingoid base analogs<br />
&&LBSP02&&Ceramides<br />
&&LBSP0201&&N-acylsphingosines (ceramides)<br />
&&LBSP0202&&N-acylsphinganines (dihydroceramides)<br />
&&LBSP0203&&N-acyl-4-hydroxysphinganines (phytoceramides)<br />
&&LBSP0204&&Acylceramides<br />
&&LBSP0205&&Ceramide 1-phosphates<br />
&&LBSP03&&Phosphosphingolipids<br />
&&LBSP0301&&Ceramide phosphocholines (sphingomyelins)<br />
&&LBSP0302&&Ceramide phosphoethanolamines<br />
&&LBSP0303&&Ceramide phosphoinositols<br />
&&LBSP04&&Phosphonosphingolipids<br />
&&LBSP05&&Neutral glycosphingolipids<br />
&&LBSP0501&&Simple Glc series (GlcCer, LacCer, etc)<br />
&&LBSP0502&&GalNAcb1-3Gala1-4Galb1-4Glc- (Globo series)<br />
&&LBSP0503&&GalNAcb1-4Galb1-4Glc- (Ganglio series)<br />
&&LBSP0504&&Galb1-3GlcNAcb1-3Galb1-4Glc- (Lacto series)<br />
&&LBSP0505&&Galb1-4GlcNAcb1-3Galb1-4Glc- (Neolacto series)<br />
&&LBSP0506&&GalNAcb1-3Gala1-3Galb1-4Glc- (Isoglobo series)<br />
&&LBSP0507&&GlcNAcb1-2Mana1-3Manb1-4Glc- (Mollu series)<br />
&&LBSP0508&&GalNAcb1-4GlcNAcb1-3Manb1-4Glc- (Arthro series)<br />
&&LBSP0509&&Gal- (Gala series)<br />
&&LBSP0510&&Other<br />
&&LBSP06&&Acidic glycosphingolipids<br />
&&LBSP0601&&Gangliosides<br />
&&LBSP0602&&Sulfoglycosphingolipids (sulfatides)<br />
&&LBSP0603&&Glucuronosphingolipids<br />
&&LBSP0604&&Phosphoglycosphingolipids<br />
&&LBSP0600&&Other<br />
&&LBSP07&&Basic glycosphingolipids<br />
&&LBSP08&&Amphoteric glycosphingolipids<br />
&&LBSP09&&Arsenosphingolipids<br />
&&LBSP00&&Other<br />
&&LBST&&Sterol Lipids<br />
&&LBST01&&Sterols<br />
&&LBST0101&&Cholesterol and derivatives<br />
&&LBST0102&&Cholesteryl esters<br />
&&LBST0103&&Phytosterols and derivatives<br />
&&LBST0104&&Marine sterols and derivatives<br />
&&LBST0105&&Fungal sterols and derivatives<br />
&&LBST02&&Steroids<br />
&&LBST0201&&C18 steroids (estrogens) and derivatives<br />
&&LBST0202&&C19 steroids (androgens) and derivatives<br />
&&LBST0203&&C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives<br />
&&LBST03&&Secosteroids<br />
&&LBST0301&&Vitamin D2 and derivatives<br />
&&LBST0302&&Vitamin D3 and derivatives<br />
&&LBST04&&Bile acids and derivatives<br />
&&LBST0401&&C24 bile acids, alcohols, and derivatives<br />
&&LBST0402&&C26 bile acids, alcohols, and derivatives<br />
&&LBST0403&&C27 bile acids, alcohols, and derivatives<br />
&&LBST0404&&C28 bile acids, alcohols, and derivatives<br />
&&LBST0405&&C22 bile acids, alcohols, and derivatives<br />
&&LBST0406&&C23 bile acids, alcohols, and derivatives<br />
&&LBST0407&&C25 bile acids, alcohols, and derivatives<br />
&&LBST0408&&C29 bile acids, alcohols, and derivatives<br />
&&LBST05&&Steroid conjugates<br />
&&LBST0501&&Glucuronides<br />
&&LBST0502&&Sulfates<br />
&&LBST0503&&Glycine conjugates<br />
&&LBST0504&&Taurine conjugates<br />
&&LBST06&&Hopanoids<br />
&&LBST00&&Other<br />
&&LBPR&&Prenol Lipids<br />
&&LBPR01&&Isoprenoids<br />
&&LBPR0101&&C5 isoprenoids<br />
&&LBPR0102&&C10 isoprenoids (monoterpenes)<br />
&&LBPR0103&&C15 isoprenoids (sesquiterpenes)<br />
&&LBPR0104&&C20 isoprenoids (diterpenes)<br />
&&LBPR0105&&C25 isoprenoids (sesterterpenes)<br />
&&LBPR0106&&C30 isoprenoids (triterpenes)<br />
&&LBPR0107&&C40 isoprenoids (tetraterpenes)<br />
&&LBPR0108&&Polyterpenes<br />
&&LBPR02&&Quinones and hydroquinones<br />
&&LBPR0201&&Ubiquinones<br />
&&LBPR0202&&Vitamin E<br />
&&LBPR0203&&Vitamin K<br />
&&LBPR03&&Polyprenols<br />
&&LBPR0301&&Bactoprenols<br />
&&LBPR0302&&Bactoprenol monophosphates<br />
&&LBPR0303&&Bactoprenol diphosphates<br />
&&LBPR0304&&Phytoprenols<br />
&&LBPR0305&&Phytoprenol monophosphates<br />
&&LBPR0306&&Phytoprenol diphosphates<br />
&&LBPR0307&&Dolichols<br />
&&LBPR0308&&Dolichol monophosphates<br />
&&LBPR0309&&Dolichol diphosphates<br />
&&LBPR00&&Other<br />
&&LBSL&&Saccharolipids<br />
&&LBSL01&&Acylaminosugars<br />
&&LBSL0101&&Monoacylaminosugars<br />
&&LBSL0102&&Diacylaminosugars<br />
&&LBSL0103&&Triacylaminosugars<br />
&&LBSL0104&&Tetraacylaminosugars<br />
&&LBSL0105&&Pentaacylaminosugars<br />
&&LBSL0106&&Hexaacylaminosugars<br />
&&LBSL0107&&Heptaacylaminosugars<br />
&&LBSL02&&Acylaminosugar glycans<br />
&&LBSL03&&Acyltrehaloses<br />
&&LBSL04&&Acyltrehalose glycans<br />
&&LBSL00&&Other<br />
&&LBPK&&Polyketides<br />
&&LBPK01&&Macrolide polyketides<br />
&&LBPK02&&Aromatic polyketides<br />
&&LBPK03&&Non-ribosomal peptide/polyketide hybrids<br />
&&LBPK00&&Other<br />
---></div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Category:LB&diff=117187
Category:LB
2023-11-29T05:33:42Z
<p>Editor: </p>
<hr />
<div>{{Huge|LipidBank Database}}<br />
{{LB/Header}}<br />
{{Twocolumn|<br />
LipidBank Database is an official data resource of [https://web.jcbl.jp/ JCBL] (Japanese Conference of Biochemistry of Lipids).<br />
Database contents are curated by [[JCBL:DBmeeting|a committee under JCBL]]. For citing this resource, please use the following information.<br />
|<br />
LipidBankデータベースは [https://web.jcbl.jp/ 日本脂質生化学会] の公式データベースです。内容はJCBLの[[JCBL:DBmeeting|構築委員会]]によって管理されています。<br />
引用される場合は以下の文献を利用してください。<br />
}}<br />
; References<br />
* History: Yasugi E, Seyama Y "Lipid database "LipidBank" and international collaboration" Tanpakushitsu Kakusan Koso. 52(11), 1357-1362, 2007 (in Japanese; 日本語)<br />
* Usage: Yasugi E, Watanabe K "LIPIDBANK for Web, the newly developed lipid database" Tanpakushitsu Kakusan Koso. 47(7), 837-841, 2002 (in Japanese; 日本語)<br />
* Glycolipid: Watanabe K., Yasugi E. and Oshima M. "How to search the glycolipid data in LIPIDBANK for Web: the newly developed lipid database" Japan Trend Glycosci. and Glycotechnol. 12, 175-184, 2000<br />
* LipidBank History & Committee page [[JCBL:DBmeeting]]<br />
<br />
; Related projects<br />
* [https://lipidbank.jp/ Original LipidBank Database]<br />
* [[Lipoquality:Database|LipoQuality Database]]<br />
<br />
<center><br />
{| class="wikitable"<br />
|-<br />
! colspan="3" | LipidBank Class Overview<br />
|-<br />
| align="left" style="vertical-align:top" width=33%|<br />
[[:Category:LBF|LBF: Fatty acyls <br><small>脂肪酸アシル</small>]] <br />
<br>[[Image:LBF.png|100px]]<br><br />
<br />
;Links to the original LipidBank<br />
:[https://lipidbank.jp/DFA.html fatty acids]<br />
:[https://lipidbank.jp/DLL.html long-chain alcohol]<br />
:[https://lipidbank.jp/DLD.html long-chain aldehyde]<br />
:[https://lipidbank.jp/XPR.html eicosanoids]<br />
:[https://lipidbank.jp/OPO.html lipid peroxide]<br />
:[https://lipidbank.jp/WWA.html wax]<br />
:[https://lipidbank.jp/MMA.html mycolic acid]<br />
<br />
<br />
| align="left" style="vertical-align:top" width=33%|<br />
[[:Category:LBG|LBG: Glycerolipids<br><small>グリセロ脂質</small>]]<br />
<br>[[Image:LBG.png|100px]]<br><br />
<br />
;Links to the original LipidBank<br />
:[https://lipidbank.jp/NAG.html acylglycerols]<br />
:[https://lipidbank.jp/PGP.html glycerophospholipid]<br />
:[https://lipidbank.jp/EEA.html ether-type lipid]<br />
:[https://lipidbank.jp/GGG.html glycoglycerolipid]<br />
* [[:Category:LBGA|LBGA: Archaeal Lipid (Ether-type)<br/><small>古細菌の脂質</small>]] <br />
<br />
| align="left" style="vertical-align:top" width=33%|<br />
[[:Category:LBS|LBS: Sphingolipids<br><small>スフィンゴ脂質</small>]] (new)<br />
<br>[[Image:LBS.png|110px]]<br><br />
<br />
* [[:Category:LBSB|LBSB: long-chain base and ceramide]]<br />
* [[:Category:LBSC|LBSC: cerebroside]]<br />
* [[:Category:LBSG|LBSG: acidic glycosphingolipid]]<br />
* [[:Category:LBSP|LBSP: phospho-sphingolipid]]<br />
<br />
|-<br />
| style="vertical-align:top"| Sterol Lipids<br />
<br/>[[File:Cholestane.png]]<br/><br />
;Links to the original LipidBank<br />
:[https://lipidbank.jp/SST.html steroid]<br />
:[https://lipidbank.jp/BBA.html bile acid]<br />
:[https://lipidbank.jp/VVD.html vitamin D]<br />
<br />
<br />
| style="vertical-align:top"| Prenol Lipids<br />
<br/><BIG>(</BIG> [[File:Isoprene.png]]<BIG>)</BIG><sub>n</sub><br/><br />
;Links to the original LipidBank<br />
:[https://lipidbank.jp/IIP.html isoprenoid]<br />
:[https://lipidbank.jp/VCA.html carotenoid]<br />
:[https://lipidbank.jp/VVA.html vitamin A]<br />
:[https://lipidbank.jp/VVK.html vitamin K]<br />
:[https://lipidbank.jp/VCQ.html coenzyme Q]<br />
<br />
<br />
| style="vertical-align:top"| Others<br />
<br />
;Links to the original LipidBank<br />
:[https://lipidbank.jp/CLS.html lipopolysaccharide]<br />
:[https://lipidbank.jp/ALA.html lipoamino acid]<br />
:[https://lipidbank.jp/TLP.html lipoprotein]<br />
:[https://lipidbank.jp/VVE.html vitamin E]<br />
:[https://lipidbank.jp/NAG.html acylglycerols]<br />
<br />
|}<br />
</center><br />
<br />
{{Twocolumn|<br />
Biogenic substances insoluble to water are collectively called as '''lipid'''. Lipid is generally classified into the following three types.<br />
* '''Simple lipid''' ... fatty acid esters of alchohol such as glycerol and sphingoid base.<br />
* '''Complex lipid''' ... glycosylated or phosphorylated version of the simple lipid.<br />
* '''Derived lipid''' ... alcohols and fatty acids derived by hydrolyzing the simple lipid. Also includes sterols and polyketides.<br />
|<br />
水に溶けない生体成分を一般に脂質と呼び、以下の3つに分けられます。<br />
* '''単純脂質''' ... アルコールと脂肪酸のエステルで、スフィンゴ骨格とグリセロ骨格のものに大別されます。<br />
* '''複合脂質''' ... 単純脂質にリン酸や糖がついたものです。<br />
* '''誘導脂質''' ... 単純脂質を分解して得られるアルコール、脂肪酸。ステロールやポリケチドもここに含めます。<br />
}}<br />
<br />
<br />
<!---- Class Information (Do not delete)<br />
&&LB&&Lipid<br />
&&LBS&&Sphingolipid<br />
&&LBSB&&Sphingoid base<br />
&&LBSR&&Ceramide<br />
&&LBSG&&Glycosphingolipid<br />
&&LBSP&&Phosphosphingolipid<br />
&&LBG&&Glycerolipid<br />
&&LBGG&&Glycoglycerolipid<br />
&&LBGP&&Phosphoglycerolipid<br />
<br />
&&LBF&&Fatty Acyl<br />
<br />
&&LBFA&&Fatty Acyl<br />
&&LBFA01&&Fatty Acids and Conjugates<br />
&&LBFA0101&&Straight chain fatty acids<br />
&&LBFA0102&&Methyl branched fatty acids<br />
&&LBFA0103&&Unsaturated fatty acids<br />
&&LBFA0104&&Hydroperoxy fatty acids<br />
&&LBFA0105&&Hydroxy fatty acids<br />
&&LBFA0106&&Oxo fatty acids<br />
&&LBFA0107&&Epoxy fatty acids<br />
&&LBFA0108&&Methoxy fatty acids<br />
&&LBFA0109&&Halogenated fatty acids<br />
&&LBFA0110&&Amino fatty acids<br />
&&LBFA0111&&Cyano fatty acids<br />
&&LBFA0112&&Nitro fatty acids<br />
&&LBFA0113&&Thia fatty acids<br />
&&LBFA0114&&Carbocyclic fatty acids<br />
&&LBFA0115&&Heterocyclic fatty acids<br />
&&LBFA0116&&Mycolic acids<br />
&&LBFA0117&&Dicarboxylic acids<br />
&&LBFA02&&Octadecanoids<br />
&&LBFA0201&&12-oxophytodienoic acid metabolites<br />
&&LBFA0202&&jasmonic acids<br />
&&LBFA03&&Eicosanoids<br />
&&LBFA0301&&Prostaglandins<br />
&&LBFA0302&&Leukotrienes<br />
&&LBFA0303&&Thromboxanes<br />
&&LBFA0304&&Lipoxins<br />
&&LBFA0305&&Hydroxyeicosatrienoic acids<br />
&&LBFA0306&&Hydroxyeicosatetraenoic acids<br />
&&LBFA0307&&Hydroxyeicosapentaenoic acids<br />
&&LBFA0308&&Epoxyeicosatetraenoic acids<br />
&&LBFA0309&&Hepoxilins<br />
&&LBFA0310&&Levuglandins<br />
&&LBFA0311&&Isoprostanes<br />
&&LBFA0312&&Clavulones<br />
&&LBFA04&&Docosanoids<br />
&&LBFA05&&Fatty alcohols<br />
&&LBFA06&&Fatty aldehydes<br />
&&LBFA07&&Fatty esters<br />
&&LBFA0701&&Wax monoesters<br />
&&LBFA0702&&Wax diesters<br />
&&LBFA0703&&Cyano esters<br />
&&LBFA0704&&Lactones<br />
&&LBFA0705&&Fatty acyl CoAs<br />
&&LBFA0706&&Fatty acyl ACPs<br />
&&LBFA0707&&Fatty acyl carnitines<br />
&&LBFA0708&&Fatty acyl adenylates<br />
&&LBFA08&&Fatty amides<br />
&&LBFA0801&&Primary amides<br />
&&LBFA0802&&N-acyl amides<br />
&&LBFA0803&&Fatty acyl homoserine lactones<br />
&&LBFA0804&&N-acyl ethanolamides (endocannabinoids)<br />
&&LBFA09&&Fatty nitriles<br />
&&LBFA10&&Fatty ethers<br />
&&LBFA11&&Hydrocarbons<br />
&&LBFA12&&Oxygenated hydrocarbons<br />
&&LBFA00&&Other<br />
&&LBGL&&Glycerolipids<br />
&&LBGL01&&Monoradylglycerols<br />
&&LBGL0101&&Monoacylglycerols<br />
&&LBGL0102&&Monoalkylglycerols<br />
&&LBGL0103&&Mono-(1Z-alkenyl)-glycerols<br />
&&LBGL0104&&Monoacylglycerolglycosides<br />
&&LBGL0105&&Monoalkylglycerolglycosides<br />
&&LBGL02&&Diradylglycerols<br />
&&LBGL0201&&Diacylglycerols<br />
&&LBGL0202&&Alkylacylglycerols<br />
&&LBGL0203&&Dialkylglycerols<br />
&&LBGL0204&&1Z-alkenylacylglycerols<br />
&&LBGL0205&&Diacylglycerolglycosides<br />
&&LBGL0206&&Alkylacylglycerolglycosides<br />
&&LBGL0207&&Dialkylglycerolglycosides<br />
&&LBGL0208&&Di-glycerol tetraethers<br />
&&LBGL0209&&Di-glycerol tetraether glycans<br />
&&LBGL03&&Triradylglycerols<br />
&&LBGL0301&&Triacylglycerols<br />
&&LBGL0302&&Alkyldiacylglycerols<br />
&&LBGL0303&&Dialkylmonoacylglycerols<br />
&&LBGL0304&&1Z-alkenyldiacylglycerols<br />
&&LBGL0305&&Estolides<br />
&&LBGL00&&Other<br />
&&LBGP&&Glycerophospholipids<br />
&&LBGP01&&Glycerophosphocholines<br />
&&LBGP0101&&Diacylglycerophosphocholines<br />
&&LBGP0102&&1-alkyl,2-acylglycerophosphocholines<br />
&&LBGP0103&&1Z-alkenyl,2-acylglycerophosphocholines<br />
&&LBGP0104&&Dialkylglycerophosphocholines<br />
&&LBGP0105&&Monoacylglycerophosphocholines<br />
&&LBGP0106&&1-alkyl glycerophosphocholines<br />
&&LBGP0107&&1Z-alkenylglycerophosphocholines<br />
&&LBGP02&&Glycerophosphoethanolamines<br />
&&LBGP0201&&Diacylglycerophosphoethanolamines<br />
&&LBGP0202&&1-alkyl,2-acylglycerophosphoethanolamines<br />
&&LBGP0203&&1Z-alkenyl,2-acylglycerophosphoethanolamines<br />
&&LBGP0204&&Dialkylglycerophosphoethanolamines<br />
&&LBGP0205&&Monoacylglycerophosphoethanolamines<br />
&&LBGP0206&&1-alkyl glycerophosphoethanolamines<br />
&&LBGP0207&&1Z-alkenylglycerophosphoethanolamines<br />
&&LBGP03&&Glycerophosphoserines<br />
&&LBGP0301&&Diacylglycerophosphoserines<br />
&&LBGP0302&&1-alkyl,2-acylglycerophosphoserines<br />
&&LBGP0303&&1Z-alkenyl,2-acylglycerophosphoserines<br />
&&LBGP0304&&Dialkylglycerophosphoserines<br />
&&LBGP0305&&Monoacylglycerophosphoserines<br />
&&LBGP0306&&1-alkyl glycerophosphoserines<br />
&&LBGP0307&&1Z-alkenylglycerophosphoserines<br />
&&LBGP04&&Glycerophosphoglycerols<br />
&&LBGP0401&&Diacylglycerophosphoglycerols<br />
&&LBGP0402&&1-alkyl,2-acylglycerophosphoglycerols<br />
&&LBGP0403&&1Z-alkenyl,2-acylglycerophosphoglycerols<br />
&&LBGP0404&&Dialkylglycerophosphoglycerols<br />
&&LBGP0405&&Monoacylglycerophosphoglycerols<br />
&&LBGP0406&&1-alkyl glycerophosphoglycerols<br />
&&LBGP0407&&1Z-alkenylglycerophosphoglycerols<br />
&&LBGP0408&&Diacylglycerophosphodiradylglycerols<br />
&&LBGP0409&&Diacylglycerophosphomonoradylglycerols<br />
&&LBGP0410&&Monoacylglycerophosphomonoradylglycerols<br />
&&LBGP05&&Glycerophosphoglycerophosphates<br />
&&LBGP0501&&Diacylglycerophosphoglycerophosphates<br />
&&LBGP0502&&1-alkyl,2-acylglycerophosphoglycerophosphates<br />
&&LBGP0503&&1Z-alkenyl,2-acylglycerophosphoglycerophosphates<br />
&&LBGP0504&&Dialkylglycerophosphoglycerophosphates<br />
&&LBGP0505&&Monoacylglycerophosphoglycerophosphates<br />
&&LBGP0506&&1-alkyl glycerophosphoglycerophosphates<br />
&&LBGP0507&&1Z-alkenylglycerophosphoglycerophosphates<br />
&&LBGP06&&Glycerophosphoinositols<br />
&&LBGP0601&&Diacylglycerophosphoinositols<br />
&&LBGP0602&&1-alkyl,2-acylglycerophosphoinositols<br />
&&LBGP0603&&1Z-alkenyl,2-acylglycerophosphoinositols<br />
&&LBGP0604&&Dialkylglycerophosphoinositols<br />
&&LBGP0605&&Monoacylglycerophosphoinositols<br />
&&LBGP0606&&1-alkyl glycerophosphoinositols<br />
&&LBGP0607&&1Z-alkenylglycerophosphoinositols<br />
&&LBGP07&&Glycerophosphoinositol monophosphates<br />
&&LBGP0701&&Diacylglycerophosphoinositol monophosphates<br />
&&LBGP0702&&1-alkyl,2-acylglycerophosphoinositol monophosphates<br />
&&LBGP0703&&1Z-alkenyl,2-acylglycerophosphoinositol monophosphates<br />
&&LBGP0704&&Dialkylglycerophosphoinositol monophosphates<br />
&&LBGP0705&&Monoacylglycerophosphoinositol monophosphates<br />
&&LBGP0706&&1-alkyl glycerophosphoinositol monophosphates<br />
&&LBGP0707&&1Z-alkenylglycerophosphoinositol monophosphates<br />
&&LBGP08&&Glycerophosphoinositol bisphosphates<br />
&&LBGP0801&&Diacylglycerophosphoinositol bisphosphates<br />
&&LBGP0802&&1-alkyl,2-acylglycerophosphoinositol bisphosphates<br />
&&LBGP0803&&1Z-alkenyl,2-acylglycerophosphoinositol bisphosphates<br />
&&LBGP0804&&Monoacylglycerophosphoinositol bisphosphates<br />
&&LBGP0805&&1-alkyl glycerophosphoinositol bisphosphates<br />
&&LBGP0806&&1Z-alkenylglycerophosphoinositol bisphosphates<br />
&&LBGP09&&Glycerophosphoinositol trisphosphates<br />
&&LBGP0901&&Diacylglycerophosphoinositol trisphosphates<br />
&&LBGP0902&&1-alkyl,2-acylglycerophosphoinositol trisphosphates<br />
&&LBGP0903&&1Z-alkenyl,2-acylglycerophosphoinositol trisphosphates<br />
&&LBGP0904&&Monoacylglycerophosphoinositol trisphosphates<br />
&&LBGP0905&&1-alkyl glycerophosphoinositol trisphosphates<br />
&&LBGP0906&&1Z-alkenylglycerophosphoinositol trisphosphates<br />
&&LBGP10&&Glycerophosphates<br />
&&LBGP1001&&Diacylglycerophosphates<br />
&&LBGP1002&&1-alkyl,2-acylglycerophosphates<br />
&&LBGP1003&&1Z-alkenyl,2-acylglycerophosphates<br />
&&LBGP1004&&Dialkylglycerophosphates<br />
&&LBGP1005&&Monoacylglycerophosphates<br />
&&LBGP1006&&1-alkyl glycerophosphates<br />
&&LBGP1007&&1Z-alkenylglycerophosphates<br />
&&LBGP11&&Glyceropyrophosphates<br />
&&LBGP1101&&Diacylglyceropyrophosphates<br />
&&LBGP1102&&Monoacylglyceropyrophosphates<br />
&&LBGP12&&Glycerophosphoglycerophosphoglycerols (Cardiolipins)<br />
&&LBGP1201&&Diacylglycerophosphoglycerophosphodiradylglycerols<br />
&&LBGP1202&&Diacylglycerophosphoglycerophosphomonoradylglycerols<br />
&&LBGP1203&&1-alkyl,2-acylglycerophosphoglycerophosphodiradylglycerols<br />
&&LBGP1204&&1-alkyl,2-acylglycerophosphoglycerophosphomonoradylglycerols<br />
&&LBGP1205&&1Z-alkenyl,2-acylglycerophosphoglycerophosphodiradylglycerols<br />
&&LBGP1206&&1Z-alkenyl,2-acylglycerophosphoglycerophosphomonoradylglycerols<br />
&&LBGP1207&&Monoacylglycerophosphoglycerophosphomonoradylglycerols<br />
&&LBGP1208&&1-alkyl glycerophosphoglycerophosphodiradylglycerols<br />
&&LBGP1209&&1-alkyl glycerophosphoglycerophosphomonoradylglycerols<br />
&&LBGP1210&&1Z-alkenylglycerophosphoglycerophosphodiradylglycerols<br />
&&LBGP1211&&1Z-alkenylglycerophosphoglycerophosphomonoradylglycerols<br />
&&LBGP13&&CDP-Glycerols<br />
&&LBGP1301&&CDP-diacylglycerols<br />
&&LBGP1302&&CDP-1-alkyl,2-acylglycerols<br />
&&LBGP1303&&CDP-1Z-alkenyl,2-acylglycerols<br />
&&LBGP1304&&CDP-Dialkylglycerols<br />
&&LBGP1305&&CDP-Monoacylglycerols<br />
&&LBGP1306&&CDP-1-alkyl glycerols<br />
&&LBGP1307&&CDP-1Z-alkenylglycerols<br />
&&LBGP14&&Glycerophosphoglucose lipids<br />
&&LBGP1401&&Diacylglycerophosphoglucose lipids<br />
&&LBGP1402&&1-alkyl,2-acylglycerophosphoglucose lipids<br />
&&LBGP1403&&1Z-alkenyl,2-acylglycerophosphoglucose lipids<br />
&&LBGP1404&&Monoacylglycerophosphoglucose lipids<br />
&&LBGP1405&&1-alkyl glycerophosphoglucose lipids<br />
&&LBGP1406&&1Z-alkenylglycerophosphoglucose lipids<br />
&&LBGP15&&Glycerophosphoinositolglycans<br />
&&LBGP1501&&Diacylglycerophosphoinositolglycans<br />
&&LBGP1502&&1-alkyl,2-acylglycerophosphoinositolglycans<br />
&&LBGP1503&&1Z-alkenyl,2-acylglycerophosphoinositolglycans<br />
&&LBGP1504&&Monoacylglycerophosphoinositolglycans<br />
&&LBGP1505&&1-alkyl glycerophosphoinositolglycans<br />
&&LBGP1506&&1Z-alkenylglycerophosphoinositolglycans<br />
&&LBGP16&&Glycerophosphonocholines<br />
&&LBGP1601&&Diacylglycerophosphonocholines<br />
&&LBGP1602&&1-alkyl,2-acylglycerophosphonocholines<br />
&&LBGP1603&&1Z-alkenyl,2-acylglycerophosphonocholines<br />
&&LBGP1604&&Dialkylglycerophosphonocholines<br />
&&LBGP1605&&Monoacylglycerophosphonocholines<br />
&&LBGP1606&&1-alkyl glycerophosphonocholines<br />
&&LBGP1607&&1Z-alkenylglycerophosphonocholines<br />
&&LBGP17&&Glycerophosphonoethanolamines<br />
&&LBGP1701&&Diacylglycerophosphonoethanolamines<br />
&&LBGP1702&&1-alkyl,2-acylglycerophosphonoethanolamines<br />
&&LBGP1703&&1Z-alkenyl,2-acylglycerophosphonoethanolamines<br />
&&LBGP1704&&Dialkylglycerophosphonoethanolamines<br />
&&LBGP1705&&Monoacylglycerophosphonoethanolamines<br />
&&LBGP1706&&1-alkyl glycerophosphonoethanolamines<br />
&&LBGP1707&&1Z-alkenylglycerophosphonoethanolamines<br />
&&LBGP18&&Di-glycerol tetraether phospholipids (caldarchaeols)<br />
&&LBGP19&&Glycerol-nonitol tetraether phospholipids<br />
&&LBGP20&&Oxidized glycerophospholipids<br />
&&LBGP00&&Other<br />
&&LBSP&&Sphingolipids<br />
&&LBSP01&&Sphingoid bases<br />
&&LBSP0101&&Sphing-4-enines (Sphingosines)<br />
&&LBSP0102&&Sphinganines<br />
&&LBSP0103&&4-Hydroxysphinganines (Phytosphingosines)<br />
&&LBSP0104&&Sphingoid base homologs and variants<br />
&&LBSP0105&&Sphingoid base 1-phosphates<br />
&&LBSP0106&&Lysosphingomyelins and lysoglycosphingolipids<br />
&&LBSP0107&&N-methylated sphingoid bases<br />
&&LBSP0108&&Sphingoid base analogs<br />
&&LBSP02&&Ceramides<br />
&&LBSP0201&&N-acylsphingosines (ceramides)<br />
&&LBSP0202&&N-acylsphinganines (dihydroceramides)<br />
&&LBSP0203&&N-acyl-4-hydroxysphinganines (phytoceramides)<br />
&&LBSP0204&&Acylceramides<br />
&&LBSP0205&&Ceramide 1-phosphates<br />
&&LBSP03&&Phosphosphingolipids<br />
&&LBSP0301&&Ceramide phosphocholines (sphingomyelins)<br />
&&LBSP0302&&Ceramide phosphoethanolamines<br />
&&LBSP0303&&Ceramide phosphoinositols<br />
&&LBSP04&&Phosphonosphingolipids<br />
&&LBSP05&&Neutral glycosphingolipids<br />
&&LBSP0501&&Simple Glc series (GlcCer, LacCer, etc)<br />
&&LBSP0502&&GalNAcb1-3Gala1-4Galb1-4Glc- (Globo series)<br />
&&LBSP0503&&GalNAcb1-4Galb1-4Glc- (Ganglio series)<br />
&&LBSP0504&&Galb1-3GlcNAcb1-3Galb1-4Glc- (Lacto series)<br />
&&LBSP0505&&Galb1-4GlcNAcb1-3Galb1-4Glc- (Neolacto series)<br />
&&LBSP0506&&GalNAcb1-3Gala1-3Galb1-4Glc- (Isoglobo series)<br />
&&LBSP0507&&GlcNAcb1-2Mana1-3Manb1-4Glc- (Mollu series)<br />
&&LBSP0508&&GalNAcb1-4GlcNAcb1-3Manb1-4Glc- (Arthro series)<br />
&&LBSP0509&&Gal- (Gala series)<br />
&&LBSP0510&&Other<br />
&&LBSP06&&Acidic glycosphingolipids<br />
&&LBSP0601&&Gangliosides<br />
&&LBSP0602&&Sulfoglycosphingolipids (sulfatides)<br />
&&LBSP0603&&Glucuronosphingolipids<br />
&&LBSP0604&&Phosphoglycosphingolipids<br />
&&LBSP0600&&Other<br />
&&LBSP07&&Basic glycosphingolipids<br />
&&LBSP08&&Amphoteric glycosphingolipids<br />
&&LBSP09&&Arsenosphingolipids<br />
&&LBSP00&&Other<br />
&&LBST&&Sterol Lipids<br />
&&LBST01&&Sterols<br />
&&LBST0101&&Cholesterol and derivatives<br />
&&LBST0102&&Cholesteryl esters<br />
&&LBST0103&&Phytosterols and derivatives<br />
&&LBST0104&&Marine sterols and derivatives<br />
&&LBST0105&&Fungal sterols and derivatives<br />
&&LBST02&&Steroids<br />
&&LBST0201&&C18 steroids (estrogens) and derivatives<br />
&&LBST0202&&C19 steroids (androgens) and derivatives<br />
&&LBST0203&&C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives<br />
&&LBST03&&Secosteroids<br />
&&LBST0301&&Vitamin D2 and derivatives<br />
&&LBST0302&&Vitamin D3 and derivatives<br />
&&LBST04&&Bile acids and derivatives<br />
&&LBST0401&&C24 bile acids, alcohols, and derivatives<br />
&&LBST0402&&C26 bile acids, alcohols, and derivatives<br />
&&LBST0403&&C27 bile acids, alcohols, and derivatives<br />
&&LBST0404&&C28 bile acids, alcohols, and derivatives<br />
&&LBST0405&&C22 bile acids, alcohols, and derivatives<br />
&&LBST0406&&C23 bile acids, alcohols, and derivatives<br />
&&LBST0407&&C25 bile acids, alcohols, and derivatives<br />
&&LBST0408&&C29 bile acids, alcohols, and derivatives<br />
&&LBST05&&Steroid conjugates<br />
&&LBST0501&&Glucuronides<br />
&&LBST0502&&Sulfates<br />
&&LBST0503&&Glycine conjugates<br />
&&LBST0504&&Taurine conjugates<br />
&&LBST06&&Hopanoids<br />
&&LBST00&&Other<br />
&&LBPR&&Prenol Lipids<br />
&&LBPR01&&Isoprenoids<br />
&&LBPR0101&&C5 isoprenoids<br />
&&LBPR0102&&C10 isoprenoids (monoterpenes)<br />
&&LBPR0103&&C15 isoprenoids (sesquiterpenes)<br />
&&LBPR0104&&C20 isoprenoids (diterpenes)<br />
&&LBPR0105&&C25 isoprenoids (sesterterpenes)<br />
&&LBPR0106&&C30 isoprenoids (triterpenes)<br />
&&LBPR0107&&C40 isoprenoids (tetraterpenes)<br />
&&LBPR0108&&Polyterpenes<br />
&&LBPR02&&Quinones and hydroquinones<br />
&&LBPR0201&&Ubiquinones<br />
&&LBPR0202&&Vitamin E<br />
&&LBPR0203&&Vitamin K<br />
&&LBPR03&&Polyprenols<br />
&&LBPR0301&&Bactoprenols<br />
&&LBPR0302&&Bactoprenol monophosphates<br />
&&LBPR0303&&Bactoprenol diphosphates<br />
&&LBPR0304&&Phytoprenols<br />
&&LBPR0305&&Phytoprenol monophosphates<br />
&&LBPR0306&&Phytoprenol diphosphates<br />
&&LBPR0307&&Dolichols<br />
&&LBPR0308&&Dolichol monophosphates<br />
&&LBPR0309&&Dolichol diphosphates<br />
&&LBPR00&&Other<br />
&&LBSL&&Saccharolipids<br />
&&LBSL01&&Acylaminosugars<br />
&&LBSL0101&&Monoacylaminosugars<br />
&&LBSL0102&&Diacylaminosugars<br />
&&LBSL0103&&Triacylaminosugars<br />
&&LBSL0104&&Tetraacylaminosugars<br />
&&LBSL0105&&Pentaacylaminosugars<br />
&&LBSL0106&&Hexaacylaminosugars<br />
&&LBSL0107&&Heptaacylaminosugars<br />
&&LBSL02&&Acylaminosugar glycans<br />
&&LBSL03&&Acyltrehaloses<br />
&&LBSL04&&Acyltrehalose glycans<br />
&&LBSL00&&Other<br />
&&LBPK&&Polyketides<br />
&&LBPK01&&Macrolide polyketides<br />
&&LBPK02&&Aromatic polyketides<br />
&&LBPK03&&Non-ribosomal peptide/polyketide hybrids<br />
&&LBPK00&&Other<br />
---></div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=PathwayMap:GLtest&diff=117186
PathwayMap:GLtest
2023-11-29T05:29:15Z
<p>Editor: Editor moved page PathwayMap:GLtest to PathwayMap:GlycerolipidBiosynthesis</p>
<hr />
<div>#REDIRECT [[PathwayMap:GlycerolipidBiosynthesis]]</div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=PathwayMap:GlycerolipidBiosynthesis&diff=117185
PathwayMap:GlycerolipidBiosynthesis
2023-11-29T05:29:15Z
<p>Editor: Editor moved page PathwayMap:GLtest to PathwayMap:GlycerolipidBiosynthesis</p>
<hr />
<div><div id="source" style="display:none"><br />
<nowiki><br />
[title] <2.5,2.5><br />
#Glycerolipid Metabolome<br />
de novo pathway of glycerophospholipid<br />
<br />
//titles<br />
[OMM_name] <88.5,42.5>css(font-size:40px;background:rgb(200,200,150;border:5px solid black;color:)<br />
Mitochondrial outer membrane <br />
<br />
[IMM_name] <88.5,35>css(font-size:40px;background:rgb(200,200,150;border:5px solid black;color:)<br />
Mitochondrial inner membrane <br />
<br />
<br />
[ER] <6,113.5>css(font-size:40px;background:rgb(200,200,150;border:5px solid black;z-index:2)<br />
Endoplasmic reticulum<br />
<br />
//=========================================Organelles======================================================<br />
//Mitochondria outer membrane<br />
[OMM] <38.5,2.5,2100,700>css(background:rgb(255,200,50;z-index:1;border:30px solid rgb(155,100,10)<br />
<br />
//Mitochondria inner membrane<br />
[IMM] <57.5,17.5,1500,350>css(background:rgb(255,200,50;z-index:2;border:30px solid rgb(155,100,10)<br />
<br />
//Endoplasmic reticulum<br />
[ER1] <1,1,400,2050>css(background:rgb(200,255,10;border-right:50px solid rgb(200,200,0;box-shadow:none;z-index:1)<br />
<br />
<br />
//Golgi<br />
[Golgi] <39,51.5,700,1000>css(background:rgb(50,140,140;border:30px solid rgb(100,200,200;box-shadow:none;z-index:1)<br />
<br />
<br />
//=========================================Metabolites=====================================================<br />
//glycerol-3-phosphate<br />
[G3P3] <29.5,1.5><br />
!GL{OH |OH|O-PO_s3s_}<br />
?[link](http://lipidbank.jp/cgi-bin/main.cgi?id=PGP "G3P")<br />
d=(l_w5)=>u[LPA]<br />
d=(l_w5)=>u[LPAmt]<br />
<br />
<br />
//lysophosphatidic acid<br />
[LPA] <22.5,13><br />
!GL{O-CO-R1|OH|O-PO_s3s_}<br />
LPA<br />
d=(l_w5)=>u[PAER]<br />
<br />
//lysophosphatidic acid<br />
[LPAmt] <36.5,13><br />
!GL{O-CO-R1|OH|O-PO_s3s_}<br />
LPA<br />
d=(l_w5)=>u[PA2]<br />
<br />
<br />
//phosphatidic acid, mitochondrial<br />
[PAER] <23,32><br />
!GL{O-CO-R1|O-CO-R2|O-PO_s3s_}<br />
?[link](http://jcbl.jp/wiki/Volatile:ListMol?my_1=LBGPA"PA")<br />
d=(l_w5)=>u[DAG2]<br />
d=(l_w5)=>u[CDP-DAGer]<br />
<br />
//phosphatidic acid, mitochondrial<br />
[PAmt] <54,15><br />
!GL{O-CO-R1|O-CO-R2|O-PO_s3s_}<br />
?[link](http://jcbl.jp/wiki/Volatile:ListMol?my_1=LBGPA"PA")<br />
r=(l_w5)=>l[CDP-DAG]<br />
<br />
//cytidine diphosphate-diacylglycerol<br />
[CDP-DAG] <73,15><br />
!GL{O-CO-R1 | O-CO-R2 | O-PO2-CMP</t>}<br />
CDP-DAG<br />
r=(l_w5)=>l[PGP]<br />
<br />
//cytidine diphosphate-diacylglycerol<br />
[CDP-DAGer] <22,60><br />
!GL{O-CO-R1 | O-CO-R2 | O-PO2-CMP</t>}<br />
CDP-DAG<br />
r=(l_w5)=>u[PI]<br />
d=(l_w5)=>u[PI2]<br />
//cytidine triphosphate<br />
[CTP] <64,14.5><br />
CTP<br />
d=(l_w2)=>d[PPi]<br />
<br />
//pyrophosphate<br />
[PPi] <68.5,13><br />
pyrophosphate<br />
<br />
//phosphatidylglycerol-phosphate<br />
[PGP] <96,14><br />
!PG{O-CO-R1 | O-CO-R2 | O-PO2-O| HO|O3P-O}<br />
PGP<br />
r=(l_w4)=>l[PG]<br />
<br />
//glycerol-3-phosphate<br />
[G3P] <82.5,9><br />
!GL{OH |OH|O-PO_s3s_}<br />
?[link](http://lipidbank.jp/cgi-bin/main.cgi?id=PGP "G3P")<br />
d=(l_w2)=>d[CMP]<br />
<br />
[CMP] <90.5,13><br />
CMP<br />
<br />
[PG] <118,13.5><br />
!PG{O-CO-R1 | O-CO-R2 | PO2-O| HO|HO }<br />
?[link](http://jcbl.jp/wiki/Volatile:ListMol?my_1=LBGPG"PG")<br />
<br />
r=(l_w4)=>[CL]<br />
[H2O] <109,14><br />
H2O<br />
d=(l_w2)=>d[Pi]<br />
<br />
[Pi] <113,14><br />
Pi<br />
<br />
[CDP-DAGbox] <128,13.5><br />
CDP-DAG<br />
d=(l_w2)=>d[CMP2]<br />
<br />
[CMP2] <134.5,13.5><br />
CMP<br />
<br />
//cardiolipin<br />
[CL] <138,12><br />
!CL{O-CO-R1|O-CO-R2|O-PO-O|HO|O-PO-O|O-CO-R3| O-CO-R4}<br />
CL<br />
u=(l_w5)=>d[CL2]<br />
<br />
[CL2] <142,3><br />
CL<br />
<br />
[PA2] <37,23.5><br />
!GL{O-CO-R1|O-CO-R2|O-PO_s3s_}<br />
PA<br />
=(l_w5)=>[PAmt]<br />
<br />
//diacylglycerol<br />
[DAG] <54,28><br />
!GL{O-CO-R1|O-CO-R1| OH}<br />
DAG<br />
u=(l_w5)=>d[PAmt]<br />
<br />
[unknown] <53,38><br />
?<br />
u==>d[DAG]<br />
<br />
//diacylglycerol<br />
[DAG2] <22,48.5><br />
!GL{O-CO-R1|O-CO-R1| OH}<br />
DAG<br />
r=(l_w5)=>[PC]<br />
<br />
//phosphatidylinositol<br />
[PI] <33.5,76><br />
!GL{O-CO-R1 | O-CO-R2 | O-PO2-Inositol}<br />
?[link](http://jcbl.jp/wiki/Volatile:ListMol?my_1=LBGPI"PI")<br />
<br />
//phosphatidylinositol<br />
[PI2] <21.5,76><br />
!GL{O-CO-R1 | O-CO-R2 | O-PO2-Inositol}<br />
?[link](http://jcbl.jp/wiki/Volatile:ListMol?my_1=LBGPI"PI")<br />
<br />
<br />
//phosphatidylcholine<br />
[PC] <53.5,48.5><br />
!GL{O-CO-R1|O-CO-R2|O-PO2-Choline}<br />
?[link](http://jcbl.jp/wiki/Volatile:ListMol?my_1=LBGPC"PC")<br />
<br />
//phosphatidylethanolamine<br />
[PE] <24,92.5><br />
!GL{O-CO-R1|O-CO-R2| O-PO2-Ethanolamine}<br />
PE<br />
<br />
//===================================Gene====================================================<br />
[Tam41] <66,17>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
Tam41<br />
<br />
<pop><br />
Enzyme: CDP-diacylglycerol synthase<br><br />
<nobr>This reaction is not catalyzed by Cds1 in mitochondria.<br />
?[link](http://www.cell.com/cell-metabolism/pdf/S1550-4131(13)00142-3.pdf"Tamura et al. 2013. Cell Metab. 17(5):709-718.")<br />
</pop><br />
<br />
//phosphatidylglycerolphosphate (PGP) synthase<br />
[aa] (gene) <87,16.5>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
PGS1<br />
<br />
//phosphatidylglycerophosphatase<br />
[PTPMT1] <109.5,17.5>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
PTPMT1<br />
<br />
//cardiolipin synthase<br />
[CRLS1] <130.5,17>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
CRLS1<br />
<br />
[PRELITRIAP1] <45.5,21>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
Transferred by <br />
PRELI1 + TRIAP1<br />
<br />
<pop><br />
<nobr>In yeast Ups1 shuffles PA between the OMM and IMM and the PA-loaded Ups1 needs the interaction with Mdm35 for stabilisation. <br />
?[link](http://science.sciencemag.org/cgi/pmidlookup?view=long&pmid=23042293"Connerth et al. 2012. Science. 338(6108):815-818.")<br />
In human, the orthologous gene of Ups1 is PRELI1 and TRIAP1 is the gene which has the function of Mdm35.<br />
?[link](https://linkinghub.elsevier.com/retrieve/pii/S1550-4131(13)00297-0"Potting et al. 2013. Cell Metab. 18(2):287-295.")<br />
</pop><br />
<br />
//nucleoside diphosphate kinase Nm23-H4<br />
[NME4] <139.5,7>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
Transffered by<br />
Nm23-H4<br />
<pop><br />
<nobr>The nucleoside diphosphate kinase Nm23-H4 (encoded by the NME4 gene) localizes in the mitochondrial inter-membrane space<br />
and seems to have a dual function either in the transfer of phosphate groups or in the transfer of CL from the IMM to the OMM.<br />
?[link](https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23150663/"Schlattner et al. 2013. J Biol Chem. 288(1):111-121.")<br />
</pop><br />
<br />
//acylglycerol kinase<br />
[AGK] <56.5,24>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
AGK<br />
<pop><br />
<nobr>There is a term "Multi-substrate lipid kinase (MuLK)" (Waggoner et al., 2004).<br />
This enzyme phosphorylates diacylglycerol, ceramide, and 1-acylglycerol but not sphingosine.<br />
?[link](http://www.jbc.org/content/279/37/38228.long"Waggoner et al. 2004. J Biol Chem. 279(37):38228-38235.")<br />
<br />
AGK deficiency results in Sengers syndrome with dysfunction of the mitochondrial energy metabolism.<br />
<br />
?[link](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3523805/"Calvo et al. 2012. Sci Transl Med. 4(118):118ra10.")<br />
?[link](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3276657/"Mayr et al. 2012. Am J Hum Genet. 90(2):314-320.")<br />
<br />
</pop><br />
<br />
[GPATer] <24.5,9>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
GPAT3,4<br />
<br />
[GPATmit] <35.5,9>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
GPAT1,2<br />
<br />
[AGPAT] <36.5,20>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
AGPAT1,4<br />
<br />
[AGPAT2] <22,24>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
AGPAT1,2,3,5<br />
<br />
//Phosphatidate phosphatase<br />
[LPIN] <23,42.5>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
LPIN<br />
?[link](http://www.genome.jp/dbget-bin/www_bget?ec:3.1.3.4"KEGG")<br />
<pop><br />
Phosphatidate phosphatase<br />
</pop><br />
<br />
//CDP-diacylglycerol--inositol 3-phosphatidyltransferase<br />
[CDIPT] <36.5,69>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
CDIPT<br />
?[link](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.8.11"KEGG")<br />
<br />
<br />
//CDP-diacylglycerol--inositol 3-phosphatidyltransferase<br />
[CDIPT2] <24,69>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
CDIPT<br />
?[link](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.8.11"KEGG")<br />
<br />
//Cholinephosphotransferase<br />
[CHPT1] <44,48.5>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
CHPT<br />
?[link](http://www.genome.jp/dbget-bin/www_bget?ec:2.7.8.2"KEGG")<br />
?[link](http://www.uniprot.org/uniprot/Q8WUD6"UniProt")<br />
<br />
<pop><br />
<nobr>Subcellular localization<br />
?[link](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC124149/"Henneberry et al.( 2002) Mol Biol Cell. 13(9):3148-3161")<br />
</pop><br />
<br />
</nowiki><br />
</div><br />
<div id="mainTxt" style="height:800px;"> </div></div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=PathwayMap:CeramideBiosynthesis&diff=117184
PathwayMap:CeramideBiosynthesis
2023-11-29T03:59:09Z
<p>Editor: Created page with "<div id="source" style="display:none"> <nowiki> [title] <2.5,2.5> #Ceramide Biosynthesis //titles [ER] <6.83,66.82>css(font-size:20px;background:rgb(200,200,150;border:5px solid black;z-index:2) Endoplasmic reticulum [Cytosol] <70,1>css(font-size:20px;background:rgb(200,200,150;border:5px solid black;z-index:2) Cytosol [PlasmaMembraneName] <91.51,4.97>css(font-size:20px;background:rgb(200,200,150;border:5px solid black;z-index:2) Plasma Membrane [LysosomeName] <82.14..."</p>
<hr />
<div><div id="source" style="display:none"><br />
<nowiki><br />
[title] <2.5,2.5><br />
#Ceramide Biosynthesis<br />
<br />
//titles<br />
[ER] <6.83,66.82>css(font-size:20px;background:rgb(200,200,150;border:5px solid black;z-index:2)<br />
Endoplasmic reticulum<br />
<br />
[Cytosol] <70,1>css(font-size:20px;background:rgb(200,200,150;border:5px solid black;z-index:2)<br />
Cytosol<br />
<br />
[PlasmaMembraneName] <91.51,4.97>css(font-size:20px;background:rgb(200,200,150;border:5px solid black;z-index:2)<br />
Plasma Membrane<br />
<br />
[LysosomeName] <82.14,16.54>css(font-size:20px;background:rgb(200,200,150;border:5px solid black;z-index:2)<br />
Lysosome<br />
<br />
[cisGLD] <24.68,41.48>css(font-size:20px;background:rgb(200,200,150;border:5px solid black;z-index:2)<br />
cis/medial Golgi<br />
<br />
[transGLD] <44.10,41.48>css(font-size:20px;background:rgb(200,200,150;border:5px solid black;z-index:2)<br />
trans Golgi<br />
<br />
[TGNName] <71.40,41.48>css(font-size:20px;background:rgb(200,200,150;border:5px solid black;z-index:2)<br />
trans Golgi network<br />
<br />
//========================================Organelle boxes========================<br />
<br />
<br />
<br />
[ER1] <3.89,0.66,166.03,1024.31>css(background:rgb(200,255,10;border-right:50px solid rgb(200,200,0;box-shadow:none;z-index:1)<br />
[ER2] <11.03,52.92,1280.14,340.00>css(background:rgb(200,255,10;border-top:50px solid rgb(200,200,0;box-shadow:none;z-index:1)<br />
[ER3] <3.84,53.16,165.38,333.00>css(background:rgb(200,255,10;box-shadow:none;z-index:1)<br />
<br />
[PlasmaMembrane] <94.81,1.10,51.19,1154.37>css(background:rgb(100,100,100;box-shadow:none;z-index:1;)<br />
<br />
//Golgi<br />
[Golgi] <24.81,20.95,162.20,324.15>css(background:rgb(50,140,140;border:30px solid rgb(100,200,200;box-shadow:none;z-index:1)<br />
<br />
//Golgi<br />
[Golgi_trans] <35.84,20.95,404.71,324.15>css(background:rgb(50,140,140;border:30px solid rgb(100,200,200;box-shadow:none;z-index:1)<br />
<br />
<br />
//Trans Golgi network<br />
[TGN] <63.40,20.95,404.71,324.15>css(background:rgb(50,140,140;border:30px solid rgb(100,200,200;box-shadow:none;z-index:1)<br />
<br />
//Lysosome<br />
[Lysosome] (mark) <77.73,0.56,170.61,255.93>css(background:rgb(130,140,140;border:30px solid rgb(130,180,180;box-shadow:none;z-index:1)<br />
<br />
//=========================================Metabolites=====================================================<br />
//Palmitoyl-CoA<br />
[PalCoA] <12.68,1.66><br />
PalCoA<br />
d=(l_w3)=>u[3KDS]<br />
<br />
//3-ketodihydrosphingosine <br />
[3KDS] <12.68,7.17><br />
3-KDS<br />
d=(l_w3)=>u[DHS]<br />
<br />
//dihydrosphingosine<br />
[DHS] <13.23,12.68><br />
DHS<br />
d=(l_w3)=>u[DHC]<br />
<br />
//dihydroceramide<br />
[DHC] <13.23,17.64><br />
DHC<br />
d=(l_w3)=>u[Cer]<br />
<br />
//Ceramide<br />
[C1P] <66.71,15.44><br />
!SP{O-PO3}<br />
C1P<br />
r=(l_w)=>[PlasmaMembrane]<br />
<br />
//Ceramide<br />
[Cer] <12.13,23.15><br />
!SP{O}<br />
Cer<br />
r=(l_w3)=>u[GlcCer]<br />
r=(l_w3)=l[CERT]<br />
<br />
//Ceramide<br />
[Cer2] <38.33,25.73><br />
Cer<br />
u=(l_w3)=>u[SM]<br />
<br />
//Ceramide<br />
[Cer3] <56.18,18.90><br />
Cer<br />
<br />
//Ceramide<br />
[Cer4] <63.95,18.19><br />
Cer<br />
d=(l_w3)=>d[C1P]<br />
<br />
//Ceramide<br />
[Cer5] <13.79,45.76><br />
Cer<br />
<br />
//Ceramide<br />
[Cer6] <52.92,51.82><br />
Cer<br />
<br />
//Ceramide<br />
[Cer7] <97.02,19.30><br />
Cer<br />
u=(l_w3)=>d[SM4]<br />
<br />
//Ceramide<br />
[Cer8] <80.48,4.97><br />
Cer<br />
<br />
//Ceramide<br />
[Cer9] <79.94,11.03><br />
Cer<br />
<br />
//Sphingosine<br />
[Sph] <13.23,32.53><br />
Sph<br />
u=(l_w3)=>d[Cer]<br />
<br />
//Glucosylceramide<br />
[GlcCer] <19.30,29.77><br />
!SP{O-Glc}<br />
GlcCer<br />
d=(l_w3)=>[GlcCer2]<br />
d=(l_w3)=l[FAPP2]<br />
d=(l_w3)=>u[Cer5]<br />
<br />
//Glucosylceramide<br />
[GlcCer2] <28.12,35.84><br />
GlcCer<br />
r=(l_w3)=>l[GlcCer3]<br />
<br />
//Glucosylceramide<br />
[GlcCer3] <38.33,35.18><br />
GlcCer<br />
d=(l_w3)=>l[LacCer]<br />
<br />
//Glucosylceramide<br />
[GlcCer4] <66.71,38.04><br />
GlcCer<br />
l=(l_w3)=>L[LacCer2]<br />
<br />
//Glucosylceramide<br />
[GlcCer5] <83.79,11.03><br />
GlcCer<br />
d=(l_w3)=>d[Cer9]<br />
<br />
//Lactosylceramide<br />
[LacCer] <46.5,36><br />
!SP{O-Glc-Gal}<br />
LacCer<br />
r=(l_w3)=>r[GM3]<br />
<br />
//Lactosylceramide<br />
[LacCer2] <67,32.5><br />
!SP{O-Glc-Gal}<br />
LacCer<br />
l=(l_w3)=>L[GB3]<br />
d=(l_w3)=>d[GA2]<br />
<br />
//Globotriaosylceramide<br />
[GB3] <66.5,27.5><br />
!SP{O-Glc-Gal-Gal}<br />
Gb3<br />
r=(l_w)=>[PlasmaMembrane]<br />
<br />
//Globoside<br />
[GA2] <76.07,34.73><br />
!SP{O-Glc-Gal-GalNAc}<br />
GA2<br />
r=(l_w)=>[PlasmaMembrane]<br />
<br />
//asialoGM1<br />
[GM3] <45.15,30.45><br />
!SP{O-Glc-Gal| SA}<br />
GM3<br />
<br />
//asialoGM 3<br />
[GM2] <71.5,22.5><br />
!SP{O-Glc-Gal-GalNAc| SA|}<br />
GM2<br />
r=(l_w)=>[PlasmaMembrane]<br />
<br />
//GM1<br />
[SM] <43.05,25.20><br />
!SP{O-Choline}<br />
SM<br />
r=(l_w3)=>d[Cer3]<br />
<br />
//Sphingomyelin<br />
[SM2] <64.50,51.82><br />
SM<br />
l=(l_w3)=>r[Cer6]<br />
<br />
//Sphingomyelin<br />
[SM3] <100.33,26.46><br />
SM<br />
u=(l_w3)=>d[Cer7]<br />
<br />
//Sphingomyelin<br />
[SM4] <96.47,12.13><br />
SM<br />
<br />
//Sphingomyelin<br />
[SM5] <84.35,4.97><br />
SM<br />
u=(l_w3)=>u[Cer8]<br />
//===============================================gene========================================<br />
//serine palmitoyl transferase<br />
[SPT] <13.23,3.86>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
SPT<br />
<br />
//3-ketodihydrosphingosine reductase<br />
[KDSR] <12.68,9.38>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
KDSR<br />
<br />
//ceramide synthase<br />
[CerS] <12.68,14.33>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
CerS<br />
<br />
//ceramide synthase<br />
[CerS2] <12.68,29.22>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
CerS<br />
<br />
<br />
//dihydroceramide Δ4-desaturase<br />
[DES] <12.68,19.84>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
DES<br />
<br />
<br />
<br />
//UDP-glucose:ceramide glucosyltransferase<br />
[UGCG] <21.50,26.46>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
UGCG<br />
<br />
//Unknown Gene<br />
[Ugen] <24.81,35.84>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
?<br />
<br />
//Unknown Gene<br />
[Ugen2] <63.95,39.69>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
?<br />
<br />
//Unknown Gene<br />
[Ugen3] <38.33,19.95>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
?<br />
<br />
//β-1,4-galactosyltransferase5 and 6 <br />
[B4GalT5] <39.38,37.80>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
B4GalT5<br />
<br />
//β-1,4-galactosyltransferase5 and 6 <br />
[B4GalT5-2] <62.84,36.38>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
B4GalT5<br />
<br />
//ST3β-galactoside α-2,3-sialyltransferase 5 <br />
[ST3GalT5] <56.23,34.18>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
ST3GalT5<br />
<br />
//Sphingomyelin synthase 1<br />
[SMS1] <42.00,22.05>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
SMS1<br />
<br />
//Sphingomyelin synthase 2<br />
[SMS2] <95.37,15.44>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
SMS2<br />
<br />
//neutral SMase 2<br />
[NSMase2] <53.55,21.53>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
NSMase 2<br />
<br />
//neutral SMase 2<br />
[NSMase1] <57.33,51.27>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
NSMase 1<br />
<br />
//four-phosphate adaptor protein 2<br />
[FAPP2] <24.81,45.76>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
transferred by FAPP2<br />
r=(l_w3)=>d[GlcCer4]<br />
<br />
//α-1,4-galactosyltransferase<br />
[A4GalT] <62.30,31.97>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
A4GalT<br />
<br />
//β-1,4-N-acetylgalactosaminyltransferase 1 (GM2/GD2 synthase)<br />
[B4GalNT1] <72.5,39>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
B4GalNT1<br />
<br />
//ceramide transfer protein<br />
[CERT] <33.08,15.23>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
transferred by CERT<br />
d=(l_w3)=>u[Cer2]<br />
r=(l_w3)=>l[Cer4]<br />
<br />
//ceramidekinase <br />
[CERK] <66.71,20.40>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
CERK<br />
<br />
//β-glucosidases 1<br />
[GBA1] <81.59,13.23>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
GBA1<br />
<br />
//β-glucosidases 2<br />
[GBA2] <12.68,42.45>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
GBA2<br />
<br />
//acidic SMase<br />
[ASMase] <98.12,23.15>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
ASMase<br />
<br />
//acidic SMase<br />
[ASMase2] <81.59,1.66>css(background:rgb(255,200,50;border:5px solid rgb(255,100,50;z-index:5)<br />
ASMase<br />
<br />
<br />
</nowiki><br />
</div><br />
<div id="mainTxt" style="height:800px;"> </div></div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Category:LBG&diff=117183
Category:LBG
2023-11-29T03:06:28Z
<p>Editor: /* Glycerophospholipid */</p>
<hr />
<div>{{Huge|{{Bilingual|グリセロ脂質|Glycerolipid}} }}<br />
{{LB/Header}}<br />
{{Hierarchy|{{PAGENAME}}}}<br />
{| style="float:right"<br />
|__TOC__<br />
|}<br />
==Class Overview==<br />
<br />
{{Twocolumn|<br />
Complex lipid is the major structural component of biological membranes (lipid bilayer), and is broadly classified into glycerolipid containing glycerol and sphingolipid containing sphingoid. The glycerolipid category (LBG) includes glycoglycerolipid and phosphoglycerolipid.<br />
|<br />
リン酸や糖などを含む脂質は複合脂質と呼ばれ、細胞膜の脂質二重層の主要な構成要素です。複合脂質は、一般的にグリセロールを含む脂質 (グリセロ脂質) とスフィンゴイドを含む脂質 (スフィンゴ脂質) に大別されます。グリセロ脂質 (LBG) には、グリセロ糖脂質 (glycoglycerolipid) とグリセロリン脂質 (glycerophospholipid) が含まれます。<br />
}}<br />
<br />
={{Bilingual|略称の記載法|Common Nomenclature}}=<br />
{{Twocolumn|<br />
[https://lipidmaps.org LipidMaps Consortium] in the US defines the standard way of structure description (nomenclature). Please follow this standard especially when exact structure is not determined due to experimental procedures.<br />
|<br />
米国の[https://lipidmaps.org LipidMaps コンソーシアム]では、構造の標準的な表記法を定めています(命名系)。とりわけ分析法により構造に曖昧な部分が残る場合は、以下の表記法を踏襲してください。<br />
}}<br />
Reference: "Update on LIPID MAPS classification, nomenclature, and shorthand notation for MS-derived lipid structures" [https://www.jlr.org/article/S0022-2275(20)60017-7/fulltext <i>J Lipid Res</i> 61(12), 1539-1555, 2020]<br />
<br />
==GlyceroLipid==<br />
<br />
{{Twocolumn|<br />
Glycerolipid is referred to as mono-, di-, and triglycerides depending on the number of acyl chains (fatty acids). When sugars are attached, the modification comes before the backbone name; SQ, MG, and DG indicate Sulfoquinovose, single hexose, and double hexoses, respectively.Hexose is commonly galactose, and MG and DG may refer to mono- and digalactose.<br />
|<br />
配位するアシル基(脂肪酸)の数により、モノ・ジ・トリアシルグリセロール(それぞれ MG, DG, TG)と呼ばれます。グリセロール骨格に糖鎖が付く場合は MG や DG の前に SQ (Sulfoquinovosyl)、MG (Monoglycosyl)、DG (Diglycosyl) をつけます。MGやDGの略称はガラクトースの意味で使われる場合もあります。<br />
}}<br />
<br />
{| class="wikitable" cellpadding="4"<br />
|-<br />
! || || Monoglycosyl (単糖) || Diglycosyl (二糖) || Sulfoquinovosyl (スルホキノボース)<br />
|-<br />
| MG : || Monoacylglycerol <br/>(モノアシルグリセロール) || MGMG || DGMG || SQMG<br />
|-<br />
| DG : || Diacylglycerol <br/>(ジアシルグリセロール) || MGDG || DGDG || SQDG<br />
|-<br />
| TG : || Triacylglycerol <br/>(トリアシルグリセロール) <br />
|colspan="3" align="center"| n.a. (該当なし) <br />
|}<br />
<br />
==Glycerophospholipid==<br />
<br />
{| class="wikitable"<br />
|-<br />
| Phosphatidic acid<br/>ホスファチジン酸 || PA, Ptd<br />
|-<br />
| Phosphatidylcholine<br/>ホスファチジルコリン || PC, PtdCho<br />
|-<br />
| Phosphatidylethanolamine<br/>ホスファチジルエタノールアミン || PE, PtdEtn<br />
|-<br />
| Phosphatidylglycerol<br/>ホスファチジルグリセロール || PG, PtdGro<br />
|-<br />
| Phosphatidylinositol<br/>ホスファチジルイノシトール || PI, PtdIns<br />
|-<br />
| Phosphatidylserine<br/>ホスファチジルセリン || PS, PtdSer<br />
|-<br />
| Cardiolipin<br/>カルジオリピン || CL, Ptd2Gro<br />
|-<br />
| Bis[monoacylglycero]phosphates<br/>ビス(モノアシルグリセロ)リン酸 || BMP<br />
|-<br />
| Phosphatidylglycerolphosphate<br/>ホスファチジルグリセロールリン酸 || PGP<br />
|-<br />
| Phosphatidylinositol-mannoside<br/>ホスファチジルイノシトールマンノシド || PIM<br />
|}<br />
<br />
<br />
<!----<br />
=={{Bilingual|分類|Classification}}==<br />
==={{Bilingual|糖の個数もしくは極性基|By the Number of Sugars or the Head Group}}===<br />
<br />
<br />
{{Twocolumn|<br />
For glycoglycerolipid, 2 digits indicate the number of sugars. For phosphoglycerolipid, common abbreviations such as PS (phosphatidylserine)or PE (phosphatidylethanolamine). <br />
|<br />
グリセロ糖脂質は結合している糖の総数を、グリセロリン脂質の場合はPS(ホスファチジルセリン)やPE(ホスファチジルエタノールアミン)等の記号を2桁で示しています。<br />
}}<br />
<br />
<br />
<br />
{| class="wikitable"<br />
|-<br />
! colspan="3" | Glycerolipid Overview<br />
|-<br />
| align="center" style="vertical-align:top" width=33%|<br />
Glycoglycerolipid<br><small>グリセロ糖脂質</small>: LBGnn<br />
<br>[[Image:LBGnn.png]]<br><br />
| align="center" style="vertical-align:top" width=33%|<br />
Phosphoglycerolipid<br><small>グリセロリン脂質</small>: LBGPn<br />
<br>[[Image:LBGPn.png]]<br><br />
|}<br />
</center><br />
<br />
<center><br />
{| class="wikitable" border="1" cellpadding="2" cellspacing="1" margin: 1em 1em 1em 1em"<br />
|+ Table 1. Classification by number of sugars or polar head group<br />
|- valign="top"<br />
|align="center"| {{MapLink|ListMol|LBGPA|LBGPA: <br>Ptd acid <br>ホスファチジン酸<br>}}<br>[[Image:LBGPA.png|90px]]<br />
|align="center"| {{MapLink|ListMol|LBGPC|LBGPC: <br>Ptd-choline<br>ホスファチジルコリン<br>}}<br>[[Image:LBGPC.png|155px]]<br />
|align="center"| {{MapLink|ListMol|LBGPE|LBGPE: <br>Ptd-ethanolamine<br>ホスファチジルエタノールアミン<br>}}<br>[[Image:LBGPE.png|135px]]<br />
|align="center"| {{MapLink|ListMol|LBGPG|LBGPG: <br>Ptd-glycerol <br>ホスファチジルグリセロール<br>}}<br>[[Image:LBGPG.png|130px]]<br />
<br />
|- valign="top"<br />
|align="center"| {{MapLink|ListMol|LBGPI|LBGPI: <br>Ptd-inositol<br>ホスファチジルイノシトール<br>}}<br>[[Image:LBGPI.png|110px]]<br />
|align="center"| {{MapLink|ListMol|LBGPS|LBGPS: <br>Ptd-serine<br>ホスファチジルセリン<br>}}<br>[[Image:LBGPS.png|150px]]<br />
|align="center"| {{MapLink|ListMol|LBGPx|LBGPx: <br>other <br>その他リン脂質<br>}}<br>[[Image:LBGPx.png|95px]]<br />
|- valign="top"<br />
|align="center"| {{MapLink|ListMol|LBGMG|LBGMG: <br>Monoacyl G<br>モノグリセリド<br>}}<br>[[Image:LBGMG.png]]<br />
|align="center"| {{MapLink|ListMol|LBGDG|LBGDG: <br>Diacyl G<br>ジグリセリド<br>}}<br>[[Image:LBGDG.png]]<br />
|align="center"| {{MapLink|ListMol|LBGTG|LBGTG: <br>Triacyl G<br>トリグリセリド<br>}}<br>[[Image:LBGTG.png]]<br />
|align="center"| {{MapLink|ListMol|LBG00|LBG00: <br>Alkyl-type G<br>含アルキル, アルケニル型<br>}}<br />
|-<br />
|align="center"| {{MapLink|ListMol|LBG01|LBG01: <br>1 sugar<br>糖の数1<br>}}<br />
|align="center"| {{MapLink|ListMol|LBG02|LBG02: <br>2 sugars<br>糖の数2<br>}}<br />
|align="center"| {{MapLink|ListMol|LBG03|LBG03: <br>3 sugars<br>糖の数3<br>}}<br />
|align="center"| {{MapLink|ListMol|LBG04|LBG04: <br>4 sugars<br>糖の数4<br>}}<br />
<br />
|}<br />
</center><br />
<br />
==={{Bilingual|その他の分類|Other Classification Charts}}===<br />
<br />
* {{#volatile:ClassMatrix|Head Group v.s. Length:Unsaturation of R1 <br>(極性基 対 R1の脂肪酸長:不飽和度)|LBG.....:.........:.........|10|12|4|5|Head_Group|Fatty_Acid_Length(R1)}}<br />
* {{#volatile:ClassMatrix|Head Group v.s. Length:Unsaturation of R2 <br>(極性基 対 R2の脂肪酸長:不飽和度)|LBG.....:.........:.........|20|22|4|5|Head_Group|Fatty_Acid_Length(R2)}}<br />
* {{#volatile:ClassMatrix|Length:Unsaturation of R1 v.s. Length:Unsaturation of R2 <br>(R2の脂肪酸長:不飽和度 対 R2の脂肪酸長:不飽和度)|LBG.....:.........:.........|10|12|20|22|Fatty_Acid_Length(R1)|Fatty_Acid_Length(R2)}}<br />
<br />
=={{Bilingual|ID番号の設計|Design of Glycerolipid Identifiers}}==<br />
<center><br />
28-DIGIT(8+9+9+2)<br />
<table border=1><br />
<tr><br />
<td style="background-color:yellowgreen;" width=15px align="center"><big>L</big><br />
<td style="background-color:yellowgreen;" width=15px align="center"><big>B</big><br />
<td style="background-color:darkseagreen;" width=15px align="center"><big>G</big><br />
<td style="background-color:Blue; color:white" width=15px align="center"><big>''a''</big><br />
<td style="background-color:Blue; color:white" width=15px align="center"><big>''a''</big><br />
<td style="background-color:aqua" width=15px align="center"><big>''b1''</big><br />
<td style="background-color:aqua" width=15px align="center"><big>''b2''</big><br />
<td style="background-color:aqua" width=15px align="center"><big>''b3''</big><br />
<td style="background-color:gray;" width=15px align="center"><big>:</big><br />
<td style="background-color:tomato; color:white" width=15px align="center"><big>''x1''</big><br />
<td style="background-color:tomato; color:white" width=15px align="center"><big>''x1''</big><br />
<td style="background-color:purple; color:white" width=15px align="center"><big>''y1''</big><br />
<td style="background-color:firebrick; color:white" width=15px align="center"><big>''z1''</big><br />
<td style="background-color:firebrick; color:white" width=15px align="center"><big>''z1''</big><br />
<td style="background-color:green; color:white" width=15px align="center"><big>''w1''</big><br />
<td style="background-color:green; color:white" width=15px align="center"><big>''w1''</big><br />
<td style="background-color:white;" width=15px align="center"><big>''c1''</big><br />
<td style="background-color:white;" width=15px align="center"><big>''c1''</big><br />
<td style="background-color:gray;" width=15px align="center"><big>:</big><br />
<td style="background-color:tomato; color:white" width=15px align="center"><big>''x2''</big><br />
<td style="background-color:tomato; color:white" width=15px align="center"><big>''x2''</big><br />
<td style="background-color:purple; color:white" width=15px align="center"><big>''y2''</big><br />
<td style="background-color:firebrick; color:white" width=15px align="center"><big>''z2''</big><br />
<td style="background-color:firebrick; color:white" width=15px align="center"><big>''z2''</big><br />
<td style="background-color:green; color:white" width=15px align="center"><big>''w2''</big><br />
<td style="background-color:green; color:white" width=15px align="center"><big>''w2''</big><br />
<td style="background-color:white;" width=15px align="center"><big>''c2''</big><br />
<td style="background-color:white;" width=15px align="center"><big>''c2''</big><br />
<td> (R3 if exists) </td><br />
</tr><br />
</table><br />
</center><br />
{{Twocolumn|<br />
* ''a'' ... the number of attached sugars (glycoglycerolipid) or the code of polar head group(phosphoglycerolipid)<br />
* ''b'' ... type of binding to fatty acid-1 through 3<br />
<br />
* ''x'' ... carbon chain length (fatty acid-1 through 3)<br />
* ''y'' ... degree of unsaturation (fatty acid-1 through 3)<br />
* ''z'' ... position of n-''z'' (n minus z; also ω-z or omega-z) nomenclature (fatty acid-1 through 3)<br />
* ''w'' ... structure type (fatty acid-1 through 3)<br />
* ''c'' ... serial number (fatty acid-1 through 3)<br />
|<br />
* ''a'' ... 修飾する糖の個数 (グリセロ糖脂質) もしくは極性基を示す略号 (グリセロリン脂質)<br />
* ''b'' ... 脂肪酸1および2の結合のタイプ<br />
<br />
* ''x'' ... 炭素鎖長 (脂肪酸1から3)<br />
* ''y'' ... 不飽和度 (脂肪酸1から3)<br />
* ''z'' ... n-''z'' (またはω-zやomega-z) における数 (脂肪酸1から3)<br />
* ''w'' ... 骨格のタイプ (脂肪酸1から3)<br />
* ''c'' ... 通し番号 (脂肪酸1から3)<br />
}}<br />
<br />
----></div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Category:LBG&diff=117182
Category:LBG
2023-11-29T03:05:07Z
<p>Editor: /* Glycerophospholipid */</p>
<hr />
<div>{{Huge|{{Bilingual|グリセロ脂質|Glycerolipid}} }}<br />
{{LB/Header}}<br />
{{Hierarchy|{{PAGENAME}}}}<br />
{| style="float:right"<br />
|__TOC__<br />
|}<br />
==Class Overview==<br />
<br />
{{Twocolumn|<br />
Complex lipid is the major structural component of biological membranes (lipid bilayer), and is broadly classified into glycerolipid containing glycerol and sphingolipid containing sphingoid. The glycerolipid category (LBG) includes glycoglycerolipid and phosphoglycerolipid.<br />
|<br />
リン酸や糖などを含む脂質は複合脂質と呼ばれ、細胞膜の脂質二重層の主要な構成要素です。複合脂質は、一般的にグリセロールを含む脂質 (グリセロ脂質) とスフィンゴイドを含む脂質 (スフィンゴ脂質) に大別されます。グリセロ脂質 (LBG) には、グリセロ糖脂質 (glycoglycerolipid) とグリセロリン脂質 (glycerophospholipid) が含まれます。<br />
}}<br />
<br />
={{Bilingual|略称の記載法|Common Nomenclature}}=<br />
{{Twocolumn|<br />
[https://lipidmaps.org LipidMaps Consortium] in the US defines the standard way of structure description (nomenclature). Please follow this standard especially when exact structure is not determined due to experimental procedures.<br />
|<br />
米国の[https://lipidmaps.org LipidMaps コンソーシアム]では、構造の標準的な表記法を定めています(命名系)。とりわけ分析法により構造に曖昧な部分が残る場合は、以下の表記法を踏襲してください。<br />
}}<br />
Reference: "Update on LIPID MAPS classification, nomenclature, and shorthand notation for MS-derived lipid structures" [https://www.jlr.org/article/S0022-2275(20)60017-7/fulltext <i>J Lipid Res</i> 61(12), 1539-1555, 2020]<br />
<br />
==GlyceroLipid==<br />
<br />
{{Twocolumn|<br />
Glycerolipid is referred to as mono-, di-, and triglycerides depending on the number of acyl chains (fatty acids). When sugars are attached, the modification comes before the backbone name; SQ, MG, and DG indicate Sulfoquinovose, single hexose, and double hexoses, respectively.Hexose is commonly galactose, and MG and DG may refer to mono- and digalactose.<br />
|<br />
配位するアシル基(脂肪酸)の数により、モノ・ジ・トリアシルグリセロール(それぞれ MG, DG, TG)と呼ばれます。グリセロール骨格に糖鎖が付く場合は MG や DG の前に SQ (Sulfoquinovosyl)、MG (Monoglycosyl)、DG (Diglycosyl) をつけます。MGやDGの略称はガラクトースの意味で使われる場合もあります。<br />
}}<br />
<br />
{| class="wikitable" cellpadding="4"<br />
|-<br />
! || || Monoglycosyl (単糖) || Diglycosyl (二糖) || Sulfoquinovosyl (スルホキノボース)<br />
|-<br />
| MG : || Monoacylglycerol <br/>(モノアシルグリセロール) || MGMG || DGMG || SQMG<br />
|-<br />
| DG : || Diacylglycerol <br/>(ジアシルグリセロール) || MGDG || DGDG || SQDG<br />
|-<br />
| TG : || Triacylglycerol <br/>(トリアシルグリセロール) <br />
|colspan="3" align="center"| n.a. (該当なし) <br />
|}<br />
<br />
==Glycerophospholipid==<br />
<br />
{| cellpadding="4"<br />
|-<br />
| Phosphatidic acid<br/>ホスファチジン酸 || PA, Ptd<br />
|-<br />
| Phosphatidylcholine<br/>ホスファチジルコリン || PC, PtdCho<br />
|-<br />
| Phosphatidylethanolamine<br/>ホスファチジルエタノールアミン || PE, PtdEtn<br />
|-<br />
| Phosphatidylglycerol<br/>ホスファチジルグリセロール || PG, PtdGro<br />
|-<br />
| Phosphatidylinositol<br/>ホスファチジルイノシトール || PI, PtdIns<br />
|-<br />
| Phosphatidylserine<br/>ホスファチジルセリン || PS, PtdSer<br />
|-<br />
| Cardiolipin<br/>カルジオリピン || CL, Ptd2Gro<br />
|-<br />
| Bis[monoacylglycero]phosphates<br/>ビス(モノアシルグリセロ)リン酸 || BMP<br />
|-<br />
| Phosphatidylglycerolphosphate<br/>ホスファチジルグリセロールリン酸 || PGP<br />
|-<br />
| Phosphatidylinositol-mannoside<br/>ホスファチジルイノシトールマンノシド || PIM<br />
|}<br />
<br />
<br />
<!----<br />
=={{Bilingual|分類|Classification}}==<br />
==={{Bilingual|糖の個数もしくは極性基|By the Number of Sugars or the Head Group}}===<br />
<br />
<br />
{{Twocolumn|<br />
For glycoglycerolipid, 2 digits indicate the number of sugars. For phosphoglycerolipid, common abbreviations such as PS (phosphatidylserine)or PE (phosphatidylethanolamine). <br />
|<br />
グリセロ糖脂質は結合している糖の総数を、グリセロリン脂質の場合はPS(ホスファチジルセリン)やPE(ホスファチジルエタノールアミン)等の記号を2桁で示しています。<br />
}}<br />
<br />
<br />
<br />
{| class="wikitable"<br />
|-<br />
! colspan="3" | Glycerolipid Overview<br />
|-<br />
| align="center" style="vertical-align:top" width=33%|<br />
Glycoglycerolipid<br><small>グリセロ糖脂質</small>: LBGnn<br />
<br>[[Image:LBGnn.png]]<br><br />
| align="center" style="vertical-align:top" width=33%|<br />
Phosphoglycerolipid<br><small>グリセロリン脂質</small>: LBGPn<br />
<br>[[Image:LBGPn.png]]<br><br />
|}<br />
</center><br />
<br />
<center><br />
{| class="wikitable" border="1" cellpadding="2" cellspacing="1" margin: 1em 1em 1em 1em"<br />
|+ Table 1. Classification by number of sugars or polar head group<br />
|- valign="top"<br />
|align="center"| {{MapLink|ListMol|LBGPA|LBGPA: <br>Ptd acid <br>ホスファチジン酸<br>}}<br>[[Image:LBGPA.png|90px]]<br />
|align="center"| {{MapLink|ListMol|LBGPC|LBGPC: <br>Ptd-choline<br>ホスファチジルコリン<br>}}<br>[[Image:LBGPC.png|155px]]<br />
|align="center"| {{MapLink|ListMol|LBGPE|LBGPE: <br>Ptd-ethanolamine<br>ホスファチジルエタノールアミン<br>}}<br>[[Image:LBGPE.png|135px]]<br />
|align="center"| {{MapLink|ListMol|LBGPG|LBGPG: <br>Ptd-glycerol <br>ホスファチジルグリセロール<br>}}<br>[[Image:LBGPG.png|130px]]<br />
<br />
|- valign="top"<br />
|align="center"| {{MapLink|ListMol|LBGPI|LBGPI: <br>Ptd-inositol<br>ホスファチジルイノシトール<br>}}<br>[[Image:LBGPI.png|110px]]<br />
|align="center"| {{MapLink|ListMol|LBGPS|LBGPS: <br>Ptd-serine<br>ホスファチジルセリン<br>}}<br>[[Image:LBGPS.png|150px]]<br />
|align="center"| {{MapLink|ListMol|LBGPx|LBGPx: <br>other <br>その他リン脂質<br>}}<br>[[Image:LBGPx.png|95px]]<br />
|- valign="top"<br />
|align="center"| {{MapLink|ListMol|LBGMG|LBGMG: <br>Monoacyl G<br>モノグリセリド<br>}}<br>[[Image:LBGMG.png]]<br />
|align="center"| {{MapLink|ListMol|LBGDG|LBGDG: <br>Diacyl G<br>ジグリセリド<br>}}<br>[[Image:LBGDG.png]]<br />
|align="center"| {{MapLink|ListMol|LBGTG|LBGTG: <br>Triacyl G<br>トリグリセリド<br>}}<br>[[Image:LBGTG.png]]<br />
|align="center"| {{MapLink|ListMol|LBG00|LBG00: <br>Alkyl-type G<br>含アルキル, アルケニル型<br>}}<br />
|-<br />
|align="center"| {{MapLink|ListMol|LBG01|LBG01: <br>1 sugar<br>糖の数1<br>}}<br />
|align="center"| {{MapLink|ListMol|LBG02|LBG02: <br>2 sugars<br>糖の数2<br>}}<br />
|align="center"| {{MapLink|ListMol|LBG03|LBG03: <br>3 sugars<br>糖の数3<br>}}<br />
|align="center"| {{MapLink|ListMol|LBG04|LBG04: <br>4 sugars<br>糖の数4<br>}}<br />
<br />
|}<br />
</center><br />
<br />
==={{Bilingual|その他の分類|Other Classification Charts}}===<br />
<br />
* {{#volatile:ClassMatrix|Head Group v.s. Length:Unsaturation of R1 <br>(極性基 対 R1の脂肪酸長:不飽和度)|LBG.....:.........:.........|10|12|4|5|Head_Group|Fatty_Acid_Length(R1)}}<br />
* {{#volatile:ClassMatrix|Head Group v.s. Length:Unsaturation of R2 <br>(極性基 対 R2の脂肪酸長:不飽和度)|LBG.....:.........:.........|20|22|4|5|Head_Group|Fatty_Acid_Length(R2)}}<br />
* {{#volatile:ClassMatrix|Length:Unsaturation of R1 v.s. Length:Unsaturation of R2 <br>(R2の脂肪酸長:不飽和度 対 R2の脂肪酸長:不飽和度)|LBG.....:.........:.........|10|12|20|22|Fatty_Acid_Length(R1)|Fatty_Acid_Length(R2)}}<br />
<br />
=={{Bilingual|ID番号の設計|Design of Glycerolipid Identifiers}}==<br />
<center><br />
28-DIGIT(8+9+9+2)<br />
<table border=1><br />
<tr><br />
<td style="background-color:yellowgreen;" width=15px align="center"><big>L</big><br />
<td style="background-color:yellowgreen;" width=15px align="center"><big>B</big><br />
<td style="background-color:darkseagreen;" width=15px align="center"><big>G</big><br />
<td style="background-color:Blue; color:white" width=15px align="center"><big>''a''</big><br />
<td style="background-color:Blue; color:white" width=15px align="center"><big>''a''</big><br />
<td style="background-color:aqua" width=15px align="center"><big>''b1''</big><br />
<td style="background-color:aqua" width=15px align="center"><big>''b2''</big><br />
<td style="background-color:aqua" width=15px align="center"><big>''b3''</big><br />
<td style="background-color:gray;" width=15px align="center"><big>:</big><br />
<td style="background-color:tomato; color:white" width=15px align="center"><big>''x1''</big><br />
<td style="background-color:tomato; color:white" width=15px align="center"><big>''x1''</big><br />
<td style="background-color:purple; color:white" width=15px align="center"><big>''y1''</big><br />
<td style="background-color:firebrick; color:white" width=15px align="center"><big>''z1''</big><br />
<td style="background-color:firebrick; color:white" width=15px align="center"><big>''z1''</big><br />
<td style="background-color:green; color:white" width=15px align="center"><big>''w1''</big><br />
<td style="background-color:green; color:white" width=15px align="center"><big>''w1''</big><br />
<td style="background-color:white;" width=15px align="center"><big>''c1''</big><br />
<td style="background-color:white;" width=15px align="center"><big>''c1''</big><br />
<td style="background-color:gray;" width=15px align="center"><big>:</big><br />
<td style="background-color:tomato; color:white" width=15px align="center"><big>''x2''</big><br />
<td style="background-color:tomato; color:white" width=15px align="center"><big>''x2''</big><br />
<td style="background-color:purple; color:white" width=15px align="center"><big>''y2''</big><br />
<td style="background-color:firebrick; color:white" width=15px align="center"><big>''z2''</big><br />
<td style="background-color:firebrick; color:white" width=15px align="center"><big>''z2''</big><br />
<td style="background-color:green; color:white" width=15px align="center"><big>''w2''</big><br />
<td style="background-color:green; color:white" width=15px align="center"><big>''w2''</big><br />
<td style="background-color:white;" width=15px align="center"><big>''c2''</big><br />
<td style="background-color:white;" width=15px align="center"><big>''c2''</big><br />
<td> (R3 if exists) </td><br />
</tr><br />
</table><br />
</center><br />
{{Twocolumn|<br />
* ''a'' ... the number of attached sugars (glycoglycerolipid) or the code of polar head group(phosphoglycerolipid)<br />
* ''b'' ... type of binding to fatty acid-1 through 3<br />
<br />
* ''x'' ... carbon chain length (fatty acid-1 through 3)<br />
* ''y'' ... degree of unsaturation (fatty acid-1 through 3)<br />
* ''z'' ... position of n-''z'' (n minus z; also ω-z or omega-z) nomenclature (fatty acid-1 through 3)<br />
* ''w'' ... structure type (fatty acid-1 through 3)<br />
* ''c'' ... serial number (fatty acid-1 through 3)<br />
|<br />
* ''a'' ... 修飾する糖の個数 (グリセロ糖脂質) もしくは極性基を示す略号 (グリセロリン脂質)<br />
* ''b'' ... 脂肪酸1および2の結合のタイプ<br />
<br />
* ''x'' ... 炭素鎖長 (脂肪酸1から3)<br />
* ''y'' ... 不飽和度 (脂肪酸1から3)<br />
* ''z'' ... n-''z'' (またはω-zやomega-z) における数 (脂肪酸1から3)<br />
* ''w'' ... 骨格のタイプ (脂肪酸1から3)<br />
* ''c'' ... 通し番号 (脂肪酸1から3)<br />
}}<br />
<br />
----></div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=JCBL:DBmeeting&diff=117181
JCBL:DBmeeting
2023-11-29T02:54:06Z
<p>Editor: /* 構築委員会の歴史 */</p>
<hr />
<div>==About LipidBank==<br />
<br />
{{Twocolumn|<br />
"LipidBank" is an open, publicly free database of natural lipids including fatty acids, glycerolipids, sphingolipids, steroids, and various vitamins.<br />
<br />
The database contains more than 6000 unique molecular structures (ChemDraw cdx format, MDL MOL format), their lipid names (common name, IUPAC), spectral information (mass, UV, IR, NMR and others), and most importantly, literature information.<br />
<br />
The database lists natural lipids only, and all molecular information is manually curated and approved by experts in lipid research (see Informant in each record).<br />
<br />
LipidBank is the official database of the Japanese Conference on the Biochemistry of Lipids (JCBL).<br />
<br />
<br/>'''Reference:'''<br/><br />
Watanabe K., Yasugi E. and Oshima M. "How to search the glycolipid data in LIPIDBANK for Web: the newly developed lipid database in Japan" Trend Glycosci. and Glycotechnol. 12, 175-184, 2000. ([https://www.jstage.jst.go.jp/article/tigg1989/12/65/12_65_175/_article/-char/ja/ PDF])<br />
|<br />
LipidBankは、脂肪酸、グリセロ脂質、スフィンゴ脂質、ステロイド、各種ビタミンを含む天然脂質の公開データベースです。<br/><br />
<br />
現在6000以上の天然物構造(ChemDraw cdx形式、MDL MOL形式)について、物質名(慣用名とIUPAC)、スペクトル情報(質量、UV, IR, NMRほか)に加えて、文献情報も掲載しています。<br/><br />
<br />
このデータベースは天然物を対象としており、全データについて監修者がチェックしています。LipidBankは日本脂質生化学会の公式データベースです。<br/><br />
<br/><br />
<br />
文献:<br/><br />
渡辺清博、八杉悦子、大島美恵子「糖脂質データを日本で新しく作成された生理活性脂質データベース[LIPIDBANK for Web]で検索してみよう」Trend Glycosci. and Glycotechnol. 12, 175-184, 2000.([https://www.jstage.jst.go.jp/article/tigg1989/12/65/12_65_175/_article/-char/ja/ PDF])<br />
}}<br />
<br />
==Bylaws==<br />
<pre><br />
日本脂質生化学会脂質データベース構築委員会 規約<br />
<br />
(名称)<br />
第1条 本会を日本脂質生化学会脂質データベース構築委員会(以下、委員会という。)と称する。<br />
(設置)<br />
第2条 委員会は、日本脂質生化学会が設置する。<br />
(目的)<br />
第3条 委員会は、脂質データベース“LipidBank”の構築・維持・更新を目的とし、脂質データの集積・更新、データベースシステムの構築・維持、<br />
ならびにこれらに関連する業務をおこなう。<br />
(委員会)<br />
第4条 委員会の委員は、脂質・バイオインフォマティクスに造詣の深い日本脂質生化学会会員で構成され、日本脂質生化学会会長が任命する。<br />
2 委員会には委員長を置くこととし、原則として日本脂質生化学会会長が兼務するが、委員の中から任命することができる。<br />
3 委員会に副委員長を置くことができ、日本脂質生化学会会長が任命する。<br />
4 委員会に顧問を置くことができ、日本脂質生化学会会長が任命する。<br />
5 顧問は委員会に出席し、意見を述べることができる。<br />
(事務局)<br />
第5条 委員会に、会務に関する事務をおこなうために事務局を置く。事務局長は委員長が指名する。<br />
(雑則)<br />
第6条 この規約に定めるもののほか、必要な事項は別に定める。<br />
<br />
附則<br />
本規約は、総会の承認を経て変更することができる。<br />
<br />
(平成17年10月1日制定)<br />
(平成29年6月15日改訂)<br />
</pre><br />
<br />
<br />
==History (歴史)==<br />
{{Twocolumn|<br />
===LIPID INFORMATION SERVICE (LIPIDBANK) (1984? - 1997)===<br />
The project was started as a database in Japanese around 1984 with Grant-in-Aid for scientific research publication (Akira Hayashi). This database was succeeded in 1989 under the <br />
committee of lipid information (President: Yoshitaka Nagai), organized by the members of The Japanese Conference on the Biochemistry of Lipids (JCBL). The actual construction of the database was managed by the JCBL committee of database construction (President: Akira Hayashi, Vice-president: Nobuo Ueta, Secretary: Kiyohiro Watanabe).<br />
<br />
The database included 16 lipid classes: fatty acid, long chain aldehyde, long chain alcohol, long chain base, bile acid, glyceride, phospholipid, glycolipid, lipoprotein, lipopolysaccharide, steroid, prostanoid, ether type lipid, mycolic acid and wax.<br />
<br />
Each record contained lipid name, biological activity, source, references, structure and spectra. About 2,700 records were collected and saved on floppy discs.<br />
|<br />
===脂質情報データベース (1984? - 1997)===<br />
LipidBankの淵源は、1984年頃に獲得された科学研究費補助金(研究成果刊行費、代表者:林 陽)により構築が開始された日本語のデータベース「脂質情報データベース」である。1989年に、このデータベースは日本脂質生化学会(JCBL)により構成された脂質情報作成委員会(委員長:永井克孝)が立ち上げたプロジェクトに引き継がれ、構築が本格化した。実務は脂質情報データベース構築委員会(委員長:林 陽、副委員長:植田伸夫、システム構築と入力:渡邊清博)が担った。<br/><br />
<br />
このデータベースは、脂質を16種類に分類して集積された(脂肪酸、長鎖アルデヒド、長鎖アルコール、長鎖塩基、胆汁酸、グリセリド、リン脂質、糖脂質、リポタンパク質、リポ多糖、ステロイド、プロスタノイド、エーテル型脂質、ミコール酸、ワックスなど)。<br/><br />
<br />
各脂質の名称、生理活性、分布、文献、化学構造、スペクトルデータなどの情報が記載された。約2,700件のデータが集積され、フロッピーディスクで配布された。<br />
}}<br />
<br />
{{Twocolumn|<br />
===LIPIDBANK for Web (1996 - 1999)===<br />
The initial three-year project started as a joint research between the International Medical Center of Japan (current National Center for Global Health and Medicine) ([http://www.ncgm.go.jp/ NCGM]) and the Japan Science and Technology Corporation ([http://www.jst.go.jp/ JST]).<br />
<br />
A new executive committee was organized (President: Shoshichi Nojima, Vice-president: Mieko Oshima, Secretary: Kiyohiro Watanabe and Etsuko Yasugi).<br />
<br />
The committee decided to collect the data on 27 lipid classes in English. Molecules in each class were collected independently under 27 team leaders and 122 data informants. <br />
<br />
The database became publicly available from October 1999. The database server was placed at the University of Tokyo where the office of JCBL was located. The total number of molecules was about 5400.<br />
<br />
|<br />
===生理活性脂質データベース (1996 - 1999)===<br />
<br />
3年間の本プロジェクトは、国立国際医療センター(現:国立国際医療研究センター)([http://www.ncgm.go.jp/ NCGM]) と科学技術振興機構 ([http://www.jst.go.jp/ JST]) との共同研究として発足した。<br />
<br />
新たに生理活性脂質データベース構築検討会(委員長:野島庄七、副委員長:大島美恵子、データ入力:渡邊清博、八杉悦子)が結成された。<br />
<br />
脂質を27種類に分類して、それぞれの脂質化合物データを英語で集積した。脂質分野ごとに、各脂質を専門とする27名のデータベース構築責任者をおき、122名のデータ提供者によりデータが収載された。<br />
<br />
1999年秋にJCBLの事務局があった東京大学にサーバーを設置し、インターネット上に公開された。5,400件の脂質化合物データが収録された。<br />
}}<br />
<br />
{{Twocolumn|<br />
===Updating LIPIDBANK for Web (1999 - 2005)===<br />
After adding one lipid class (lipid peroxides), 28 lipid classes were reorganized into 17 lipid groups. <br />
<br />
The DERIVED LIPIDS group now includes fatty acid, long chain alcohol, long chain aldehyde, and long chain base and ceramide. The FAT-SOLUBLE VITAMIN group includes carotenoid, coenzyme Q, vitamin A, vitamin D, vitamin E, and vitamin K. The GLYCOLIPID group includes glycosphingolipid, glycoglycerolipid and others. The PHOSPHOLIPID group includes glycerophospholipid, PAF, and sphingophospholipid. <br />
<br />
In 2004, JCBL officially established an executive committee (President: Yousuke Seyama, Secretary: Etsuko Yasugi) for updating the database.<br />
<br />
|<br />
===生理活性脂質データベースの維持・更新(1999 - 2005)===<br />
新たに過酸化脂質の項目を加えて、17種類の脂質グループに分類して、28種類の脂質化合物について、データ集積をおこなった。<br />
<br />
誘導脂質には、脂肪酸、長鎖アルコール、長鎖アルデヒド、長鎖塩基とセラミドが含まれる。脂溶性ビタミンは、カロテノイド、コエンザイムQ、ビタミンA、D、E、Kから構成されている。糖脂質にはスフィンゴ糖脂質とグリセロ糖脂質が、リン脂質にはグリセロリン脂質、PAF、スフィンゴリン脂質が含まれる。<br />
<br />
2004年には、脂質データベース構築委員会(委員長:脊山洋右、データ入力:八杉悦子)がJCBLから公認された。<br />
}}<br />
<br />
{{Twocolumn|<br />
===Renovating LIPIDBANK for Web (2006-2007)===<br />
LIPIDBANK for Web became the official database of JCBL, to which all rights were delegated from NCGM and JST. The name of database changed to "LipidBank". <br />
<br />
The Hopanoid group was removed and the number of category is now 16. The database system and its contents were updated and reorganized by the JCBL committee members (President: Masahiro Nishijima).<br />
<br />
|<br />
===生理活性脂質データベースの刷新(2006 - 2007)===<br />
生理活性脂質データベースは2006年にNCGMとJSTから譲渡され、JCBL公認のデータベースとなった。データベースの名称を"LipidBank"と改めた。<br/><br />
<br />
脂質項目のうちホパノイドを削除し、16種類の脂質グループとした。脂質データベース構築委員会(委員長:西島正弘)が、データベースのシステムと内容の維持・更新を担当。<br />
<br />
}}<br />
<br />
{{Twocolumn|<br />
=== Linking with the Wiki version (2017-2022)===<br />
With financial support from the AMED program "Studies on Specific Activities and Functions of Lipid Molecules to Develop Innovative Medical Technologies" (PS: YOKOYAMA Shinji), wiki-based database was updated for glycosphingolipid and others.<br />
<br />
Categories in the original LipidBank were translated into static HTML pages due to security issues.<br />
|<br />
=== LipidBank Wiki との連携 (2017-2022)===<br />
AMED革新的先端研究開発支援事業 「画期的医薬品等の創出をめざす脂質の生理活性と機能の解明」(総括:横山信治)よりwiki版データベース構築の支援を受け、スフィンゴ糖脂質を中心に情報を整理、更新。<br />
<br />
旧LipidBankの各カテゴリーはセキュリティ脆弱性のためにコンテンツをHTML固定ページに変換。<br />
}}<br />
<br />
<br />
===Contact Address===<br />
{{Twocolumn|<br />
If you have questions or suggestions, please contact with:<br />
<br />
::Masanori Arita<br />
:::arita@nig.ac.jp<br />
::National Institute of Genetics<br />
|<br />
ご意見やご質問は、下記へお寄せください。<br />
<br/><br />
::有田正規<br />
:::arita@nig.ac.jp<br />
::国立遺伝学研究所<br />
}}<br />
<br />
==Members of Executive Committee of Lipid Database (脂質データベース構築委員会メンバー)==<br />
2019年 2月 27日<br />
<center><br />
{| class="wikitable"<br />
|-<br />
! colspan="3" style="text-align:center"| 委員長: 和泉 孝志 (Takashi Izumi)<br />
|-<br />
! colspan="3" style="text-align:center"| 委員<br />
|-<br />
| 青木 淳賢 (Junken Aoki) || 有田 誠 (Makoto Arita) || 有田 正規 (Masanori Arita)<br />
|-<br />
| 糸乗 前 (Saki Itonori) || 今井 博之 (Hiroyuki Imai) || 笠間 健嗣 (Takeshi Kasama)<br />
|-<br />
| 北 芳博 (Yoshihiro Kita) || 小林 哲幸 (Tetsuyuki Kobayashi) || 酒井 祥太 (Shota Sakai)<br />
|-<br />
| 清水 孝雄 (Takao Shimizu) || 中村 和生 (Kazuo Nakamura) || 八杉 悦子 (Etsuko Yasugi)<br />
|-<br />
| 横山 和明 (Kazuaki Yokoyama) || ||<br />
|-<br />
! colspan="3" style="text-align:center"| Advisors<br />
|-<br />
| 大島 美恵子(Mieko Oshima) || 脊山 洋右(Yousuke Seyama) || 西島 正弘(Masahiro Nishijima)<br />
|}<br />
</center><br />
<br />
==Funding (資金)==<br />
{|<br />
|-<br />
|colspan="2"| <big>'''1989 - 1997'''</big><br />
|-<br />
|LIPID INFORMATION SERVICE was funded by a Grant-in-Aid for Scientific Research (Grant-in-Aid for Publication of Scientific Research Results) from the Japan Society for the Promotion of Science.<br />
|LIPID INFORMATION SERVICEが日本学術振興会([http://www.jsps.go.jp/ JSPS])科学研究費に採択される。<br />
|-<br />
|colspan="2"| <big>'''1996 - 2002'''</big><br />
|-<br />
|LIPIDBANK for Web was funded by the Database Development Program of the Japan Science and Technology Agency (JST).<br />
|LIPIDBANK for Webが科学技術振興機構([http://www.jst.go.jp/ JST])に採択される。<br />
|-<br />
|colspan="2"| <big>'''2003 - 2006''', '''2009 - 2016'''</big><br />
|-<br />
|LIPIDBANK for Web was funded by a Grant-in-Aid for Scientific Research (Grant-in-Aid for Publication of Scientific Research Results) from the Japan Society for the Promotion of Science.<br />
|日本学術振興会([http://www.jsps.go.jp/ JSPS])科学研究費の研究成果公開促進費データベース事業による更新。<br />
|-<br />
|colspan="2"| <big>'''2017 - 2022'''</big><br />
|-<br />
|LIPIDBANK was funded by AMED-CREST in "Studies on Specific Activities and Functions of Lipid Molecules to Develop Innovative Medical Technologies".<br />
|AMED革新的先端研究開発支援事業 「画期的医薬品等の創出をめざす脂質の生理活性と機能の解明」(総括:横山信治)による更新。<br />
|}<br />
<br />
==構築委員会の歴史==<br />
{| class="wikitable"<br />
|-<br />
| 第1回 || 1997年1月8日 || 国立国際医療センター研究所 || 生理活性脂質データベース構築委員会<br />
|-<br />
| 第10回 || 2004年3月25日 ||学士会分館 || 脂質情報データベース推進委員会<br />
|-<br />
| 第20回 || 2007年3月8日 || 東京大学 医学部 || 脂質データベース構築委員会<br />
|-<br />
| 第30回 || 2015年5月29日 || 東京大学 薬学部 || 脂質データベース構築委員会<br />
|-<br />
| 第34回 || 2019年7月5日 || 北海道大学 || 脂質データベース構築委員会<br />
|-<br />
|colspan="4"| 2020-2022 年はCOVID-19のために中止。JCBLホームページを2010-2021年まで本サーバで維持管理してきたが、2021年より新サイト (jcbl.jp) に移行。<br />
|-<br />
| <br />
|}</div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=JCBL:DBmeeting&diff=117180
JCBL:DBmeeting
2023-11-29T02:53:18Z
<p>Editor: </p>
<hr />
<div>==About LipidBank==<br />
<br />
{{Twocolumn|<br />
"LipidBank" is an open, publicly free database of natural lipids including fatty acids, glycerolipids, sphingolipids, steroids, and various vitamins.<br />
<br />
The database contains more than 6000 unique molecular structures (ChemDraw cdx format, MDL MOL format), their lipid names (common name, IUPAC), spectral information (mass, UV, IR, NMR and others), and most importantly, literature information.<br />
<br />
The database lists natural lipids only, and all molecular information is manually curated and approved by experts in lipid research (see Informant in each record).<br />
<br />
LipidBank is the official database of the Japanese Conference on the Biochemistry of Lipids (JCBL).<br />
<br />
<br/>'''Reference:'''<br/><br />
Watanabe K., Yasugi E. and Oshima M. "How to search the glycolipid data in LIPIDBANK for Web: the newly developed lipid database in Japan" Trend Glycosci. and Glycotechnol. 12, 175-184, 2000. ([https://www.jstage.jst.go.jp/article/tigg1989/12/65/12_65_175/_article/-char/ja/ PDF])<br />
|<br />
LipidBankは、脂肪酸、グリセロ脂質、スフィンゴ脂質、ステロイド、各種ビタミンを含む天然脂質の公開データベースです。<br/><br />
<br />
現在6000以上の天然物構造(ChemDraw cdx形式、MDL MOL形式)について、物質名(慣用名とIUPAC)、スペクトル情報(質量、UV, IR, NMRほか)に加えて、文献情報も掲載しています。<br/><br />
<br />
このデータベースは天然物を対象としており、全データについて監修者がチェックしています。LipidBankは日本脂質生化学会の公式データベースです。<br/><br />
<br/><br />
<br />
文献:<br/><br />
渡辺清博、八杉悦子、大島美恵子「糖脂質データを日本で新しく作成された生理活性脂質データベース[LIPIDBANK for Web]で検索してみよう」Trend Glycosci. and Glycotechnol. 12, 175-184, 2000.([https://www.jstage.jst.go.jp/article/tigg1989/12/65/12_65_175/_article/-char/ja/ PDF])<br />
}}<br />
<br />
==Bylaws==<br />
<pre><br />
日本脂質生化学会脂質データベース構築委員会 規約<br />
<br />
(名称)<br />
第1条 本会を日本脂質生化学会脂質データベース構築委員会(以下、委員会という。)と称する。<br />
(設置)<br />
第2条 委員会は、日本脂質生化学会が設置する。<br />
(目的)<br />
第3条 委員会は、脂質データベース“LipidBank”の構築・維持・更新を目的とし、脂質データの集積・更新、データベースシステムの構築・維持、<br />
ならびにこれらに関連する業務をおこなう。<br />
(委員会)<br />
第4条 委員会の委員は、脂質・バイオインフォマティクスに造詣の深い日本脂質生化学会会員で構成され、日本脂質生化学会会長が任命する。<br />
2 委員会には委員長を置くこととし、原則として日本脂質生化学会会長が兼務するが、委員の中から任命することができる。<br />
3 委員会に副委員長を置くことができ、日本脂質生化学会会長が任命する。<br />
4 委員会に顧問を置くことができ、日本脂質生化学会会長が任命する。<br />
5 顧問は委員会に出席し、意見を述べることができる。<br />
(事務局)<br />
第5条 委員会に、会務に関する事務をおこなうために事務局を置く。事務局長は委員長が指名する。<br />
(雑則)<br />
第6条 この規約に定めるもののほか、必要な事項は別に定める。<br />
<br />
附則<br />
本規約は、総会の承認を経て変更することができる。<br />
<br />
(平成17年10月1日制定)<br />
(平成29年6月15日改訂)<br />
</pre><br />
<br />
<br />
==History (歴史)==<br />
{{Twocolumn|<br />
===LIPID INFORMATION SERVICE (LIPIDBANK) (1984? - 1997)===<br />
The project was started as a database in Japanese around 1984 with Grant-in-Aid for scientific research publication (Akira Hayashi). This database was succeeded in 1989 under the <br />
committee of lipid information (President: Yoshitaka Nagai), organized by the members of The Japanese Conference on the Biochemistry of Lipids (JCBL). The actual construction of the database was managed by the JCBL committee of database construction (President: Akira Hayashi, Vice-president: Nobuo Ueta, Secretary: Kiyohiro Watanabe).<br />
<br />
The database included 16 lipid classes: fatty acid, long chain aldehyde, long chain alcohol, long chain base, bile acid, glyceride, phospholipid, glycolipid, lipoprotein, lipopolysaccharide, steroid, prostanoid, ether type lipid, mycolic acid and wax.<br />
<br />
Each record contained lipid name, biological activity, source, references, structure and spectra. About 2,700 records were collected and saved on floppy discs.<br />
|<br />
===脂質情報データベース (1984? - 1997)===<br />
LipidBankの淵源は、1984年頃に獲得された科学研究費補助金(研究成果刊行費、代表者:林 陽)により構築が開始された日本語のデータベース「脂質情報データベース」である。1989年に、このデータベースは日本脂質生化学会(JCBL)により構成された脂質情報作成委員会(委員長:永井克孝)が立ち上げたプロジェクトに引き継がれ、構築が本格化した。実務は脂質情報データベース構築委員会(委員長:林 陽、副委員長:植田伸夫、システム構築と入力:渡邊清博)が担った。<br/><br />
<br />
このデータベースは、脂質を16種類に分類して集積された(脂肪酸、長鎖アルデヒド、長鎖アルコール、長鎖塩基、胆汁酸、グリセリド、リン脂質、糖脂質、リポタンパク質、リポ多糖、ステロイド、プロスタノイド、エーテル型脂質、ミコール酸、ワックスなど)。<br/><br />
<br />
各脂質の名称、生理活性、分布、文献、化学構造、スペクトルデータなどの情報が記載された。約2,700件のデータが集積され、フロッピーディスクで配布された。<br />
}}<br />
<br />
{{Twocolumn|<br />
===LIPIDBANK for Web (1996 - 1999)===<br />
The initial three-year project started as a joint research between the International Medical Center of Japan (current National Center for Global Health and Medicine) ([http://www.ncgm.go.jp/ NCGM]) and the Japan Science and Technology Corporation ([http://www.jst.go.jp/ JST]).<br />
<br />
A new executive committee was organized (President: Shoshichi Nojima, Vice-president: Mieko Oshima, Secretary: Kiyohiro Watanabe and Etsuko Yasugi).<br />
<br />
The committee decided to collect the data on 27 lipid classes in English. Molecules in each class were collected independently under 27 team leaders and 122 data informants. <br />
<br />
The database became publicly available from October 1999. The database server was placed at the University of Tokyo where the office of JCBL was located. The total number of molecules was about 5400.<br />
<br />
|<br />
===生理活性脂質データベース (1996 - 1999)===<br />
<br />
3年間の本プロジェクトは、国立国際医療センター(現:国立国際医療研究センター)([http://www.ncgm.go.jp/ NCGM]) と科学技術振興機構 ([http://www.jst.go.jp/ JST]) との共同研究として発足した。<br />
<br />
新たに生理活性脂質データベース構築検討会(委員長:野島庄七、副委員長:大島美恵子、データ入力:渡邊清博、八杉悦子)が結成された。<br />
<br />
脂質を27種類に分類して、それぞれの脂質化合物データを英語で集積した。脂質分野ごとに、各脂質を専門とする27名のデータベース構築責任者をおき、122名のデータ提供者によりデータが収載された。<br />
<br />
1999年秋にJCBLの事務局があった東京大学にサーバーを設置し、インターネット上に公開された。5,400件の脂質化合物データが収録された。<br />
}}<br />
<br />
{{Twocolumn|<br />
===Updating LIPIDBANK for Web (1999 - 2005)===<br />
After adding one lipid class (lipid peroxides), 28 lipid classes were reorganized into 17 lipid groups. <br />
<br />
The DERIVED LIPIDS group now includes fatty acid, long chain alcohol, long chain aldehyde, and long chain base and ceramide. The FAT-SOLUBLE VITAMIN group includes carotenoid, coenzyme Q, vitamin A, vitamin D, vitamin E, and vitamin K. The GLYCOLIPID group includes glycosphingolipid, glycoglycerolipid and others. The PHOSPHOLIPID group includes glycerophospholipid, PAF, and sphingophospholipid. <br />
<br />
In 2004, JCBL officially established an executive committee (President: Yousuke Seyama, Secretary: Etsuko Yasugi) for updating the database.<br />
<br />
|<br />
===生理活性脂質データベースの維持・更新(1999 - 2005)===<br />
新たに過酸化脂質の項目を加えて、17種類の脂質グループに分類して、28種類の脂質化合物について、データ集積をおこなった。<br />
<br />
誘導脂質には、脂肪酸、長鎖アルコール、長鎖アルデヒド、長鎖塩基とセラミドが含まれる。脂溶性ビタミンは、カロテノイド、コエンザイムQ、ビタミンA、D、E、Kから構成されている。糖脂質にはスフィンゴ糖脂質とグリセロ糖脂質が、リン脂質にはグリセロリン脂質、PAF、スフィンゴリン脂質が含まれる。<br />
<br />
2004年には、脂質データベース構築委員会(委員長:脊山洋右、データ入力:八杉悦子)がJCBLから公認された。<br />
}}<br />
<br />
{{Twocolumn|<br />
===Renovating LIPIDBANK for Web (2006-2007)===<br />
LIPIDBANK for Web became the official database of JCBL, to which all rights were delegated from NCGM and JST. The name of database changed to "LipidBank". <br />
<br />
The Hopanoid group was removed and the number of category is now 16. The database system and its contents were updated and reorganized by the JCBL committee members (President: Masahiro Nishijima).<br />
<br />
|<br />
===生理活性脂質データベースの刷新(2006 - 2007)===<br />
生理活性脂質データベースは2006年にNCGMとJSTから譲渡され、JCBL公認のデータベースとなった。データベースの名称を"LipidBank"と改めた。<br/><br />
<br />
脂質項目のうちホパノイドを削除し、16種類の脂質グループとした。脂質データベース構築委員会(委員長:西島正弘)が、データベースのシステムと内容の維持・更新を担当。<br />
<br />
}}<br />
<br />
{{Twocolumn|<br />
=== Linking with the Wiki version (2017-2022)===<br />
With financial support from the AMED program "Studies on Specific Activities and Functions of Lipid Molecules to Develop Innovative Medical Technologies" (PS: YOKOYAMA Shinji), wiki-based database was updated for glycosphingolipid and others.<br />
<br />
Categories in the original LipidBank were translated into static HTML pages due to security issues.<br />
|<br />
=== LipidBank Wiki との連携 (2017-2022)===<br />
AMED革新的先端研究開発支援事業 「画期的医薬品等の創出をめざす脂質の生理活性と機能の解明」(総括:横山信治)よりwiki版データベース構築の支援を受け、スフィンゴ糖脂質を中心に情報を整理、更新。<br />
<br />
旧LipidBankの各カテゴリーはセキュリティ脆弱性のためにコンテンツをHTML固定ページに変換。<br />
}}<br />
<br />
<br />
===Contact Address===<br />
{{Twocolumn|<br />
If you have questions or suggestions, please contact with:<br />
<br />
::Masanori Arita<br />
:::arita@nig.ac.jp<br />
::National Institute of Genetics<br />
|<br />
ご意見やご質問は、下記へお寄せください。<br />
<br/><br />
::有田正規<br />
:::arita@nig.ac.jp<br />
::国立遺伝学研究所<br />
}}<br />
<br />
==Members of Executive Committee of Lipid Database (脂質データベース構築委員会メンバー)==<br />
2019年 2月 27日<br />
<center><br />
{| class="wikitable"<br />
|-<br />
! colspan="3" style="text-align:center"| 委員長: 和泉 孝志 (Takashi Izumi)<br />
|-<br />
! colspan="3" style="text-align:center"| 委員<br />
|-<br />
| 青木 淳賢 (Junken Aoki) || 有田 誠 (Makoto Arita) || 有田 正規 (Masanori Arita)<br />
|-<br />
| 糸乗 前 (Saki Itonori) || 今井 博之 (Hiroyuki Imai) || 笠間 健嗣 (Takeshi Kasama)<br />
|-<br />
| 北 芳博 (Yoshihiro Kita) || 小林 哲幸 (Tetsuyuki Kobayashi) || 酒井 祥太 (Shota Sakai)<br />
|-<br />
| 清水 孝雄 (Takao Shimizu) || 中村 和生 (Kazuo Nakamura) || 八杉 悦子 (Etsuko Yasugi)<br />
|-<br />
| 横山 和明 (Kazuaki Yokoyama) || ||<br />
|-<br />
! colspan="3" style="text-align:center"| Advisors<br />
|-<br />
| 大島 美恵子(Mieko Oshima) || 脊山 洋右(Yousuke Seyama) || 西島 正弘(Masahiro Nishijima)<br />
|}<br />
</center><br />
<br />
==Funding (資金)==<br />
{|<br />
|-<br />
|colspan="2"| <big>'''1989 - 1997'''</big><br />
|-<br />
|LIPID INFORMATION SERVICE was funded by a Grant-in-Aid for Scientific Research (Grant-in-Aid for Publication of Scientific Research Results) from the Japan Society for the Promotion of Science.<br />
|LIPID INFORMATION SERVICEが日本学術振興会([http://www.jsps.go.jp/ JSPS])科学研究費に採択される。<br />
|-<br />
|colspan="2"| <big>'''1996 - 2002'''</big><br />
|-<br />
|LIPIDBANK for Web was funded by the Database Development Program of the Japan Science and Technology Agency (JST).<br />
|LIPIDBANK for Webが科学技術振興機構([http://www.jst.go.jp/ JST])に採択される。<br />
|-<br />
|colspan="2"| <big>'''2003 - 2006''', '''2009 - 2016'''</big><br />
|-<br />
|LIPIDBANK for Web was funded by a Grant-in-Aid for Scientific Research (Grant-in-Aid for Publication of Scientific Research Results) from the Japan Society for the Promotion of Science.<br />
|日本学術振興会([http://www.jsps.go.jp/ JSPS])科学研究費の研究成果公開促進費データベース事業による更新。<br />
|-<br />
|colspan="2"| <big>'''2017 - 2022'''</big><br />
|-<br />
|LIPIDBANK was funded by AMED-CREST in "Studies on Specific Activities and Functions of Lipid Molecules to Develop Innovative Medical Technologies".<br />
|AMED革新的先端研究開発支援事業 「画期的医薬品等の創出をめざす脂質の生理活性と機能の解明」(総括:横山信治)による更新。<br />
|}<br />
<br />
==構築委員会の歴史==<br />
{| class="wikitable"<br />
|-<br />
| 第1回 || 1997年1月8日 || 国立国際医療センター研究所 || 生理活性脂質データベース構築委員会<br />
|-<br />
| 第10回 || 2004年3月25日 ||学士会分館 || 脂質情報データベース推進委員会<br />
|-<br />
| 第20回 || 2007年3月8日 || 東京大学 医学部 || 脂質データベース構築委員会<br />
|-<br />
| 第30回 || 2015年5月29日 || 東京大学 薬学部 || 脂質データベース構築委員会<br />
|-<br />
| 第34回 || 2019年7月5日 || 北海道大学 || 脂質データベース構築委員会<br />
|-<br />
| 2020-2022 年はCOVID-19のために中止。JCBLホームページを2010-2021年まで本サーバで維持管理してきたが、2021年より新サイト (jcbl.jp) に移行。<br />
|-<br />
| <br />
|}</div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Category:LB&diff=117179
Category:LB
2023-11-29T01:49:49Z
<p>Editor: </p>
<hr />
<div>{{Huge|LipidBank Database}}<br />
{{LB/Header}}<br />
{{Twocolumn|<br />
LipidBank Database is an official data resource of [https://web.jcbl.jp/ JCBL] (Japanese Conference of Biochemistry of Lipids).<br />
Database contents are curated by [[JCBL:DBmeeting|a committee under JCBL]]. For citing this resource, please use the following information.<br />
|<br />
LipidBankデータベースは [https://web.jcbl.jp/ 日本脂質生化学会] の公式データベースです。内容はJCBLの[[JCBL:DBmeeting|構築委員会]]によって管理されています。<br />
引用される場合は以下の文献を利用してください。<br />
}}<br />
; References<br />
* Yasugi E, Watanabe K "LIPIDBANK for Web, the newly developed lipid database" Tanpakushitsu Kakusan Koso. 47(7), 837-841, 2002 (in Japanese; 日本語)<br />
* Watanabe K., Yasugi E. and Oshima M. "How to search the glycolipid data in LIPIDBANK for Web: the newly developed lipid database" Japan Trend Glycosci. and Glycotechnol. 12, 175-184, 2000<br />
* [[JCBL:DBmeeting|LipidBank History & Committee page]]<br />
<br />
; Related projects<br />
* [https://lipidbank.jp/ Original LipidBank Database]<br />
* [[Lipoquality:Database|LipoQuality Database]]<br />
<br />
<center><br />
{| class="wikitable"<br />
|-<br />
! colspan="3" | LipidBank Class Overview<br />
|-<br />
| align="left" style="vertical-align:top" width=33%|<br />
[[:Category:LBF|LBF: Fatty acyls <br><small>脂肪酸アシル</small>]] <br />
<br>[[Image:LBF.png|100px]]<br><br />
<br />
;Links to the original LipidBank<br />
:[https://lipidbank.jp/DFA.html fatty acids]<br />
:[https://lipidbank.jp/DLL.html long-chain alcohol]<br />
:[https://lipidbank.jp/DLD.html long-chain aldehyde]<br />
:[https://lipidbank.jp/XPR.html eicosanoids]<br />
:[https://lipidbank.jp/OPO.html lipid peroxide]<br />
:[https://lipidbank.jp/WWA.html wax]<br />
:[https://lipidbank.jp/MMA.html mycolic acid]<br />
<br />
<br />
| align="left" style="vertical-align:top" width=33%|<br />
[[:Category:LBG|LBG: Glycerolipids<br><small>グリセロ脂質</small>]]<br />
<br>[[Image:LBG.png|100px]]<br><br />
<br />
;Links to the original LipidBank<br />
:[https://lipidbank.jp/NAG.html acylglycerols]<br />
:[https://lipidbank.jp/PGP.html glycerophospholipid]<br />
:[https://lipidbank.jp/EEA.html ether-type lipid]<br />
:[https://lipidbank.jp/GGG.html glycoglycerolipid]<br />
* [[:Category:LBGA|LBGA: Archaeal Lipid (Ether-type)<br/><small>古細菌の脂質</small>]] <br />
<br />
| align="left" style="vertical-align:top" width=33%|<br />
[[:Category:LBS|LBS: Sphingolipids<br><small>スフィンゴ脂質</small>]] (new)<br />
<br>[[Image:LBS.png|110px]]<br><br />
<br />
* [[:Category:LBSB|LBSB: long-chain base and ceramide]]<br />
* [[:Category:LBSC|LBSC: cerebroside]]<br />
* [[:Category:LBSG|LBSG: acidic glycosphingolipid]]<br />
* [[:Category:LBSP|LBSP: phospho-sphingolipid]]<br />
<br />
|-<br />
| style="vertical-align:top"| Sterol Lipids<br />
<br/>[[File:Cholestane.png]]<br/><br />
;Links to the original LipidBank<br />
:[https://lipidbank.jp/SST.html steroid]<br />
:[https://lipidbank.jp/BBA.html bile acid]<br />
:[https://lipidbank.jp/VVD.html vitamin D]<br />
<br />
<br />
| style="vertical-align:top"| Prenol Lipids<br />
<br/><BIG>(</BIG> [[File:Isoprene.png]]<BIG>)</BIG><sub>n</sub><br/><br />
;Links to the original LipidBank<br />
:[https://lipidbank.jp/IIP.html isoprenoid]<br />
:[https://lipidbank.jp/VCA.html carotenoid]<br />
:[https://lipidbank.jp/VVA.html vitamin A]<br />
:[https://lipidbank.jp/VVK.html vitamin K]<br />
:[https://lipidbank.jp/VCQ.html coenzyme Q]<br />
<br />
<br />
| style="vertical-align:top"| Others<br />
<br />
;Links to the original LipidBank<br />
:[https://lipidbank.jp/CLS.html lipopolysaccharide]<br />
:[https://lipidbank.jp/ALA.html lipoamino acid]<br />
:[https://lipidbank.jp/TLP.html lipoprotein]<br />
:[https://lipidbank.jp/VVE.html vitamin E]<br />
:[https://lipidbank.jp/NAG.html acylglycerols]<br />
<br />
|}<br />
</center><br />
<br />
{{Twocolumn|<br />
Biogenic substances insoluble to water are collectively called as '''lipid'''. Lipid is generally classified into the following three types.<br />
* '''Simple lipid''' ... fatty acid esters of alchohol such as glycerol and sphingoid base.<br />
* '''Complex lipid''' ... glycosylated or phosphorylated version of the simple lipid.<br />
* '''Derived lipid''' ... alcohols and fatty acids derived by hydrolyzing the simple lipid. Also includes sterols and polyketides.<br />
|<br />
水に溶けない生体成分を一般に脂質と呼び、以下の3つに分けられます。<br />
* '''単純脂質''' ... アルコールと脂肪酸のエステルで、スフィンゴ骨格とグリセロ骨格のものに大別されます。<br />
* '''複合脂質''' ... 単純脂質にリン酸や糖がついたものです。<br />
* '''誘導脂質''' ... 単純脂質を分解して得られるアルコール、脂肪酸。ステロールやポリケチドもここに含めます。<br />
}}<br />
<br />
<br />
<!---- Class Information (Do not delete)<br />
&&LB&&Lipid<br />
&&LBS&&Sphingolipid<br />
&&LBSB&&Sphingoid base<br />
&&LBSR&&Ceramide<br />
&&LBSG&&Glycosphingolipid<br />
&&LBSP&&Phosphosphingolipid<br />
&&LBG&&Glycerolipid<br />
&&LBGG&&Glycoglycerolipid<br />
&&LBGP&&Phosphoglycerolipid<br />
<br />
&&LBF&&Fatty Acyl<br />
<br />
&&LBFA&&Fatty Acyl<br />
&&LBFA01&&Fatty Acids and Conjugates<br />
&&LBFA0101&&Straight chain fatty acids<br />
&&LBFA0102&&Methyl branched fatty acids<br />
&&LBFA0103&&Unsaturated fatty acids<br />
&&LBFA0104&&Hydroperoxy fatty acids<br />
&&LBFA0105&&Hydroxy fatty acids<br />
&&LBFA0106&&Oxo fatty acids<br />
&&LBFA0107&&Epoxy fatty acids<br />
&&LBFA0108&&Methoxy fatty acids<br />
&&LBFA0109&&Halogenated fatty acids<br />
&&LBFA0110&&Amino fatty acids<br />
&&LBFA0111&&Cyano fatty acids<br />
&&LBFA0112&&Nitro fatty acids<br />
&&LBFA0113&&Thia fatty acids<br />
&&LBFA0114&&Carbocyclic fatty acids<br />
&&LBFA0115&&Heterocyclic fatty acids<br />
&&LBFA0116&&Mycolic acids<br />
&&LBFA0117&&Dicarboxylic acids<br />
&&LBFA02&&Octadecanoids<br />
&&LBFA0201&&12-oxophytodienoic acid metabolites<br />
&&LBFA0202&&jasmonic acids<br />
&&LBFA03&&Eicosanoids<br />
&&LBFA0301&&Prostaglandins<br />
&&LBFA0302&&Leukotrienes<br />
&&LBFA0303&&Thromboxanes<br />
&&LBFA0304&&Lipoxins<br />
&&LBFA0305&&Hydroxyeicosatrienoic acids<br />
&&LBFA0306&&Hydroxyeicosatetraenoic acids<br />
&&LBFA0307&&Hydroxyeicosapentaenoic acids<br />
&&LBFA0308&&Epoxyeicosatetraenoic acids<br />
&&LBFA0309&&Hepoxilins<br />
&&LBFA0310&&Levuglandins<br />
&&LBFA0311&&Isoprostanes<br />
&&LBFA0312&&Clavulones<br />
&&LBFA04&&Docosanoids<br />
&&LBFA05&&Fatty alcohols<br />
&&LBFA06&&Fatty aldehydes<br />
&&LBFA07&&Fatty esters<br />
&&LBFA0701&&Wax monoesters<br />
&&LBFA0702&&Wax diesters<br />
&&LBFA0703&&Cyano esters<br />
&&LBFA0704&&Lactones<br />
&&LBFA0705&&Fatty acyl CoAs<br />
&&LBFA0706&&Fatty acyl ACPs<br />
&&LBFA0707&&Fatty acyl carnitines<br />
&&LBFA0708&&Fatty acyl adenylates<br />
&&LBFA08&&Fatty amides<br />
&&LBFA0801&&Primary amides<br />
&&LBFA0802&&N-acyl amides<br />
&&LBFA0803&&Fatty acyl homoserine lactones<br />
&&LBFA0804&&N-acyl ethanolamides (endocannabinoids)<br />
&&LBFA09&&Fatty nitriles<br />
&&LBFA10&&Fatty ethers<br />
&&LBFA11&&Hydrocarbons<br />
&&LBFA12&&Oxygenated hydrocarbons<br />
&&LBFA00&&Other<br />
&&LBGL&&Glycerolipids<br />
&&LBGL01&&Monoradylglycerols<br />
&&LBGL0101&&Monoacylglycerols<br />
&&LBGL0102&&Monoalkylglycerols<br />
&&LBGL0103&&Mono-(1Z-alkenyl)-glycerols<br />
&&LBGL0104&&Monoacylglycerolglycosides<br />
&&LBGL0105&&Monoalkylglycerolglycosides<br />
&&LBGL02&&Diradylglycerols<br />
&&LBGL0201&&Diacylglycerols<br />
&&LBGL0202&&Alkylacylglycerols<br />
&&LBGL0203&&Dialkylglycerols<br />
&&LBGL0204&&1Z-alkenylacylglycerols<br />
&&LBGL0205&&Diacylglycerolglycosides<br />
&&LBGL0206&&Alkylacylglycerolglycosides<br />
&&LBGL0207&&Dialkylglycerolglycosides<br />
&&LBGL0208&&Di-glycerol tetraethers<br />
&&LBGL0209&&Di-glycerol tetraether glycans<br />
&&LBGL03&&Triradylglycerols<br />
&&LBGL0301&&Triacylglycerols<br />
&&LBGL0302&&Alkyldiacylglycerols<br />
&&LBGL0303&&Dialkylmonoacylglycerols<br />
&&LBGL0304&&1Z-alkenyldiacylglycerols<br />
&&LBGL0305&&Estolides<br />
&&LBGL00&&Other<br />
&&LBGP&&Glycerophospholipids<br />
&&LBGP01&&Glycerophosphocholines<br />
&&LBGP0101&&Diacylglycerophosphocholines<br />
&&LBGP0102&&1-alkyl,2-acylglycerophosphocholines<br />
&&LBGP0103&&1Z-alkenyl,2-acylglycerophosphocholines<br />
&&LBGP0104&&Dialkylglycerophosphocholines<br />
&&LBGP0105&&Monoacylglycerophosphocholines<br />
&&LBGP0106&&1-alkyl glycerophosphocholines<br />
&&LBGP0107&&1Z-alkenylglycerophosphocholines<br />
&&LBGP02&&Glycerophosphoethanolamines<br />
&&LBGP0201&&Diacylglycerophosphoethanolamines<br />
&&LBGP0202&&1-alkyl,2-acylglycerophosphoethanolamines<br />
&&LBGP0203&&1Z-alkenyl,2-acylglycerophosphoethanolamines<br />
&&LBGP0204&&Dialkylglycerophosphoethanolamines<br />
&&LBGP0205&&Monoacylglycerophosphoethanolamines<br />
&&LBGP0206&&1-alkyl glycerophosphoethanolamines<br />
&&LBGP0207&&1Z-alkenylglycerophosphoethanolamines<br />
&&LBGP03&&Glycerophosphoserines<br />
&&LBGP0301&&Diacylglycerophosphoserines<br />
&&LBGP0302&&1-alkyl,2-acylglycerophosphoserines<br />
&&LBGP0303&&1Z-alkenyl,2-acylglycerophosphoserines<br />
&&LBGP0304&&Dialkylglycerophosphoserines<br />
&&LBGP0305&&Monoacylglycerophosphoserines<br />
&&LBGP0306&&1-alkyl glycerophosphoserines<br />
&&LBGP0307&&1Z-alkenylglycerophosphoserines<br />
&&LBGP04&&Glycerophosphoglycerols<br />
&&LBGP0401&&Diacylglycerophosphoglycerols<br />
&&LBGP0402&&1-alkyl,2-acylglycerophosphoglycerols<br />
&&LBGP0403&&1Z-alkenyl,2-acylglycerophosphoglycerols<br />
&&LBGP0404&&Dialkylglycerophosphoglycerols<br />
&&LBGP0405&&Monoacylglycerophosphoglycerols<br />
&&LBGP0406&&1-alkyl glycerophosphoglycerols<br />
&&LBGP0407&&1Z-alkenylglycerophosphoglycerols<br />
&&LBGP0408&&Diacylglycerophosphodiradylglycerols<br />
&&LBGP0409&&Diacylglycerophosphomonoradylglycerols<br />
&&LBGP0410&&Monoacylglycerophosphomonoradylglycerols<br />
&&LBGP05&&Glycerophosphoglycerophosphates<br />
&&LBGP0501&&Diacylglycerophosphoglycerophosphates<br />
&&LBGP0502&&1-alkyl,2-acylglycerophosphoglycerophosphates<br />
&&LBGP0503&&1Z-alkenyl,2-acylglycerophosphoglycerophosphates<br />
&&LBGP0504&&Dialkylglycerophosphoglycerophosphates<br />
&&LBGP0505&&Monoacylglycerophosphoglycerophosphates<br />
&&LBGP0506&&1-alkyl glycerophosphoglycerophosphates<br />
&&LBGP0507&&1Z-alkenylglycerophosphoglycerophosphates<br />
&&LBGP06&&Glycerophosphoinositols<br />
&&LBGP0601&&Diacylglycerophosphoinositols<br />
&&LBGP0602&&1-alkyl,2-acylglycerophosphoinositols<br />
&&LBGP0603&&1Z-alkenyl,2-acylglycerophosphoinositols<br />
&&LBGP0604&&Dialkylglycerophosphoinositols<br />
&&LBGP0605&&Monoacylglycerophosphoinositols<br />
&&LBGP0606&&1-alkyl glycerophosphoinositols<br />
&&LBGP0607&&1Z-alkenylglycerophosphoinositols<br />
&&LBGP07&&Glycerophosphoinositol monophosphates<br />
&&LBGP0701&&Diacylglycerophosphoinositol monophosphates<br />
&&LBGP0702&&1-alkyl,2-acylglycerophosphoinositol monophosphates<br />
&&LBGP0703&&1Z-alkenyl,2-acylglycerophosphoinositol monophosphates<br />
&&LBGP0704&&Dialkylglycerophosphoinositol monophosphates<br />
&&LBGP0705&&Monoacylglycerophosphoinositol monophosphates<br />
&&LBGP0706&&1-alkyl glycerophosphoinositol monophosphates<br />
&&LBGP0707&&1Z-alkenylglycerophosphoinositol monophosphates<br />
&&LBGP08&&Glycerophosphoinositol bisphosphates<br />
&&LBGP0801&&Diacylglycerophosphoinositol bisphosphates<br />
&&LBGP0802&&1-alkyl,2-acylglycerophosphoinositol bisphosphates<br />
&&LBGP0803&&1Z-alkenyl,2-acylglycerophosphoinositol bisphosphates<br />
&&LBGP0804&&Monoacylglycerophosphoinositol bisphosphates<br />
&&LBGP0805&&1-alkyl glycerophosphoinositol bisphosphates<br />
&&LBGP0806&&1Z-alkenylglycerophosphoinositol bisphosphates<br />
&&LBGP09&&Glycerophosphoinositol trisphosphates<br />
&&LBGP0901&&Diacylglycerophosphoinositol trisphosphates<br />
&&LBGP0902&&1-alkyl,2-acylglycerophosphoinositol trisphosphates<br />
&&LBGP0903&&1Z-alkenyl,2-acylglycerophosphoinositol trisphosphates<br />
&&LBGP0904&&Monoacylglycerophosphoinositol trisphosphates<br />
&&LBGP0905&&1-alkyl glycerophosphoinositol trisphosphates<br />
&&LBGP0906&&1Z-alkenylglycerophosphoinositol trisphosphates<br />
&&LBGP10&&Glycerophosphates<br />
&&LBGP1001&&Diacylglycerophosphates<br />
&&LBGP1002&&1-alkyl,2-acylglycerophosphates<br />
&&LBGP1003&&1Z-alkenyl,2-acylglycerophosphates<br />
&&LBGP1004&&Dialkylglycerophosphates<br />
&&LBGP1005&&Monoacylglycerophosphates<br />
&&LBGP1006&&1-alkyl glycerophosphates<br />
&&LBGP1007&&1Z-alkenylglycerophosphates<br />
&&LBGP11&&Glyceropyrophosphates<br />
&&LBGP1101&&Diacylglyceropyrophosphates<br />
&&LBGP1102&&Monoacylglyceropyrophosphates<br />
&&LBGP12&&Glycerophosphoglycerophosphoglycerols (Cardiolipins)<br />
&&LBGP1201&&Diacylglycerophosphoglycerophosphodiradylglycerols<br />
&&LBGP1202&&Diacylglycerophosphoglycerophosphomonoradylglycerols<br />
&&LBGP1203&&1-alkyl,2-acylglycerophosphoglycerophosphodiradylglycerols<br />
&&LBGP1204&&1-alkyl,2-acylglycerophosphoglycerophosphomonoradylglycerols<br />
&&LBGP1205&&1Z-alkenyl,2-acylglycerophosphoglycerophosphodiradylglycerols<br />
&&LBGP1206&&1Z-alkenyl,2-acylglycerophosphoglycerophosphomonoradylglycerols<br />
&&LBGP1207&&Monoacylglycerophosphoglycerophosphomonoradylglycerols<br />
&&LBGP1208&&1-alkyl glycerophosphoglycerophosphodiradylglycerols<br />
&&LBGP1209&&1-alkyl glycerophosphoglycerophosphomonoradylglycerols<br />
&&LBGP1210&&1Z-alkenylglycerophosphoglycerophosphodiradylglycerols<br />
&&LBGP1211&&1Z-alkenylglycerophosphoglycerophosphomonoradylglycerols<br />
&&LBGP13&&CDP-Glycerols<br />
&&LBGP1301&&CDP-diacylglycerols<br />
&&LBGP1302&&CDP-1-alkyl,2-acylglycerols<br />
&&LBGP1303&&CDP-1Z-alkenyl,2-acylglycerols<br />
&&LBGP1304&&CDP-Dialkylglycerols<br />
&&LBGP1305&&CDP-Monoacylglycerols<br />
&&LBGP1306&&CDP-1-alkyl glycerols<br />
&&LBGP1307&&CDP-1Z-alkenylglycerols<br />
&&LBGP14&&Glycerophosphoglucose lipids<br />
&&LBGP1401&&Diacylglycerophosphoglucose lipids<br />
&&LBGP1402&&1-alkyl,2-acylglycerophosphoglucose lipids<br />
&&LBGP1403&&1Z-alkenyl,2-acylglycerophosphoglucose lipids<br />
&&LBGP1404&&Monoacylglycerophosphoglucose lipids<br />
&&LBGP1405&&1-alkyl glycerophosphoglucose lipids<br />
&&LBGP1406&&1Z-alkenylglycerophosphoglucose lipids<br />
&&LBGP15&&Glycerophosphoinositolglycans<br />
&&LBGP1501&&Diacylglycerophosphoinositolglycans<br />
&&LBGP1502&&1-alkyl,2-acylglycerophosphoinositolglycans<br />
&&LBGP1503&&1Z-alkenyl,2-acylglycerophosphoinositolglycans<br />
&&LBGP1504&&Monoacylglycerophosphoinositolglycans<br />
&&LBGP1505&&1-alkyl glycerophosphoinositolglycans<br />
&&LBGP1506&&1Z-alkenylglycerophosphoinositolglycans<br />
&&LBGP16&&Glycerophosphonocholines<br />
&&LBGP1601&&Diacylglycerophosphonocholines<br />
&&LBGP1602&&1-alkyl,2-acylglycerophosphonocholines<br />
&&LBGP1603&&1Z-alkenyl,2-acylglycerophosphonocholines<br />
&&LBGP1604&&Dialkylglycerophosphonocholines<br />
&&LBGP1605&&Monoacylglycerophosphonocholines<br />
&&LBGP1606&&1-alkyl glycerophosphonocholines<br />
&&LBGP1607&&1Z-alkenylglycerophosphonocholines<br />
&&LBGP17&&Glycerophosphonoethanolamines<br />
&&LBGP1701&&Diacylglycerophosphonoethanolamines<br />
&&LBGP1702&&1-alkyl,2-acylglycerophosphonoethanolamines<br />
&&LBGP1703&&1Z-alkenyl,2-acylglycerophosphonoethanolamines<br />
&&LBGP1704&&Dialkylglycerophosphonoethanolamines<br />
&&LBGP1705&&Monoacylglycerophosphonoethanolamines<br />
&&LBGP1706&&1-alkyl glycerophosphonoethanolamines<br />
&&LBGP1707&&1Z-alkenylglycerophosphonoethanolamines<br />
&&LBGP18&&Di-glycerol tetraether phospholipids (caldarchaeols)<br />
&&LBGP19&&Glycerol-nonitol tetraether phospholipids<br />
&&LBGP20&&Oxidized glycerophospholipids<br />
&&LBGP00&&Other<br />
&&LBSP&&Sphingolipids<br />
&&LBSP01&&Sphingoid bases<br />
&&LBSP0101&&Sphing-4-enines (Sphingosines)<br />
&&LBSP0102&&Sphinganines<br />
&&LBSP0103&&4-Hydroxysphinganines (Phytosphingosines)<br />
&&LBSP0104&&Sphingoid base homologs and variants<br />
&&LBSP0105&&Sphingoid base 1-phosphates<br />
&&LBSP0106&&Lysosphingomyelins and lysoglycosphingolipids<br />
&&LBSP0107&&N-methylated sphingoid bases<br />
&&LBSP0108&&Sphingoid base analogs<br />
&&LBSP02&&Ceramides<br />
&&LBSP0201&&N-acylsphingosines (ceramides)<br />
&&LBSP0202&&N-acylsphinganines (dihydroceramides)<br />
&&LBSP0203&&N-acyl-4-hydroxysphinganines (phytoceramides)<br />
&&LBSP0204&&Acylceramides<br />
&&LBSP0205&&Ceramide 1-phosphates<br />
&&LBSP03&&Phosphosphingolipids<br />
&&LBSP0301&&Ceramide phosphocholines (sphingomyelins)<br />
&&LBSP0302&&Ceramide phosphoethanolamines<br />
&&LBSP0303&&Ceramide phosphoinositols<br />
&&LBSP04&&Phosphonosphingolipids<br />
&&LBSP05&&Neutral glycosphingolipids<br />
&&LBSP0501&&Simple Glc series (GlcCer, LacCer, etc)<br />
&&LBSP0502&&GalNAcb1-3Gala1-4Galb1-4Glc- (Globo series)<br />
&&LBSP0503&&GalNAcb1-4Galb1-4Glc- (Ganglio series)<br />
&&LBSP0504&&Galb1-3GlcNAcb1-3Galb1-4Glc- (Lacto series)<br />
&&LBSP0505&&Galb1-4GlcNAcb1-3Galb1-4Glc- (Neolacto series)<br />
&&LBSP0506&&GalNAcb1-3Gala1-3Galb1-4Glc- (Isoglobo series)<br />
&&LBSP0507&&GlcNAcb1-2Mana1-3Manb1-4Glc- (Mollu series)<br />
&&LBSP0508&&GalNAcb1-4GlcNAcb1-3Manb1-4Glc- (Arthro series)<br />
&&LBSP0509&&Gal- (Gala series)<br />
&&LBSP0510&&Other<br />
&&LBSP06&&Acidic glycosphingolipids<br />
&&LBSP0601&&Gangliosides<br />
&&LBSP0602&&Sulfoglycosphingolipids (sulfatides)<br />
&&LBSP0603&&Glucuronosphingolipids<br />
&&LBSP0604&&Phosphoglycosphingolipids<br />
&&LBSP0600&&Other<br />
&&LBSP07&&Basic glycosphingolipids<br />
&&LBSP08&&Amphoteric glycosphingolipids<br />
&&LBSP09&&Arsenosphingolipids<br />
&&LBSP00&&Other<br />
&&LBST&&Sterol Lipids<br />
&&LBST01&&Sterols<br />
&&LBST0101&&Cholesterol and derivatives<br />
&&LBST0102&&Cholesteryl esters<br />
&&LBST0103&&Phytosterols and derivatives<br />
&&LBST0104&&Marine sterols and derivatives<br />
&&LBST0105&&Fungal sterols and derivatives<br />
&&LBST02&&Steroids<br />
&&LBST0201&&C18 steroids (estrogens) and derivatives<br />
&&LBST0202&&C19 steroids (androgens) and derivatives<br />
&&LBST0203&&C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives<br />
&&LBST03&&Secosteroids<br />
&&LBST0301&&Vitamin D2 and derivatives<br />
&&LBST0302&&Vitamin D3 and derivatives<br />
&&LBST04&&Bile acids and derivatives<br />
&&LBST0401&&C24 bile acids, alcohols, and derivatives<br />
&&LBST0402&&C26 bile acids, alcohols, and derivatives<br />
&&LBST0403&&C27 bile acids, alcohols, and derivatives<br />
&&LBST0404&&C28 bile acids, alcohols, and derivatives<br />
&&LBST0405&&C22 bile acids, alcohols, and derivatives<br />
&&LBST0406&&C23 bile acids, alcohols, and derivatives<br />
&&LBST0407&&C25 bile acids, alcohols, and derivatives<br />
&&LBST0408&&C29 bile acids, alcohols, and derivatives<br />
&&LBST05&&Steroid conjugates<br />
&&LBST0501&&Glucuronides<br />
&&LBST0502&&Sulfates<br />
&&LBST0503&&Glycine conjugates<br />
&&LBST0504&&Taurine conjugates<br />
&&LBST06&&Hopanoids<br />
&&LBST00&&Other<br />
&&LBPR&&Prenol Lipids<br />
&&LBPR01&&Isoprenoids<br />
&&LBPR0101&&C5 isoprenoids<br />
&&LBPR0102&&C10 isoprenoids (monoterpenes)<br />
&&LBPR0103&&C15 isoprenoids (sesquiterpenes)<br />
&&LBPR0104&&C20 isoprenoids (diterpenes)<br />
&&LBPR0105&&C25 isoprenoids (sesterterpenes)<br />
&&LBPR0106&&C30 isoprenoids (triterpenes)<br />
&&LBPR0107&&C40 isoprenoids (tetraterpenes)<br />
&&LBPR0108&&Polyterpenes<br />
&&LBPR02&&Quinones and hydroquinones<br />
&&LBPR0201&&Ubiquinones<br />
&&LBPR0202&&Vitamin E<br />
&&LBPR0203&&Vitamin K<br />
&&LBPR03&&Polyprenols<br />
&&LBPR0301&&Bactoprenols<br />
&&LBPR0302&&Bactoprenol monophosphates<br />
&&LBPR0303&&Bactoprenol diphosphates<br />
&&LBPR0304&&Phytoprenols<br />
&&LBPR0305&&Phytoprenol monophosphates<br />
&&LBPR0306&&Phytoprenol diphosphates<br />
&&LBPR0307&&Dolichols<br />
&&LBPR0308&&Dolichol monophosphates<br />
&&LBPR0309&&Dolichol diphosphates<br />
&&LBPR00&&Other<br />
&&LBSL&&Saccharolipids<br />
&&LBSL01&&Acylaminosugars<br />
&&LBSL0101&&Monoacylaminosugars<br />
&&LBSL0102&&Diacylaminosugars<br />
&&LBSL0103&&Triacylaminosugars<br />
&&LBSL0104&&Tetraacylaminosugars<br />
&&LBSL0105&&Pentaacylaminosugars<br />
&&LBSL0106&&Hexaacylaminosugars<br />
&&LBSL0107&&Heptaacylaminosugars<br />
&&LBSL02&&Acylaminosugar glycans<br />
&&LBSL03&&Acyltrehaloses<br />
&&LBSL04&&Acyltrehalose glycans<br />
&&LBSL00&&Other<br />
&&LBPK&&Polyketides<br />
&&LBPK01&&Macrolide polyketides<br />
&&LBPK02&&Aromatic polyketides<br />
&&LBPK03&&Non-ribosomal peptide/polyketide hybrids<br />
&&LBPK00&&Other<br />
---></div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Category:LB&diff=117178
Category:LB
2023-11-29T00:28:10Z
<p>Editor: </p>
<hr />
<div>{{Huge|LipidBank Database}}<br />
{{LB/Header}}<br />
<br />
{{Twocolumn|<br />
LipidBank Database is an official data resource of [https://web.jcbl.jp/ JCBL] (Japanese Conference of Biochemistry of Lipids).<br />
Database contents are curated by a committee under JCBL. For citing this resource, please use the following articles.<br />
|<br />
LipidBankデータベースは [https://web.jcbl.jp/ 日本脂質生化学会] の公式データベースです。内容はJCBLの構築委員会によって管理されています。<br />
引用される場合は以下の文献を明記してください。<br />
}}<br />
; LipidBank References<br />
* Yasugi E, Watanabe K "LIPIDBANK for Web, the newly developed lipid database" Tanpakushitsu Kakusan Koso. 47(7), 837-841, 2002<br />
* Watanabe K., Yasugi E. and Oshima M. "How to search the glycolipid data in LIPIDBANK for Web: the newly developed lipid database" Japan Trend Glycosci. and Glycotechnol. 12, 175-184, 2000<br />
<br />
; Related projects<br />
* [https://lipidbank.jp/ Original LipidBank Database]<br />
* [[Lipoquality:Database|LipoQuality Database]]<br />
<br />
<center><br />
{| class="wikitable"<br />
|-<br />
! colspan="3" | LipidBank Class Overview<br />
|-<br />
| align="left" style="vertical-align:top" width=33%|<br />
[[:Category:LBF|LBF: Fatty acyls <br><small>脂肪酸アシル</small>]] <br />
<br>[[Image:LBF.png|100px]]<br><br />
<br />
;Links to the original LipidBank<br />
:[https://lipidbank.jp/DFA.html fatty acids]<br />
:[https://lipidbank.jp/DLL.html long-chain alcohol]<br />
:[https://lipidbank.jp/DLD.html long-chain aldehyde]<br />
:[https://lipidbank.jp/XPR.html eicosanoids]<br />
:[https://lipidbank.jp/OPO.html lipid peroxide]<br />
:[https://lipidbank.jp/WWA.html wax]<br />
:[https://lipidbank.jp/MMA.html mycolic acid]<br />
<br />
<br />
| align="left" style="vertical-align:top" width=33%|<br />
[[:Category:LBG|LBG: Glycerolipids<br><small>グリセロ脂質</small>]]<br />
<br>[[Image:LBG.png|100px]]<br><br />
<br />
;Links to the original LipidBank<br />
:[https://lipidbank.jp/NAG.html acylglycerols]<br />
:[https://lipidbank.jp/PGP.html glycerophospholipid]<br />
:[https://lipidbank.jp/EEA.html ether-type lipid]<br />
:[https://lipidbank.jp/GGG.html glycoglycerolipid]<br />
* [[:Category:LBGA|LBGA: Archaeal Lipid (Ether-type)<br/><small>古細菌の脂質</small>]] <br />
<br />
| align="left" style="vertical-align:top" width=33%|<br />
[[:Category:LBS|LBS: Sphingolipids<br><small>スフィンゴ脂質</small>]] (new)<br />
<br>[[Image:LBS.png|110px]]<br><br />
<br />
* [[:Category:LBSB|LBSB: long-chain base and ceramide]]<br />
* [[:Category:LBSC|LBSC: cerebroside]]<br />
* [[:Category:LBSG|LBSG: acidic glycosphingolipid]]<br />
* [[:Category:LBSP|LBSP: phospho-sphingolipid]]<br />
<br />
|-<br />
| style="vertical-align:top"| Sterol Lipids<br />
<br/>[[File:Cholestane.png]]<br/><br />
;Links to the original LipidBank<br />
:[https://lipidbank.jp/SST.html steroid]<br />
:[https://lipidbank.jp/BBA.html bile acid]<br />
:[https://lipidbank.jp/VVD.html vitamin D]<br />
<br />
<br />
| style="vertical-align:top"| Prenol Lipids<br />
<br/><BIG>(</BIG> [[File:Isoprene.png]]<BIG>)</BIG><sub>n</sub><br/><br />
;Links to the original LipidBank<br />
:[https://lipidbank.jp/IIP.html isoprenoid]<br />
:[https://lipidbank.jp/VCA.html carotenoid]<br />
:[https://lipidbank.jp/VVA.html vitamin A]<br />
:[https://lipidbank.jp/VVK.html vitamin K]<br />
:[https://lipidbank.jp/VCQ.html coenzyme Q]<br />
<br />
<br />
| style="vertical-align:top"| Others<br />
<br />
;Links to the original LipidBank<br />
:[https://lipidbank.jp/CLS.html lipopolysaccharide]<br />
:[https://lipidbank.jp/ALA.html lipoamino acid]<br />
:[https://lipidbank.jp/TLP.html lipoprotein]<br />
:[https://lipidbank.jp/VVE.html vitamin E]<br />
:[https://lipidbank.jp/NAG.html acylglycerols]<br />
<br />
|}<br />
</center><br />
<br />
{{Twocolumn|<br />
Biogenic substances insoluble to water are collectively called as '''lipid'''. Lipid is generally classified into the following three types.<br />
* '''Simple lipid''' ... fatty acid esters of alchohol such as glycerol and sphingoid base.<br />
* '''Complex lipid''' ... glycosylated or phosphorylated version of the simple lipid.<br />
* '''Derived lipid''' ... alcohols and fatty acids derived by hydrolyzing the simple lipid. Also includes sterols and polyketides.<br />
|<br />
水に溶けない生体成分を一般に脂質と呼び、以下の3つに分けられます。<br />
* '''単純脂質''' ... アルコールと脂肪酸のエステルで、スフィンゴ骨格とグリセロ骨格のものに大別されます。<br />
* '''複合脂質''' ... 単純脂質にリン酸や糖がついたものです。<br />
* '''誘導脂質''' ... 単純脂質を分解して得られるアルコール、脂肪酸。ステロールやポリケチドもここに含めます。<br />
}}<br />
<br />
<br />
<!---- Class Information (Do not delete)<br />
&&LB&&Lipid<br />
&&LBS&&Sphingolipid<br />
&&LBSB&&Sphingoid base<br />
&&LBSR&&Ceramide<br />
&&LBSG&&Glycosphingolipid<br />
&&LBSP&&Phosphosphingolipid<br />
&&LBG&&Glycerolipid<br />
&&LBGG&&Glycoglycerolipid<br />
&&LBGP&&Phosphoglycerolipid<br />
<br />
&&LBF&&Fatty Acyl<br />
<br />
&&LBFA&&Fatty Acyl<br />
&&LBFA01&&Fatty Acids and Conjugates<br />
&&LBFA0101&&Straight chain fatty acids<br />
&&LBFA0102&&Methyl branched fatty acids<br />
&&LBFA0103&&Unsaturated fatty acids<br />
&&LBFA0104&&Hydroperoxy fatty acids<br />
&&LBFA0105&&Hydroxy fatty acids<br />
&&LBFA0106&&Oxo fatty acids<br />
&&LBFA0107&&Epoxy fatty acids<br />
&&LBFA0108&&Methoxy fatty acids<br />
&&LBFA0109&&Halogenated fatty acids<br />
&&LBFA0110&&Amino fatty acids<br />
&&LBFA0111&&Cyano fatty acids<br />
&&LBFA0112&&Nitro fatty acids<br />
&&LBFA0113&&Thia fatty acids<br />
&&LBFA0114&&Carbocyclic fatty acids<br />
&&LBFA0115&&Heterocyclic fatty acids<br />
&&LBFA0116&&Mycolic acids<br />
&&LBFA0117&&Dicarboxylic acids<br />
&&LBFA02&&Octadecanoids<br />
&&LBFA0201&&12-oxophytodienoic acid metabolites<br />
&&LBFA0202&&jasmonic acids<br />
&&LBFA03&&Eicosanoids<br />
&&LBFA0301&&Prostaglandins<br />
&&LBFA0302&&Leukotrienes<br />
&&LBFA0303&&Thromboxanes<br />
&&LBFA0304&&Lipoxins<br />
&&LBFA0305&&Hydroxyeicosatrienoic acids<br />
&&LBFA0306&&Hydroxyeicosatetraenoic acids<br />
&&LBFA0307&&Hydroxyeicosapentaenoic acids<br />
&&LBFA0308&&Epoxyeicosatetraenoic acids<br />
&&LBFA0309&&Hepoxilins<br />
&&LBFA0310&&Levuglandins<br />
&&LBFA0311&&Isoprostanes<br />
&&LBFA0312&&Clavulones<br />
&&LBFA04&&Docosanoids<br />
&&LBFA05&&Fatty alcohols<br />
&&LBFA06&&Fatty aldehydes<br />
&&LBFA07&&Fatty esters<br />
&&LBFA0701&&Wax monoesters<br />
&&LBFA0702&&Wax diesters<br />
&&LBFA0703&&Cyano esters<br />
&&LBFA0704&&Lactones<br />
&&LBFA0705&&Fatty acyl CoAs<br />
&&LBFA0706&&Fatty acyl ACPs<br />
&&LBFA0707&&Fatty acyl carnitines<br />
&&LBFA0708&&Fatty acyl adenylates<br />
&&LBFA08&&Fatty amides<br />
&&LBFA0801&&Primary amides<br />
&&LBFA0802&&N-acyl amides<br />
&&LBFA0803&&Fatty acyl homoserine lactones<br />
&&LBFA0804&&N-acyl ethanolamides (endocannabinoids)<br />
&&LBFA09&&Fatty nitriles<br />
&&LBFA10&&Fatty ethers<br />
&&LBFA11&&Hydrocarbons<br />
&&LBFA12&&Oxygenated hydrocarbons<br />
&&LBFA00&&Other<br />
&&LBGL&&Glycerolipids<br />
&&LBGL01&&Monoradylglycerols<br />
&&LBGL0101&&Monoacylglycerols<br />
&&LBGL0102&&Monoalkylglycerols<br />
&&LBGL0103&&Mono-(1Z-alkenyl)-glycerols<br />
&&LBGL0104&&Monoacylglycerolglycosides<br />
&&LBGL0105&&Monoalkylglycerolglycosides<br />
&&LBGL02&&Diradylglycerols<br />
&&LBGL0201&&Diacylglycerols<br />
&&LBGL0202&&Alkylacylglycerols<br />
&&LBGL0203&&Dialkylglycerols<br />
&&LBGL0204&&1Z-alkenylacylglycerols<br />
&&LBGL0205&&Diacylglycerolglycosides<br />
&&LBGL0206&&Alkylacylglycerolglycosides<br />
&&LBGL0207&&Dialkylglycerolglycosides<br />
&&LBGL0208&&Di-glycerol tetraethers<br />
&&LBGL0209&&Di-glycerol tetraether glycans<br />
&&LBGL03&&Triradylglycerols<br />
&&LBGL0301&&Triacylglycerols<br />
&&LBGL0302&&Alkyldiacylglycerols<br />
&&LBGL0303&&Dialkylmonoacylglycerols<br />
&&LBGL0304&&1Z-alkenyldiacylglycerols<br />
&&LBGL0305&&Estolides<br />
&&LBGL00&&Other<br />
&&LBGP&&Glycerophospholipids<br />
&&LBGP01&&Glycerophosphocholines<br />
&&LBGP0101&&Diacylglycerophosphocholines<br />
&&LBGP0102&&1-alkyl,2-acylglycerophosphocholines<br />
&&LBGP0103&&1Z-alkenyl,2-acylglycerophosphocholines<br />
&&LBGP0104&&Dialkylglycerophosphocholines<br />
&&LBGP0105&&Monoacylglycerophosphocholines<br />
&&LBGP0106&&1-alkyl glycerophosphocholines<br />
&&LBGP0107&&1Z-alkenylglycerophosphocholines<br />
&&LBGP02&&Glycerophosphoethanolamines<br />
&&LBGP0201&&Diacylglycerophosphoethanolamines<br />
&&LBGP0202&&1-alkyl,2-acylglycerophosphoethanolamines<br />
&&LBGP0203&&1Z-alkenyl,2-acylglycerophosphoethanolamines<br />
&&LBGP0204&&Dialkylglycerophosphoethanolamines<br />
&&LBGP0205&&Monoacylglycerophosphoethanolamines<br />
&&LBGP0206&&1-alkyl glycerophosphoethanolamines<br />
&&LBGP0207&&1Z-alkenylglycerophosphoethanolamines<br />
&&LBGP03&&Glycerophosphoserines<br />
&&LBGP0301&&Diacylglycerophosphoserines<br />
&&LBGP0302&&1-alkyl,2-acylglycerophosphoserines<br />
&&LBGP0303&&1Z-alkenyl,2-acylglycerophosphoserines<br />
&&LBGP0304&&Dialkylglycerophosphoserines<br />
&&LBGP0305&&Monoacylglycerophosphoserines<br />
&&LBGP0306&&1-alkyl glycerophosphoserines<br />
&&LBGP0307&&1Z-alkenylglycerophosphoserines<br />
&&LBGP04&&Glycerophosphoglycerols<br />
&&LBGP0401&&Diacylglycerophosphoglycerols<br />
&&LBGP0402&&1-alkyl,2-acylglycerophosphoglycerols<br />
&&LBGP0403&&1Z-alkenyl,2-acylglycerophosphoglycerols<br />
&&LBGP0404&&Dialkylglycerophosphoglycerols<br />
&&LBGP0405&&Monoacylglycerophosphoglycerols<br />
&&LBGP0406&&1-alkyl glycerophosphoglycerols<br />
&&LBGP0407&&1Z-alkenylglycerophosphoglycerols<br />
&&LBGP0408&&Diacylglycerophosphodiradylglycerols<br />
&&LBGP0409&&Diacylglycerophosphomonoradylglycerols<br />
&&LBGP0410&&Monoacylglycerophosphomonoradylglycerols<br />
&&LBGP05&&Glycerophosphoglycerophosphates<br />
&&LBGP0501&&Diacylglycerophosphoglycerophosphates<br />
&&LBGP0502&&1-alkyl,2-acylglycerophosphoglycerophosphates<br />
&&LBGP0503&&1Z-alkenyl,2-acylglycerophosphoglycerophosphates<br />
&&LBGP0504&&Dialkylglycerophosphoglycerophosphates<br />
&&LBGP0505&&Monoacylglycerophosphoglycerophosphates<br />
&&LBGP0506&&1-alkyl glycerophosphoglycerophosphates<br />
&&LBGP0507&&1Z-alkenylglycerophosphoglycerophosphates<br />
&&LBGP06&&Glycerophosphoinositols<br />
&&LBGP0601&&Diacylglycerophosphoinositols<br />
&&LBGP0602&&1-alkyl,2-acylglycerophosphoinositols<br />
&&LBGP0603&&1Z-alkenyl,2-acylglycerophosphoinositols<br />
&&LBGP0604&&Dialkylglycerophosphoinositols<br />
&&LBGP0605&&Monoacylglycerophosphoinositols<br />
&&LBGP0606&&1-alkyl glycerophosphoinositols<br />
&&LBGP0607&&1Z-alkenylglycerophosphoinositols<br />
&&LBGP07&&Glycerophosphoinositol monophosphates<br />
&&LBGP0701&&Diacylglycerophosphoinositol monophosphates<br />
&&LBGP0702&&1-alkyl,2-acylglycerophosphoinositol monophosphates<br />
&&LBGP0703&&1Z-alkenyl,2-acylglycerophosphoinositol monophosphates<br />
&&LBGP0704&&Dialkylglycerophosphoinositol monophosphates<br />
&&LBGP0705&&Monoacylglycerophosphoinositol monophosphates<br />
&&LBGP0706&&1-alkyl glycerophosphoinositol monophosphates<br />
&&LBGP0707&&1Z-alkenylglycerophosphoinositol monophosphates<br />
&&LBGP08&&Glycerophosphoinositol bisphosphates<br />
&&LBGP0801&&Diacylglycerophosphoinositol bisphosphates<br />
&&LBGP0802&&1-alkyl,2-acylglycerophosphoinositol bisphosphates<br />
&&LBGP0803&&1Z-alkenyl,2-acylglycerophosphoinositol bisphosphates<br />
&&LBGP0804&&Monoacylglycerophosphoinositol bisphosphates<br />
&&LBGP0805&&1-alkyl glycerophosphoinositol bisphosphates<br />
&&LBGP0806&&1Z-alkenylglycerophosphoinositol bisphosphates<br />
&&LBGP09&&Glycerophosphoinositol trisphosphates<br />
&&LBGP0901&&Diacylglycerophosphoinositol trisphosphates<br />
&&LBGP0902&&1-alkyl,2-acylglycerophosphoinositol trisphosphates<br />
&&LBGP0903&&1Z-alkenyl,2-acylglycerophosphoinositol trisphosphates<br />
&&LBGP0904&&Monoacylglycerophosphoinositol trisphosphates<br />
&&LBGP0905&&1-alkyl glycerophosphoinositol trisphosphates<br />
&&LBGP0906&&1Z-alkenylglycerophosphoinositol trisphosphates<br />
&&LBGP10&&Glycerophosphates<br />
&&LBGP1001&&Diacylglycerophosphates<br />
&&LBGP1002&&1-alkyl,2-acylglycerophosphates<br />
&&LBGP1003&&1Z-alkenyl,2-acylglycerophosphates<br />
&&LBGP1004&&Dialkylglycerophosphates<br />
&&LBGP1005&&Monoacylglycerophosphates<br />
&&LBGP1006&&1-alkyl glycerophosphates<br />
&&LBGP1007&&1Z-alkenylglycerophosphates<br />
&&LBGP11&&Glyceropyrophosphates<br />
&&LBGP1101&&Diacylglyceropyrophosphates<br />
&&LBGP1102&&Monoacylglyceropyrophosphates<br />
&&LBGP12&&Glycerophosphoglycerophosphoglycerols (Cardiolipins)<br />
&&LBGP1201&&Diacylglycerophosphoglycerophosphodiradylglycerols<br />
&&LBGP1202&&Diacylglycerophosphoglycerophosphomonoradylglycerols<br />
&&LBGP1203&&1-alkyl,2-acylglycerophosphoglycerophosphodiradylglycerols<br />
&&LBGP1204&&1-alkyl,2-acylglycerophosphoglycerophosphomonoradylglycerols<br />
&&LBGP1205&&1Z-alkenyl,2-acylglycerophosphoglycerophosphodiradylglycerols<br />
&&LBGP1206&&1Z-alkenyl,2-acylglycerophosphoglycerophosphomonoradylglycerols<br />
&&LBGP1207&&Monoacylglycerophosphoglycerophosphomonoradylglycerols<br />
&&LBGP1208&&1-alkyl glycerophosphoglycerophosphodiradylglycerols<br />
&&LBGP1209&&1-alkyl glycerophosphoglycerophosphomonoradylglycerols<br />
&&LBGP1210&&1Z-alkenylglycerophosphoglycerophosphodiradylglycerols<br />
&&LBGP1211&&1Z-alkenylglycerophosphoglycerophosphomonoradylglycerols<br />
&&LBGP13&&CDP-Glycerols<br />
&&LBGP1301&&CDP-diacylglycerols<br />
&&LBGP1302&&CDP-1-alkyl,2-acylglycerols<br />
&&LBGP1303&&CDP-1Z-alkenyl,2-acylglycerols<br />
&&LBGP1304&&CDP-Dialkylglycerols<br />
&&LBGP1305&&CDP-Monoacylglycerols<br />
&&LBGP1306&&CDP-1-alkyl glycerols<br />
&&LBGP1307&&CDP-1Z-alkenylglycerols<br />
&&LBGP14&&Glycerophosphoglucose lipids<br />
&&LBGP1401&&Diacylglycerophosphoglucose lipids<br />
&&LBGP1402&&1-alkyl,2-acylglycerophosphoglucose lipids<br />
&&LBGP1403&&1Z-alkenyl,2-acylglycerophosphoglucose lipids<br />
&&LBGP1404&&Monoacylglycerophosphoglucose lipids<br />
&&LBGP1405&&1-alkyl glycerophosphoglucose lipids<br />
&&LBGP1406&&1Z-alkenylglycerophosphoglucose lipids<br />
&&LBGP15&&Glycerophosphoinositolglycans<br />
&&LBGP1501&&Diacylglycerophosphoinositolglycans<br />
&&LBGP1502&&1-alkyl,2-acylglycerophosphoinositolglycans<br />
&&LBGP1503&&1Z-alkenyl,2-acylglycerophosphoinositolglycans<br />
&&LBGP1504&&Monoacylglycerophosphoinositolglycans<br />
&&LBGP1505&&1-alkyl glycerophosphoinositolglycans<br />
&&LBGP1506&&1Z-alkenylglycerophosphoinositolglycans<br />
&&LBGP16&&Glycerophosphonocholines<br />
&&LBGP1601&&Diacylglycerophosphonocholines<br />
&&LBGP1602&&1-alkyl,2-acylglycerophosphonocholines<br />
&&LBGP1603&&1Z-alkenyl,2-acylglycerophosphonocholines<br />
&&LBGP1604&&Dialkylglycerophosphonocholines<br />
&&LBGP1605&&Monoacylglycerophosphonocholines<br />
&&LBGP1606&&1-alkyl glycerophosphonocholines<br />
&&LBGP1607&&1Z-alkenylglycerophosphonocholines<br />
&&LBGP17&&Glycerophosphonoethanolamines<br />
&&LBGP1701&&Diacylglycerophosphonoethanolamines<br />
&&LBGP1702&&1-alkyl,2-acylglycerophosphonoethanolamines<br />
&&LBGP1703&&1Z-alkenyl,2-acylglycerophosphonoethanolamines<br />
&&LBGP1704&&Dialkylglycerophosphonoethanolamines<br />
&&LBGP1705&&Monoacylglycerophosphonoethanolamines<br />
&&LBGP1706&&1-alkyl glycerophosphonoethanolamines<br />
&&LBGP1707&&1Z-alkenylglycerophosphonoethanolamines<br />
&&LBGP18&&Di-glycerol tetraether phospholipids (caldarchaeols)<br />
&&LBGP19&&Glycerol-nonitol tetraether phospholipids<br />
&&LBGP20&&Oxidized glycerophospholipids<br />
&&LBGP00&&Other<br />
&&LBSP&&Sphingolipids<br />
&&LBSP01&&Sphingoid bases<br />
&&LBSP0101&&Sphing-4-enines (Sphingosines)<br />
&&LBSP0102&&Sphinganines<br />
&&LBSP0103&&4-Hydroxysphinganines (Phytosphingosines)<br />
&&LBSP0104&&Sphingoid base homologs and variants<br />
&&LBSP0105&&Sphingoid base 1-phosphates<br />
&&LBSP0106&&Lysosphingomyelins and lysoglycosphingolipids<br />
&&LBSP0107&&N-methylated sphingoid bases<br />
&&LBSP0108&&Sphingoid base analogs<br />
&&LBSP02&&Ceramides<br />
&&LBSP0201&&N-acylsphingosines (ceramides)<br />
&&LBSP0202&&N-acylsphinganines (dihydroceramides)<br />
&&LBSP0203&&N-acyl-4-hydroxysphinganines (phytoceramides)<br />
&&LBSP0204&&Acylceramides<br />
&&LBSP0205&&Ceramide 1-phosphates<br />
&&LBSP03&&Phosphosphingolipids<br />
&&LBSP0301&&Ceramide phosphocholines (sphingomyelins)<br />
&&LBSP0302&&Ceramide phosphoethanolamines<br />
&&LBSP0303&&Ceramide phosphoinositols<br />
&&LBSP04&&Phosphonosphingolipids<br />
&&LBSP05&&Neutral glycosphingolipids<br />
&&LBSP0501&&Simple Glc series (GlcCer, LacCer, etc)<br />
&&LBSP0502&&GalNAcb1-3Gala1-4Galb1-4Glc- (Globo series)<br />
&&LBSP0503&&GalNAcb1-4Galb1-4Glc- (Ganglio series)<br />
&&LBSP0504&&Galb1-3GlcNAcb1-3Galb1-4Glc- (Lacto series)<br />
&&LBSP0505&&Galb1-4GlcNAcb1-3Galb1-4Glc- (Neolacto series)<br />
&&LBSP0506&&GalNAcb1-3Gala1-3Galb1-4Glc- (Isoglobo series)<br />
&&LBSP0507&&GlcNAcb1-2Mana1-3Manb1-4Glc- (Mollu series)<br />
&&LBSP0508&&GalNAcb1-4GlcNAcb1-3Manb1-4Glc- (Arthro series)<br />
&&LBSP0509&&Gal- (Gala series)<br />
&&LBSP0510&&Other<br />
&&LBSP06&&Acidic glycosphingolipids<br />
&&LBSP0601&&Gangliosides<br />
&&LBSP0602&&Sulfoglycosphingolipids (sulfatides)<br />
&&LBSP0603&&Glucuronosphingolipids<br />
&&LBSP0604&&Phosphoglycosphingolipids<br />
&&LBSP0600&&Other<br />
&&LBSP07&&Basic glycosphingolipids<br />
&&LBSP08&&Amphoteric glycosphingolipids<br />
&&LBSP09&&Arsenosphingolipids<br />
&&LBSP00&&Other<br />
&&LBST&&Sterol Lipids<br />
&&LBST01&&Sterols<br />
&&LBST0101&&Cholesterol and derivatives<br />
&&LBST0102&&Cholesteryl esters<br />
&&LBST0103&&Phytosterols and derivatives<br />
&&LBST0104&&Marine sterols and derivatives<br />
&&LBST0105&&Fungal sterols and derivatives<br />
&&LBST02&&Steroids<br />
&&LBST0201&&C18 steroids (estrogens) and derivatives<br />
&&LBST0202&&C19 steroids (androgens) and derivatives<br />
&&LBST0203&&C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives<br />
&&LBST03&&Secosteroids<br />
&&LBST0301&&Vitamin D2 and derivatives<br />
&&LBST0302&&Vitamin D3 and derivatives<br />
&&LBST04&&Bile acids and derivatives<br />
&&LBST0401&&C24 bile acids, alcohols, and derivatives<br />
&&LBST0402&&C26 bile acids, alcohols, and derivatives<br />
&&LBST0403&&C27 bile acids, alcohols, and derivatives<br />
&&LBST0404&&C28 bile acids, alcohols, and derivatives<br />
&&LBST0405&&C22 bile acids, alcohols, and derivatives<br />
&&LBST0406&&C23 bile acids, alcohols, and derivatives<br />
&&LBST0407&&C25 bile acids, alcohols, and derivatives<br />
&&LBST0408&&C29 bile acids, alcohols, and derivatives<br />
&&LBST05&&Steroid conjugates<br />
&&LBST0501&&Glucuronides<br />
&&LBST0502&&Sulfates<br />
&&LBST0503&&Glycine conjugates<br />
&&LBST0504&&Taurine conjugates<br />
&&LBST06&&Hopanoids<br />
&&LBST00&&Other<br />
&&LBPR&&Prenol Lipids<br />
&&LBPR01&&Isoprenoids<br />
&&LBPR0101&&C5 isoprenoids<br />
&&LBPR0102&&C10 isoprenoids (monoterpenes)<br />
&&LBPR0103&&C15 isoprenoids (sesquiterpenes)<br />
&&LBPR0104&&C20 isoprenoids (diterpenes)<br />
&&LBPR0105&&C25 isoprenoids (sesterterpenes)<br />
&&LBPR0106&&C30 isoprenoids (triterpenes)<br />
&&LBPR0107&&C40 isoprenoids (tetraterpenes)<br />
&&LBPR0108&&Polyterpenes<br />
&&LBPR02&&Quinones and hydroquinones<br />
&&LBPR0201&&Ubiquinones<br />
&&LBPR0202&&Vitamin E<br />
&&LBPR0203&&Vitamin K<br />
&&LBPR03&&Polyprenols<br />
&&LBPR0301&&Bactoprenols<br />
&&LBPR0302&&Bactoprenol monophosphates<br />
&&LBPR0303&&Bactoprenol diphosphates<br />
&&LBPR0304&&Phytoprenols<br />
&&LBPR0305&&Phytoprenol monophosphates<br />
&&LBPR0306&&Phytoprenol diphosphates<br />
&&LBPR0307&&Dolichols<br />
&&LBPR0308&&Dolichol monophosphates<br />
&&LBPR0309&&Dolichol diphosphates<br />
&&LBPR00&&Other<br />
&&LBSL&&Saccharolipids<br />
&&LBSL01&&Acylaminosugars<br />
&&LBSL0101&&Monoacylaminosugars<br />
&&LBSL0102&&Diacylaminosugars<br />
&&LBSL0103&&Triacylaminosugars<br />
&&LBSL0104&&Tetraacylaminosugars<br />
&&LBSL0105&&Pentaacylaminosugars<br />
&&LBSL0106&&Hexaacylaminosugars<br />
&&LBSL0107&&Heptaacylaminosugars<br />
&&LBSL02&&Acylaminosugar glycans<br />
&&LBSL03&&Acyltrehaloses<br />
&&LBSL04&&Acyltrehalose glycans<br />
&&LBSL00&&Other<br />
&&LBPK&&Polyketides<br />
&&LBPK01&&Macrolide polyketides<br />
&&LBPK02&&Aromatic polyketides<br />
&&LBPK03&&Non-ribosomal peptide/polyketide hybrids<br />
&&LBPK00&&Other<br />
---></div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Category:LB&diff=117177
Category:LB
2023-11-29T00:16:21Z
<p>Editor: </p>
<hr />
<div>{{Huge|LipidBank Database}}<br />
{{LB/Header}}<br />
<br />
; Related projects<br />
* [https://lipidbank.jp/ Original LipidBank Database]<br />
* [[Lipoquality:Database|LipoQuality Database]]<br />
<br />
<br />
<center><br />
{| class="wikitable"<br />
|-<br />
! colspan="3" | LipidBank Class Overview<br />
|-<br />
| align="left" style="vertical-align:top" width=33%|<br />
[[:Category:LBF|LBF: Fatty acyls <br><small>脂肪酸アシル</small>]] <br />
<br>[[Image:LBF.png|100px]]<br><br />
<br />
;Links to the original LipidBank<br />
:[https://lipidbank.jp/DFA.html fatty acids]<br />
:[https://lipidbank.jp/DLL.html long-chain alcohol]<br />
:[https://lipidbank.jp/DLD.html long-chain aldehyde]<br />
:[https://lipidbank.jp/XPR.html eicosanoids]<br />
:[https://lipidbank.jp/OPO.html lipid peroxide]<br />
:[https://lipidbank.jp/WWA.html wax]<br />
:[https://lipidbank.jp/MMA.html mycolic acid]<br />
<br />
<br />
| align="left" style="vertical-align:top" width=33%|<br />
[[:Category:LBG|LBG: Glycerolipids<br><small>グリセロ脂質</small>]]<br />
<br>[[Image:LBG.png|100px]]<br><br />
<br />
;Links to the original LipidBank<br />
:[https://lipidbank.jp/NAG.html acylglycerols]<br />
:[https://lipidbank.jp/PGP.html glycerophospholipid]<br />
:[https://lipidbank.jp/EEA.html ether-type lipid]<br />
:[https://lipidbank.jp/GGG.html glycoglycerolipid]<br />
* [[:Category:LBGA|LBGA: Archaeal Lipid (Ether-type)<br/><small>古細菌の脂質</small>]] <br />
<br />
| align="left" style="vertical-align:top" width=33%|<br />
[[:Category:LBS|LBS: Sphingolipids<br><small>スフィンゴ脂質</small>]] (new)<br />
<br>[[Image:LBS.png|110px]]<br><br />
<br />
* [[:Category:LBSB|LBSB: long-chain base and ceramide]]<br />
* [[:Category:LBSC|LBSC: cerebroside]]<br />
* [[:Category:LBSG|LBSG: acidic glycosphingolipid]]<br />
* [[:Category:LBSP|LBSP: phospho-sphingolipid]]<br />
<br />
|-<br />
| style="vertical-align:top"| Sterol Lipids<br />
<br/>[[File:Cholestane.png]]<br/><br />
;Links to the original LipidBank<br />
:[https://lipidbank.jp/SST.html steroid]<br />
:[https://lipidbank.jp/BBA.html bile acid]<br />
:[https://lipidbank.jp/VVD.html vitamin D]<br />
<br />
<br />
| style="vertical-align:top"| Prenol Lipids<br />
<br/><BIG>(</BIG> [[File:Isoprene.png]]<BIG>)</BIG><sub>n</sub><br/><br />
;Links to the original LipidBank<br />
:[https://lipidbank.jp/IIP.html isoprenoid]<br />
:[https://lipidbank.jp/VCA.html carotenoid]<br />
:[https://lipidbank.jp/VVA.html vitamin A]<br />
:[https://lipidbank.jp/VVK.html vitamin K]<br />
:[https://lipidbank.jp/VCQ.html coenzyme Q]<br />
<br />
<br />
| style="vertical-align:top"| Others<br />
<br />
;Links to the original LipidBank<br />
:[https://lipidbank.jp/CLS.html lipopolysaccharide]<br />
:[https://lipidbank.jp/ALA.html lipoamino acid]<br />
:[https://lipidbank.jp/TLP.html lipoprotein]<br />
:[https://lipidbank.jp/VVE.html vitamin E]<br />
:[https://lipidbank.jp/NAG.html acylglycerols]<br />
<br />
|}<br />
</center><br />
<br />
{{Twocolumn|<br />
Biogenic substances insoluble to water are collectively called as '''lipid'''. Lipid is generally classified into the following three types.<br />
* '''Simple lipid''' ... fatty acid esters of alchohol such as glycerol and sphingoid base.<br />
* '''Complex lipid''' ... glycosylated or phosphorylated version of the simple lipid.<br />
* '''Derived lipid''' ... alcohols and fatty acids derived by hydrolyzing the simple lipid. Also includes sterols and polyketides.<br />
|<br />
水に溶けない生体成分を一般に脂質と呼び、以下の3つに分けられます。<br />
* '''単純脂質''' ... アルコールと脂肪酸のエステルで、スフィンゴ骨格とグリセロ骨格のものに大別されます。<br />
* '''複合脂質''' ... 単純脂質にリン酸や糖がついたものです。<br />
* '''誘導脂質''' ... 単純脂質を分解して得られるアルコール、脂肪酸。ステロールやポリケチドもここに含めます。<br />
}}<br />
<br />
<br />
<!---- Class Information (Do not delete)<br />
&&LB&&Lipid<br />
&&LBS&&Sphingolipid<br />
&&LBSB&&Sphingoid base<br />
&&LBSR&&Ceramide<br />
&&LBSG&&Glycosphingolipid<br />
&&LBSP&&Phosphosphingolipid<br />
&&LBG&&Glycerolipid<br />
&&LBGG&&Glycoglycerolipid<br />
&&LBGP&&Phosphoglycerolipid<br />
<br />
&&LBF&&Fatty Acyl<br />
<br />
&&LBFA&&Fatty Acyl<br />
&&LBFA01&&Fatty Acids and Conjugates<br />
&&LBFA0101&&Straight chain fatty acids<br />
&&LBFA0102&&Methyl branched fatty acids<br />
&&LBFA0103&&Unsaturated fatty acids<br />
&&LBFA0104&&Hydroperoxy fatty acids<br />
&&LBFA0105&&Hydroxy fatty acids<br />
&&LBFA0106&&Oxo fatty acids<br />
&&LBFA0107&&Epoxy fatty acids<br />
&&LBFA0108&&Methoxy fatty acids<br />
&&LBFA0109&&Halogenated fatty acids<br />
&&LBFA0110&&Amino fatty acids<br />
&&LBFA0111&&Cyano fatty acids<br />
&&LBFA0112&&Nitro fatty acids<br />
&&LBFA0113&&Thia fatty acids<br />
&&LBFA0114&&Carbocyclic fatty acids<br />
&&LBFA0115&&Heterocyclic fatty acids<br />
&&LBFA0116&&Mycolic acids<br />
&&LBFA0117&&Dicarboxylic acids<br />
&&LBFA02&&Octadecanoids<br />
&&LBFA0201&&12-oxophytodienoic acid metabolites<br />
&&LBFA0202&&jasmonic acids<br />
&&LBFA03&&Eicosanoids<br />
&&LBFA0301&&Prostaglandins<br />
&&LBFA0302&&Leukotrienes<br />
&&LBFA0303&&Thromboxanes<br />
&&LBFA0304&&Lipoxins<br />
&&LBFA0305&&Hydroxyeicosatrienoic acids<br />
&&LBFA0306&&Hydroxyeicosatetraenoic acids<br />
&&LBFA0307&&Hydroxyeicosapentaenoic acids<br />
&&LBFA0308&&Epoxyeicosatetraenoic acids<br />
&&LBFA0309&&Hepoxilins<br />
&&LBFA0310&&Levuglandins<br />
&&LBFA0311&&Isoprostanes<br />
&&LBFA0312&&Clavulones<br />
&&LBFA04&&Docosanoids<br />
&&LBFA05&&Fatty alcohols<br />
&&LBFA06&&Fatty aldehydes<br />
&&LBFA07&&Fatty esters<br />
&&LBFA0701&&Wax monoesters<br />
&&LBFA0702&&Wax diesters<br />
&&LBFA0703&&Cyano esters<br />
&&LBFA0704&&Lactones<br />
&&LBFA0705&&Fatty acyl CoAs<br />
&&LBFA0706&&Fatty acyl ACPs<br />
&&LBFA0707&&Fatty acyl carnitines<br />
&&LBFA0708&&Fatty acyl adenylates<br />
&&LBFA08&&Fatty amides<br />
&&LBFA0801&&Primary amides<br />
&&LBFA0802&&N-acyl amides<br />
&&LBFA0803&&Fatty acyl homoserine lactones<br />
&&LBFA0804&&N-acyl ethanolamides (endocannabinoids)<br />
&&LBFA09&&Fatty nitriles<br />
&&LBFA10&&Fatty ethers<br />
&&LBFA11&&Hydrocarbons<br />
&&LBFA12&&Oxygenated hydrocarbons<br />
&&LBFA00&&Other<br />
&&LBGL&&Glycerolipids<br />
&&LBGL01&&Monoradylglycerols<br />
&&LBGL0101&&Monoacylglycerols<br />
&&LBGL0102&&Monoalkylglycerols<br />
&&LBGL0103&&Mono-(1Z-alkenyl)-glycerols<br />
&&LBGL0104&&Monoacylglycerolglycosides<br />
&&LBGL0105&&Monoalkylglycerolglycosides<br />
&&LBGL02&&Diradylglycerols<br />
&&LBGL0201&&Diacylglycerols<br />
&&LBGL0202&&Alkylacylglycerols<br />
&&LBGL0203&&Dialkylglycerols<br />
&&LBGL0204&&1Z-alkenylacylglycerols<br />
&&LBGL0205&&Diacylglycerolglycosides<br />
&&LBGL0206&&Alkylacylglycerolglycosides<br />
&&LBGL0207&&Dialkylglycerolglycosides<br />
&&LBGL0208&&Di-glycerol tetraethers<br />
&&LBGL0209&&Di-glycerol tetraether glycans<br />
&&LBGL03&&Triradylglycerols<br />
&&LBGL0301&&Triacylglycerols<br />
&&LBGL0302&&Alkyldiacylglycerols<br />
&&LBGL0303&&Dialkylmonoacylglycerols<br />
&&LBGL0304&&1Z-alkenyldiacylglycerols<br />
&&LBGL0305&&Estolides<br />
&&LBGL00&&Other<br />
&&LBGP&&Glycerophospholipids<br />
&&LBGP01&&Glycerophosphocholines<br />
&&LBGP0101&&Diacylglycerophosphocholines<br />
&&LBGP0102&&1-alkyl,2-acylglycerophosphocholines<br />
&&LBGP0103&&1Z-alkenyl,2-acylglycerophosphocholines<br />
&&LBGP0104&&Dialkylglycerophosphocholines<br />
&&LBGP0105&&Monoacylglycerophosphocholines<br />
&&LBGP0106&&1-alkyl glycerophosphocholines<br />
&&LBGP0107&&1Z-alkenylglycerophosphocholines<br />
&&LBGP02&&Glycerophosphoethanolamines<br />
&&LBGP0201&&Diacylglycerophosphoethanolamines<br />
&&LBGP0202&&1-alkyl,2-acylglycerophosphoethanolamines<br />
&&LBGP0203&&1Z-alkenyl,2-acylglycerophosphoethanolamines<br />
&&LBGP0204&&Dialkylglycerophosphoethanolamines<br />
&&LBGP0205&&Monoacylglycerophosphoethanolamines<br />
&&LBGP0206&&1-alkyl glycerophosphoethanolamines<br />
&&LBGP0207&&1Z-alkenylglycerophosphoethanolamines<br />
&&LBGP03&&Glycerophosphoserines<br />
&&LBGP0301&&Diacylglycerophosphoserines<br />
&&LBGP0302&&1-alkyl,2-acylglycerophosphoserines<br />
&&LBGP0303&&1Z-alkenyl,2-acylglycerophosphoserines<br />
&&LBGP0304&&Dialkylglycerophosphoserines<br />
&&LBGP0305&&Monoacylglycerophosphoserines<br />
&&LBGP0306&&1-alkyl glycerophosphoserines<br />
&&LBGP0307&&1Z-alkenylglycerophosphoserines<br />
&&LBGP04&&Glycerophosphoglycerols<br />
&&LBGP0401&&Diacylglycerophosphoglycerols<br />
&&LBGP0402&&1-alkyl,2-acylglycerophosphoglycerols<br />
&&LBGP0403&&1Z-alkenyl,2-acylglycerophosphoglycerols<br />
&&LBGP0404&&Dialkylglycerophosphoglycerols<br />
&&LBGP0405&&Monoacylglycerophosphoglycerols<br />
&&LBGP0406&&1-alkyl glycerophosphoglycerols<br />
&&LBGP0407&&1Z-alkenylglycerophosphoglycerols<br />
&&LBGP0408&&Diacylglycerophosphodiradylglycerols<br />
&&LBGP0409&&Diacylglycerophosphomonoradylglycerols<br />
&&LBGP0410&&Monoacylglycerophosphomonoradylglycerols<br />
&&LBGP05&&Glycerophosphoglycerophosphates<br />
&&LBGP0501&&Diacylglycerophosphoglycerophosphates<br />
&&LBGP0502&&1-alkyl,2-acylglycerophosphoglycerophosphates<br />
&&LBGP0503&&1Z-alkenyl,2-acylglycerophosphoglycerophosphates<br />
&&LBGP0504&&Dialkylglycerophosphoglycerophosphates<br />
&&LBGP0505&&Monoacylglycerophosphoglycerophosphates<br />
&&LBGP0506&&1-alkyl glycerophosphoglycerophosphates<br />
&&LBGP0507&&1Z-alkenylglycerophosphoglycerophosphates<br />
&&LBGP06&&Glycerophosphoinositols<br />
&&LBGP0601&&Diacylglycerophosphoinositols<br />
&&LBGP0602&&1-alkyl,2-acylglycerophosphoinositols<br />
&&LBGP0603&&1Z-alkenyl,2-acylglycerophosphoinositols<br />
&&LBGP0604&&Dialkylglycerophosphoinositols<br />
&&LBGP0605&&Monoacylglycerophosphoinositols<br />
&&LBGP0606&&1-alkyl glycerophosphoinositols<br />
&&LBGP0607&&1Z-alkenylglycerophosphoinositols<br />
&&LBGP07&&Glycerophosphoinositol monophosphates<br />
&&LBGP0701&&Diacylglycerophosphoinositol monophosphates<br />
&&LBGP0702&&1-alkyl,2-acylglycerophosphoinositol monophosphates<br />
&&LBGP0703&&1Z-alkenyl,2-acylglycerophosphoinositol monophosphates<br />
&&LBGP0704&&Dialkylglycerophosphoinositol monophosphates<br />
&&LBGP0705&&Monoacylglycerophosphoinositol monophosphates<br />
&&LBGP0706&&1-alkyl glycerophosphoinositol monophosphates<br />
&&LBGP0707&&1Z-alkenylglycerophosphoinositol monophosphates<br />
&&LBGP08&&Glycerophosphoinositol bisphosphates<br />
&&LBGP0801&&Diacylglycerophosphoinositol bisphosphates<br />
&&LBGP0802&&1-alkyl,2-acylglycerophosphoinositol bisphosphates<br />
&&LBGP0803&&1Z-alkenyl,2-acylglycerophosphoinositol bisphosphates<br />
&&LBGP0804&&Monoacylglycerophosphoinositol bisphosphates<br />
&&LBGP0805&&1-alkyl glycerophosphoinositol bisphosphates<br />
&&LBGP0806&&1Z-alkenylglycerophosphoinositol bisphosphates<br />
&&LBGP09&&Glycerophosphoinositol trisphosphates<br />
&&LBGP0901&&Diacylglycerophosphoinositol trisphosphates<br />
&&LBGP0902&&1-alkyl,2-acylglycerophosphoinositol trisphosphates<br />
&&LBGP0903&&1Z-alkenyl,2-acylglycerophosphoinositol trisphosphates<br />
&&LBGP0904&&Monoacylglycerophosphoinositol trisphosphates<br />
&&LBGP0905&&1-alkyl glycerophosphoinositol trisphosphates<br />
&&LBGP0906&&1Z-alkenylglycerophosphoinositol trisphosphates<br />
&&LBGP10&&Glycerophosphates<br />
&&LBGP1001&&Diacylglycerophosphates<br />
&&LBGP1002&&1-alkyl,2-acylglycerophosphates<br />
&&LBGP1003&&1Z-alkenyl,2-acylglycerophosphates<br />
&&LBGP1004&&Dialkylglycerophosphates<br />
&&LBGP1005&&Monoacylglycerophosphates<br />
&&LBGP1006&&1-alkyl glycerophosphates<br />
&&LBGP1007&&1Z-alkenylglycerophosphates<br />
&&LBGP11&&Glyceropyrophosphates<br />
&&LBGP1101&&Diacylglyceropyrophosphates<br />
&&LBGP1102&&Monoacylglyceropyrophosphates<br />
&&LBGP12&&Glycerophosphoglycerophosphoglycerols (Cardiolipins)<br />
&&LBGP1201&&Diacylglycerophosphoglycerophosphodiradylglycerols<br />
&&LBGP1202&&Diacylglycerophosphoglycerophosphomonoradylglycerols<br />
&&LBGP1203&&1-alkyl,2-acylglycerophosphoglycerophosphodiradylglycerols<br />
&&LBGP1204&&1-alkyl,2-acylglycerophosphoglycerophosphomonoradylglycerols<br />
&&LBGP1205&&1Z-alkenyl,2-acylglycerophosphoglycerophosphodiradylglycerols<br />
&&LBGP1206&&1Z-alkenyl,2-acylglycerophosphoglycerophosphomonoradylglycerols<br />
&&LBGP1207&&Monoacylglycerophosphoglycerophosphomonoradylglycerols<br />
&&LBGP1208&&1-alkyl glycerophosphoglycerophosphodiradylglycerols<br />
&&LBGP1209&&1-alkyl glycerophosphoglycerophosphomonoradylglycerols<br />
&&LBGP1210&&1Z-alkenylglycerophosphoglycerophosphodiradylglycerols<br />
&&LBGP1211&&1Z-alkenylglycerophosphoglycerophosphomonoradylglycerols<br />
&&LBGP13&&CDP-Glycerols<br />
&&LBGP1301&&CDP-diacylglycerols<br />
&&LBGP1302&&CDP-1-alkyl,2-acylglycerols<br />
&&LBGP1303&&CDP-1Z-alkenyl,2-acylglycerols<br />
&&LBGP1304&&CDP-Dialkylglycerols<br />
&&LBGP1305&&CDP-Monoacylglycerols<br />
&&LBGP1306&&CDP-1-alkyl glycerols<br />
&&LBGP1307&&CDP-1Z-alkenylglycerols<br />
&&LBGP14&&Glycerophosphoglucose lipids<br />
&&LBGP1401&&Diacylglycerophosphoglucose lipids<br />
&&LBGP1402&&1-alkyl,2-acylglycerophosphoglucose lipids<br />
&&LBGP1403&&1Z-alkenyl,2-acylglycerophosphoglucose lipids<br />
&&LBGP1404&&Monoacylglycerophosphoglucose lipids<br />
&&LBGP1405&&1-alkyl glycerophosphoglucose lipids<br />
&&LBGP1406&&1Z-alkenylglycerophosphoglucose lipids<br />
&&LBGP15&&Glycerophosphoinositolglycans<br />
&&LBGP1501&&Diacylglycerophosphoinositolglycans<br />
&&LBGP1502&&1-alkyl,2-acylglycerophosphoinositolglycans<br />
&&LBGP1503&&1Z-alkenyl,2-acylglycerophosphoinositolglycans<br />
&&LBGP1504&&Monoacylglycerophosphoinositolglycans<br />
&&LBGP1505&&1-alkyl glycerophosphoinositolglycans<br />
&&LBGP1506&&1Z-alkenylglycerophosphoinositolglycans<br />
&&LBGP16&&Glycerophosphonocholines<br />
&&LBGP1601&&Diacylglycerophosphonocholines<br />
&&LBGP1602&&1-alkyl,2-acylglycerophosphonocholines<br />
&&LBGP1603&&1Z-alkenyl,2-acylglycerophosphonocholines<br />
&&LBGP1604&&Dialkylglycerophosphonocholines<br />
&&LBGP1605&&Monoacylglycerophosphonocholines<br />
&&LBGP1606&&1-alkyl glycerophosphonocholines<br />
&&LBGP1607&&1Z-alkenylglycerophosphonocholines<br />
&&LBGP17&&Glycerophosphonoethanolamines<br />
&&LBGP1701&&Diacylglycerophosphonoethanolamines<br />
&&LBGP1702&&1-alkyl,2-acylglycerophosphonoethanolamines<br />
&&LBGP1703&&1Z-alkenyl,2-acylglycerophosphonoethanolamines<br />
&&LBGP1704&&Dialkylglycerophosphonoethanolamines<br />
&&LBGP1705&&Monoacylglycerophosphonoethanolamines<br />
&&LBGP1706&&1-alkyl glycerophosphonoethanolamines<br />
&&LBGP1707&&1Z-alkenylglycerophosphonoethanolamines<br />
&&LBGP18&&Di-glycerol tetraether phospholipids (caldarchaeols)<br />
&&LBGP19&&Glycerol-nonitol tetraether phospholipids<br />
&&LBGP20&&Oxidized glycerophospholipids<br />
&&LBGP00&&Other<br />
&&LBSP&&Sphingolipids<br />
&&LBSP01&&Sphingoid bases<br />
&&LBSP0101&&Sphing-4-enines (Sphingosines)<br />
&&LBSP0102&&Sphinganines<br />
&&LBSP0103&&4-Hydroxysphinganines (Phytosphingosines)<br />
&&LBSP0104&&Sphingoid base homologs and variants<br />
&&LBSP0105&&Sphingoid base 1-phosphates<br />
&&LBSP0106&&Lysosphingomyelins and lysoglycosphingolipids<br />
&&LBSP0107&&N-methylated sphingoid bases<br />
&&LBSP0108&&Sphingoid base analogs<br />
&&LBSP02&&Ceramides<br />
&&LBSP0201&&N-acylsphingosines (ceramides)<br />
&&LBSP0202&&N-acylsphinganines (dihydroceramides)<br />
&&LBSP0203&&N-acyl-4-hydroxysphinganines (phytoceramides)<br />
&&LBSP0204&&Acylceramides<br />
&&LBSP0205&&Ceramide 1-phosphates<br />
&&LBSP03&&Phosphosphingolipids<br />
&&LBSP0301&&Ceramide phosphocholines (sphingomyelins)<br />
&&LBSP0302&&Ceramide phosphoethanolamines<br />
&&LBSP0303&&Ceramide phosphoinositols<br />
&&LBSP04&&Phosphonosphingolipids<br />
&&LBSP05&&Neutral glycosphingolipids<br />
&&LBSP0501&&Simple Glc series (GlcCer, LacCer, etc)<br />
&&LBSP0502&&GalNAcb1-3Gala1-4Galb1-4Glc- (Globo series)<br />
&&LBSP0503&&GalNAcb1-4Galb1-4Glc- (Ganglio series)<br />
&&LBSP0504&&Galb1-3GlcNAcb1-3Galb1-4Glc- (Lacto series)<br />
&&LBSP0505&&Galb1-4GlcNAcb1-3Galb1-4Glc- (Neolacto series)<br />
&&LBSP0506&&GalNAcb1-3Gala1-3Galb1-4Glc- (Isoglobo series)<br />
&&LBSP0507&&GlcNAcb1-2Mana1-3Manb1-4Glc- (Mollu series)<br />
&&LBSP0508&&GalNAcb1-4GlcNAcb1-3Manb1-4Glc- (Arthro series)<br />
&&LBSP0509&&Gal- (Gala series)<br />
&&LBSP0510&&Other<br />
&&LBSP06&&Acidic glycosphingolipids<br />
&&LBSP0601&&Gangliosides<br />
&&LBSP0602&&Sulfoglycosphingolipids (sulfatides)<br />
&&LBSP0603&&Glucuronosphingolipids<br />
&&LBSP0604&&Phosphoglycosphingolipids<br />
&&LBSP0600&&Other<br />
&&LBSP07&&Basic glycosphingolipids<br />
&&LBSP08&&Amphoteric glycosphingolipids<br />
&&LBSP09&&Arsenosphingolipids<br />
&&LBSP00&&Other<br />
&&LBST&&Sterol Lipids<br />
&&LBST01&&Sterols<br />
&&LBST0101&&Cholesterol and derivatives<br />
&&LBST0102&&Cholesteryl esters<br />
&&LBST0103&&Phytosterols and derivatives<br />
&&LBST0104&&Marine sterols and derivatives<br />
&&LBST0105&&Fungal sterols and derivatives<br />
&&LBST02&&Steroids<br />
&&LBST0201&&C18 steroids (estrogens) and derivatives<br />
&&LBST0202&&C19 steroids (androgens) and derivatives<br />
&&LBST0203&&C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives<br />
&&LBST03&&Secosteroids<br />
&&LBST0301&&Vitamin D2 and derivatives<br />
&&LBST0302&&Vitamin D3 and derivatives<br />
&&LBST04&&Bile acids and derivatives<br />
&&LBST0401&&C24 bile acids, alcohols, and derivatives<br />
&&LBST0402&&C26 bile acids, alcohols, and derivatives<br />
&&LBST0403&&C27 bile acids, alcohols, and derivatives<br />
&&LBST0404&&C28 bile acids, alcohols, and derivatives<br />
&&LBST0405&&C22 bile acids, alcohols, and derivatives<br />
&&LBST0406&&C23 bile acids, alcohols, and derivatives<br />
&&LBST0407&&C25 bile acids, alcohols, and derivatives<br />
&&LBST0408&&C29 bile acids, alcohols, and derivatives<br />
&&LBST05&&Steroid conjugates<br />
&&LBST0501&&Glucuronides<br />
&&LBST0502&&Sulfates<br />
&&LBST0503&&Glycine conjugates<br />
&&LBST0504&&Taurine conjugates<br />
&&LBST06&&Hopanoids<br />
&&LBST00&&Other<br />
&&LBPR&&Prenol Lipids<br />
&&LBPR01&&Isoprenoids<br />
&&LBPR0101&&C5 isoprenoids<br />
&&LBPR0102&&C10 isoprenoids (monoterpenes)<br />
&&LBPR0103&&C15 isoprenoids (sesquiterpenes)<br />
&&LBPR0104&&C20 isoprenoids (diterpenes)<br />
&&LBPR0105&&C25 isoprenoids (sesterterpenes)<br />
&&LBPR0106&&C30 isoprenoids (triterpenes)<br />
&&LBPR0107&&C40 isoprenoids (tetraterpenes)<br />
&&LBPR0108&&Polyterpenes<br />
&&LBPR02&&Quinones and hydroquinones<br />
&&LBPR0201&&Ubiquinones<br />
&&LBPR0202&&Vitamin E<br />
&&LBPR0203&&Vitamin K<br />
&&LBPR03&&Polyprenols<br />
&&LBPR0301&&Bactoprenols<br />
&&LBPR0302&&Bactoprenol monophosphates<br />
&&LBPR0303&&Bactoprenol diphosphates<br />
&&LBPR0304&&Phytoprenols<br />
&&LBPR0305&&Phytoprenol monophosphates<br />
&&LBPR0306&&Phytoprenol diphosphates<br />
&&LBPR0307&&Dolichols<br />
&&LBPR0308&&Dolichol monophosphates<br />
&&LBPR0309&&Dolichol diphosphates<br />
&&LBPR00&&Other<br />
&&LBSL&&Saccharolipids<br />
&&LBSL01&&Acylaminosugars<br />
&&LBSL0101&&Monoacylaminosugars<br />
&&LBSL0102&&Diacylaminosugars<br />
&&LBSL0103&&Triacylaminosugars<br />
&&LBSL0104&&Tetraacylaminosugars<br />
&&LBSL0105&&Pentaacylaminosugars<br />
&&LBSL0106&&Hexaacylaminosugars<br />
&&LBSL0107&&Heptaacylaminosugars<br />
&&LBSL02&&Acylaminosugar glycans<br />
&&LBSL03&&Acyltrehaloses<br />
&&LBSL04&&Acyltrehalose glycans<br />
&&LBSL00&&Other<br />
&&LBPK&&Polyketides<br />
&&LBPK01&&Macrolide polyketides<br />
&&LBPK02&&Aromatic polyketides<br />
&&LBPK03&&Non-ribosomal peptide/polyketide hybrids<br />
&&LBPK00&&Other<br />
---></div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Lipoquality:Database&diff=117176
Lipoquality:Database
2023-11-29T00:14:21Z
<p>Editor: </p>
<hr />
<div>; Homo sapiens : NIST plasma (SRM 1950)<br />
; <nowiki>Mus musculus (background: C57BL/6J; diet: CE2, chows of PUFA-dietary controled studies)</nowiki> : Adrenal gland, Atrium, Brain, Brown adipose tissue, Cerebellum, Cortex, Epididymis, Eye, Feces, Heart, Kidney, Large intestine, Liver, Lung, Macrophage, Medulla, Pancreas, Plasma, Seminal, Skeletal muscle, Skin, Small intestine, Spleen, Stomach, Testis, Thymus, Tongue, Ventricle, White adipose tissue<br />
; Human cultured cell : HEK293, HeLa, Jurkat, LNCaP, PC3, TPC-1<br />
; Mouse cultured cell : 3T3-L1, C2C12<br />
; Plant : <i>Arabidopsis thaliana, Oryza sativa, Solanum melongena</i><br />
; Algae : <i>Auxenochlorella protothecoides, Chlamydomonas reinhardtii, Chlorella sorokiniana, Chlorella variabilis, Dunaliella salina, Euglena gracilis, Nannochloropsis oculata, Pavlova lutheri, Pleurochrysis carterae</i><br />
; Measurement : See [http://metabolonote.kazusa.or.jp/Main_Page Metabolonote] (see [http://metabolonote.kazusa.or.jp/SE196:/ SE196], [http://metabolonote.kazusa.or.jp/SE197:/ SE197]) database.<br />
<br />
<br />
<h1>Data download</h1><br />
<br />
[http://jcbl.jp//lipodata/download/AllData_20200206.zip AllData_20200206.zip] Feb 6, 2020 (22M)<br />
<br />
<br />
<h1>{{Bilingual|脂質記載法|Notation}}</h1><br />
<br />
The style follows the proposal for lipidomics nomenclature<br />
(Liebisch G et al. J Lipid Res 2013. PMID 23549332). Please visit [http://prime.psc.riken.jp/Metabolomics_Software/MS-DIAL/index5.html the MS-DIAL page] for more details.<br />
<br />
{|<br />
|valign="top"|<br />
; Phosphoglycerolipid symbols<br />
{| class="wikitable"<br />
! Name<br />
! Notation<br />
|-<br />
| Phosphatidic acid <br />
| PA<br />
|-<br />
| R2-lyso-PA<br />
| LPA<br />
|-<br />
| Phosphatidyl-choline<br />
| PC<br />
|-<br />
| R2-lyso-PC<br />
| LPC<br />
|-<br />
| R1-ether-PC<br />
| EtherPC<br />
|-<br />
| Phosphatidyl-ethanolamine<br />
| PE<br />
|-<br />
| R2-lyso-PE<br />
| LPE<br />
|-<br />
| R1-ether-PE<br />
| EtherPE<br />
|-<br />
| Phosphatidyl-inositol<br />
| PI<br />
|-<br />
| R2-lyso-PI<br />
| LPI<br />
|-<br />
| Phosphatidyl-serine<br />
| PS<br />
|-<br />
| R2-lyso-PS<br />
| LPS<br />
|-<br />
| Phosphatidyl-glycerol<br />
| PG<br />
|-<br />
| R2-lyso-PG<br />
| LPG<br />
|-<br />
| Bis(monoacylglycero)phosphate<br />
| BMP<br />
|-<br />
| 1-Monoacylglycerol-phospho-2,3-diacylglycerol<br />
| HBMP<br />
|-<br />
| Cardiolipin<br />
| CL<br />
|}<br />
|valign="top"|<br />
;Glycerolipid, Plant lipid, and other symbols<br />
{| class="wikitable"<br />
! Name<br />
! Notation<br />
|-<br />
| Triacylglycerol<br />
| TG<br />
|-<br />
| Diacylglycerol<br />
| DG<br />
|-<br />
| Monoacylglycerol<br />
| MG<br />
|-<br />
| Monogalactosyl-diacylglycerol<br />
| MGDG<br />
|-<br />
| Digalactosyl-diacylglycerol<br />
| DGDG<br />
|-<br />
| Sulfoquinovosyl-diacylglycerol<br />
| SQDG<br />
|-<br />
| Diacylglyceryl-trimethylhomoserine<br />
| DGTS<br />
|-<br />
| Glucuronosyl-diacylglycerol <br />
| DGGA<br />
|-<br />
| Fatty acid<br />
| FA<br />
|-<br />
| Fatty acid ester of hydroxyl fatty acid <br />
| FAHFA<br />
|-<br />
| Acylcarnitine<br />
| CAR<br />
|-<br />
| Sphingomyelin<br />
| SM<br />
|}<br />
|}<br />
<br />
; Ceramide symbols<ref>Masukawa Y et al. "Characterization of overall ceramide species in human stratum corneums" J Lipid Res 49:1466-1476, 2008</ref> <br />
{| class="wikitable"<br />
! <br />
! ''non-hydroxy FA''<br/>[N]<br />
! ''&alpha;-hydroxy FA''<br/>[A]<br />
! ''&beta;-hydroxy FA'' <br/>[B]<br />
! ''esterified &omega;-hydroxy FA''<br/>[EO]<br />
|-<br />
! ''dihydrosphingosine''<br/>[DS]<br />
| Cer-NDS<br />
| Cer-ADS<br />
| Cer-BDS<br />
| Cer-EODS<br />
|-<br />
! ''sphingosine''<br/>[S]<br />
| Cer-NS<br />
| Cer-AS<br />
| Cer-BS<br />
| Cer-EOS<br />
|-<br />
! ''phytosphingosine''<br/>[P]<br />
| Cer-NP<br />
| Cer-AP<br />
| Cer-BP<br />
| Cer-EOP<br />
|-<br />
! ''6-hydroxy sphingosine''<br/>[H]<br />
| Cer-NH<br />
| Cer-AH<br />
| Cer-BH<br />
| Cer-EOH<br />
|}<br />
<br />
<references/></div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Lipoquality:Database&diff=117175
Lipoquality:Database
2023-11-29T00:13:08Z
<p>Editor: </p>
<hr />
<div><h1>Lipidomics data resource</h1><br />
<br />
; Homo sapiens : NIST plasma (SRM 1950)<br />
; <nowiki>Mus musculus (background: C57BL/6J; diet: CE2, chows of PUFA-dietary controled studies)</nowiki> : Adrenal gland, Atrium, Brain, Brown adipose tissue, Cerebellum, Cortex, Epididymis, Eye, Feces, Heart, Kidney, Large intestine, Liver, Lung, Macrophage, Medulla, Pancreas, Plasma, Seminal, Skeletal muscle, Skin, Small intestine, Spleen, Stomach, Testis, Thymus, Tongue, Ventricle, White adipose tissue<br />
; Human cultured cell : HEK293, HeLa, Jurkat, LNCaP, PC3, TPC-1<br />
; Mouse cultured cell : 3T3-L1, C2C12<br />
; Plant : <i>Arabidopsis thaliana, Oryza sativa, Solanum melongena</i><br />
; Algae : <i>Auxenochlorella protothecoides, Chlamydomonas reinhardtii, Chlorella sorokiniana, Chlorella variabilis, Dunaliella salina, Euglena gracilis, Nannochloropsis oculata, Pavlova lutheri, Pleurochrysis carterae</i><br />
; Measurement : See [http://metabolonote.kazusa.or.jp/Main_Page Metabolonote] (see [http://metabolonote.kazusa.or.jp/SE196:/ SE196], [http://metabolonote.kazusa.or.jp/SE197:/ SE197]) database.<br />
<br />
<br />
<h1>Data download</h1><br />
<br />
[http://jcbl.jp//lipodata/download/AllData_20200206.zip AllData_20200206.zip] Feb 6, 2020 (22M)<br />
<br />
<br />
<h1>{{Bilingual|脂質記載法|Notation}}</h1><br />
<br />
The style follows the proposal for lipidomics nomenclature<br />
(Liebisch G et al. J Lipid Res 2013. PMID 23549332). Please visit [http://prime.psc.riken.jp/Metabolomics_Software/MS-DIAL/index5.html the MS-DIAL page] for more details.<br />
<br />
{|<br />
|valign="top"|<br />
; Phosphoglycerolipid symbols<br />
{| class="wikitable"<br />
! Name<br />
! Notation<br />
|-<br />
| Phosphatidic acid <br />
| PA<br />
|-<br />
| R2-lyso-PA<br />
| LPA<br />
|-<br />
| Phosphatidyl-choline<br />
| PC<br />
|-<br />
| R2-lyso-PC<br />
| LPC<br />
|-<br />
| R1-ether-PC<br />
| EtherPC<br />
|-<br />
| Phosphatidyl-ethanolamine<br />
| PE<br />
|-<br />
| R2-lyso-PE<br />
| LPE<br />
|-<br />
| R1-ether-PE<br />
| EtherPE<br />
|-<br />
| Phosphatidyl-inositol<br />
| PI<br />
|-<br />
| R2-lyso-PI<br />
| LPI<br />
|-<br />
| Phosphatidyl-serine<br />
| PS<br />
|-<br />
| R2-lyso-PS<br />
| LPS<br />
|-<br />
| Phosphatidyl-glycerol<br />
| PG<br />
|-<br />
| R2-lyso-PG<br />
| LPG<br />
|-<br />
| Bis(monoacylglycero)phosphate<br />
| BMP<br />
|-<br />
| 1-Monoacylglycerol-phospho-2,3-diacylglycerol<br />
| HBMP<br />
|-<br />
| Cardiolipin<br />
| CL<br />
|}<br />
|valign="top"|<br />
;Glycerolipid, Plant lipid, and other symbols<br />
{| class="wikitable"<br />
! Name<br />
! Notation<br />
|-<br />
| Triacylglycerol<br />
| TG<br />
|-<br />
| Diacylglycerol<br />
| DG<br />
|-<br />
| Monoacylglycerol<br />
| MG<br />
|-<br />
| Monogalactosyl-diacylglycerol<br />
| MGDG<br />
|-<br />
| Digalactosyl-diacylglycerol<br />
| DGDG<br />
|-<br />
| Sulfoquinovosyl-diacylglycerol<br />
| SQDG<br />
|-<br />
| Diacylglyceryl-trimethylhomoserine<br />
| DGTS<br />
|-<br />
| Glucuronosyl-diacylglycerol <br />
| DGGA<br />
|-<br />
| Fatty acid<br />
| FA<br />
|-<br />
| Fatty acid ester of hydroxyl fatty acid <br />
| FAHFA<br />
|-<br />
| Acylcarnitine<br />
| CAR<br />
|-<br />
| Sphingomyelin<br />
| SM<br />
|}<br />
|}<br />
<br />
; Ceramide symbols<ref>Masukawa Y et al. "Characterization of overall ceramide species in human stratum corneums" J Lipid Res 49:1466-1476, 2008</ref> <br />
{| class="wikitable"<br />
! <br />
! ''non-hydroxy FA''<br/>[N]<br />
! ''&alpha;-hydroxy FA''<br/>[A]<br />
! ''&beta;-hydroxy FA'' <br/>[B]<br />
! ''esterified &omega;-hydroxy FA''<br/>[EO]<br />
|-<br />
! ''dihydrosphingosine''<br/>[DS]<br />
| Cer-NDS<br />
| Cer-ADS<br />
| Cer-BDS<br />
| Cer-EODS<br />
|-<br />
! ''sphingosine''<br/>[S]<br />
| Cer-NS<br />
| Cer-AS<br />
| Cer-BS<br />
| Cer-EOS<br />
|-<br />
! ''phytosphingosine''<br/>[P]<br />
| Cer-NP<br />
| Cer-AP<br />
| Cer-BP<br />
| Cer-EOP<br />
|-<br />
! ''6-hydroxy sphingosine''<br/>[H]<br />
| Cer-NH<br />
| Cer-AH<br />
| Cer-BH<br />
| Cer-EOH<br />
|}<br />
<br />
<references/></div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Category:LBG&diff=117174
Category:LBG
2023-11-27T23:39:48Z
<p>Editor: /* Glycerophospholipid */</p>
<hr />
<div>{{Huge|{{Bilingual|グリセロ脂質|Glycerolipid}} }}<br />
{{LB/Header}}<br />
{{Hierarchy|{{PAGENAME}}}}<br />
{| style="float:right"<br />
|__TOC__<br />
|}<br />
==Class Overview==<br />
<br />
{{Twocolumn|<br />
Complex lipid is the major structural component of biological membranes (lipid bilayer), and is broadly classified into glycerolipid containing glycerol and sphingolipid containing sphingoid. The glycerolipid category (LBG) includes glycoglycerolipid and phosphoglycerolipid.<br />
|<br />
リン酸や糖などを含む脂質は複合脂質と呼ばれ、細胞膜の脂質二重層の主要な構成要素です。複合脂質は、一般的にグリセロールを含む脂質 (グリセロ脂質) とスフィンゴイドを含む脂質 (スフィンゴ脂質) に大別されます。グリセロ脂質 (LBG) には、グリセロ糖脂質 (glycoglycerolipid) とグリセロリン脂質 (glycerophospholipid) が含まれます。<br />
}}<br />
<br />
={{Bilingual|略称の記載法|Common Nomenclature}}=<br />
{{Twocolumn|<br />
[https://lipidmaps.org LipidMaps Consortium] in the US defines the standard way of structure description (nomenclature). Please follow this standard especially when exact structure is not determined due to experimental procedures.<br />
|<br />
米国の[https://lipidmaps.org LipidMaps コンソーシアム]では、構造の標準的な表記法を定めています(命名系)。とりわけ分析法により構造に曖昧な部分が残る場合は、以下の表記法を踏襲してください。<br />
}}<br />
Reference: "Update on LIPID MAPS classification, nomenclature, and shorthand notation for MS-derived lipid structures" [https://www.jlr.org/article/S0022-2275(20)60017-7/fulltext <i>J Lipid Res</i> 61(12), 1539-1555, 2020]<br />
<br />
==GlyceroLipid==<br />
<br />
{{Twocolumn|<br />
Glycerolipid is referred to as mono-, di-, and triglycerides depending on the number of acyl chains (fatty acids). When sugars are attached, the modification comes before the backbone name; SQ, MG, and DG indicate Sulfoquinovose, single hexose, and double hexoses, respectively.Hexose is commonly galactose, and MG and DG may refer to mono- and digalactose.<br />
|<br />
配位するアシル基(脂肪酸)の数により、モノ・ジ・トリアシルグリセロール(それぞれ MG, DG, TG)と呼ばれます。グリセロール骨格に糖鎖が付く場合は MG や DG の前に SQ (Sulfoquinovosyl)、MG (Monoglycosyl)、DG (Diglycosyl) をつけます。MGやDGの略称はガラクトースの意味で使われる場合もあります。<br />
}}<br />
<br />
{| class="wikitable" cellpadding="4"<br />
|-<br />
! || || Monoglycosyl (単糖) || Diglycosyl (二糖) || Sulfoquinovosyl (スルホキノボース)<br />
|-<br />
| MG : || Monoacylglycerol <br/>(モノアシルグリセロール) || MGMG || DGMG || SQMG<br />
|-<br />
| DG : || Diacylglycerol <br/>(ジアシルグリセロール) || MGDG || DGDG || SQDG<br />
|-<br />
| TG : || Triacylglycerol <br/>(トリアシルグリセロール) <br />
|colspan="3" align="center"| n.a. (該当なし) <br />
|}<br />
<br />
==Glycerophospholipid==<br />
<br />
{| cellpadding="4"<br />
|-<br />
| PA, Ptd: || Phosphatidic acid || ホスファチジン酸<br />
|-<br />
| PC, PtdCho: || Phosphatidylcholine || ホスファチジルコリン<br />
|-<br />
| PE, PtdEtn: || Phosphatidylethanolamine || ホスファチジルエタノールアミン<br />
|-<br />
| PG, PtdGro: || Phosphatidylglycerol || ホスファチジルグリセロール<br />
|-<br />
| PI, PtdIns: || Phosphatidylinositol || ホスファチジルイノシトール<br />
|-<br />
| PS, PtdSer: || Phosphatidylserine || ホスファチジルセリン<br />
|-<br />
| CL, Ptd2Gro: || Cardiolipin || カルジオリピン<br />
|}<br />
<br />
<br />
<!----<br />
=={{Bilingual|分類|Classification}}==<br />
==={{Bilingual|糖の個数もしくは極性基|By the Number of Sugars or the Head Group}}===<br />
<br />
<br />
{{Twocolumn|<br />
For glycoglycerolipid, 2 digits indicate the number of sugars. For phosphoglycerolipid, common abbreviations such as PS (phosphatidylserine)or PE (phosphatidylethanolamine). <br />
|<br />
グリセロ糖脂質は結合している糖の総数を、グリセロリン脂質の場合はPS(ホスファチジルセリン)やPE(ホスファチジルエタノールアミン)等の記号を2桁で示しています。<br />
}}<br />
<br />
<br />
<br />
{| class="wikitable"<br />
|-<br />
! colspan="3" | Glycerolipid Overview<br />
|-<br />
| align="center" style="vertical-align:top" width=33%|<br />
Glycoglycerolipid<br><small>グリセロ糖脂質</small>: LBGnn<br />
<br>[[Image:LBGnn.png]]<br><br />
| align="center" style="vertical-align:top" width=33%|<br />
Phosphoglycerolipid<br><small>グリセロリン脂質</small>: LBGPn<br />
<br>[[Image:LBGPn.png]]<br><br />
|}<br />
</center><br />
<br />
<center><br />
{| class="wikitable" border="1" cellpadding="2" cellspacing="1" margin: 1em 1em 1em 1em"<br />
|+ Table 1. Classification by number of sugars or polar head group<br />
|- valign="top"<br />
|align="center"| {{MapLink|ListMol|LBGPA|LBGPA: <br>Ptd acid <br>ホスファチジン酸<br>}}<br>[[Image:LBGPA.png|90px]]<br />
|align="center"| {{MapLink|ListMol|LBGPC|LBGPC: <br>Ptd-choline<br>ホスファチジルコリン<br>}}<br>[[Image:LBGPC.png|155px]]<br />
|align="center"| {{MapLink|ListMol|LBGPE|LBGPE: <br>Ptd-ethanolamine<br>ホスファチジルエタノールアミン<br>}}<br>[[Image:LBGPE.png|135px]]<br />
|align="center"| {{MapLink|ListMol|LBGPG|LBGPG: <br>Ptd-glycerol <br>ホスファチジルグリセロール<br>}}<br>[[Image:LBGPG.png|130px]]<br />
<br />
|- valign="top"<br />
|align="center"| {{MapLink|ListMol|LBGPI|LBGPI: <br>Ptd-inositol<br>ホスファチジルイノシトール<br>}}<br>[[Image:LBGPI.png|110px]]<br />
|align="center"| {{MapLink|ListMol|LBGPS|LBGPS: <br>Ptd-serine<br>ホスファチジルセリン<br>}}<br>[[Image:LBGPS.png|150px]]<br />
|align="center"| {{MapLink|ListMol|LBGPx|LBGPx: <br>other <br>その他リン脂質<br>}}<br>[[Image:LBGPx.png|95px]]<br />
|- valign="top"<br />
|align="center"| {{MapLink|ListMol|LBGMG|LBGMG: <br>Monoacyl G<br>モノグリセリド<br>}}<br>[[Image:LBGMG.png]]<br />
|align="center"| {{MapLink|ListMol|LBGDG|LBGDG: <br>Diacyl G<br>ジグリセリド<br>}}<br>[[Image:LBGDG.png]]<br />
|align="center"| {{MapLink|ListMol|LBGTG|LBGTG: <br>Triacyl G<br>トリグリセリド<br>}}<br>[[Image:LBGTG.png]]<br />
|align="center"| {{MapLink|ListMol|LBG00|LBG00: <br>Alkyl-type G<br>含アルキル, アルケニル型<br>}}<br />
|-<br />
|align="center"| {{MapLink|ListMol|LBG01|LBG01: <br>1 sugar<br>糖の数1<br>}}<br />
|align="center"| {{MapLink|ListMol|LBG02|LBG02: <br>2 sugars<br>糖の数2<br>}}<br />
|align="center"| {{MapLink|ListMol|LBG03|LBG03: <br>3 sugars<br>糖の数3<br>}}<br />
|align="center"| {{MapLink|ListMol|LBG04|LBG04: <br>4 sugars<br>糖の数4<br>}}<br />
<br />
|}<br />
</center><br />
<br />
==={{Bilingual|その他の分類|Other Classification Charts}}===<br />
<br />
* {{#volatile:ClassMatrix|Head Group v.s. Length:Unsaturation of R1 <br>(極性基 対 R1の脂肪酸長:不飽和度)|LBG.....:.........:.........|10|12|4|5|Head_Group|Fatty_Acid_Length(R1)}}<br />
* {{#volatile:ClassMatrix|Head Group v.s. Length:Unsaturation of R2 <br>(極性基 対 R2の脂肪酸長:不飽和度)|LBG.....:.........:.........|20|22|4|5|Head_Group|Fatty_Acid_Length(R2)}}<br />
* {{#volatile:ClassMatrix|Length:Unsaturation of R1 v.s. Length:Unsaturation of R2 <br>(R2の脂肪酸長:不飽和度 対 R2の脂肪酸長:不飽和度)|LBG.....:.........:.........|10|12|20|22|Fatty_Acid_Length(R1)|Fatty_Acid_Length(R2)}}<br />
<br />
=={{Bilingual|ID番号の設計|Design of Glycerolipid Identifiers}}==<br />
<center><br />
28-DIGIT(8+9+9+2)<br />
<table border=1><br />
<tr><br />
<td style="background-color:yellowgreen;" width=15px align="center"><big>L</big><br />
<td style="background-color:yellowgreen;" width=15px align="center"><big>B</big><br />
<td style="background-color:darkseagreen;" width=15px align="center"><big>G</big><br />
<td style="background-color:Blue; color:white" width=15px align="center"><big>''a''</big><br />
<td style="background-color:Blue; color:white" width=15px align="center"><big>''a''</big><br />
<td style="background-color:aqua" width=15px align="center"><big>''b1''</big><br />
<td style="background-color:aqua" width=15px align="center"><big>''b2''</big><br />
<td style="background-color:aqua" width=15px align="center"><big>''b3''</big><br />
<td style="background-color:gray;" width=15px align="center"><big>:</big><br />
<td style="background-color:tomato; color:white" width=15px align="center"><big>''x1''</big><br />
<td style="background-color:tomato; color:white" width=15px align="center"><big>''x1''</big><br />
<td style="background-color:purple; color:white" width=15px align="center"><big>''y1''</big><br />
<td style="background-color:firebrick; color:white" width=15px align="center"><big>''z1''</big><br />
<td style="background-color:firebrick; color:white" width=15px align="center"><big>''z1''</big><br />
<td style="background-color:green; color:white" width=15px align="center"><big>''w1''</big><br />
<td style="background-color:green; color:white" width=15px align="center"><big>''w1''</big><br />
<td style="background-color:white;" width=15px align="center"><big>''c1''</big><br />
<td style="background-color:white;" width=15px align="center"><big>''c1''</big><br />
<td style="background-color:gray;" width=15px align="center"><big>:</big><br />
<td style="background-color:tomato; color:white" width=15px align="center"><big>''x2''</big><br />
<td style="background-color:tomato; color:white" width=15px align="center"><big>''x2''</big><br />
<td style="background-color:purple; color:white" width=15px align="center"><big>''y2''</big><br />
<td style="background-color:firebrick; color:white" width=15px align="center"><big>''z2''</big><br />
<td style="background-color:firebrick; color:white" width=15px align="center"><big>''z2''</big><br />
<td style="background-color:green; color:white" width=15px align="center"><big>''w2''</big><br />
<td style="background-color:green; color:white" width=15px align="center"><big>''w2''</big><br />
<td style="background-color:white;" width=15px align="center"><big>''c2''</big><br />
<td style="background-color:white;" width=15px align="center"><big>''c2''</big><br />
<td> (R3 if exists) </td><br />
</tr><br />
</table><br />
</center><br />
{{Twocolumn|<br />
* ''a'' ... the number of attached sugars (glycoglycerolipid) or the code of polar head group(phosphoglycerolipid)<br />
* ''b'' ... type of binding to fatty acid-1 through 3<br />
<br />
* ''x'' ... carbon chain length (fatty acid-1 through 3)<br />
* ''y'' ... degree of unsaturation (fatty acid-1 through 3)<br />
* ''z'' ... position of n-''z'' (n minus z; also ω-z or omega-z) nomenclature (fatty acid-1 through 3)<br />
* ''w'' ... structure type (fatty acid-1 through 3)<br />
* ''c'' ... serial number (fatty acid-1 through 3)<br />
|<br />
* ''a'' ... 修飾する糖の個数 (グリセロ糖脂質) もしくは極性基を示す略号 (グリセロリン脂質)<br />
* ''b'' ... 脂肪酸1および2の結合のタイプ<br />
<br />
* ''x'' ... 炭素鎖長 (脂肪酸1から3)<br />
* ''y'' ... 不飽和度 (脂肪酸1から3)<br />
* ''z'' ... n-''z'' (またはω-zやomega-z) における数 (脂肪酸1から3)<br />
* ''w'' ... 骨格のタイプ (脂肪酸1から3)<br />
* ''c'' ... 通し番号 (脂肪酸1から3)<br />
}}<br />
<br />
----></div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Category:LBG&diff=117173
Category:LBG
2023-11-27T23:39:16Z
<p>Editor: /* GlyceroLipid */</p>
<hr />
<div>{{Huge|{{Bilingual|グリセロ脂質|Glycerolipid}} }}<br />
{{LB/Header}}<br />
{{Hierarchy|{{PAGENAME}}}}<br />
{| style="float:right"<br />
|__TOC__<br />
|}<br />
==Class Overview==<br />
<br />
{{Twocolumn|<br />
Complex lipid is the major structural component of biological membranes (lipid bilayer), and is broadly classified into glycerolipid containing glycerol and sphingolipid containing sphingoid. The glycerolipid category (LBG) includes glycoglycerolipid and phosphoglycerolipid.<br />
|<br />
リン酸や糖などを含む脂質は複合脂質と呼ばれ、細胞膜の脂質二重層の主要な構成要素です。複合脂質は、一般的にグリセロールを含む脂質 (グリセロ脂質) とスフィンゴイドを含む脂質 (スフィンゴ脂質) に大別されます。グリセロ脂質 (LBG) には、グリセロ糖脂質 (glycoglycerolipid) とグリセロリン脂質 (glycerophospholipid) が含まれます。<br />
}}<br />
<br />
={{Bilingual|略称の記載法|Common Nomenclature}}=<br />
{{Twocolumn|<br />
[https://lipidmaps.org LipidMaps Consortium] in the US defines the standard way of structure description (nomenclature). Please follow this standard especially when exact structure is not determined due to experimental procedures.<br />
|<br />
米国の[https://lipidmaps.org LipidMaps コンソーシアム]では、構造の標準的な表記法を定めています(命名系)。とりわけ分析法により構造に曖昧な部分が残る場合は、以下の表記法を踏襲してください。<br />
}}<br />
Reference: "Update on LIPID MAPS classification, nomenclature, and shorthand notation for MS-derived lipid structures" [https://www.jlr.org/article/S0022-2275(20)60017-7/fulltext <i>J Lipid Res</i> 61(12), 1539-1555, 2020]<br />
<br />
==GlyceroLipid==<br />
<br />
{{Twocolumn|<br />
Glycerolipid is referred to as mono-, di-, and triglycerides depending on the number of acyl chains (fatty acids). When sugars are attached, the modification comes before the backbone name; SQ, MG, and DG indicate Sulfoquinovose, single hexose, and double hexoses, respectively.Hexose is commonly galactose, and MG and DG may refer to mono- and digalactose.<br />
|<br />
配位するアシル基(脂肪酸)の数により、モノ・ジ・トリアシルグリセロール(それぞれ MG, DG, TG)と呼ばれます。グリセロール骨格に糖鎖が付く場合は MG や DG の前に SQ (Sulfoquinovosyl)、MG (Monoglycosyl)、DG (Diglycosyl) をつけます。MGやDGの略称はガラクトースの意味で使われる場合もあります。<br />
}}<br />
<br />
{| class="wikitable" cellpadding="4"<br />
|-<br />
! || || Monoglycosyl (単糖) || Diglycosyl (二糖) || Sulfoquinovosyl (スルホキノボース)<br />
|-<br />
| MG : || Monoacylglycerol <br/>(モノアシルグリセロール) || MGMG || DGMG || SQMG<br />
|-<br />
| DG : || Diacylglycerol <br/>(ジアシルグリセロール) || MGDG || DGDG || SQDG<br />
|-<br />
| TG : || Triacylglycerol <br/>(トリアシルグリセロール) <br />
|colspan="3" align="center"| n.a. (該当なし) <br />
|}<br />
<br />
==Glycerophospholipid==<br />
<br />
{| cellpadding="4"<br />
|-<br />
| PA, Ptd: || Phosphatidic acid || ホスファチジン酸<br />
|-<br />
| PC, PtdCho: || Phosphatidylcholine || ホスファチジルコリン<br />
|-<br />
| PE, PtdEtn: || Phosphatidylethanolamine || ホスファチジルエタノールアミン<br />
|-<br />
| PG, PtdGro: || Phosphatidylglycerol || ホスファチジルグリセロール<br />
|-<br />
| PI, PtdIns: || Phosphatidylinositol || ホスファチジルイノシトール<br />
|-<br />
| PS, PtdSer: || Phosphatidylserine || ホスファチジルセリン<br />
|-<br />
| CL, Ptd2Gro: || Cardiolipin || カルジオリピン<br />
<br />
}}<br />
<br />
<br />
<!----<br />
=={{Bilingual|分類|Classification}}==<br />
==={{Bilingual|糖の個数もしくは極性基|By the Number of Sugars or the Head Group}}===<br />
<br />
<br />
{{Twocolumn|<br />
For glycoglycerolipid, 2 digits indicate the number of sugars. For phosphoglycerolipid, common abbreviations such as PS (phosphatidylserine)or PE (phosphatidylethanolamine). <br />
|<br />
グリセロ糖脂質は結合している糖の総数を、グリセロリン脂質の場合はPS(ホスファチジルセリン)やPE(ホスファチジルエタノールアミン)等の記号を2桁で示しています。<br />
}}<br />
<br />
<br />
<br />
{| class="wikitable"<br />
|-<br />
! colspan="3" | Glycerolipid Overview<br />
|-<br />
| align="center" style="vertical-align:top" width=33%|<br />
Glycoglycerolipid<br><small>グリセロ糖脂質</small>: LBGnn<br />
<br>[[Image:LBGnn.png]]<br><br />
| align="center" style="vertical-align:top" width=33%|<br />
Phosphoglycerolipid<br><small>グリセロリン脂質</small>: LBGPn<br />
<br>[[Image:LBGPn.png]]<br><br />
|}<br />
</center><br />
<br />
<center><br />
{| class="wikitable" border="1" cellpadding="2" cellspacing="1" margin: 1em 1em 1em 1em"<br />
|+ Table 1. Classification by number of sugars or polar head group<br />
|- valign="top"<br />
|align="center"| {{MapLink|ListMol|LBGPA|LBGPA: <br>Ptd acid <br>ホスファチジン酸<br>}}<br>[[Image:LBGPA.png|90px]]<br />
|align="center"| {{MapLink|ListMol|LBGPC|LBGPC: <br>Ptd-choline<br>ホスファチジルコリン<br>}}<br>[[Image:LBGPC.png|155px]]<br />
|align="center"| {{MapLink|ListMol|LBGPE|LBGPE: <br>Ptd-ethanolamine<br>ホスファチジルエタノールアミン<br>}}<br>[[Image:LBGPE.png|135px]]<br />
|align="center"| {{MapLink|ListMol|LBGPG|LBGPG: <br>Ptd-glycerol <br>ホスファチジルグリセロール<br>}}<br>[[Image:LBGPG.png|130px]]<br />
<br />
|- valign="top"<br />
|align="center"| {{MapLink|ListMol|LBGPI|LBGPI: <br>Ptd-inositol<br>ホスファチジルイノシトール<br>}}<br>[[Image:LBGPI.png|110px]]<br />
|align="center"| {{MapLink|ListMol|LBGPS|LBGPS: <br>Ptd-serine<br>ホスファチジルセリン<br>}}<br>[[Image:LBGPS.png|150px]]<br />
|align="center"| {{MapLink|ListMol|LBGPx|LBGPx: <br>other <br>その他リン脂質<br>}}<br>[[Image:LBGPx.png|95px]]<br />
|- valign="top"<br />
|align="center"| {{MapLink|ListMol|LBGMG|LBGMG: <br>Monoacyl G<br>モノグリセリド<br>}}<br>[[Image:LBGMG.png]]<br />
|align="center"| {{MapLink|ListMol|LBGDG|LBGDG: <br>Diacyl G<br>ジグリセリド<br>}}<br>[[Image:LBGDG.png]]<br />
|align="center"| {{MapLink|ListMol|LBGTG|LBGTG: <br>Triacyl G<br>トリグリセリド<br>}}<br>[[Image:LBGTG.png]]<br />
|align="center"| {{MapLink|ListMol|LBG00|LBG00: <br>Alkyl-type G<br>含アルキル, アルケニル型<br>}}<br />
|-<br />
|align="center"| {{MapLink|ListMol|LBG01|LBG01: <br>1 sugar<br>糖の数1<br>}}<br />
|align="center"| {{MapLink|ListMol|LBG02|LBG02: <br>2 sugars<br>糖の数2<br>}}<br />
|align="center"| {{MapLink|ListMol|LBG03|LBG03: <br>3 sugars<br>糖の数3<br>}}<br />
|align="center"| {{MapLink|ListMol|LBG04|LBG04: <br>4 sugars<br>糖の数4<br>}}<br />
<br />
|}<br />
</center><br />
<br />
==={{Bilingual|その他の分類|Other Classification Charts}}===<br />
<br />
* {{#volatile:ClassMatrix|Head Group v.s. Length:Unsaturation of R1 <br>(極性基 対 R1の脂肪酸長:不飽和度)|LBG.....:.........:.........|10|12|4|5|Head_Group|Fatty_Acid_Length(R1)}}<br />
* {{#volatile:ClassMatrix|Head Group v.s. Length:Unsaturation of R2 <br>(極性基 対 R2の脂肪酸長:不飽和度)|LBG.....:.........:.........|20|22|4|5|Head_Group|Fatty_Acid_Length(R2)}}<br />
* {{#volatile:ClassMatrix|Length:Unsaturation of R1 v.s. Length:Unsaturation of R2 <br>(R2の脂肪酸長:不飽和度 対 R2の脂肪酸長:不飽和度)|LBG.....:.........:.........|10|12|20|22|Fatty_Acid_Length(R1)|Fatty_Acid_Length(R2)}}<br />
<br />
=={{Bilingual|ID番号の設計|Design of Glycerolipid Identifiers}}==<br />
<center><br />
28-DIGIT(8+9+9+2)<br />
<table border=1><br />
<tr><br />
<td style="background-color:yellowgreen;" width=15px align="center"><big>L</big><br />
<td style="background-color:yellowgreen;" width=15px align="center"><big>B</big><br />
<td style="background-color:darkseagreen;" width=15px align="center"><big>G</big><br />
<td style="background-color:Blue; color:white" width=15px align="center"><big>''a''</big><br />
<td style="background-color:Blue; color:white" width=15px align="center"><big>''a''</big><br />
<td style="background-color:aqua" width=15px align="center"><big>''b1''</big><br />
<td style="background-color:aqua" width=15px align="center"><big>''b2''</big><br />
<td style="background-color:aqua" width=15px align="center"><big>''b3''</big><br />
<td style="background-color:gray;" width=15px align="center"><big>:</big><br />
<td style="background-color:tomato; color:white" width=15px align="center"><big>''x1''</big><br />
<td style="background-color:tomato; color:white" width=15px align="center"><big>''x1''</big><br />
<td style="background-color:purple; color:white" width=15px align="center"><big>''y1''</big><br />
<td style="background-color:firebrick; color:white" width=15px align="center"><big>''z1''</big><br />
<td style="background-color:firebrick; color:white" width=15px align="center"><big>''z1''</big><br />
<td style="background-color:green; color:white" width=15px align="center"><big>''w1''</big><br />
<td style="background-color:green; color:white" width=15px align="center"><big>''w1''</big><br />
<td style="background-color:white;" width=15px align="center"><big>''c1''</big><br />
<td style="background-color:white;" width=15px align="center"><big>''c1''</big><br />
<td style="background-color:gray;" width=15px align="center"><big>:</big><br />
<td style="background-color:tomato; color:white" width=15px align="center"><big>''x2''</big><br />
<td style="background-color:tomato; color:white" width=15px align="center"><big>''x2''</big><br />
<td style="background-color:purple; color:white" width=15px align="center"><big>''y2''</big><br />
<td style="background-color:firebrick; color:white" width=15px align="center"><big>''z2''</big><br />
<td style="background-color:firebrick; color:white" width=15px align="center"><big>''z2''</big><br />
<td style="background-color:green; color:white" width=15px align="center"><big>''w2''</big><br />
<td style="background-color:green; color:white" width=15px align="center"><big>''w2''</big><br />
<td style="background-color:white;" width=15px align="center"><big>''c2''</big><br />
<td style="background-color:white;" width=15px align="center"><big>''c2''</big><br />
<td> (R3 if exists) </td><br />
</tr><br />
</table><br />
</center><br />
{{Twocolumn|<br />
* ''a'' ... the number of attached sugars (glycoglycerolipid) or the code of polar head group(phosphoglycerolipid)<br />
* ''b'' ... type of binding to fatty acid-1 through 3<br />
<br />
* ''x'' ... carbon chain length (fatty acid-1 through 3)<br />
* ''y'' ... degree of unsaturation (fatty acid-1 through 3)<br />
* ''z'' ... position of n-''z'' (n minus z; also ω-z or omega-z) nomenclature (fatty acid-1 through 3)<br />
* ''w'' ... structure type (fatty acid-1 through 3)<br />
* ''c'' ... serial number (fatty acid-1 through 3)<br />
|<br />
* ''a'' ... 修飾する糖の個数 (グリセロ糖脂質) もしくは極性基を示す略号 (グリセロリン脂質)<br />
* ''b'' ... 脂肪酸1および2の結合のタイプ<br />
<br />
* ''x'' ... 炭素鎖長 (脂肪酸1から3)<br />
* ''y'' ... 不飽和度 (脂肪酸1から3)<br />
* ''z'' ... n-''z'' (またはω-zやomega-z) における数 (脂肪酸1から3)<br />
* ''w'' ... 骨格のタイプ (脂肪酸1から3)<br />
* ''c'' ... 通し番号 (脂肪酸1から3)<br />
}}<br />
<br />
----></div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Category:LBG&diff=117172
Category:LBG
2023-11-27T23:36:13Z
<p>Editor: </p>
<hr />
<div>{{Huge|{{Bilingual|グリセロ脂質|Glycerolipid}} }}<br />
{{LB/Header}}<br />
{{Hierarchy|{{PAGENAME}}}}<br />
{| style="float:right"<br />
|__TOC__<br />
|}<br />
==Class Overview==<br />
<br />
{{Twocolumn|<br />
Complex lipid is the major structural component of biological membranes (lipid bilayer), and is broadly classified into glycerolipid containing glycerol and sphingolipid containing sphingoid. The glycerolipid category (LBG) includes glycoglycerolipid and phosphoglycerolipid.<br />
|<br />
リン酸や糖などを含む脂質は複合脂質と呼ばれ、細胞膜の脂質二重層の主要な構成要素です。複合脂質は、一般的にグリセロールを含む脂質 (グリセロ脂質) とスフィンゴイドを含む脂質 (スフィンゴ脂質) に大別されます。グリセロ脂質 (LBG) には、グリセロ糖脂質 (glycoglycerolipid) とグリセロリン脂質 (glycerophospholipid) が含まれます。<br />
}}<br />
<br />
={{Bilingual|略称の記載法|Common Nomenclature}}=<br />
{{Twocolumn|<br />
[https://lipidmaps.org LipidMaps Consortium] in the US defines the standard way of structure description (nomenclature). Please follow this standard especially when exact structure is not determined due to experimental procedures.<br />
|<br />
米国の[https://lipidmaps.org LipidMaps コンソーシアム]では、構造の標準的な表記法を定めています(命名系)。とりわけ分析法により構造に曖昧な部分が残る場合は、以下の表記法を踏襲してください。<br />
}}<br />
Reference: "Update on LIPID MAPS classification, nomenclature, and shorthand notation for MS-derived lipid structures" [https://www.jlr.org/article/S0022-2275(20)60017-7/fulltext <i>J Lipid Res</i> 61(12), 1539-1555, 2020]<br />
<br />
==GlyceroLipid==<br />
<br />
{{Twocolumn|<br />
Glycerolipid is referred to as mono-, di-, and triglycerides depending on the number of acyl chains (fatty acids). When sugars are attached, the modification comes before the backbone name; SQ, MG, and DG indicate Sulfoquinovose, single hexose, and double hexoses, respectively.Hexose is commonly galactose, and MG and DG may refer to mono- and digalactose.<br />
|<br />
配位するアシル基(脂肪酸)の数により、モノ・ジ・トリアシルグリセロール(それぞれ MG, DG, TG)と呼ばれます。グリセロール骨格に糖鎖が付く場合は MG や DG の前に SQ (Sulfoquinovosyl)、MG (Monoglycosyl)、DG (Diglycosyl) をつけます。MGやDGの略称はガラクトースの意味で使われる場合もあります。<br />
}}<br />
<br />
{| class="wikitable" cellpadding="4"<br />
|-<br />
! || || Monoglycosyl (単糖) || Diglycosyl (二糖) || Sulfoquinovosyl (スルホキノボース)<br />
|-<br />
| MG : || Monoacylglycerol <br/>(モノアシルグリセロール) || MGMG || DGMG || SQMG<br />
|-<br />
| DG : || Diacylglycerol <br/>(ジアシルグリセロール) || MGDG || DGDG || SQDG<br />
|-<br />
| TG : || Triacylglycerol <br/>(トリアシルグリセロール) || || ||<br />
|}<br />
<br />
<br />
<br />
==Glycerophospholipid==<br />
<br />
{| cellpadding="4"<br />
|-<br />
| PA, Ptd: || Phosphatidic acid || ホスファチジン酸<br />
|-<br />
| PC, PtdCho: || Phosphatidylcholine || ホスファチジルコリン<br />
|-<br />
| PE, PtdEtn: || Phosphatidylethanolamine || ホスファチジルエタノールアミン<br />
|-<br />
| PG, PtdGro: || Phosphatidylglycerol || ホスファチジルグリセロール<br />
|-<br />
| PI, PtdIns: || Phosphatidylinositol || ホスファチジルイノシトール<br />
|-<br />
| PS, PtdSer: || Phosphatidylserine || ホスファチジルセリン<br />
|-<br />
| CL, Ptd2Gro: || Cardiolipin || カルジオリピン<br />
<br />
}}<br />
<br />
<br />
<!----<br />
=={{Bilingual|分類|Classification}}==<br />
==={{Bilingual|糖の個数もしくは極性基|By the Number of Sugars or the Head Group}}===<br />
<br />
<br />
{{Twocolumn|<br />
For glycoglycerolipid, 2 digits indicate the number of sugars. For phosphoglycerolipid, common abbreviations such as PS (phosphatidylserine)or PE (phosphatidylethanolamine). <br />
|<br />
グリセロ糖脂質は結合している糖の総数を、グリセロリン脂質の場合はPS(ホスファチジルセリン)やPE(ホスファチジルエタノールアミン)等の記号を2桁で示しています。<br />
}}<br />
<br />
<br />
<br />
{| class="wikitable"<br />
|-<br />
! colspan="3" | Glycerolipid Overview<br />
|-<br />
| align="center" style="vertical-align:top" width=33%|<br />
Glycoglycerolipid<br><small>グリセロ糖脂質</small>: LBGnn<br />
<br>[[Image:LBGnn.png]]<br><br />
| align="center" style="vertical-align:top" width=33%|<br />
Phosphoglycerolipid<br><small>グリセロリン脂質</small>: LBGPn<br />
<br>[[Image:LBGPn.png]]<br><br />
|}<br />
</center><br />
<br />
<center><br />
{| class="wikitable" border="1" cellpadding="2" cellspacing="1" margin: 1em 1em 1em 1em"<br />
|+ Table 1. Classification by number of sugars or polar head group<br />
|- valign="top"<br />
|align="center"| {{MapLink|ListMol|LBGPA|LBGPA: <br>Ptd acid <br>ホスファチジン酸<br>}}<br>[[Image:LBGPA.png|90px]]<br />
|align="center"| {{MapLink|ListMol|LBGPC|LBGPC: <br>Ptd-choline<br>ホスファチジルコリン<br>}}<br>[[Image:LBGPC.png|155px]]<br />
|align="center"| {{MapLink|ListMol|LBGPE|LBGPE: <br>Ptd-ethanolamine<br>ホスファチジルエタノールアミン<br>}}<br>[[Image:LBGPE.png|135px]]<br />
|align="center"| {{MapLink|ListMol|LBGPG|LBGPG: <br>Ptd-glycerol <br>ホスファチジルグリセロール<br>}}<br>[[Image:LBGPG.png|130px]]<br />
<br />
|- valign="top"<br />
|align="center"| {{MapLink|ListMol|LBGPI|LBGPI: <br>Ptd-inositol<br>ホスファチジルイノシトール<br>}}<br>[[Image:LBGPI.png|110px]]<br />
|align="center"| {{MapLink|ListMol|LBGPS|LBGPS: <br>Ptd-serine<br>ホスファチジルセリン<br>}}<br>[[Image:LBGPS.png|150px]]<br />
|align="center"| {{MapLink|ListMol|LBGPx|LBGPx: <br>other <br>その他リン脂質<br>}}<br>[[Image:LBGPx.png|95px]]<br />
|- valign="top"<br />
|align="center"| {{MapLink|ListMol|LBGMG|LBGMG: <br>Monoacyl G<br>モノグリセリド<br>}}<br>[[Image:LBGMG.png]]<br />
|align="center"| {{MapLink|ListMol|LBGDG|LBGDG: <br>Diacyl G<br>ジグリセリド<br>}}<br>[[Image:LBGDG.png]]<br />
|align="center"| {{MapLink|ListMol|LBGTG|LBGTG: <br>Triacyl G<br>トリグリセリド<br>}}<br>[[Image:LBGTG.png]]<br />
|align="center"| {{MapLink|ListMol|LBG00|LBG00: <br>Alkyl-type G<br>含アルキル, アルケニル型<br>}}<br />
|-<br />
|align="center"| {{MapLink|ListMol|LBG01|LBG01: <br>1 sugar<br>糖の数1<br>}}<br />
|align="center"| {{MapLink|ListMol|LBG02|LBG02: <br>2 sugars<br>糖の数2<br>}}<br />
|align="center"| {{MapLink|ListMol|LBG03|LBG03: <br>3 sugars<br>糖の数3<br>}}<br />
|align="center"| {{MapLink|ListMol|LBG04|LBG04: <br>4 sugars<br>糖の数4<br>}}<br />
<br />
|}<br />
</center><br />
<br />
==={{Bilingual|その他の分類|Other Classification Charts}}===<br />
<br />
* {{#volatile:ClassMatrix|Head Group v.s. Length:Unsaturation of R1 <br>(極性基 対 R1の脂肪酸長:不飽和度)|LBG.....:.........:.........|10|12|4|5|Head_Group|Fatty_Acid_Length(R1)}}<br />
* {{#volatile:ClassMatrix|Head Group v.s. Length:Unsaturation of R2 <br>(極性基 対 R2の脂肪酸長:不飽和度)|LBG.....:.........:.........|20|22|4|5|Head_Group|Fatty_Acid_Length(R2)}}<br />
* {{#volatile:ClassMatrix|Length:Unsaturation of R1 v.s. Length:Unsaturation of R2 <br>(R2の脂肪酸長:不飽和度 対 R2の脂肪酸長:不飽和度)|LBG.....:.........:.........|10|12|20|22|Fatty_Acid_Length(R1)|Fatty_Acid_Length(R2)}}<br />
<br />
=={{Bilingual|ID番号の設計|Design of Glycerolipid Identifiers}}==<br />
<center><br />
28-DIGIT(8+9+9+2)<br />
<table border=1><br />
<tr><br />
<td style="background-color:yellowgreen;" width=15px align="center"><big>L</big><br />
<td style="background-color:yellowgreen;" width=15px align="center"><big>B</big><br />
<td style="background-color:darkseagreen;" width=15px align="center"><big>G</big><br />
<td style="background-color:Blue; color:white" width=15px align="center"><big>''a''</big><br />
<td style="background-color:Blue; color:white" width=15px align="center"><big>''a''</big><br />
<td style="background-color:aqua" width=15px align="center"><big>''b1''</big><br />
<td style="background-color:aqua" width=15px align="center"><big>''b2''</big><br />
<td style="background-color:aqua" width=15px align="center"><big>''b3''</big><br />
<td style="background-color:gray;" width=15px align="center"><big>:</big><br />
<td style="background-color:tomato; color:white" width=15px align="center"><big>''x1''</big><br />
<td style="background-color:tomato; color:white" width=15px align="center"><big>''x1''</big><br />
<td style="background-color:purple; color:white" width=15px align="center"><big>''y1''</big><br />
<td style="background-color:firebrick; color:white" width=15px align="center"><big>''z1''</big><br />
<td style="background-color:firebrick; color:white" width=15px align="center"><big>''z1''</big><br />
<td style="background-color:green; color:white" width=15px align="center"><big>''w1''</big><br />
<td style="background-color:green; color:white" width=15px align="center"><big>''w1''</big><br />
<td style="background-color:white;" width=15px align="center"><big>''c1''</big><br />
<td style="background-color:white;" width=15px align="center"><big>''c1''</big><br />
<td style="background-color:gray;" width=15px align="center"><big>:</big><br />
<td style="background-color:tomato; color:white" width=15px align="center"><big>''x2''</big><br />
<td style="background-color:tomato; color:white" width=15px align="center"><big>''x2''</big><br />
<td style="background-color:purple; color:white" width=15px align="center"><big>''y2''</big><br />
<td style="background-color:firebrick; color:white" width=15px align="center"><big>''z2''</big><br />
<td style="background-color:firebrick; color:white" width=15px align="center"><big>''z2''</big><br />
<td style="background-color:green; color:white" width=15px align="center"><big>''w2''</big><br />
<td style="background-color:green; color:white" width=15px align="center"><big>''w2''</big><br />
<td style="background-color:white;" width=15px align="center"><big>''c2''</big><br />
<td style="background-color:white;" width=15px align="center"><big>''c2''</big><br />
<td> (R3 if exists) </td><br />
</tr><br />
</table><br />
</center><br />
{{Twocolumn|<br />
* ''a'' ... the number of attached sugars (glycoglycerolipid) or the code of polar head group(phosphoglycerolipid)<br />
* ''b'' ... type of binding to fatty acid-1 through 3<br />
<br />
* ''x'' ... carbon chain length (fatty acid-1 through 3)<br />
* ''y'' ... degree of unsaturation (fatty acid-1 through 3)<br />
* ''z'' ... position of n-''z'' (n minus z; also ω-z or omega-z) nomenclature (fatty acid-1 through 3)<br />
* ''w'' ... structure type (fatty acid-1 through 3)<br />
* ''c'' ... serial number (fatty acid-1 through 3)<br />
|<br />
* ''a'' ... 修飾する糖の個数 (グリセロ糖脂質) もしくは極性基を示す略号 (グリセロリン脂質)<br />
* ''b'' ... 脂肪酸1および2の結合のタイプ<br />
<br />
* ''x'' ... 炭素鎖長 (脂肪酸1から3)<br />
* ''y'' ... 不飽和度 (脂肪酸1から3)<br />
* ''z'' ... n-''z'' (またはω-zやomega-z) における数 (脂肪酸1から3)<br />
* ''w'' ... 骨格のタイプ (脂肪酸1から3)<br />
* ''c'' ... 通し番号 (脂肪酸1から3)<br />
}}<br />
<br />
----></div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Category:LB&diff=117171
Category:LB
2023-11-27T06:29:42Z
<p>Editor: </p>
<hr />
<div>{{Huge|LipidBank}}<br />
{{LB/Header}}<br />
==Class Overview==<br />
<br />
{{Twocolumn|<br />
Biogenic substances insoluble to water are collectively called as '''lipid'''. Lipid is generally classified into the following three types.<br />
* '''Simple lipid''' ... fatty acid esters of alchohol such as glycerol and sphingoid base.<br />
* '''Complex lipid''' ... glycosylated or phosphorylated version of the simple lipid.<br />
* '''Derived lipid''' ... alcohols and fatty acids derived by hydrolyzing the simple lipid. Also includes sterols and polyketides.<br />
|<br />
水に溶けない生体成分を一般に脂質と呼び、以下の3つに分けられます。<br />
* '''単純脂質''' ... アルコールと脂肪酸のエステルで、スフィンゴ骨格とグリセロ骨格のものに大別されます。<br />
* '''複合脂質''' ... 単純脂質にリン酸や糖がついたものです。<br />
* '''誘導脂質''' ... 単純脂質を分解して得られるアルコール、脂肪酸。ステロールやポリケチドもここに含めます。<br />
}}<br />
<br />
<center><br />
{| class="wikitable"<br />
|-<br />
! colspan="3" | Lipid Overview<br />
|-<br />
| align="left" style="vertical-align:top" width=33%|<br />
[[:Category:LBF|LBF: Fatty acyls <br><small>脂肪酸アシル</small>]] <br />
<br>[[Image:LBF.png|100px]]<br><br />
<br />
;Links to the original LipidBank<br />
:[https://lipidbank.jp/DFA.html fatty acids]<br />
:[https://lipidbank.jp/DLL.html long-chain alcohol]<br />
:[https://lipidbank.jp/DLD.html long-chain aldehyde]<br />
:[https://lipidbank.jp/XPR.html eicosanoids]<br />
:[https://lipidbank.jp/OPO.html lipid peroxide]<br />
:[https://lipidbank.jp/WWA.html wax]<br />
:[https://lipidbank.jp/MMA.html mycolic acid]<br />
<br />
<br />
| align="left" style="vertical-align:top" width=33%|<br />
[[:Category:LBG|LBG: Glycerolipids<br><small>グリセロ脂質</small>]]<br />
<br>[[Image:LBG.png|100px]]<br><br />
<br />
;Links to the original LipidBank<br />
:[https://lipidbank.jp/NAG.html acylglycerols]<br />
:[https://lipidbank.jp/PGP.html glycerophospholipid]<br />
:[https://lipidbank.jp/EEA.html ether-type lipid]<br />
:[https://lipidbank.jp/GGG.html glycoglycerolipid]<br />
* [[:Category:LBGA|LBGA: Archaeal Lipid (Ether-type)<br/><small>古細菌の脂質</small>]] <br />
<br />
| align="left" style="vertical-align:top" width=33%|<br />
[[:Category:LBS|LBS: Sphingolipids<br><small>スフィンゴ脂質</small>]] (new)<br />
<br>[[Image:LBS.png|110px]]<br><br />
<br />
* [[:Category:LBSB|LBSB: long-chain base and ceramide]]<br />
* [[:Category:LBSC|LBSC: cerebroside]]<br />
* [[:Category:LBSG|LBSG: acidic glycosphingolipid]]<br />
* [[:Category:LBSP|LBSP: phospho-sphingolipid]]<br />
<br />
|-<br />
| style="vertical-align:top"| Sterol Lipids<br />
<br/>[[File:Cholestane.png]]<br/><br />
;Links to the original LipidBank<br />
:[https://lipidbank.jp/SST.html steroid]<br />
:[https://lipidbank.jp/BBA.html bile acid]<br />
:[https://lipidbank.jp/VVD.html vitamin D]<br />
<br />
<br />
| style="vertical-align:top"| Prenol Lipids<br />
<br/><BIG>(</BIG> [[File:Isoprene.png]]<BIG>)</BIG><sub>n</sub><br/><br />
;Links to the original LipidBank<br />
:[https://lipidbank.jp/IIP.html isoprenoid]<br />
:[https://lipidbank.jp/VCA.html carotenoid]<br />
:[https://lipidbank.jp/VVA.html vitamin A]<br />
:[https://lipidbank.jp/VVK.html vitamin K]<br />
:[https://lipidbank.jp/VCQ.html coenzyme Q]<br />
<br />
<br />
| style="vertical-align:top"| Others<br />
<br />
;Links to the original LipidBank<br />
:[https://lipidbank.jp/CLS.html lipopolysaccharide]<br />
:[https://lipidbank.jp/ALA.html lipoamino acid]<br />
:[https://lipidbank.jp/TLP.html lipoprotein]<br />
:[https://lipidbank.jp/VVE.html vitamin E]<br />
:[https://lipidbank.jp/NAG.html acylglycerols]<br />
<br />
|}<br />
</center><br />
<br />
; Related projects<br />
* [[Lipoquality:Database|LipoQuality Database]]<br />
<br />
<!---- Class Information (Do not delete)<br />
&&LB&&Lipid<br />
&&LBS&&Sphingolipid<br />
&&LBSB&&Sphingoid base<br />
&&LBSR&&Ceramide<br />
&&LBSG&&Glycosphingolipid<br />
&&LBSP&&Phosphosphingolipid<br />
&&LBG&&Glycerolipid<br />
&&LBGG&&Glycoglycerolipid<br />
&&LBGP&&Phosphoglycerolipid<br />
<br />
&&LBF&&Fatty Acyl<br />
<br />
&&LBFA&&Fatty Acyl<br />
&&LBFA01&&Fatty Acids and Conjugates<br />
&&LBFA0101&&Straight chain fatty acids<br />
&&LBFA0102&&Methyl branched fatty acids<br />
&&LBFA0103&&Unsaturated fatty acids<br />
&&LBFA0104&&Hydroperoxy fatty acids<br />
&&LBFA0105&&Hydroxy fatty acids<br />
&&LBFA0106&&Oxo fatty acids<br />
&&LBFA0107&&Epoxy fatty acids<br />
&&LBFA0108&&Methoxy fatty acids<br />
&&LBFA0109&&Halogenated fatty acids<br />
&&LBFA0110&&Amino fatty acids<br />
&&LBFA0111&&Cyano fatty acids<br />
&&LBFA0112&&Nitro fatty acids<br />
&&LBFA0113&&Thia fatty acids<br />
&&LBFA0114&&Carbocyclic fatty acids<br />
&&LBFA0115&&Heterocyclic fatty acids<br />
&&LBFA0116&&Mycolic acids<br />
&&LBFA0117&&Dicarboxylic acids<br />
&&LBFA02&&Octadecanoids<br />
&&LBFA0201&&12-oxophytodienoic acid metabolites<br />
&&LBFA0202&&jasmonic acids<br />
&&LBFA03&&Eicosanoids<br />
&&LBFA0301&&Prostaglandins<br />
&&LBFA0302&&Leukotrienes<br />
&&LBFA0303&&Thromboxanes<br />
&&LBFA0304&&Lipoxins<br />
&&LBFA0305&&Hydroxyeicosatrienoic acids<br />
&&LBFA0306&&Hydroxyeicosatetraenoic acids<br />
&&LBFA0307&&Hydroxyeicosapentaenoic acids<br />
&&LBFA0308&&Epoxyeicosatetraenoic acids<br />
&&LBFA0309&&Hepoxilins<br />
&&LBFA0310&&Levuglandins<br />
&&LBFA0311&&Isoprostanes<br />
&&LBFA0312&&Clavulones<br />
&&LBFA04&&Docosanoids<br />
&&LBFA05&&Fatty alcohols<br />
&&LBFA06&&Fatty aldehydes<br />
&&LBFA07&&Fatty esters<br />
&&LBFA0701&&Wax monoesters<br />
&&LBFA0702&&Wax diesters<br />
&&LBFA0703&&Cyano esters<br />
&&LBFA0704&&Lactones<br />
&&LBFA0705&&Fatty acyl CoAs<br />
&&LBFA0706&&Fatty acyl ACPs<br />
&&LBFA0707&&Fatty acyl carnitines<br />
&&LBFA0708&&Fatty acyl adenylates<br />
&&LBFA08&&Fatty amides<br />
&&LBFA0801&&Primary amides<br />
&&LBFA0802&&N-acyl amides<br />
&&LBFA0803&&Fatty acyl homoserine lactones<br />
&&LBFA0804&&N-acyl ethanolamides (endocannabinoids)<br />
&&LBFA09&&Fatty nitriles<br />
&&LBFA10&&Fatty ethers<br />
&&LBFA11&&Hydrocarbons<br />
&&LBFA12&&Oxygenated hydrocarbons<br />
&&LBFA00&&Other<br />
&&LBGL&&Glycerolipids<br />
&&LBGL01&&Monoradylglycerols<br />
&&LBGL0101&&Monoacylglycerols<br />
&&LBGL0102&&Monoalkylglycerols<br />
&&LBGL0103&&Mono-(1Z-alkenyl)-glycerols<br />
&&LBGL0104&&Monoacylglycerolglycosides<br />
&&LBGL0105&&Monoalkylglycerolglycosides<br />
&&LBGL02&&Diradylglycerols<br />
&&LBGL0201&&Diacylglycerols<br />
&&LBGL0202&&Alkylacylglycerols<br />
&&LBGL0203&&Dialkylglycerols<br />
&&LBGL0204&&1Z-alkenylacylglycerols<br />
&&LBGL0205&&Diacylglycerolglycosides<br />
&&LBGL0206&&Alkylacylglycerolglycosides<br />
&&LBGL0207&&Dialkylglycerolglycosides<br />
&&LBGL0208&&Di-glycerol tetraethers<br />
&&LBGL0209&&Di-glycerol tetraether glycans<br />
&&LBGL03&&Triradylglycerols<br />
&&LBGL0301&&Triacylglycerols<br />
&&LBGL0302&&Alkyldiacylglycerols<br />
&&LBGL0303&&Dialkylmonoacylglycerols<br />
&&LBGL0304&&1Z-alkenyldiacylglycerols<br />
&&LBGL0305&&Estolides<br />
&&LBGL00&&Other<br />
&&LBGP&&Glycerophospholipids<br />
&&LBGP01&&Glycerophosphocholines<br />
&&LBGP0101&&Diacylglycerophosphocholines<br />
&&LBGP0102&&1-alkyl,2-acylglycerophosphocholines<br />
&&LBGP0103&&1Z-alkenyl,2-acylglycerophosphocholines<br />
&&LBGP0104&&Dialkylglycerophosphocholines<br />
&&LBGP0105&&Monoacylglycerophosphocholines<br />
&&LBGP0106&&1-alkyl glycerophosphocholines<br />
&&LBGP0107&&1Z-alkenylglycerophosphocholines<br />
&&LBGP02&&Glycerophosphoethanolamines<br />
&&LBGP0201&&Diacylglycerophosphoethanolamines<br />
&&LBGP0202&&1-alkyl,2-acylglycerophosphoethanolamines<br />
&&LBGP0203&&1Z-alkenyl,2-acylglycerophosphoethanolamines<br />
&&LBGP0204&&Dialkylglycerophosphoethanolamines<br />
&&LBGP0205&&Monoacylglycerophosphoethanolamines<br />
&&LBGP0206&&1-alkyl glycerophosphoethanolamines<br />
&&LBGP0207&&1Z-alkenylglycerophosphoethanolamines<br />
&&LBGP03&&Glycerophosphoserines<br />
&&LBGP0301&&Diacylglycerophosphoserines<br />
&&LBGP0302&&1-alkyl,2-acylglycerophosphoserines<br />
&&LBGP0303&&1Z-alkenyl,2-acylglycerophosphoserines<br />
&&LBGP0304&&Dialkylglycerophosphoserines<br />
&&LBGP0305&&Monoacylglycerophosphoserines<br />
&&LBGP0306&&1-alkyl glycerophosphoserines<br />
&&LBGP0307&&1Z-alkenylglycerophosphoserines<br />
&&LBGP04&&Glycerophosphoglycerols<br />
&&LBGP0401&&Diacylglycerophosphoglycerols<br />
&&LBGP0402&&1-alkyl,2-acylglycerophosphoglycerols<br />
&&LBGP0403&&1Z-alkenyl,2-acylglycerophosphoglycerols<br />
&&LBGP0404&&Dialkylglycerophosphoglycerols<br />
&&LBGP0405&&Monoacylglycerophosphoglycerols<br />
&&LBGP0406&&1-alkyl glycerophosphoglycerols<br />
&&LBGP0407&&1Z-alkenylglycerophosphoglycerols<br />
&&LBGP0408&&Diacylglycerophosphodiradylglycerols<br />
&&LBGP0409&&Diacylglycerophosphomonoradylglycerols<br />
&&LBGP0410&&Monoacylglycerophosphomonoradylglycerols<br />
&&LBGP05&&Glycerophosphoglycerophosphates<br />
&&LBGP0501&&Diacylglycerophosphoglycerophosphates<br />
&&LBGP0502&&1-alkyl,2-acylglycerophosphoglycerophosphates<br />
&&LBGP0503&&1Z-alkenyl,2-acylglycerophosphoglycerophosphates<br />
&&LBGP0504&&Dialkylglycerophosphoglycerophosphates<br />
&&LBGP0505&&Monoacylglycerophosphoglycerophosphates<br />
&&LBGP0506&&1-alkyl glycerophosphoglycerophosphates<br />
&&LBGP0507&&1Z-alkenylglycerophosphoglycerophosphates<br />
&&LBGP06&&Glycerophosphoinositols<br />
&&LBGP0601&&Diacylglycerophosphoinositols<br />
&&LBGP0602&&1-alkyl,2-acylglycerophosphoinositols<br />
&&LBGP0603&&1Z-alkenyl,2-acylglycerophosphoinositols<br />
&&LBGP0604&&Dialkylglycerophosphoinositols<br />
&&LBGP0605&&Monoacylglycerophosphoinositols<br />
&&LBGP0606&&1-alkyl glycerophosphoinositols<br />
&&LBGP0607&&1Z-alkenylglycerophosphoinositols<br />
&&LBGP07&&Glycerophosphoinositol monophosphates<br />
&&LBGP0701&&Diacylglycerophosphoinositol monophosphates<br />
&&LBGP0702&&1-alkyl,2-acylglycerophosphoinositol monophosphates<br />
&&LBGP0703&&1Z-alkenyl,2-acylglycerophosphoinositol monophosphates<br />
&&LBGP0704&&Dialkylglycerophosphoinositol monophosphates<br />
&&LBGP0705&&Monoacylglycerophosphoinositol monophosphates<br />
&&LBGP0706&&1-alkyl glycerophosphoinositol monophosphates<br />
&&LBGP0707&&1Z-alkenylglycerophosphoinositol monophosphates<br />
&&LBGP08&&Glycerophosphoinositol bisphosphates<br />
&&LBGP0801&&Diacylglycerophosphoinositol bisphosphates<br />
&&LBGP0802&&1-alkyl,2-acylglycerophosphoinositol bisphosphates<br />
&&LBGP0803&&1Z-alkenyl,2-acylglycerophosphoinositol bisphosphates<br />
&&LBGP0804&&Monoacylglycerophosphoinositol bisphosphates<br />
&&LBGP0805&&1-alkyl glycerophosphoinositol bisphosphates<br />
&&LBGP0806&&1Z-alkenylglycerophosphoinositol bisphosphates<br />
&&LBGP09&&Glycerophosphoinositol trisphosphates<br />
&&LBGP0901&&Diacylglycerophosphoinositol trisphosphates<br />
&&LBGP0902&&1-alkyl,2-acylglycerophosphoinositol trisphosphates<br />
&&LBGP0903&&1Z-alkenyl,2-acylglycerophosphoinositol trisphosphates<br />
&&LBGP0904&&Monoacylglycerophosphoinositol trisphosphates<br />
&&LBGP0905&&1-alkyl glycerophosphoinositol trisphosphates<br />
&&LBGP0906&&1Z-alkenylglycerophosphoinositol trisphosphates<br />
&&LBGP10&&Glycerophosphates<br />
&&LBGP1001&&Diacylglycerophosphates<br />
&&LBGP1002&&1-alkyl,2-acylglycerophosphates<br />
&&LBGP1003&&1Z-alkenyl,2-acylglycerophosphates<br />
&&LBGP1004&&Dialkylglycerophosphates<br />
&&LBGP1005&&Monoacylglycerophosphates<br />
&&LBGP1006&&1-alkyl glycerophosphates<br />
&&LBGP1007&&1Z-alkenylglycerophosphates<br />
&&LBGP11&&Glyceropyrophosphates<br />
&&LBGP1101&&Diacylglyceropyrophosphates<br />
&&LBGP1102&&Monoacylglyceropyrophosphates<br />
&&LBGP12&&Glycerophosphoglycerophosphoglycerols (Cardiolipins)<br />
&&LBGP1201&&Diacylglycerophosphoglycerophosphodiradylglycerols<br />
&&LBGP1202&&Diacylglycerophosphoglycerophosphomonoradylglycerols<br />
&&LBGP1203&&1-alkyl,2-acylglycerophosphoglycerophosphodiradylglycerols<br />
&&LBGP1204&&1-alkyl,2-acylglycerophosphoglycerophosphomonoradylglycerols<br />
&&LBGP1205&&1Z-alkenyl,2-acylglycerophosphoglycerophosphodiradylglycerols<br />
&&LBGP1206&&1Z-alkenyl,2-acylglycerophosphoglycerophosphomonoradylglycerols<br />
&&LBGP1207&&Monoacylglycerophosphoglycerophosphomonoradylglycerols<br />
&&LBGP1208&&1-alkyl glycerophosphoglycerophosphodiradylglycerols<br />
&&LBGP1209&&1-alkyl glycerophosphoglycerophosphomonoradylglycerols<br />
&&LBGP1210&&1Z-alkenylglycerophosphoglycerophosphodiradylglycerols<br />
&&LBGP1211&&1Z-alkenylglycerophosphoglycerophosphomonoradylglycerols<br />
&&LBGP13&&CDP-Glycerols<br />
&&LBGP1301&&CDP-diacylglycerols<br />
&&LBGP1302&&CDP-1-alkyl,2-acylglycerols<br />
&&LBGP1303&&CDP-1Z-alkenyl,2-acylglycerols<br />
&&LBGP1304&&CDP-Dialkylglycerols<br />
&&LBGP1305&&CDP-Monoacylglycerols<br />
&&LBGP1306&&CDP-1-alkyl glycerols<br />
&&LBGP1307&&CDP-1Z-alkenylglycerols<br />
&&LBGP14&&Glycerophosphoglucose lipids<br />
&&LBGP1401&&Diacylglycerophosphoglucose lipids<br />
&&LBGP1402&&1-alkyl,2-acylglycerophosphoglucose lipids<br />
&&LBGP1403&&1Z-alkenyl,2-acylglycerophosphoglucose lipids<br />
&&LBGP1404&&Monoacylglycerophosphoglucose lipids<br />
&&LBGP1405&&1-alkyl glycerophosphoglucose lipids<br />
&&LBGP1406&&1Z-alkenylglycerophosphoglucose lipids<br />
&&LBGP15&&Glycerophosphoinositolglycans<br />
&&LBGP1501&&Diacylglycerophosphoinositolglycans<br />
&&LBGP1502&&1-alkyl,2-acylglycerophosphoinositolglycans<br />
&&LBGP1503&&1Z-alkenyl,2-acylglycerophosphoinositolglycans<br />
&&LBGP1504&&Monoacylglycerophosphoinositolglycans<br />
&&LBGP1505&&1-alkyl glycerophosphoinositolglycans<br />
&&LBGP1506&&1Z-alkenylglycerophosphoinositolglycans<br />
&&LBGP16&&Glycerophosphonocholines<br />
&&LBGP1601&&Diacylglycerophosphonocholines<br />
&&LBGP1602&&1-alkyl,2-acylglycerophosphonocholines<br />
&&LBGP1603&&1Z-alkenyl,2-acylglycerophosphonocholines<br />
&&LBGP1604&&Dialkylglycerophosphonocholines<br />
&&LBGP1605&&Monoacylglycerophosphonocholines<br />
&&LBGP1606&&1-alkyl glycerophosphonocholines<br />
&&LBGP1607&&1Z-alkenylglycerophosphonocholines<br />
&&LBGP17&&Glycerophosphonoethanolamines<br />
&&LBGP1701&&Diacylglycerophosphonoethanolamines<br />
&&LBGP1702&&1-alkyl,2-acylglycerophosphonoethanolamines<br />
&&LBGP1703&&1Z-alkenyl,2-acylglycerophosphonoethanolamines<br />
&&LBGP1704&&Dialkylglycerophosphonoethanolamines<br />
&&LBGP1705&&Monoacylglycerophosphonoethanolamines<br />
&&LBGP1706&&1-alkyl glycerophosphonoethanolamines<br />
&&LBGP1707&&1Z-alkenylglycerophosphonoethanolamines<br />
&&LBGP18&&Di-glycerol tetraether phospholipids (caldarchaeols)<br />
&&LBGP19&&Glycerol-nonitol tetraether phospholipids<br />
&&LBGP20&&Oxidized glycerophospholipids<br />
&&LBGP00&&Other<br />
&&LBSP&&Sphingolipids<br />
&&LBSP01&&Sphingoid bases<br />
&&LBSP0101&&Sphing-4-enines (Sphingosines)<br />
&&LBSP0102&&Sphinganines<br />
&&LBSP0103&&4-Hydroxysphinganines (Phytosphingosines)<br />
&&LBSP0104&&Sphingoid base homologs and variants<br />
&&LBSP0105&&Sphingoid base 1-phosphates<br />
&&LBSP0106&&Lysosphingomyelins and lysoglycosphingolipids<br />
&&LBSP0107&&N-methylated sphingoid bases<br />
&&LBSP0108&&Sphingoid base analogs<br />
&&LBSP02&&Ceramides<br />
&&LBSP0201&&N-acylsphingosines (ceramides)<br />
&&LBSP0202&&N-acylsphinganines (dihydroceramides)<br />
&&LBSP0203&&N-acyl-4-hydroxysphinganines (phytoceramides)<br />
&&LBSP0204&&Acylceramides<br />
&&LBSP0205&&Ceramide 1-phosphates<br />
&&LBSP03&&Phosphosphingolipids<br />
&&LBSP0301&&Ceramide phosphocholines (sphingomyelins)<br />
&&LBSP0302&&Ceramide phosphoethanolamines<br />
&&LBSP0303&&Ceramide phosphoinositols<br />
&&LBSP04&&Phosphonosphingolipids<br />
&&LBSP05&&Neutral glycosphingolipids<br />
&&LBSP0501&&Simple Glc series (GlcCer, LacCer, etc)<br />
&&LBSP0502&&GalNAcb1-3Gala1-4Galb1-4Glc- (Globo series)<br />
&&LBSP0503&&GalNAcb1-4Galb1-4Glc- (Ganglio series)<br />
&&LBSP0504&&Galb1-3GlcNAcb1-3Galb1-4Glc- (Lacto series)<br />
&&LBSP0505&&Galb1-4GlcNAcb1-3Galb1-4Glc- (Neolacto series)<br />
&&LBSP0506&&GalNAcb1-3Gala1-3Galb1-4Glc- (Isoglobo series)<br />
&&LBSP0507&&GlcNAcb1-2Mana1-3Manb1-4Glc- (Mollu series)<br />
&&LBSP0508&&GalNAcb1-4GlcNAcb1-3Manb1-4Glc- (Arthro series)<br />
&&LBSP0509&&Gal- (Gala series)<br />
&&LBSP0510&&Other<br />
&&LBSP06&&Acidic glycosphingolipids<br />
&&LBSP0601&&Gangliosides<br />
&&LBSP0602&&Sulfoglycosphingolipids (sulfatides)<br />
&&LBSP0603&&Glucuronosphingolipids<br />
&&LBSP0604&&Phosphoglycosphingolipids<br />
&&LBSP0600&&Other<br />
&&LBSP07&&Basic glycosphingolipids<br />
&&LBSP08&&Amphoteric glycosphingolipids<br />
&&LBSP09&&Arsenosphingolipids<br />
&&LBSP00&&Other<br />
&&LBST&&Sterol Lipids<br />
&&LBST01&&Sterols<br />
&&LBST0101&&Cholesterol and derivatives<br />
&&LBST0102&&Cholesteryl esters<br />
&&LBST0103&&Phytosterols and derivatives<br />
&&LBST0104&&Marine sterols and derivatives<br />
&&LBST0105&&Fungal sterols and derivatives<br />
&&LBST02&&Steroids<br />
&&LBST0201&&C18 steroids (estrogens) and derivatives<br />
&&LBST0202&&C19 steroids (androgens) and derivatives<br />
&&LBST0203&&C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives<br />
&&LBST03&&Secosteroids<br />
&&LBST0301&&Vitamin D2 and derivatives<br />
&&LBST0302&&Vitamin D3 and derivatives<br />
&&LBST04&&Bile acids and derivatives<br />
&&LBST0401&&C24 bile acids, alcohols, and derivatives<br />
&&LBST0402&&C26 bile acids, alcohols, and derivatives<br />
&&LBST0403&&C27 bile acids, alcohols, and derivatives<br />
&&LBST0404&&C28 bile acids, alcohols, and derivatives<br />
&&LBST0405&&C22 bile acids, alcohols, and derivatives<br />
&&LBST0406&&C23 bile acids, alcohols, and derivatives<br />
&&LBST0407&&C25 bile acids, alcohols, and derivatives<br />
&&LBST0408&&C29 bile acids, alcohols, and derivatives<br />
&&LBST05&&Steroid conjugates<br />
&&LBST0501&&Glucuronides<br />
&&LBST0502&&Sulfates<br />
&&LBST0503&&Glycine conjugates<br />
&&LBST0504&&Taurine conjugates<br />
&&LBST06&&Hopanoids<br />
&&LBST00&&Other<br />
&&LBPR&&Prenol Lipids<br />
&&LBPR01&&Isoprenoids<br />
&&LBPR0101&&C5 isoprenoids<br />
&&LBPR0102&&C10 isoprenoids (monoterpenes)<br />
&&LBPR0103&&C15 isoprenoids (sesquiterpenes)<br />
&&LBPR0104&&C20 isoprenoids (diterpenes)<br />
&&LBPR0105&&C25 isoprenoids (sesterterpenes)<br />
&&LBPR0106&&C30 isoprenoids (triterpenes)<br />
&&LBPR0107&&C40 isoprenoids (tetraterpenes)<br />
&&LBPR0108&&Polyterpenes<br />
&&LBPR02&&Quinones and hydroquinones<br />
&&LBPR0201&&Ubiquinones<br />
&&LBPR0202&&Vitamin E<br />
&&LBPR0203&&Vitamin K<br />
&&LBPR03&&Polyprenols<br />
&&LBPR0301&&Bactoprenols<br />
&&LBPR0302&&Bactoprenol monophosphates<br />
&&LBPR0303&&Bactoprenol diphosphates<br />
&&LBPR0304&&Phytoprenols<br />
&&LBPR0305&&Phytoprenol monophosphates<br />
&&LBPR0306&&Phytoprenol diphosphates<br />
&&LBPR0307&&Dolichols<br />
&&LBPR0308&&Dolichol monophosphates<br />
&&LBPR0309&&Dolichol diphosphates<br />
&&LBPR00&&Other<br />
&&LBSL&&Saccharolipids<br />
&&LBSL01&&Acylaminosugars<br />
&&LBSL0101&&Monoacylaminosugars<br />
&&LBSL0102&&Diacylaminosugars<br />
&&LBSL0103&&Triacylaminosugars<br />
&&LBSL0104&&Tetraacylaminosugars<br />
&&LBSL0105&&Pentaacylaminosugars<br />
&&LBSL0106&&Hexaacylaminosugars<br />
&&LBSL0107&&Heptaacylaminosugars<br />
&&LBSL02&&Acylaminosugar glycans<br />
&&LBSL03&&Acyltrehaloses<br />
&&LBSL04&&Acyltrehalose glycans<br />
&&LBSL00&&Other<br />
&&LBPK&&Polyketides<br />
&&LBPK01&&Macrolide polyketides<br />
&&LBPK02&&Aromatic polyketides<br />
&&LBPK03&&Non-ribosomal peptide/polyketide hybrids<br />
&&LBPK00&&Other<br />
---></div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=File:Cholestane.png&diff=117170
File:Cholestane.png
2023-11-27T06:28:37Z
<p>Editor: </p>
<hr />
<div></div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=File:Isoprene.png&diff=117169
File:Isoprene.png
2023-11-27T06:25:13Z
<p>Editor: </p>
<hr />
<div></div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Category:LBSB&diff=117168
Category:LBSB
2023-11-27T05:51:03Z
<p>Editor: </p>
<hr />
<div>{{LB/Header}}<br />
{{Hierarchy|{{PAGENAME}}}}<br />
<br />
{{Twocolumn|<br />
Long-chain base (LCB or sphingoid base) is a 2-aminoalkane (or alkene) 1,3-diol. In cells, it constitutes sphingolipids and little exists as a free form.<br />
When LCB is linked with a long-chain fatty acid via an amide bond, it is called a ceramide (Cer).<ref>Yamaji T, Hanada K "Sphingolipid metabolism and interorganellar localization of sphingolipid enzymes and lipid transfer proteins" Traffic 2015 16:101-122. PMID 25382749</ref><br />
|<br />
長鎖塩基 LCB(またはスフィンゴイド塩基)は 2-アミノアルカン(またはアルケン) 1,3-ジオールを指し、生体内ではスフィンゴ脂質の構成成分です。遊離のLCBは微量しか存在しません。長鎖塩基に長鎖脂肪酸がアミド結合したものを、セラミドと呼びます。<br />
}}<br />
<references/><br />
<br />
[https://lipidbank.jp/DLB.html Link to the original LipidBank]<br />
<br />
<br />
==Notation 表記法 ==<br />
{|<br />
|style="background:lightgray" width="200px"| <font size="+2">Sph<br/>d18:1</font>&nbsp;<br />
|Sph is an abbreviation of LCB.<br/>''d'' or ''t'' stands for double or triple hydroxy groups, respectively. (We count the terminal alcohol.)<br/>18 is the carbon chain length.<br/>1 after the colon is the number of unsaturated bonds (double bonds).<br />
|width="30%"|<br />
長鎖塩基 LCB は Sph と表します。 ''d'', ''t'' はそれぞれ 2, 3 個の水酸基 (アルコールの水酸基含む)を意味し、18は炭素鎖長です。コロンの次にくる1は不飽和結合(二重結合)の数を表します。<br />
|}<br />
<br />
{|<br />
|style="background:lightgray" width="200px"| <font size="+2">Cer&nbsp;<br/>d18:1<sup>&Delta;8E</sup>/20:0</font>&nbsp;<br />
| Cer is an abbreviations of ceramide. The first part indicates the sphingoid base and the second, after the slash, fatty acid.<br/>In this website we do not use superscripts or subscripts for readability.<br/>Also we do not italicize E (or trans) and Z (or cis) for the same reason.<br />
|width="30%"| セラミドは Cer と表します。左側が長鎖塩基、スラッシュを挟んで右側は脂肪酸を表しています。このサイトでは上付き/下付きは使用せず(見づらいため)、 E (トランス), Z (シス)もイタリックにしていません。<br />
|}<br />
<br />
{| style="border-spacing: 20px;"<br />
|-<br />
! '''Common Name'''<br />
| sphingosine <br/>(= (4E)-sphingenine)<br/> スフィンゴシン<br />
| sphinganine <br/>(= dihydrosphingosine)<br/> スフィンガニン<br />
| phytosphingosine<br/>(= 4-hydroxydihydrosphingosine)<br/> フィトスフィンゴシン<br />
| 6-hydroxysphingosine<br/><br/> 6-ヒドロキシスフィンゴシン<br />
|-<br />
! '''Abbreviation'''<br />
| d18:1 or So<br />
| d18:0 or Sa (DHSo)<br />
| t18:0 or Phyto<br />
| t18:1 or 6-t18:1<br />
|-<br />
! '''Structure 構造'''<br />
| <small>{{LBS/Sph|OH}}</small><br />
| <small>{{LBS/DHSph|OH}}</small><br />
| <small>{{LBS/PhytoSph|OH}}</small><br />
| <small>{{LBS/6HSph|OH}}</small><br />
|-<br />
! '''Source 分布'''<br />
| Major in mammals<br />
| Major in mammals<br />
| Major in fungi and plant<br />
| Found in skin<br />
|}<br />
<br />
==Long-chain base 長鎖塩基==<br />
<br />
{{Twocolumn|<br />
The structural variation of LCB depends on biological species.<ref>Merrill AH "Sphingolipid and Glycosphingolipid Metabolic Pathways in the Era of Sphingolipidomics" Chem. Rev. 2011 111:6387–6422. PMID 21942574</ref><br />
|生物種によってLCBの構造は大きく異なります。<br />
}}<br />
<br />
{| class="wikitable"<br />
! Classification || Long-chain base<br />
|-<br />
| Mammalia || sphingosine (= (4E)-d18:1)<br/> (4E)-d20:1 (nerve tissue), t18:0 (intestine)<br />
|-<br />
| Arthropoda || short-chain sphingosine (d14:1, d16:1) <ref>Guan XL, Cestra G, Shui G, Kuhrs A, Schittenhelm RB, Hafen E, van der Goot FG, Robinett CC, Gatti M, Gonzalez-Gaitan M, Wenk MR "Biochemical membrane lipidomics during Drosophila development" Dev Cell 2013 24:98-111. PMID 23260625</ref><br />
|-<br />
| Plantae || (8E/Z)-d18:1, (8E/Z)-t18:1, (4E,8E/Z)-d18:2<br />
|-<br />
| Fungi || 9-methyl (4E,8E)-d18:2, t18:0<br />
|}<br />
<br />
<br />
===Bioactivity===<br />
{{Twocolumn|<br />
* Free LCB induces apoptosis.<ref>Hung WC, Chang HC, Chuang LY "Activation of caspase-3-like proteases in apoptosis induced by sphingosine and other long-chain bases in Hep3B hepatoma cells" Biochem J. 1999 338:161-166. PMID 9931312</ref><br />
* Sphingosine 1-phosphate is a lipid mediator of cell proliferation and motility control.<ref>Takabe K, Spiegel S."Export of sphingosine-1-phosphate and cancer progression"J Lipid Res. 2014 55:1839-46. PMID 24474820</ref><br />
|<br />
* 遊離のLCBはアポトーシスを惹起します。<br />
* スフィンゴシン 1リン酸 (Sph-1-P) は脂質メディエータとして細胞増殖や運動制御に働きます。<br />
}}<br />
<br />
<references/><br />
<br />
==Ceramide セラミド==<br />
<br />
{{Twocolumn|<br />
The conjugated fatty acids are often length 16 to 26. In normal tissues, little ceramide exists as an intermediate of phospho- and glycosphingolipid, whereas in the skin (corneocyte), ceramides and fatty-acid conjugated acyl-ceramides dominates and exhibit the barrier function.<br />
| セラミドに結合する脂肪酸の炭素鎖長は16から26が多く、通常組織ではスフィンゴリン脂質やスフィンゴ糖脂質の中間体として少量存在します。皮膚の角質層にはセラミドに更に脂肪酸が結合したアシルセラミドがあり、皮膚のバリア機能を担います。<br />
}}<br />
<br />
===Composition===<br />
{| class="wikitable"<br />
|-<br />
!rowspan="2"| Species<br />
!colspan="3"| Glycosylceramide<br />
!colspan="3"| Glycosyl inositol phosphoceramide (GIPC)<br />
|-<br />
! Fatty acid<br />
! Long chain base<br />
! References<br />
! Fatty acid<br />
! Long chain base<br />
! References<br />
|-<br />
!Plants<br />
| 16:0 - 26:0<br/>16:1 - 26:1<br/>16:0<br/>VLCFA<br />
| d18:2&Delta;4E8E/Z<br/>d18:2&Delta;4E8E/Z<br/>d18:1&Delta;8E/Z<br/>t18:1&Delta;8E/Z<br />
| <ref name=Mark>Markham JE, Lynch DV, Napier JA, Dunn TM, Cahoon EB. "Plant sphingolipids: function follows form" Curr Opin Plant Biol. 2013 16: 350-7. PMID 23499054</ref><ref name="War">Warnecke D, Heinz E."Recently discovered functions of glucosylceramides in plants and fungi" Cell Mol Life Sci. 2003 60:919-41.PMID 12827281</ref><br/><ref name="Mark"/><ref name="War"/><br/><ref name="Mark"/><br/><ref name="Mark"/><ref name="War"/><br />
| VLCFA<br/>14:0 - 26:0<br/>20:1 - 26:1<br />
| t18:1&Delta;8E/Z<br/>t18:1&Delta;8E/Z, t18:0<br/>t18:1&Delta;8E/Z, t18:0<br />
| <ref name="Mark"/><br/><ref name="Bure">Buré C, Cacas JL, Mongrand S, Schmitter JM. "Characterization of glycosyl inositol phosphoryl ceramides from plants and fungi by mass spectrometry" Anal Bioanal Chem. 2013 406:995-1010 PMID 23887274</ref><br/><ref name="Mark"/><ref name="Bure"/><br />
|-<br />
!Fungi<br />
| 16:0 - 18:0<br/>16:1 - 18:1<br />
| 9-methyl d18:2&Delta;4E,8E<br/>9-methyl d18:2&Delta;4E,8E<br />
| <ref name="Nim">Nimrichter L, Rodrigues ML. "Fungal glucosylceramides: from structural components to biologically active targets of new antimicrobials" Front Microbiol. 2011 2:212.PMID 22025918</ref><ref name="War"/><br/><ref name="Nim"/><ref name="War"/><br />
| 24:0 - 26:0<br/>24:1 - 26:1<br/>16:0 - 26:0<br />
| t18:0<br/>t18:0<br/>t18:0, t20:0<br />
| <ref name="Nim"/><br/><ref name="War"/><br/><ref name="War"/><ref name="Bure"/><br />
|}<br />
<br />
===Bioactivity===<br />
<br />
{{Twocolumn|<br />
* Atopic dermatitis (and dry skin) is associated with a decrease and compositional change of ceramides.<ref>Macheleidt O, Kaiser HW, Sandhoff K "Deficiency of epidermal protein-bound omega-hydroxyceramides in atopic dermatitis" J Invest Dermatol. 2002 119:166-173. PMID 12164940</ref><br />
* Ceramides involve in cell proliferation and autophagy, and ceramide 1-phosphate functions as a lipid mediator.<ref>Young MM, Kester M, Wang HG "Sphingolipids: regulators of crosstalk between apoptosis and autophagy" J Lipid Res.2013 54:5-19. PMID 23152582</ref><br />
|<br />
* アトピー性皮膚炎や乾燥肌ではセラミド量が減少し、組成も変化しています。<br />
* 通常細胞内ではLCBと同様に細胞増殖やオートファジーに関与し、セラミド末端にリン酸が結合した Cer-1-P も脂質メディエータとして働きます。<br />
}}<br />
<br />
<br />
<references/><br />
<br />
===Metabolism===<br />
<br />
[[:Category:LBS/Biosynthesis|Metabolism, Glycosphingolipid in Plant and Fungi]]</div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Category:LBS&diff=117167
Category:LBS
2023-05-26T01:15:53Z
<p>Editor: /* {{Bilingual|生合成|Biosynthesis}} */</p>
<hr />
<div>{{Huge|{{Bilingual|スフィンゴ脂質|Sphingolipid}}}}<br />
{{LB/Header}}<br />
{{Hierarchy|{{PAGENAME}}}}<br />
{| style="float:left"<br />
| __TOC__<br />
|}<br />
=={{Bilingual|概要|Class Overview}}==<br />
<br />
{{Twocolumn|<br />
Three Sphingolipid categories (LBS) exist in this database. <br />
|このデータベースではスフィンゴ脂質を以下に分けています。<br />
}}<br />
<br />
<center><br />
{| <br />
|-<br />
| style="vertical-align:top" width="33%"|<br />
[[:Category:LBSB| '''Ceramide''']]<br/>{{LBS/Cer|OH}}<br/><small>セラミド</small><br />
| style="vertical-align:top" width="33%"|<br />
'''Glycosphingolipid'''<br/>{{LBS/Cer|O-(sugar)}}<br/><small>スフィンゴ糖脂質</small><br />
| style="vertical-align:top" width="33%"|<br />
[[:Category:LBSP| '''Phosphosphingolipid''']]<br/>{{LBS/Cer|O-(phosphate)}}<br/><small>スフィンゴリン脂質</small><br />
|-<br />
|<br />
*[[:Category:LBSB|Long-chain base and ceramide]]<br />
|<br />
*[[:Category:LBSC|Cerebroside <small>(monohexosyl ceramides)</small>]]<br />
*[[:Category:LBSG|Acidic glycosphingolipid]]<br />
|<br />
*[[:Category:LBSP|Sphingomyelin, CPE, CAEP and GIPC]]<br />
|}<br />
</center><br />
<br />
<center><br />
{| class="wikitable"<br />
|<big><br />
[[:Category:LBS/Search|{{Bilingual|スフィンゴ脂質検索画面にいく|Go to Sphingolipid search.}}]]<br />
</big><br />
|}<br />
</center><br />
<br />
<br />
=={{Bilingual|スフィンゴ脂質|Sphingolipid}}==<br />
<br />
==={{Bilingual|表記法|Notation}}===<br />
{| class="wikitable collapsible collapsed" style="width:80%"<br />
!colspan="4" align="center" style="background:lightgray"| Symbol Abbreviations (e.g. Glc = glucose)<br />
|-<br />
!colspan="4" align="center" style="background:lightgray"| Backbones<br />
{{#repeatnum:LBS/AbbrevRow|1|<br />
Cer && ceramide && セラミド && <br />
Sph && sphingosine && スフィンゴシン && <br />
}}<br />
|-<br />
!colspan="4" align="center" style="background:lightgray"| Sugars<br />
{{#repeatnum:LBS/AbbrevRow|1|<br />
Glc && glucose && グルコース && C6H12O6 && <br />
Gal && galactose && ガラクトース && C6H12O6 && <br />
GlcNAc && ''N''-acetyl-glucosamine && ''N''-アセチルグルコサミン && C8H15NO6 <br />
GalNAc && ''N''-acetyl-galactosamine && ''N''-アセチルガラクトサミン && C8H15NO6<br />
GlcN && glucosamine && グルコサミン && C6H13NO5<br />
GalN && galactosamine && ガラクトサミン && C6H13NO5<br />
GlcA && glucuronic acid && グルクロン酸 && C6H10O7<br />
GalA && galacturonic acid && ガラクツロン酸 && C6H10O7 && <br />
Man && mannose && マンノース && C6H12O6 && 18950<br />
Rha && rhamnose (= 6-deoxy-mannose) && ラムノース (6-デオキシマンノース) && C6H12O5 && 19233<br />
Ins && inositol && イノシトール && C6H12O6 && 892<br />
Fuc && fucose (= 6-deoxy-galactose) && フコース (6-デオキシガラクトース) && C6H12O5 && 17106<br />
Ara && arabinose && アラビノース && C5H10O5 && 5460291<br />
Xyl && xylose && キシロース && C5H10O5 && 135191<br />
NeuNH && (deacetyl) neuraminic acid<br/>(pyruvate + mannosamine) && ノイラミン酸<br/>(ピルビン酸+マンノサミン) && C9H17N1O8 && 513472<br />
NeuAc && ''N''-acetyl-neuraminic acid && ''N''-アセチルノイラミン酸 && C11H19NO9 && 439197<br />
NeuGc && ''N''-glycolyl-neuraminic acid && ''N''-グリコリルノイラミン酸 && C11H19NO10 && 123802<br />
Kdn && 2-keto-3-deoxy-D-glycero-<br/>D-galacto-nononic acid && デアミノノイラミン酸 && C9H16O9 && 13991616<br />
}}<br />
|-<br />
!colspan="4" align="center" style="background:lightgray"| Modifiers<br />
{{#repeatnum:LBS/AbbrevRow|1|<br />
AEPn && aminoethylphosphonic acid, or<br/>(2-aminoethyl)hydroxyphosphoryl- && アミノエチルホスホン酸(C-P結合)<br />
MAEPn && ''N''-methyl aminoethylphosphonic acid, or<br/>(''N''-methyl-2-aminoethyl) hydroxyphosphoryl- && AEPnの''N''-メチル体(C-P結合)<br />
EtnP && phosphoethanolamine (PEA), or<br/>2-aminoethanolphospho- && ホスホエタノールアミン<br />
PC && Phosphocholine && ホスホコリン<br />
Butenyl && Butenyl && ブテニル基<br />
Me && Methyl && メチル基<br />
Et && Ethyl && エチル基<br />
}}<br />
|}<br />
<br />
==={{Bilingual|分類体系|Page/ID-Code Design}}===<br />
{{Twocolumn|<br />
Major series of phosphosphingolipids are determined by molecules bound to their phosphates, and the series of glycosphingolipids are determined by oligosaccharides bound to their ceramides. The IUPAC series of glycosphingolipids (1977) were based on the order and bonding patterns of four sugars rooting at the long-chain base. Our series, however, are based on three sugars. Two original series, Echino and Schisto, are also added.<br />
|スフィンゴリン脂質はリン酸に結合する分子や糖の種類、スフィンゴ糖脂質はセラミドに結合する糖鎖により系列を作成しています。1977年にIUPACが提唱したスフィンゴ糖脂質の系列は、長鎖塩基に結合する四糖の並びと結合を基準にしています。ここではより広い糖鎖の系列を検索できるよう、三糖を基準に分類しています。また新たにEchinoとSchistoの系列を加えています。<br />
}}<br />
<br />
{|<br />
|<br />
<table border=1><br />
<tr><br />
<td style="background-color:yellowgreen;" width=20px align="center"><big>L</big><br />
<td style="background-color:yellowgreen;" width=20px align="center"><big>B</big><br />
<td style="background-color:yellowgreen;" width=20px align="center"><big>S</big><br />
<td style="background-color:green;" width=20px align="center"><big>''G/P''</big><br />
<td style="background-color:Blue; color:white" width=20px align="center"><big>''s1''</big><br />
<td style="background-color:Blue; color:white" width=20px align="center"><big>''s2''</big><br />
<td style="background-color:tomato; color:white" width=20px align="center"><big>''n1''</big><br />
<td style="background-color:tomato; color:white" width=20px align="center"><big>''n2''</big><br />
<td style="background-color:firebrick; color:white" width=20px align="center"><big>''y''</big><br />
<td style="background-color:white;" width=20px align="center"><big>''c1''</big><br />
<td style="background-color:white;" width=20px align="center"><big>''c2''</big><br />
</tr><br />
</table><br />
| &nbsp;<br />
|<br />
{| class="wikitable"<br />
! '''G/P''' || '''G''' (glyco) || '''P''' (phospho) <br />
|-<br />
! '''s1, s2''' <br />
|colspan="3"| structure code as explained below<br />
|-<br />
! '''n1, n2''' <br />
|colspan="2"| number of sugars (2 digits)<br />
|-<br />
! '''y'''<br />
|colspan="2"| number of sialic acids (1 digit)<br />
|-<br />
! '''c1, c2'''<br />
|colspan="2"| serial numbers<br />
|}<br />
|}<br />
<br />
==={{Bilingual|スフィンゴ糖脂質1文字目|First (s1) Digit for Glycosphingolipid}}===<br />
<span id="SphingolipidClass"></span><br />
{| class="wikitable" style="text-align:right; background-color:white"<br />
! First sugar || Code || Root sequence<br />
! colspan=2 | Major Series <br />
|-<br />
! Cerebroside <br />
| colspan="3" style="text-align:left" | '''For GalCer and GlcCer, visit [[:Category:LBSC|this page]].'''<br />
|-<br />
! starting with<br/><big>Galactose</big><br />
| {{#volatile:ListMol/LBStitle|<b>G1</b>|LBSG1}} <br /> ({{#volatile:ClassMatrix|{{#countTitle:LBSG1}} items|LBSG1.....|7|8|9|9|Number_of_Sugars|Number_of_Sialic_acids}})<br />
|style="text-align:right"| '''Gal'''-Cer<br />
|<br />
{| style="width:100%;"<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Gala / Neogala|Mainchain.*Gala1-4?6?Galb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|Gala1-4/6Galb1-Cer}} <br />
|-<br />
|style="border:0;text-align:left"|{{#volatile:ListMol/LBS|Spirometo|Mainchain.*Galb1-4Glcb1-3Galb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|Galb1-4Glcb1-3Galb1-Cer}}<br />
|}<br />
|-<br />
! rowspan="8" | starting with<br/><big>Glucose</big><br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>G2</b>|LBSG2}} <br /> ({{#volatile:ClassMatrix|{{#countTitle:LBSG2}} items|LBSG2.....|7|8|9|9|Number_of_Sugars|Number_of_Sialic_acids}})<br />
|style="text-align:right"| '''GalNAc<sub>&beta;</sub>'''-Gal<sub>&beta;</sub>-Glc<sub>&beta;</sub>-Cer<br />
|<br />
{| style="width:100%"<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Ganglio|Mainchain.*GalNAcb1-4Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GalNAcb1-4Galb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Isoganglio|Mainchain.*GalNAcb1-3Galb1-4Glcb1-Cer}}<ref name="iso">In IUPAC, "iso" refers to a change from position 4 to position 3.</ref><br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GalNAcb1-3Galb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Lactoganglio|Structure.*GlcNAcb1-3\(.*GalNAcb1-4\)Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GlcNAcb1-3(GalNAcb1-4)Galb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|a-series|Structure.*\(?NeuAca2-3\)?Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GalNAcb1-4(NeuAca2-3)Galb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|b-series|Structure.*\(?NeuAca2-8NeuAca2-3\)?Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GalNAcb1-4(NeuAca2-8NeuAca2-3)Galb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|c-series|Structure.*\(?NeuAca2-8NeuAca2-8NeuAca2-3\)?Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GalNAcb1-4(NeuAca2-8NeuAca2-8NeuAca2-3)Galb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|&alpha;-series|Structure.*\(?NeuAca2-6\)?GalNAcb1-4Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|...(NeuAca2-6)GalNAcb1-4Galb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|&beta;-series|Structure.*\(?NeuAca2-8NeuAca2-6\)?GalNAcb1-4Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|...(NeuAca2-8NeuAca2-6)GalNAcb1-4Galb1-4Glcb1-Cer}}<br />
|}<br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>G3</b>|LBSG3}} <br /> ({{#volatile:ClassMatrix|{{#countTitle:LBSG3}} items|LBSG3.....|7|8|9|9|Number_of_Sugars|Number_of_Sialic_acids}})<br />
|style="text-align:right"| '''GlcNAc<sub>&beta;</sub>'''-Gal<sub>&beta;</sub>-Glc<sub>&beta;</sub>-Cer<br />
|<br />
{| style="width:100%"<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Lacto|Mainchain.*Galb1-3GlcNAcb1-3Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|Galb1-3GlcNAcb1-3Galb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Neolacto|Mainchain.*Gal.1-4GlcNAcb1-3Galb1-4Glcb1-Cer}}<ref name="neo">In IUPAC, "neo" refers to a change from position 3 to position 4.</ref><br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|Galb1-4GlcNAcb1-3Galb1-4Glcb1-Cer}}<br />
|}<br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>G4</b>|LBSG4}} <br /> ({{#volatile:ClassMatrix|{{#countTitle:LBSG4}} items|LBSG4.....|7|8|9|9|Number_of_Sugars|Number_of_Sialic_acids}})<br />
|style="text-align:right"| '''Gal<sub>&alpha;</sub>'''-Gal<sub>&beta;</sub>-Glc<sub>&beta;</sub>-Cer<br />
|<br />
{| style="width:100%"<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Globo|Mainchain.*Gala1-4Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|Gala1-4Galb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Isoglobo|Mainchain.*Gala1-3Galb1-4Glcb1-Cer}}<ref name="iso"/><br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|Gala1-3Galb1-4Glcb1-Cer}}<br />
|}<br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>G5</b>|LBSG5}} <br /> ({{#volatile:ClassMatrix|{{#countTitle:LBSG5}} items|LBSG5.....|7|8|9|9|Number_of_Sugars|Number_of_Sialic_acids}})<br />
|style="text-align:right"| Gal-Glc-Cer<br/>(Other than G2&sim;G4)<br />
|<br />
{| style="width:100%"<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Muco|Mainchain.*Galb1-4Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|Galb1-4Galb1-4Glcb1-Cer}}<br />
|}<br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>G6</b>|LBSG6}} <br /> ({{#volatile:ClassMatrix|{{#countTitle:LBSG6}} items|LBSG6.....|7|8|9|9|Number_of_Sugars|Number_of_Sialic_acids}})<br />
|style="text-align:right"| '''Man'''-Glc<sub>&beta;</sub>-Cer<br />
|<br />
{| style="width:100%"<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Arthro|Mainchain.*GlcNAcb1-3Manb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GlcNAcb1-3Manb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Mollu|Mainchain.*Mana1-3Manb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|Mana1-3Manb1-4Glcb1-Cer}}<br />
|}<br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>G7</b>|LBSG7}} <br /> ({{#volatile:ClassMatrix|{{#countTitle:LBSG7}} items|LBSG7.....|7|8|9|9|Number_of_Sugars|Number_of_Sialic_acids}})<br />
|style="text-align:right"| '''NeuAc'''/'''NeuGc'''-Glc<sub>&beta;</sub>-Cer<br />
|<br />
{| style="width:100%"<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Echino|Mainchain.*Neu(A~G)c.2-6Glcb1-Cer}}<br />
|style="border:0;text-align:right"| <font color=purple>'''NeuGc'''</font> or {{#invoke:LBS|FormatSugar|NeuAca2-6Glcb1-Cer}}<br />
|}<br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>G8</b>|LBSG8}} <br /> ({{#volatile:ClassMatrix|{{#countTitle:LBSG8}} items|LBSG8.....|7|8|9|9|Number_of_Sugars|Number_of_Sialic_acids}})<br />
|style="text-align:right"| '''GalNAc'''-Glc-Cer<br />
|<br />
{| style="width:100%"<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Schisto|Mainchain.*GalNAc.1-4Glc.1-Cer}}<ref>Makaaru CK, Damian RT, Smith DF, Cummings RD. "The human blood fluke Schistosoma mansoni synthesizes a novel type of glycosphingolipid" J Biol Chem 1992 267:2251-2257 PMID 1733932</ref><br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GalNAcb1-4Glcb1-Cer}}<br />
|}<br />
|-<br />
! starting with<br/><big>Other Sugars</big><br />
| {{#volatile:ListMol/LBStitle|<b>G</b>(<b>A</b>&sim;<b>R</b>)|LBSG(A~B~C~D~E~F~G~H~J~K~M~N~O~P~Q~R)}}<br />
|colspan="2"| Symbols follow the Sugar-digit table.<br />
|}<br />
<references/><br />
<br />
==={{Bilingual|スフィンゴリン脂質1文字目|First (s1) Digit for Phosphosphingolipid}}===<br />
{| class="wikitable" style="text-align:right; background-color:white"<br />
! First sugar || Code || Root sequence <br />
!colspan="2"| Major Series<br />
|-<br />
! No Sugar Attached<br />
| '''P1''' ([[:Category:LBSP|LBSP]])<br />
| R-P-Cer<br />
| Sphingomyelin and Ceramide phosphoetanolamine<br/>(Visit [[:Category:LBSP|this page]].)<br />
|-<br />
! rowspan="4" | starting with<br/><big>Inositol</big><br />
| {{#volatile:ListMol/LBStitle|<b>P2</b>|LBSP2}} <br /> ({{#countTitle:LBSP2}} items)<br />
| style="text-align:right"| '''GlcN'''<sub>&alpha;/&beta;1&minus;2/6</sub>Ins<sub>1</sub>-P-Cer<br />
|<br />
{|style="width:100%"<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Protozoa & Fungi-specific|Mainchain.*GlcN.1-.Ins-P-Cer}}<br />
| style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GlcNa/b1-2/6Ins1-P-Cer}}<br />
|}<br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>P3</b>|LBSP3}} <br /> ({{#countTitle:LBSP3}} items) <br />
|style="text-align:right"| '''GlcA'''<sub>&alpha;/&beta;1&minus;2/6</sub>Ins<sub>1</sub>-P-Cer<br />
|<br />
{|style="width:100%"<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Plant-specific|Mainchain.*GlcA.1-.Ins-P-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GlcAa/b1-2/6Ins1-P-Cer}}<br />
|}<br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>P4</b>|LBSP4}} <br /> ({{#countTitle:LBSP4}} items)<br />
| style="text-align:right"| '''Man'''<sub>&alpha;/&beta;1&minus;2/6</sub>Ins<sub>1</sub>-P-Cer<br />
|<br />
{| style="width:100%"<br />
| style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Fungi-specific|Mainchain.*Man.1-.Ins-P-Cer}}<br />
| style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|Mana/b1-2/6Ins1-P-Cer}}<br />
|}<br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>P5</b>|LBSP5}} <br /> ({{#countTitle:LBSP5}} items)<br />
| style="text-align:right"| Gal, Glc, and Others<br />
| style="text-align:right"| {{#invoke:LBS|FormatSugar|X-Ins1-P-Cer}}<br />
|}<br />
<br />
==={{Bilingual|コード2文字目|Second (s2) Digit}}===<br />
<span id="SphingolipidSugar"></span><br />
{{Bilingual|クリックすると一覧が出ます。記号の略称については|Click to see the full list. For abbreviations, see}} [[#Notation]].<br />
<br />
{| <br />
|-<br />
| valign="top"|<br />
{| class="wikitable"<br />
|-<br />
! Code || Structure<br />
|-<br />
! '''A'''<br />
| Glc [[File:LBS-Monomer-Glc.png]]<br />
|-<br />
! '''B'''<br />
| Gal [[File:LBS-Monomer-Gal.png]]<br />
|-<br />
! '''C'''<br />
| GlcNAc [[File:LBS-Monomer-GlcNAc.png]]<br />
|-<br />
! '''D'''<br />
| GalNAc [[File:LBS-Monomer-GalNAc.png]]<br />
|-<br />
! '''E'''<br />
| GlcN [[File:LBS-Monomer-GlcN.png]]<br />
|-<br />
! '''F'''<br />
| GalN [[File:LBS-Monomer-GalN.png]]<br />
|-<br />
! '''G'''<br />
| GlcA [[File:LBS-Monomer-GlcA.png]]<br />
|-<br />
! '''H'''<br />
| GalA [[File:LBS-Monomer-GalA.png]]<br />
|-<br />
! '''I'''<br />
| not used<br />
|}<br />
|valign="top"|<br />
{| class="wikitable"<br />
|-<br />
! Code || Structure<br />
|-<br />
! '''J'''<br />
| {{#volatile:ListMol/LBS|Mannose|Structure.*Man}} [[File:LBS-Monomer-Man.png]]<br />
|-<br />
! '''K'''<br />
| {{#volatile:ListMol/LBS|Rhamnose|Structure.*Rha}} [[File:LBS-Monomer-Rha.png]]<br />
|-<br />
! '''L'''<br />
| {{#volatile:ListMol/LBS|Inositol|Structure.*Ins(Me)?-P-[^Cer]}} <br />
|-<br />
! '''M'''<br />
| Fucose ({{#volatile:ListMol/LBS| 1|Structure[^F]+Fuc[^F]+$}}, {{#volatile:ListMol/LBS|2|Structure([^F]+Fuc){2}[^F]+$}}, {{#volatile:ListMol/LBS|>3|Structure([^F]+Fuc){3} }}) [[File:LBS-Monomer-Fuc.png]]<br />
|-<br />
! '''N'''<br />
| {{#volatile:ListMol/LBS|Arabinose|Structure.*Ara}} [[File:LBS-Monomer-Ara.png]]<br />
|-<br />
! '''O'''<br />
| {{#volatile:ListMol/LBS|Xylose|Structure.*Xyl}} [[File:LBS-Monomer-Xyl.png]]<br />
|-<br />
! '''P'''<br />
| {{#volatile:ListMol/LBS|NeuAc / NeuNH|Structure.*(NeuAc~NeuNH)}} [[File:LBS-Monomer-NeuAc.png]]<br />
|-<br />
! '''Q'''<br />
| {{#volatile:ListMol/LBS|NeuGc|Structure.*(NeuGc)}} [[File:LBS-Monomer-NeuGc.png]]<br />
|-<br />
! '''R'''<br />
| {{#volatile:ListMol/LBS|Kdn|Structure.*(KDN)}} [[File:LBS-Monomer-KDN.png]]<br />
|}<br />
|valign="top"|<br />
{| class="wikitable"<br />
|-<br />
! Code || Structure<br />
|-<br />
! '''S'''<br />
| {{#volatile:ListMol/LBS|Phosphate (except GIPC)|Structure.*(Phospho)}} [[File:LBS-Monomer-P.png]]<br />
|-<br />
! '''T'''<br />
| {{#volatile:ListMol/LBS|(M)AEPn|Structure.*(AEPn)}}, {{#volatile:ListMol/LBS|EtnP|Structure.*(EtnP)}}, {{#volatile:ListMol/LBS|PC|Structure.*(PC)}} [[File:LBS-Monomer-AEPn.png]]<br />
|-<br />
! '''U'''<br />
| {{#volatile:ListMol/LBS|Sulfate|Structure.*Sulfo}} [[File:LBS-Monomer-S.png]]<br />
|-<br />
! '''V'''<br />
| acyl/alkyl/alkenyl chain [[File:LBS-Monomer-Alkyl.png]]<br />
|}<br />
<br />
=={{Bilingual|生合成|Biosynthesis}}==<br />
{{Twocolumn|<br />
Sphingosine is synthesized from decarboxylating condensation of palmitoyl CoA with serine on the ER membrane. It is a 18-carbon amino alcohol (16 carbons from palmitic acid and 2 from serine) with one unsaturated bond (trans-form) at the C-4 position (2-amino-4-octadecene-1,3-diol). ([[:Category:LBS/Biosynthesis|more details]])<br />
|<br />
スフィンゴシンはパルミトイルCoAがアミノ酸セリンと脱炭酸縮合して生成します。炭素を18個含むアミノアルコール(16個がパルミチン酸、2個がセリン由来)でトランス型の不飽和結合をC-4に1つ含みます。([[:Category:LBS/Biosynthesis|詳細はこちら]])<br />
}}<br />
<br />
<br />
=={{Bilingual|スフィンゴ脂質の歴史|History of Sphingolipids}}==<br />
{{Twocolumn|<br />
Sphingolipids were first isolated from brain by J.L.W. Thudichum (1829-1901) as lipids of unknown function and structure.<ref>Thudichum J.L.W.?"A Treatise on the Chemical Constitution of the Balliere" Tindall and Cox, London,?1884</ref> The basic structure is a long-chain base (long-chain amino-alcohol) whose amino-group is acylated with a long-chain fatty acid. This hydrophobic structure is called ceramides.<br />
Sphingolipid consists of phospho-sphingolipid and glyco-sphingolipid, whose ceramide structure is bonded with phosphate and (oligo)saccharides, respectively. Phosphosphingolipid includes sphingomyelin, and glycosphingolipid, cerebrosides and gangliosides. Both are abundant in neural tissues.<ref>Gault CR,?Obeid LM,?Hannun YA "An overview of sphingolipid synthesis to breakdown" Adv Exp Med Biol.?2010;688:1-23. PMID 20919643</ref><br />
|<br />
スフィンゴ脂質は J.L.W. Thudichum (1829-1901) により機能や構造未知の脂質として脳から見いだされました。基本骨格は長鎖塩基 (長鎖アミノアルコール) のアミノ基が長鎖脂肪酸とアミド結合したもので、セラミドと呼ばれます。<br />
スフィンゴ脂質はセラミドにリン酸が結合したスフィンゴリン脂質と糖が結合したスフィンゴ糖脂質に分けられます。スフィンゴリン脂質にはスフィンゴミエリンが、スフィンゴ糖脂質にはセレブロシドやガングリオシドなどが含まれ、いずれも神経系に多く存在します。<br />
}}<br />
<br />
<references/><br />
<br />
<!---<br />
{|<br />
|valign="top"|<br />
{| class="wikitable" style="text-align:center"<br />
!width="5%"| code<br />
!colspan="2"| Galactose<br />
|-<br />
| '''0''' <br />
|colspan="2"| no sugar<br />
|-<br />
| '''1''' <br />
|rowspan="3"| <b>Galactose</b><br/>(&alpha; form)<br />
| {{#invoke:LBS|FormatSugar|Gala1-3 ...}}<br />
|-<br />
| '''2''' || {{#invoke:LBS|FormatSugar|Gala1-4 ...}}<br />
|-<br />
| '''3''' || {{#invoke:LBS|FormatSugar|Gala1-6 ...}}<br />
|-<br />
| '''4'''<br />
|rowspan="3"| <b>Galactose</b><br/>(&beta; form)<br />
| {{#invoke:LBS|FormatSugar|Galb1-3 ...}}<br />
|-<br />
| '''5''' || {{#invoke:LBS|FormatSugar|Galb1-4 ...}}<br />
|-<br />
| '''6''' || {{#invoke:LBS|FormatSugar|Galb1-6 ...}}<br />
|}<br />
|valign="top"|<br />
{| class="wikitable" style="text-align:center"<br />
!width="5%"| code<br />
!colspan="2"| ''N''-Acetylated Sugars<br />
|-<br />
|-<br />
| '''7''' <br />
|rowspan="3"| <b>''N''-Acetyl Galactosamine</b><br/>(&beta; form)<br />
| {{#invoke:LBS|FormatSugar|GalNAcb1-3 ...}}<br />
|-<br />
| '''8''' || {{#invoke:LBS|FormatSugar|GalNAcb1-4 ...}}<br />
|-<br />
| '''9''' || {{#invoke:LBS|FormatSugar|GalNAcb1-6 ...}}<br />
|-<br />
| '''A''' <br />
|rowspan="3"| <b>''N''-Acetyl Glucosamine</b><br/>(&beta; form)<br />
| {{#invoke:LBS|FormatSugar|GlcNAcb1-3 ...}}<br />
|-<br />
| '''B'''<br />
| {{#invoke:LBS|FormatSugar|GlcNAcb1-4 ...}}<br />
|-<br />
| '''C'''<br />
| {{#invoke:LBS|FormatSugar|GlcNAcb1-6 ...}}<br />
|}<br />
|}<br />
<br />
<br />
{|<br />
|valign="top"|<br />
{| class="wikitable" style="text-align:center"<br />
!width="5%"| code<br />
!colspan="2"| Galactose & Glucose<br />
|-<br />
| '''D''' <br />
|rowspan="2"| <b>Aminated Sugars</b><br/>(Except for Code 7&sim;C)<br />
| {{#invoke:LBS|FormatSugar|GalNAc, GalN}}<br />
|-<br />
| '''E''' || {{#invoke:LBS|FormatSugar|GlcNAc, GlcN}}<br />
|-<br />
| '''F''' <br />
| <b>Galactose</b><br/>(Except Code 1&sim;6)<br />
| <span style="color:gold"><b>Gal</b></span><br />
|-<br />
| '''G''' <br />
| <b>Glucose</b><br />
| <span style="color:blue"><b>Glc</b></span><br />
|}<br />
|valign="top"|<br />
{| class="wikitable" style="text-align:center"<br />
!width="5%"| code<br />
! Other Sugars<br />
|-<br />
| '''J''' || Inositol (<span style="color:"><b>Ins</b></span>)<br />
|-<br />
| '''K''' || Fucose (<span style="color:red"><b>Fuc</b></span>)<br />
|-<br />
| '''L''' || Pentose sugars<br/>(<span style="color:DarkOrange"><b>Ara, Xyl</b></span>)<br />
|-<br />
| '''M''' || Mannose and Rhamnose (= 6-deoxymannose)<br/>(<span style="color:green"><b>Man, Rha</b></span>)<br />
|-<br />
| '''N''' || Sialic acids<br/>(<b><span style="color:Purple">NeuAc, NeuNH</span>, <span style="color:gray">NeuGc</span>, <span style="color:Green">Kdn</span></b>)<br />
|}<br />
|}<br />
<br />
{|<br />
|valign="top"|<br />
{| class="wikitable" style="text-align:center"<br />
!width="5%"| code<br />
!colspan="2"| Modifiers<br />
|-<br />
| '''P''' || Phosphate (<b>HPO4</b>), Sulphate (<b>HSO4</b>),<br/>and Phosphocholine (<b>PC</b>)<br />
|-<br />
| '''Q''' || Aminoethylphosphates<br/><b>AEPn, MAEPn, MAEPr, EtnP</b><br />
|-<br />
| '''R''' || Alkyl and acyl groups<br/><b>OAc, Methyl, Butenyl</b><br />
|}<br />
|valign="top"|<br />
{| class="wikitable" style="text-align:center"<br />
!width="5%"| code<br />
!colspan="2"| Abbreviations<br />
|-<br />
| '''Y''' || {{#invoke:LBS|FormatSugar|GlcNAcb1-3Manb1-4Glcb1-1Cer}}<br />
|-<br />
| '''Z''' || {{#invoke:LBS|FormatSugar|Galb1-4Glcb1-1bCer}}<br />
|}<br />
|}<br />
<br />
<br />
<br />
==={{Bilingual|よく知られたパターン|Common Patterns}}===<br />
<br />
{| class="wikitable"<br />
! Common Name || Records || Sequence<br />
|-<br />
|colspan="3" style="background:#efefef; text-align:center"| By GalCer Synthase (EC 2.4.1.62)<br />
{{#repeat:LBS/AbbrevTable/Row|1|<br />
Gala_(Ga) Gala1-4/6Galb1-Cer LBSF%5b23%5d.<br />
Spirometo_(Sp) Galb1-4Glcb1-3Galb1-Cer LBSFG5<br />
}}<br />
|-<br />
|colspan="3" style="background:#efefef; text-align:center"| By GlcCer Synthase (EC 2.4.1.80)<br />
{{#repeat:LBS/AbbrevTable/Row|1|<br />
Ganglio_(Gg) GalNAcb1-4Galb1-4Glcb1-Cer LBSZ8.<br />
Isoganglio_(iGg) GalNAcb1-3Galb1-4Glcb1-Cer LBSZ7.<br />
Globo_(Gb) Gala1-4Galb1-4Glcb1-Cer LBSZ2.<br />
Isoglobo_(iGb) Gala1-3Galb1-4Glcb1-Cer LBSZ1.<br />
Lacto_(Lc) Galb1-3GlcNAcb1-3Galb1-4Glcb1-Cer LBSZD4<br />
NeoLacto_(nLc) Galb1-4GlcNAcb1-3Galb1-4Glcb1-Cer LBSZA5<br />
Muco_(Mc) Galb1-4Galb1-4Glcb1-Cer LBSZ5.<br />
}}<br />
|-<br />
|colspan="3" style="background:#efefef; text-align:center"| With Mannose<br />
{{#repeat:LBS/AbbrevTable/Row|1|<br />
Arthro_(At) GlcNAcb1-3Manb1-4Glcb1-Cer LBSY<br />
Mollu_(Mu) Mana1-3Manb1-4Glcb1-Cer LBSGMM<br />
}}<br />
|}<br />
<br />
==={{Bilingual|分類|Classification}}===<br />
===={{Bilingual|糖の個数|By the Number of Sugars}}====<br />
<br />
{| class="wikitable" border="1" cellpadding="2" cellspacing="1" margin: 1em 1em 1em 1em"<br />
|+ Table 1. Classification by the Number of Sugars<br />
! # of sugars || {{Bilingual|脊椎動物 (V)|'''V'''ertebrate}} ({{#expr:{{#countTitle:LBS.....V}}+{{#countTitle:LBS.....N}}}} items) || {{Bilingual|無脊椎動物 (I)|'''I'''nvertebrate}} ({{#expr:{{#countTitle:LBS.....I}}+{{#countTitle:LBS.....N}}}} items)<br />
|- valign="top"<br />
| 1 || {{MapLink|ListMol|LBS...01V|LBS...01V}} || {{MapLink|ListMol|LBS...01I|LBS...01I}}<br />
|-<br />
| 2 || {{MapLink|ListMol|LBS...02V|LBS...02V}} || {{MapLink|ListMol|LBS...02I|LBS...02I}}<br />
|-<br />
| 3 || {{MapLink|ListMol|LBS...03V|LBS...03V}} || {{MapLink|ListMol|LBS...03I|LBS...03I}}<br />
|-<br />
| 4 || {{MapLink|ListMol|LBS...04V|LBS...04V}} || {{MapLink|ListMol|LBS...04I|LBS...04I}}<br />
|-<br />
| 5 || {{MapLink|ListMol|LBS...05V|LBS...05V}} || {{MapLink|ListMol|LBS...05I|LBS...05I}}<br />
|-<br />
| 6 || {{MapLink|ListMol|LBS...06V|LBS...06V}} || {{MapLink|ListMol|LBS...06I|LBS...06I}}<br />
|-<br />
| 7 || {{MapLink|ListMol|LBS...07V|LBS...07V}} || {{MapLink|ListMol|LBS...07I|LBS...07I}}<br />
|-<br />
| 8 || {{MapLink|ListMol|LBS...08V|LBS...08V}} || {{MapLink|ListMol|LBS...08I|LBS...08I}}<br />
|-<br />
| 9 || {{MapLink|ListMol|LBS...09V|LBS...09V}} || {{MapLink|ListMol|LBS...09I|LBS...09I}}<br />
|-<br />
| 10-19 || {{MapLink|ListMol|LBS...1.V|LBS...1.<VN>}} || {{MapLink|ListMol|LBS...1.I|LBS...1.<IN>}}<br />
|-<br />
| 20-29 || {{MapLink|ListMol|LBS...2.V|LBS...2.<VN>}} || {{MapLink|ListMol|LBS...2.I|LBS...2.<IN>}}<br />
|}<br />
<br />
===={{Bilingual|シアル酸の個数|By the Number of Sialic acids}}====<br />
<br />
{| class="wikitable" border="1" cellpadding="2" cellspacing="1" margin: 1em 1em 1em 1em"<br />
|+ Table 2. Classification by the Number of Sialic acids<br />
! # of sialic acids || {{Bilingual|脊椎動物 (V)|'''V'''ertebrate}} ({{#expr:{{#countTitle:LBS.....V}}+{{#countTitle:LBS.....N}}}} items) || {{Bilingual|無脊椎動物 (I)|'''I'''nvertebrate}} ({{#expr:{{#countTitle:LBS.....I}}+{{#countTitle:LBS.....N}}}} items)<br />
|- valign="top"<br />
| 1 || {{MapLink|ListMol|LBS.....V1|LBS.....V1}} || {{MapLink|ListMol|LBS.....I1|LBS.....I1}}<br />
|-<br />
| 2 || {{MapLink|ListMol|LBS.....V2|LBS.....V2}} || {{MapLink|ListMol|LBS.....I2|LBS.....I2}}<br />
|-<br />
| 3 || {{MapLink|ListMol|LBS.....V3|LBS.....V3}} || {{MapLink|ListMol|LBS.....I3|LBS.....I3}}<br />
|-<br />
| 4 || {{MapLink|ListMol|LBS.....V4|LBS.....V4}} || {{MapLink|ListMol|LBS.....I4|LBS.....I4}}<br />
|-<br />
| 5 || {{MapLink|ListMol|LBS.....V5|LBS.....V5}} || {{MapLink|ListMol|LBS.....I5|LBS.....I5}}<br />
|-<br />
| 6 || {{MapLink|ListMol|LBS.....V6|LBS.....V6}} || {{MapLink|ListMol|LBS.....I6|LBS.....I6}}<br />
|-<br />
| 7 || {{MapLink|ListMol|LBS.....V7|LBS.....V7}} || {{MapLink|ListMol|LBS.....I7|LBS.....I7}}<br />
|-<br />
| 8 || {{MapLink|ListMol|LBS.....V8|LBS.....V8}} || {{MapLink|ListMol|LBS.....I8|LBS.....I8}}<br />
|}<br />
<br />
---></div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Category:LBS&diff=117166
Category:LBS
2023-05-26T01:15:29Z
<p>Editor: </p>
<hr />
<div>{{Huge|{{Bilingual|スフィンゴ脂質|Sphingolipid}}}}<br />
{{LB/Header}}<br />
{{Hierarchy|{{PAGENAME}}}}<br />
{| style="float:left"<br />
| __TOC__<br />
|}<br />
=={{Bilingual|概要|Class Overview}}==<br />
<br />
{{Twocolumn|<br />
Three Sphingolipid categories (LBS) exist in this database. <br />
|このデータベースではスフィンゴ脂質を以下に分けています。<br />
}}<br />
<br />
<center><br />
{| <br />
|-<br />
| style="vertical-align:top" width="33%"|<br />
[[:Category:LBSB| '''Ceramide''']]<br/>{{LBS/Cer|OH}}<br/><small>セラミド</small><br />
| style="vertical-align:top" width="33%"|<br />
'''Glycosphingolipid'''<br/>{{LBS/Cer|O-(sugar)}}<br/><small>スフィンゴ糖脂質</small><br />
| style="vertical-align:top" width="33%"|<br />
[[:Category:LBSP| '''Phosphosphingolipid''']]<br/>{{LBS/Cer|O-(phosphate)}}<br/><small>スフィンゴリン脂質</small><br />
|-<br />
|<br />
*[[:Category:LBSB|Long-chain base and ceramide]]<br />
|<br />
*[[:Category:LBSC|Cerebroside <small>(monohexosyl ceramides)</small>]]<br />
*[[:Category:LBSG|Acidic glycosphingolipid]]<br />
|<br />
*[[:Category:LBSP|Sphingomyelin, CPE, CAEP and GIPC]]<br />
|}<br />
</center><br />
<br />
<center><br />
{| class="wikitable"<br />
|<big><br />
[[:Category:LBS/Search|{{Bilingual|スフィンゴ脂質検索画面にいく|Go to Sphingolipid search.}}]]<br />
</big><br />
|}<br />
</center><br />
<br />
<br />
=={{Bilingual|スフィンゴ脂質|Sphingolipid}}==<br />
<br />
==={{Bilingual|表記法|Notation}}===<br />
{| class="wikitable collapsible collapsed" style="width:80%"<br />
!colspan="4" align="center" style="background:lightgray"| Symbol Abbreviations (e.g. Glc = glucose)<br />
|-<br />
!colspan="4" align="center" style="background:lightgray"| Backbones<br />
{{#repeatnum:LBS/AbbrevRow|1|<br />
Cer && ceramide && セラミド && <br />
Sph && sphingosine && スフィンゴシン && <br />
}}<br />
|-<br />
!colspan="4" align="center" style="background:lightgray"| Sugars<br />
{{#repeatnum:LBS/AbbrevRow|1|<br />
Glc && glucose && グルコース && C6H12O6 && <br />
Gal && galactose && ガラクトース && C6H12O6 && <br />
GlcNAc && ''N''-acetyl-glucosamine && ''N''-アセチルグルコサミン && C8H15NO6 <br />
GalNAc && ''N''-acetyl-galactosamine && ''N''-アセチルガラクトサミン && C8H15NO6<br />
GlcN && glucosamine && グルコサミン && C6H13NO5<br />
GalN && galactosamine && ガラクトサミン && C6H13NO5<br />
GlcA && glucuronic acid && グルクロン酸 && C6H10O7<br />
GalA && galacturonic acid && ガラクツロン酸 && C6H10O7 && <br />
Man && mannose && マンノース && C6H12O6 && 18950<br />
Rha && rhamnose (= 6-deoxy-mannose) && ラムノース (6-デオキシマンノース) && C6H12O5 && 19233<br />
Ins && inositol && イノシトール && C6H12O6 && 892<br />
Fuc && fucose (= 6-deoxy-galactose) && フコース (6-デオキシガラクトース) && C6H12O5 && 17106<br />
Ara && arabinose && アラビノース && C5H10O5 && 5460291<br />
Xyl && xylose && キシロース && C5H10O5 && 135191<br />
NeuNH && (deacetyl) neuraminic acid<br/>(pyruvate + mannosamine) && ノイラミン酸<br/>(ピルビン酸+マンノサミン) && C9H17N1O8 && 513472<br />
NeuAc && ''N''-acetyl-neuraminic acid && ''N''-アセチルノイラミン酸 && C11H19NO9 && 439197<br />
NeuGc && ''N''-glycolyl-neuraminic acid && ''N''-グリコリルノイラミン酸 && C11H19NO10 && 123802<br />
Kdn && 2-keto-3-deoxy-D-glycero-<br/>D-galacto-nononic acid && デアミノノイラミン酸 && C9H16O9 && 13991616<br />
}}<br />
|-<br />
!colspan="4" align="center" style="background:lightgray"| Modifiers<br />
{{#repeatnum:LBS/AbbrevRow|1|<br />
AEPn && aminoethylphosphonic acid, or<br/>(2-aminoethyl)hydroxyphosphoryl- && アミノエチルホスホン酸(C-P結合)<br />
MAEPn && ''N''-methyl aminoethylphosphonic acid, or<br/>(''N''-methyl-2-aminoethyl) hydroxyphosphoryl- && AEPnの''N''-メチル体(C-P結合)<br />
EtnP && phosphoethanolamine (PEA), or<br/>2-aminoethanolphospho- && ホスホエタノールアミン<br />
PC && Phosphocholine && ホスホコリン<br />
Butenyl && Butenyl && ブテニル基<br />
Me && Methyl && メチル基<br />
Et && Ethyl && エチル基<br />
}}<br />
|}<br />
<br />
==={{Bilingual|分類体系|Page/ID-Code Design}}===<br />
{{Twocolumn|<br />
Major series of phosphosphingolipids are determined by molecules bound to their phosphates, and the series of glycosphingolipids are determined by oligosaccharides bound to their ceramides. The IUPAC series of glycosphingolipids (1977) were based on the order and bonding patterns of four sugars rooting at the long-chain base. Our series, however, are based on three sugars. Two original series, Echino and Schisto, are also added.<br />
|スフィンゴリン脂質はリン酸に結合する分子や糖の種類、スフィンゴ糖脂質はセラミドに結合する糖鎖により系列を作成しています。1977年にIUPACが提唱したスフィンゴ糖脂質の系列は、長鎖塩基に結合する四糖の並びと結合を基準にしています。ここではより広い糖鎖の系列を検索できるよう、三糖を基準に分類しています。また新たにEchinoとSchistoの系列を加えています。<br />
}}<br />
<br />
{|<br />
|<br />
<table border=1><br />
<tr><br />
<td style="background-color:yellowgreen;" width=20px align="center"><big>L</big><br />
<td style="background-color:yellowgreen;" width=20px align="center"><big>B</big><br />
<td style="background-color:yellowgreen;" width=20px align="center"><big>S</big><br />
<td style="background-color:green;" width=20px align="center"><big>''G/P''</big><br />
<td style="background-color:Blue; color:white" width=20px align="center"><big>''s1''</big><br />
<td style="background-color:Blue; color:white" width=20px align="center"><big>''s2''</big><br />
<td style="background-color:tomato; color:white" width=20px align="center"><big>''n1''</big><br />
<td style="background-color:tomato; color:white" width=20px align="center"><big>''n2''</big><br />
<td style="background-color:firebrick; color:white" width=20px align="center"><big>''y''</big><br />
<td style="background-color:white;" width=20px align="center"><big>''c1''</big><br />
<td style="background-color:white;" width=20px align="center"><big>''c2''</big><br />
</tr><br />
</table><br />
| &nbsp;<br />
|<br />
{| class="wikitable"<br />
! '''G/P''' || '''G''' (glyco) || '''P''' (phospho) <br />
|-<br />
! '''s1, s2''' <br />
|colspan="3"| structure code as explained below<br />
|-<br />
! '''n1, n2''' <br />
|colspan="2"| number of sugars (2 digits)<br />
|-<br />
! '''y'''<br />
|colspan="2"| number of sialic acids (1 digit)<br />
|-<br />
! '''c1, c2'''<br />
|colspan="2"| serial numbers<br />
|}<br />
|}<br />
<br />
==={{Bilingual|スフィンゴ糖脂質1文字目|First (s1) Digit for Glycosphingolipid}}===<br />
<span id="SphingolipidClass"></span><br />
{| class="wikitable" style="text-align:right; background-color:white"<br />
! First sugar || Code || Root sequence<br />
! colspan=2 | Major Series <br />
|-<br />
! Cerebroside <br />
| colspan="3" style="text-align:left" | '''For GalCer and GlcCer, visit [[:Category:LBSC|this page]].'''<br />
|-<br />
! starting with<br/><big>Galactose</big><br />
| {{#volatile:ListMol/LBStitle|<b>G1</b>|LBSG1}} <br /> ({{#volatile:ClassMatrix|{{#countTitle:LBSG1}} items|LBSG1.....|7|8|9|9|Number_of_Sugars|Number_of_Sialic_acids}})<br />
|style="text-align:right"| '''Gal'''-Cer<br />
|<br />
{| style="width:100%;"<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Gala / Neogala|Mainchain.*Gala1-4?6?Galb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|Gala1-4/6Galb1-Cer}} <br />
|-<br />
|style="border:0;text-align:left"|{{#volatile:ListMol/LBS|Spirometo|Mainchain.*Galb1-4Glcb1-3Galb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|Galb1-4Glcb1-3Galb1-Cer}}<br />
|}<br />
|-<br />
! rowspan="8" | starting with<br/><big>Glucose</big><br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>G2</b>|LBSG2}} <br /> ({{#volatile:ClassMatrix|{{#countTitle:LBSG2}} items|LBSG2.....|7|8|9|9|Number_of_Sugars|Number_of_Sialic_acids}})<br />
|style="text-align:right"| '''GalNAc<sub>&beta;</sub>'''-Gal<sub>&beta;</sub>-Glc<sub>&beta;</sub>-Cer<br />
|<br />
{| style="width:100%"<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Ganglio|Mainchain.*GalNAcb1-4Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GalNAcb1-4Galb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Isoganglio|Mainchain.*GalNAcb1-3Galb1-4Glcb1-Cer}}<ref name="iso">In IUPAC, "iso" refers to a change from position 4 to position 3.</ref><br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GalNAcb1-3Galb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Lactoganglio|Structure.*GlcNAcb1-3\(.*GalNAcb1-4\)Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GlcNAcb1-3(GalNAcb1-4)Galb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|a-series|Structure.*\(?NeuAca2-3\)?Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GalNAcb1-4(NeuAca2-3)Galb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|b-series|Structure.*\(?NeuAca2-8NeuAca2-3\)?Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GalNAcb1-4(NeuAca2-8NeuAca2-3)Galb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|c-series|Structure.*\(?NeuAca2-8NeuAca2-8NeuAca2-3\)?Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GalNAcb1-4(NeuAca2-8NeuAca2-8NeuAca2-3)Galb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|&alpha;-series|Structure.*\(?NeuAca2-6\)?GalNAcb1-4Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|...(NeuAca2-6)GalNAcb1-4Galb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|&beta;-series|Structure.*\(?NeuAca2-8NeuAca2-6\)?GalNAcb1-4Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|...(NeuAca2-8NeuAca2-6)GalNAcb1-4Galb1-4Glcb1-Cer}}<br />
|}<br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>G3</b>|LBSG3}} <br /> ({{#volatile:ClassMatrix|{{#countTitle:LBSG3}} items|LBSG3.....|7|8|9|9|Number_of_Sugars|Number_of_Sialic_acids}})<br />
|style="text-align:right"| '''GlcNAc<sub>&beta;</sub>'''-Gal<sub>&beta;</sub>-Glc<sub>&beta;</sub>-Cer<br />
|<br />
{| style="width:100%"<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Lacto|Mainchain.*Galb1-3GlcNAcb1-3Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|Galb1-3GlcNAcb1-3Galb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Neolacto|Mainchain.*Gal.1-4GlcNAcb1-3Galb1-4Glcb1-Cer}}<ref name="neo">In IUPAC, "neo" refers to a change from position 3 to position 4.</ref><br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|Galb1-4GlcNAcb1-3Galb1-4Glcb1-Cer}}<br />
|}<br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>G4</b>|LBSG4}} <br /> ({{#volatile:ClassMatrix|{{#countTitle:LBSG4}} items|LBSG4.....|7|8|9|9|Number_of_Sugars|Number_of_Sialic_acids}})<br />
|style="text-align:right"| '''Gal<sub>&alpha;</sub>'''-Gal<sub>&beta;</sub>-Glc<sub>&beta;</sub>-Cer<br />
|<br />
{| style="width:100%"<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Globo|Mainchain.*Gala1-4Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|Gala1-4Galb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Isoglobo|Mainchain.*Gala1-3Galb1-4Glcb1-Cer}}<ref name="iso"/><br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|Gala1-3Galb1-4Glcb1-Cer}}<br />
|}<br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>G5</b>|LBSG5}} <br /> ({{#volatile:ClassMatrix|{{#countTitle:LBSG5}} items|LBSG5.....|7|8|9|9|Number_of_Sugars|Number_of_Sialic_acids}})<br />
|style="text-align:right"| Gal-Glc-Cer<br/>(Other than G2&sim;G4)<br />
|<br />
{| style="width:100%"<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Muco|Mainchain.*Galb1-4Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|Galb1-4Galb1-4Glcb1-Cer}}<br />
|}<br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>G6</b>|LBSG6}} <br /> ({{#volatile:ClassMatrix|{{#countTitle:LBSG6}} items|LBSG6.....|7|8|9|9|Number_of_Sugars|Number_of_Sialic_acids}})<br />
|style="text-align:right"| '''Man'''-Glc<sub>&beta;</sub>-Cer<br />
|<br />
{| style="width:100%"<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Arthro|Mainchain.*GlcNAcb1-3Manb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GlcNAcb1-3Manb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Mollu|Mainchain.*Mana1-3Manb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|Mana1-3Manb1-4Glcb1-Cer}}<br />
|}<br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>G7</b>|LBSG7}} <br /> ({{#volatile:ClassMatrix|{{#countTitle:LBSG7}} items|LBSG7.....|7|8|9|9|Number_of_Sugars|Number_of_Sialic_acids}})<br />
|style="text-align:right"| '''NeuAc'''/'''NeuGc'''-Glc<sub>&beta;</sub>-Cer<br />
|<br />
{| style="width:100%"<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Echino|Mainchain.*Neu(A~G)c.2-6Glcb1-Cer}}<br />
|style="border:0;text-align:right"| <font color=purple>'''NeuGc'''</font> or {{#invoke:LBS|FormatSugar|NeuAca2-6Glcb1-Cer}}<br />
|}<br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>G8</b>|LBSG8}} <br /> ({{#volatile:ClassMatrix|{{#countTitle:LBSG8}} items|LBSG8.....|7|8|9|9|Number_of_Sugars|Number_of_Sialic_acids}})<br />
|style="text-align:right"| '''GalNAc'''-Glc-Cer<br />
|<br />
{| style="width:100%"<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Schisto|Mainchain.*GalNAc.1-4Glc.1-Cer}}<ref>Makaaru CK, Damian RT, Smith DF, Cummings RD. "The human blood fluke Schistosoma mansoni synthesizes a novel type of glycosphingolipid" J Biol Chem 1992 267:2251-2257 PMID 1733932</ref><br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GalNAcb1-4Glcb1-Cer}}<br />
|}<br />
|-<br />
! starting with<br/><big>Other Sugars</big><br />
| {{#volatile:ListMol/LBStitle|<b>G</b>(<b>A</b>&sim;<b>R</b>)|LBSG(A~B~C~D~E~F~G~H~J~K~M~N~O~P~Q~R)}}<br />
|colspan="2"| Symbols follow the Sugar-digit table.<br />
|}<br />
<references/><br />
<br />
==={{Bilingual|スフィンゴリン脂質1文字目|First (s1) Digit for Phosphosphingolipid}}===<br />
{| class="wikitable" style="text-align:right; background-color:white"<br />
! First sugar || Code || Root sequence <br />
!colspan="2"| Major Series<br />
|-<br />
! No Sugar Attached<br />
| '''P1''' ([[:Category:LBSP|LBSP]])<br />
| R-P-Cer<br />
| Sphingomyelin and Ceramide phosphoetanolamine<br/>(Visit [[:Category:LBSP|this page]].)<br />
|-<br />
! rowspan="4" | starting with<br/><big>Inositol</big><br />
| {{#volatile:ListMol/LBStitle|<b>P2</b>|LBSP2}} <br /> ({{#countTitle:LBSP2}} items)<br />
| style="text-align:right"| '''GlcN'''<sub>&alpha;/&beta;1&minus;2/6</sub>Ins<sub>1</sub>-P-Cer<br />
|<br />
{|style="width:100%"<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Protozoa & Fungi-specific|Mainchain.*GlcN.1-.Ins-P-Cer}}<br />
| style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GlcNa/b1-2/6Ins1-P-Cer}}<br />
|}<br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>P3</b>|LBSP3}} <br /> ({{#countTitle:LBSP3}} items) <br />
|style="text-align:right"| '''GlcA'''<sub>&alpha;/&beta;1&minus;2/6</sub>Ins<sub>1</sub>-P-Cer<br />
|<br />
{|style="width:100%"<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Plant-specific|Mainchain.*GlcA.1-.Ins-P-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GlcAa/b1-2/6Ins1-P-Cer}}<br />
|}<br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>P4</b>|LBSP4}} <br /> ({{#countTitle:LBSP4}} items)<br />
| style="text-align:right"| '''Man'''<sub>&alpha;/&beta;1&minus;2/6</sub>Ins<sub>1</sub>-P-Cer<br />
|<br />
{| style="width:100%"<br />
| style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Fungi-specific|Mainchain.*Man.1-.Ins-P-Cer}}<br />
| style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|Mana/b1-2/6Ins1-P-Cer}}<br />
|}<br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>P5</b>|LBSP5}} <br /> ({{#countTitle:LBSP5}} items)<br />
| style="text-align:right"| Gal, Glc, and Others<br />
| style="text-align:right"| {{#invoke:LBS|FormatSugar|X-Ins1-P-Cer}}<br />
|}<br />
<br />
==={{Bilingual|コード2文字目|Second (s2) Digit}}===<br />
<span id="SphingolipidSugar"></span><br />
{{Bilingual|クリックすると一覧が出ます。記号の略称については|Click to see the full list. For abbreviations, see}} [[#Notation]].<br />
<br />
{| <br />
|-<br />
| valign="top"|<br />
{| class="wikitable"<br />
|-<br />
! Code || Structure<br />
|-<br />
! '''A'''<br />
| Glc [[File:LBS-Monomer-Glc.png]]<br />
|-<br />
! '''B'''<br />
| Gal [[File:LBS-Monomer-Gal.png]]<br />
|-<br />
! '''C'''<br />
| GlcNAc [[File:LBS-Monomer-GlcNAc.png]]<br />
|-<br />
! '''D'''<br />
| GalNAc [[File:LBS-Monomer-GalNAc.png]]<br />
|-<br />
! '''E'''<br />
| GlcN [[File:LBS-Monomer-GlcN.png]]<br />
|-<br />
! '''F'''<br />
| GalN [[File:LBS-Monomer-GalN.png]]<br />
|-<br />
! '''G'''<br />
| GlcA [[File:LBS-Monomer-GlcA.png]]<br />
|-<br />
! '''H'''<br />
| GalA [[File:LBS-Monomer-GalA.png]]<br />
|-<br />
! '''I'''<br />
| not used<br />
|}<br />
|valign="top"|<br />
{| class="wikitable"<br />
|-<br />
! Code || Structure<br />
|-<br />
! '''J'''<br />
| {{#volatile:ListMol/LBS|Mannose|Structure.*Man}} [[File:LBS-Monomer-Man.png]]<br />
|-<br />
! '''K'''<br />
| {{#volatile:ListMol/LBS|Rhamnose|Structure.*Rha}} [[File:LBS-Monomer-Rha.png]]<br />
|-<br />
! '''L'''<br />
| {{#volatile:ListMol/LBS|Inositol|Structure.*Ins(Me)?-P-[^Cer]}} <br />
|-<br />
! '''M'''<br />
| Fucose ({{#volatile:ListMol/LBS| 1|Structure[^F]+Fuc[^F]+$}}, {{#volatile:ListMol/LBS|2|Structure([^F]+Fuc){2}[^F]+$}}, {{#volatile:ListMol/LBS|>3|Structure([^F]+Fuc){3} }}) [[File:LBS-Monomer-Fuc.png]]<br />
|-<br />
! '''N'''<br />
| {{#volatile:ListMol/LBS|Arabinose|Structure.*Ara}} [[File:LBS-Monomer-Ara.png]]<br />
|-<br />
! '''O'''<br />
| {{#volatile:ListMol/LBS|Xylose|Structure.*Xyl}} [[File:LBS-Monomer-Xyl.png]]<br />
|-<br />
! '''P'''<br />
| {{#volatile:ListMol/LBS|NeuAc / NeuNH|Structure.*(NeuAc~NeuNH)}} [[File:LBS-Monomer-NeuAc.png]]<br />
|-<br />
! '''Q'''<br />
| {{#volatile:ListMol/LBS|NeuGc|Structure.*(NeuGc)}} [[File:LBS-Monomer-NeuGc.png]]<br />
|-<br />
! '''R'''<br />
| {{#volatile:ListMol/LBS|Kdn|Structure.*(KDN)}} [[File:LBS-Monomer-KDN.png]]<br />
|}<br />
|valign="top"|<br />
{| class="wikitable"<br />
|-<br />
! Code || Structure<br />
|-<br />
! '''S'''<br />
| {{#volatile:ListMol/LBS|Phosphate (except GIPC)|Structure.*(Phospho)}} [[File:LBS-Monomer-P.png]]<br />
|-<br />
! '''T'''<br />
| {{#volatile:ListMol/LBS|(M)AEPn|Structure.*(AEPn)}}, {{#volatile:ListMol/LBS|EtnP|Structure.*(EtnP)}}, {{#volatile:ListMol/LBS|PC|Structure.*(PC)}} [[File:LBS-Monomer-AEPn.png]]<br />
|-<br />
! '''U'''<br />
| {{#volatile:ListMol/LBS|Sulfate|Structure.*Sulfo}} [[File:LBS-Monomer-S.png]]<br />
|-<br />
! '''V'''<br />
| acyl/alkyl/alkenyl chain [[File:LBS-Monomer-Alkyl.png]]<br />
|}<br />
<br />
=={{Bilingual|生合成|Biosynthesis}}==<br />
{{Twocolumn|<br />
Sphingosine is synthesized from decarboxylating condensation of palmitoyl CoA with serine on the ER membrane. It is a 18-carbon amino alcohol (16 carbons from palmitic acid and 2 from serine) with one unsaturated bond (trans-form) at the C-4 position (2-amino-4-octadecene-1,3-diol). ([[:Category:LBS/Biosynthesis|more details]])<br />
|<br />
スフィンゴシンはパルミトイルCoAがアミノ酸セリンと脱炭酸縮合して生成します。炭素を18個含むアミノアルコール(16個がパルミチン酸、2個がセリン由来)でトランス型の不飽和結合をC-4に1つ含みます。([[:Category:LBS/Biosynthesis|詳細はこちら]])<br />
}}<br />
<br />
<br />
==={{Bilingual|スフィンゴ脂質の歴史|History of Sphingolipids}}===<br />
{{Twocolumn|<br />
Sphingolipids were first isolated from brain by J.L.W. Thudichum (1829-1901) as lipids of unknown function and structure.<ref>Thudichum J.L.W.?"A Treatise on the Chemical Constitution of the Balliere" Tindall and Cox, London,?1884</ref> The basic structure is a long-chain base (long-chain amino-alcohol) whose amino-group is acylated with a long-chain fatty acid. This hydrophobic structure is called ceramides.<br />
Sphingolipid consists of phospho-sphingolipid and glyco-sphingolipid, whose ceramide structure is bonded with phosphate and (oligo)saccharides, respectively. Phosphosphingolipid includes sphingomyelin, and glycosphingolipid, cerebrosides and gangliosides. Both are abundant in neural tissues.<ref>Gault CR,?Obeid LM,?Hannun YA "An overview of sphingolipid synthesis to breakdown" Adv Exp Med Biol.?2010;688:1-23. PMID 20919643</ref><br />
|<br />
スフィンゴ脂質は J.L.W. Thudichum (1829-1901) により機能や構造未知の脂質として脳から見いだされました。基本骨格は長鎖塩基 (長鎖アミノアルコール) のアミノ基が長鎖脂肪酸とアミド結合したもので、セラミドと呼ばれます。<br />
スフィンゴ脂質はセラミドにリン酸が結合したスフィンゴリン脂質と糖が結合したスフィンゴ糖脂質に分けられます。スフィンゴリン脂質にはスフィンゴミエリンが、スフィンゴ糖脂質にはセレブロシドやガングリオシドなどが含まれ、いずれも神経系に多く存在します。<br />
}}<br />
<br />
<references/><br />
<br />
<!---<br />
{|<br />
|valign="top"|<br />
{| class="wikitable" style="text-align:center"<br />
!width="5%"| code<br />
!colspan="2"| Galactose<br />
|-<br />
| '''0''' <br />
|colspan="2"| no sugar<br />
|-<br />
| '''1''' <br />
|rowspan="3"| <b>Galactose</b><br/>(&alpha; form)<br />
| {{#invoke:LBS|FormatSugar|Gala1-3 ...}}<br />
|-<br />
| '''2''' || {{#invoke:LBS|FormatSugar|Gala1-4 ...}}<br />
|-<br />
| '''3''' || {{#invoke:LBS|FormatSugar|Gala1-6 ...}}<br />
|-<br />
| '''4'''<br />
|rowspan="3"| <b>Galactose</b><br/>(&beta; form)<br />
| {{#invoke:LBS|FormatSugar|Galb1-3 ...}}<br />
|-<br />
| '''5''' || {{#invoke:LBS|FormatSugar|Galb1-4 ...}}<br />
|-<br />
| '''6''' || {{#invoke:LBS|FormatSugar|Galb1-6 ...}}<br />
|}<br />
|valign="top"|<br />
{| class="wikitable" style="text-align:center"<br />
!width="5%"| code<br />
!colspan="2"| ''N''-Acetylated Sugars<br />
|-<br />
|-<br />
| '''7''' <br />
|rowspan="3"| <b>''N''-Acetyl Galactosamine</b><br/>(&beta; form)<br />
| {{#invoke:LBS|FormatSugar|GalNAcb1-3 ...}}<br />
|-<br />
| '''8''' || {{#invoke:LBS|FormatSugar|GalNAcb1-4 ...}}<br />
|-<br />
| '''9''' || {{#invoke:LBS|FormatSugar|GalNAcb1-6 ...}}<br />
|-<br />
| '''A''' <br />
|rowspan="3"| <b>''N''-Acetyl Glucosamine</b><br/>(&beta; form)<br />
| {{#invoke:LBS|FormatSugar|GlcNAcb1-3 ...}}<br />
|-<br />
| '''B'''<br />
| {{#invoke:LBS|FormatSugar|GlcNAcb1-4 ...}}<br />
|-<br />
| '''C'''<br />
| {{#invoke:LBS|FormatSugar|GlcNAcb1-6 ...}}<br />
|}<br />
|}<br />
<br />
<br />
{|<br />
|valign="top"|<br />
{| class="wikitable" style="text-align:center"<br />
!width="5%"| code<br />
!colspan="2"| Galactose & Glucose<br />
|-<br />
| '''D''' <br />
|rowspan="2"| <b>Aminated Sugars</b><br/>(Except for Code 7&sim;C)<br />
| {{#invoke:LBS|FormatSugar|GalNAc, GalN}}<br />
|-<br />
| '''E''' || {{#invoke:LBS|FormatSugar|GlcNAc, GlcN}}<br />
|-<br />
| '''F''' <br />
| <b>Galactose</b><br/>(Except Code 1&sim;6)<br />
| <span style="color:gold"><b>Gal</b></span><br />
|-<br />
| '''G''' <br />
| <b>Glucose</b><br />
| <span style="color:blue"><b>Glc</b></span><br />
|}<br />
|valign="top"|<br />
{| class="wikitable" style="text-align:center"<br />
!width="5%"| code<br />
! Other Sugars<br />
|-<br />
| '''J''' || Inositol (<span style="color:"><b>Ins</b></span>)<br />
|-<br />
| '''K''' || Fucose (<span style="color:red"><b>Fuc</b></span>)<br />
|-<br />
| '''L''' || Pentose sugars<br/>(<span style="color:DarkOrange"><b>Ara, Xyl</b></span>)<br />
|-<br />
| '''M''' || Mannose and Rhamnose (= 6-deoxymannose)<br/>(<span style="color:green"><b>Man, Rha</b></span>)<br />
|-<br />
| '''N''' || Sialic acids<br/>(<b><span style="color:Purple">NeuAc, NeuNH</span>, <span style="color:gray">NeuGc</span>, <span style="color:Green">Kdn</span></b>)<br />
|}<br />
|}<br />
<br />
{|<br />
|valign="top"|<br />
{| class="wikitable" style="text-align:center"<br />
!width="5%"| code<br />
!colspan="2"| Modifiers<br />
|-<br />
| '''P''' || Phosphate (<b>HPO4</b>), Sulphate (<b>HSO4</b>),<br/>and Phosphocholine (<b>PC</b>)<br />
|-<br />
| '''Q''' || Aminoethylphosphates<br/><b>AEPn, MAEPn, MAEPr, EtnP</b><br />
|-<br />
| '''R''' || Alkyl and acyl groups<br/><b>OAc, Methyl, Butenyl</b><br />
|}<br />
|valign="top"|<br />
{| class="wikitable" style="text-align:center"<br />
!width="5%"| code<br />
!colspan="2"| Abbreviations<br />
|-<br />
| '''Y''' || {{#invoke:LBS|FormatSugar|GlcNAcb1-3Manb1-4Glcb1-1Cer}}<br />
|-<br />
| '''Z''' || {{#invoke:LBS|FormatSugar|Galb1-4Glcb1-1bCer}}<br />
|}<br />
|}<br />
<br />
<br />
<br />
==={{Bilingual|よく知られたパターン|Common Patterns}}===<br />
<br />
{| class="wikitable"<br />
! Common Name || Records || Sequence<br />
|-<br />
|colspan="3" style="background:#efefef; text-align:center"| By GalCer Synthase (EC 2.4.1.62)<br />
{{#repeat:LBS/AbbrevTable/Row|1|<br />
Gala_(Ga) Gala1-4/6Galb1-Cer LBSF%5b23%5d.<br />
Spirometo_(Sp) Galb1-4Glcb1-3Galb1-Cer LBSFG5<br />
}}<br />
|-<br />
|colspan="3" style="background:#efefef; text-align:center"| By GlcCer Synthase (EC 2.4.1.80)<br />
{{#repeat:LBS/AbbrevTable/Row|1|<br />
Ganglio_(Gg) GalNAcb1-4Galb1-4Glcb1-Cer LBSZ8.<br />
Isoganglio_(iGg) GalNAcb1-3Galb1-4Glcb1-Cer LBSZ7.<br />
Globo_(Gb) Gala1-4Galb1-4Glcb1-Cer LBSZ2.<br />
Isoglobo_(iGb) Gala1-3Galb1-4Glcb1-Cer LBSZ1.<br />
Lacto_(Lc) Galb1-3GlcNAcb1-3Galb1-4Glcb1-Cer LBSZD4<br />
NeoLacto_(nLc) Galb1-4GlcNAcb1-3Galb1-4Glcb1-Cer LBSZA5<br />
Muco_(Mc) Galb1-4Galb1-4Glcb1-Cer LBSZ5.<br />
}}<br />
|-<br />
|colspan="3" style="background:#efefef; text-align:center"| With Mannose<br />
{{#repeat:LBS/AbbrevTable/Row|1|<br />
Arthro_(At) GlcNAcb1-3Manb1-4Glcb1-Cer LBSY<br />
Mollu_(Mu) Mana1-3Manb1-4Glcb1-Cer LBSGMM<br />
}}<br />
|}<br />
<br />
==={{Bilingual|分類|Classification}}===<br />
===={{Bilingual|糖の個数|By the Number of Sugars}}====<br />
<br />
{| class="wikitable" border="1" cellpadding="2" cellspacing="1" margin: 1em 1em 1em 1em"<br />
|+ Table 1. Classification by the Number of Sugars<br />
! # of sugars || {{Bilingual|脊椎動物 (V)|'''V'''ertebrate}} ({{#expr:{{#countTitle:LBS.....V}}+{{#countTitle:LBS.....N}}}} items) || {{Bilingual|無脊椎動物 (I)|'''I'''nvertebrate}} ({{#expr:{{#countTitle:LBS.....I}}+{{#countTitle:LBS.....N}}}} items)<br />
|- valign="top"<br />
| 1 || {{MapLink|ListMol|LBS...01V|LBS...01V}} || {{MapLink|ListMol|LBS...01I|LBS...01I}}<br />
|-<br />
| 2 || {{MapLink|ListMol|LBS...02V|LBS...02V}} || {{MapLink|ListMol|LBS...02I|LBS...02I}}<br />
|-<br />
| 3 || {{MapLink|ListMol|LBS...03V|LBS...03V}} || {{MapLink|ListMol|LBS...03I|LBS...03I}}<br />
|-<br />
| 4 || {{MapLink|ListMol|LBS...04V|LBS...04V}} || {{MapLink|ListMol|LBS...04I|LBS...04I}}<br />
|-<br />
| 5 || {{MapLink|ListMol|LBS...05V|LBS...05V}} || {{MapLink|ListMol|LBS...05I|LBS...05I}}<br />
|-<br />
| 6 || {{MapLink|ListMol|LBS...06V|LBS...06V}} || {{MapLink|ListMol|LBS...06I|LBS...06I}}<br />
|-<br />
| 7 || {{MapLink|ListMol|LBS...07V|LBS...07V}} || {{MapLink|ListMol|LBS...07I|LBS...07I}}<br />
|-<br />
| 8 || {{MapLink|ListMol|LBS...08V|LBS...08V}} || {{MapLink|ListMol|LBS...08I|LBS...08I}}<br />
|-<br />
| 9 || {{MapLink|ListMol|LBS...09V|LBS...09V}} || {{MapLink|ListMol|LBS...09I|LBS...09I}}<br />
|-<br />
| 10-19 || {{MapLink|ListMol|LBS...1.V|LBS...1.<VN>}} || {{MapLink|ListMol|LBS...1.I|LBS...1.<IN>}}<br />
|-<br />
| 20-29 || {{MapLink|ListMol|LBS...2.V|LBS...2.<VN>}} || {{MapLink|ListMol|LBS...2.I|LBS...2.<IN>}}<br />
|}<br />
<br />
===={{Bilingual|シアル酸の個数|By the Number of Sialic acids}}====<br />
<br />
{| class="wikitable" border="1" cellpadding="2" cellspacing="1" margin: 1em 1em 1em 1em"<br />
|+ Table 2. Classification by the Number of Sialic acids<br />
! # of sialic acids || {{Bilingual|脊椎動物 (V)|'''V'''ertebrate}} ({{#expr:{{#countTitle:LBS.....V}}+{{#countTitle:LBS.....N}}}} items) || {{Bilingual|無脊椎動物 (I)|'''I'''nvertebrate}} ({{#expr:{{#countTitle:LBS.....I}}+{{#countTitle:LBS.....N}}}} items)<br />
|- valign="top"<br />
| 1 || {{MapLink|ListMol|LBS.....V1|LBS.....V1}} || {{MapLink|ListMol|LBS.....I1|LBS.....I1}}<br />
|-<br />
| 2 || {{MapLink|ListMol|LBS.....V2|LBS.....V2}} || {{MapLink|ListMol|LBS.....I2|LBS.....I2}}<br />
|-<br />
| 3 || {{MapLink|ListMol|LBS.....V3|LBS.....V3}} || {{MapLink|ListMol|LBS.....I3|LBS.....I3}}<br />
|-<br />
| 4 || {{MapLink|ListMol|LBS.....V4|LBS.....V4}} || {{MapLink|ListMol|LBS.....I4|LBS.....I4}}<br />
|-<br />
| 5 || {{MapLink|ListMol|LBS.....V5|LBS.....V5}} || {{MapLink|ListMol|LBS.....I5|LBS.....I5}}<br />
|-<br />
| 6 || {{MapLink|ListMol|LBS.....V6|LBS.....V6}} || {{MapLink|ListMol|LBS.....I6|LBS.....I6}}<br />
|-<br />
| 7 || {{MapLink|ListMol|LBS.....V7|LBS.....V7}} || {{MapLink|ListMol|LBS.....I7|LBS.....I7}}<br />
|-<br />
| 8 || {{MapLink|ListMol|LBS.....V8|LBS.....V8}} || {{MapLink|ListMol|LBS.....I8|LBS.....I8}}<br />
|}<br />
<br />
---></div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Category:LBSC&diff=117165
Category:LBSC
2023-05-18T05:12:50Z
<p>Editor: /* Galactosylceramide (GalCer) */</p>
<hr />
<div><font size="+2">Cerebroside</font><br />
{{LB/Header}}<br />
{{Hierarchy|{{PAGENAME}}}}<br />
{|<br />
|{{LBS/Cer|O-<b>Glucose</b>}} <b>GlcCer</b><br />
|{{LBS/Cer|O-<b>Galactose</b>}} <b>GalCer</b><br />
|-<br />
|colspan=2|<br />
{{Twocolumn|<br />
Monoglycosylceramides (or cerebrosides) are glycosphingolipids where a single sugar is attached to the ceramide structure. Especially, glucopyranose-attached Glucosylceramide (GlcCer) and galactopyranose-attached Galactosylceramide (GalCer) are widely observed in all kingdoms. <br />
GlcCer and GalCer are not registered in LipidBank. Instead, we summarize their distribution with bibliographic references with species information.<br />
<br />
|<br />
モノグリコシルセラミド (またはセレブロシド) はセラミドに糖が1個エステル結合したスフィンゴ糖脂質です。特にグルコース(ピラノース型)が&beta;結合したグルコシルセラミド (GlcCer) とガラクトース(ピラノース型)が&beta;結合したガラクトシルセラミド (GalCer) は生物界に広く分布します。データベース中には掲載せず、ここに解説と生物種ごとの報告例を掲載します。<br />
}}<br />
|}<br />
<br />
==Glucosylceramide (GlcCer)==<br />
<br />
{{Twocolumn|<br />
GlcCer is widely observed not only in Animal, Plant or Fungi kingdoms, but also in Protozoa Kingdom<ref>Tan RX, Chen JH. "The cerebrosides" Nat Prod Rep. 2003;20:509-34.PMID 14620845, Yu R.K. Yanagisawa M. Ariga T. Glycosphingolipid Structures,in Comprehensive Glycoscience Vol.1,pp. 73-122,doi 10.1016/B978-044451967-2/00003-9, Itonori S, Sugita M. Glycophylogenetic Aspects of Lower Animals. in Comprehensive Glycoscience Vol.3, pp. 253-84, doi 10.1016/B978-044451967-2/00050-7 (J.P. Kamerling, ed.) Elsevier, Oxford (UK). (2007)</ref>. Ceramide structures (hydrocarbon chain length, the number and position of double bonds, existence of hydroxy and other modification groups) may vary, and become complex especially in Plant and Fungi Kingdoms, and Protostomia <ref>Sphingoid base chain may terminate with an isopropyl group in spongia, annelida, echinodermata, and bacteria. Terminal isobutyl or sec-pentyl group has been found only in echinodermata. Methylated or cyclopropane-containing sphingoid base is found in spongia, echinodermata, protochordata, and fungi.</ref>.<br />
In Animal Kingdom, GlcCer is the basic structure for different derivative series such as Globo, Lacto, and Ganglio Series. In Protostomia, GlcCer is the major ceramide in its nerve tissue, e.g. shrimp brain <ref>Okamura N, Stoskopf M, Hendricks F, Kishimoto Y. "Phylogenetic dichotomy of nerve glycosphingolipids" Proc Natl Acad Sci, 1985 82:6779-6782 PMID 3863128 </ref>, and its amide-linked fatty acids do not contain hydroxy groups. GlcCer in plants contains many &alpha;-hydroxy fatty acids. In some cold-resistant plants &omega;9-unsaturated fatty acids are detected. In Mammalia (of Deuterostomia), GlcCer is major in the spleen, blood, and skin.<br />
<br />
Gaucher's disease is an inborn metabolic disorder in which GlcCer accumulates in the liver and spleen because of the deficiency of the enzyme glucocerebrosidase to dissociate glucose from the ceramide structure <ref> Brady RO, Kanfer JN, Shapiro D. "Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher's desease" Biochem Biophys Res Commun. 1965;18:221-5 PMID 14282020 </ref>.<br />
|<br />
'''GlcCer'''は系統発生的にみると動物の各組織に広く分布するだけでなく、植物界や菌界、原生生物界にも含まれます。セラミド構造(炭化水素の鎖長、二重結合の数と位置、水酸基の有無、修飾基の有無など)の組み合わせは多岐にわたり、特に植物界や菌界、旧口動物のセラミドは複雑です。動物界において、GlcCerはさまざまな糖鎖を持つ糖脂質の基本構造になり、グロボ系列、ラクト系列、ガングリオ系列などが生成されます。旧口(前口)動物の神経系にはGlcCerが多く含まれ(例えばエビ)、セラミド骨格の脂肪酸に水酸基を含みません。対して、植物は &alpha;-水酸化の脂肪酸が多く、耐冷性植物の一部からは &omega;9-不飽和の脂肪酸も見いだされます。後口動物の哺乳綱において、GlcCerは、脾臓、血液、皮膚などに多く含まれます。<br />
<br />
先天性代謝異常症であるゴーシェ (Gaucher) 病は、GlcCerを分解するグルコセレブロシダーゼが欠損し、肝臓や脾臓にGlcCerが蓄積して発症します。<br />
}}<br />
<br />
==Galactosylceramide (GalCer)==<br />
{{Twocolumn|<br />
GalCer has been observed in Eubacterial Domain, but not in Protozoa, Plant, or Fungi (except Ascomycota). It is widely observed in Animal Kingdom, but not in Ecdysozoa (cuticle-shedding animals) of Protostomia. Its ceramide structure differs widely as in GlcCer but not so complex as GlcCer in Plant and Fungi. GalCer is the basic structure for sulfatide (3-O-sulfogalactosylceramide or SM4) and Gala Series often found in Annelida (segmented worm). In Mammalia (of Deuterostomia), GalCer is major in the nerve tissue, especially myelin sheath, whose amido-linked fatty acids are hydroxylated at the C-2 position for more than 50%.<br />
<br />
Krabbe disease (globoid cell leukodystrophy) is an inborn metabolic disorder in which a small amount of psychosine (galactosylsphingosine, i.e., the lyso form of GalCer) induces demyelination because of the deficiency of the enzyme galactosylceramidase <ref>Suzuki K. "Globoid cell leukodystrophy (Krabbe's disease): update" J Child Neurol. 2003;18:595-603.PMID 14572137, Suzuki K. "Evolving concept of the pathogenesis of globoid cell leukodystrophy (Krabbe disease)" Proc Jpn Acad Ser B Phys Biol Sci 2003; 79:1-8</ref>. &alpha;-GalCer, found from Porifera (marine sponge), in which galactose is &alpha;-bonded to ceramide (not the usual &beta;-bond), uniquely binds to human or mouse NKT cells and is considered a potent anti-tumor agent.<ref>Kitamura H, Iwakabe K, Yahata T, Nishimura S, Ohta A, Ohmi Y, Sato M, Takeda K, Okumura K, Van Kaer L, Kawano T, Taniguchi M, Nishimura T. "The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells" J Exp Med. 1999; 5;189(7):1121-8. PMID 10190903 </ref> Recently, &alpha;-linked GlcCer and GalCer were reported in NKT cells in trace amount<ref>Kain L et al. "The Identification of the Endogenous Ligands of Natural Killer T Cells Reveals the Presence of Mammalian α-Linked Glycosylceramides" Immunity 41(4), 543-554, 2014 PMID 25367571</ref>.<br />
<br />
'''GalCer'''は真正細菌に存在しますが、原生生物界、植物界、菌界(子嚢菌を除く)では報告がありません。動物界に広く分布しますが旧口動物である脱皮動物には確認されていません。セラミド構造は、GlcCerと同様に多様ですが、植物や菌類のGlcCerほど複雑ではありません。GalCerはスルファチド (3-O-硫酸化ガラクトシルセラミドまたはSM4) や環形動物門に多く含まれるガラ系列の基本構造です。<br />
後口動物である哺乳綱では神経系、特にミエリン鞘にGalCerが多く含まれ、その脂肪酸の50%以上は、C2位が水酸化されています。<br />
<br />
クラッベ病(グロボイド細胞ロイコジストロフィー; GLD)はガラクトシルセラミダーゼの欠損により微量のサイコシン(ガラクトシルスフィンゴシン、つまり GalCer のリゾ体)が蓄積して脱髄(ミエリンの破壊)を起こす遺伝性疾患です。また、海綿動物門に発見された&alpha;-GalCerは、ガラクトースがセラミドに(通常の&beta;でなく)&alpha;結合しており、ヒトやマウスのナチュラルキラーT (NKT) 細胞に特異的に結合し抗腫瘍効果がみられます。&alpha;結合型の GlcCer および GalCer はNKT細胞に微量に存在します。<br />
}}<br />
<br />
<references/><br />
<br />
==Cerebrosides in Mammals==<br />
<br />
====Lipids in Heart Muscle====<br />
<br />
{| class="wikitable collapsible collapsed"<br />
|-<br />
! <br />
! Lipid (% wet weight)<br />
! Phospholipid (% dry weight)<br />
! Phosphatidylethanolamine<br/>PE (% dry weight)<br />
! Phosphatidylcholine<br/>PC (% dry weight)<br />
! Sphingomyelin (% dry weight)<br />
! '''Cerebroside''' (% dry weight)<br />
! Total cholesterol (% dry weight)<br />
|-<br />
! Human<br />
| 8.3<br />
| 6.3 - 7.5<br />
| 1.4 - 2.8<br />
| 3.3 - 5.7<br />
| 0.2 - 0.5<br />
| -<br />
| -<br />
|-<br />
! Cow<br />
| 3.1 - 19.5<br />
| 7.4 - 11.8<br />
| 5.3<br />
| 4<br />
| 0.5<br />
| 2<br />
| 0.4 (free)<br />
|-<br />
! Rat<br />
| 0.4 - 2.4<br />
| 5 - 8<br />
| 0.84 (% wet)<br />
| 2 (% wet)<br />
| 0.14 (% wet)<br />
| 1.4<br />
| 0.4 - 0.6<br />
|-<br />
|colspan="8"|生化学データブック[I] 14. 臓器・組織の成分、心臓 脂質 p1636 1981 日本生化学会編 東京化学同人 ISBN 978-4-807901-74-6 <br />
|}<br />
<br />
====Lipids in Rat Testis====<br />
{| class="wikitable collapsible collapsed"<br />
|-<br />
! Fraction<br />
! Total Lipid (mg/mg protein)<br />
! Phosphate (ug/mg protein)<br />
! Phospholipid<br/>(% total lipid)<br />
! Neutral Lipid<br/>(% total lipid)<br />
! '''Cerebroside''' (% total lipid)<br />
! Sulfated glycolipid<br/>(nmol/g total weight)<br />
|-<br />
! Total testis<br />
| 0.40<br />
| 62.88<br />
| 62.9<br />
| 34.6<br />
| 2.5<br />
| 556 &plusmn; 34<br />
|-<br />
! Golgi<br />
| 1.26<br />
| 18.49<br />
| 58.3<br />
| 39.4<br />
| 2.3<br />
| -<br />
|-<br />
! Remnant granule<br />
| 0.60<br />
| 19.67<br />
| 29.5<br />
| 68.0<br />
| 2.5<br />
| -<br />
|-<br />
! Microsome<br />
| 0.63<br />
| 53.21<br />
| 83.8<br />
| 14.5<br />
| 1.7<br />
| -<br />
|-<br />
! Lipid corpuscle<br />
| > 19<br />
| 12<br />
| 1.5<br />
| 98.5<br />
| -<br />
| -<br />
|-<br />
|colspan="7"| Keenan TW et al. "Lipid composition of subcellular fractions from rat testis"Biochim Biophys Acta 1972; 270:433-443, PMID 4340988 Suzuki A et al. "Decrease of seminolipid content in the testes of rats with vitamin A deficiency determined by high performance liquid chromatography"J Biochem 1977; 82:461-7 PMID 91479 <br />
|}<br />
<br />
====Cerebroside and Sulfatide Ratio in Animal Brain ====<br />
<br />
{| class="wikitable sortable collapsible collapsed"<br />
|-<br />
! Animal<br />
! Kerasin<br/>(GalCer with straight fatty-acyl chain)<br />
! Phrenosin<br/>(GalCer with hydroxy fatty-acyl chain)<br />
! Sulfatide<br />
|-<br />
! Human cinerea (gray matter)<br />
| 25<br />
| 52<br />
| 23<br />
|-<br />
! Human alba (white matter)<br />
| 28<br />
| 47<br />
| 25<br />
|-<br />
! Cow cinerea<br />
| 15<br />
| 56<br />
| 29<br />
|-<br />
! Cow alba<br />
| 35<br />
| 48<br />
| 17<br />
|-<br />
! Dog<br />
| 21<br />
| 57<br />
| 22<br />
|-<br />
! Cat<br />
| 21<br />
| 60<br />
| 19<br />
|-<br />
! Mouse (4 weeks)<br />
| 24<br />
| 56<br />
| 20<br />
|-<br />
! Rat (10 days)<br />
| 35<br />
| 42<br />
| 23<br />
|-<br />
! Rat (35 days)<br />
| 21<br />
| 61<br />
| 18<br />
|-<br />
! Rabbit<br />
| 13<br />
| 66<br />
| 21<br />
|-<br />
! Guinea pig<br />
| 28<br />
| 54<br />
| 18<br />
|-<br />
! Sheep<br />
| 27<br />
| 47<br />
| 26<br />
|-<br />
! Chicken<br />
| 44<br />
| 37<br />
| 19<br />
|-<br />
! Tuna<br />
| 50<br />
| 25<br />
| 25<br />
|-<br />
! Shark<br />
| 44<br />
| 24<br />
| 32<br />
|-<br />
| colspan="4" | (weight %) From: Yamakawa T, Nishimura S. "Cerebroside composition in animal brain" Jpn J Exp 1966; 36:101-2 PMID 5297247 <br />
|}<br />
<br />
====Fatty acid composition of bovine brains====<br />
<br />
{| class="wikitable sortable collapsible collapsed"<br />
|-<br />
!colspan="5"| Nonhydroxy fatty acid (adjusted GC peak %)<br />
!colspan="3"| Hydroxy fatty acid<br />
|-<br />
! fatty acid || Ceramide || Sphingomyelin || Cerebroside || Sulfatide || fatty acid || Cerebroside || Sulfatide<br />
|-<br />
|12:0<br />
|colspan="4"| - || 12h:0 || 0.4 || 0.3<br />
|-<br />
|13:0<br />
|colspan="4"| - || 13h:0 || 0.2 || 0.2<br />
|-<br />
| 14:0 || 0.6 || 0.3 || 0.2 || 0.8 || 14h:0 || 0.8 || 3.9<br />
|-<br />
| 15:0 || 0.2 || 0.1 || tr. || 0.3 || 15h:0 || tr. || 0.3<br />
|-<br />
| 16:0 || 4.5 || 5.9 || 3.5 || 4.1 || 16h:0 || 0.1 || 0.7<br />
|-<br />
| 16:1 || 0.4 || tr. || 0.1 || 0.7 || 16h:1 || tr. || 1.7<br />
|-<br />
| 17:0 || tr. || 0.3 || tr. || tr. || 17h:0 || 0.2 || 0.9<br />
|-<br />
| 18:0 || 35.2 || 40.1 || 5.8 || 3.3 || 18h:0 || 16.2 || 12.3<br />
|-<br />
| 18:1 || 2.1 || 0.7 || 2.7 || 5.2 || 18h:1 || - || -<br />
|- <br />
| 19:0 || 0.1 || 0.1 || 0.2 || 0.3 || 19h:0 || 0.4 || 0.3<br />
|-<br />
| 20:0 || 1.0 || 0.4 || 0.6 || 0.3 || 20h:0 || 0.5 || 0.7<br />
|-<br />
| 20:1 || 0.5 || tr. || 0.3 || 0.4 || 20h:1 || - || -<br />
|-<br />
| 21:0 || tr. || tr. || - || - || 21h:1 || - || -<br />
|-<br />
| 22:0 || 3.3 || 3.5 || 3.6 || 3.5 || 22h:0 || 5.8 || 7.7<br />
|-<br />
| 22:1 || 0.5 || 0.6 || 0.6 || 0.6 || 22h:1 || - || -<br />
|-<br />
| 23:0 || 3.7 || 2.8 || 5.2 || 3.1 || 23h:0 || 8.9 || 6.5<br />
|-<br />
| 23:1 || 1.0 || 1.0 || 1.2 || 0.8 || 23h:1 || - || -<br />
|-<br />
| 24:0 || 9.8 || 10.7 || 17.4 || 17.8 || 24h:0 || 30.1 || 26.0<br />
|-<br />
| 24:1 || 18.4 || 24.6 || 39.3 || 39.5 || 24h:1 || 14.6 || 16.7<br />
|-<br />
| 25:0 || 1.4 || 1.5 || 3.6 || 2.2 || 25h:0 || 7.0 || 4.5<br />
|-<br />
| 25:1 || 3.0 || 3.3 || 6.2 || 5.2 || 25h:1 || 3.0 || 2.8<br />
|-<br />
| 26:0 || 2.3 || 0.6 || 1.7 || 2.3 || 26h:0 || 3.9 || 3.8<br />
|-<br />
| 26:1 || 3.6 || 2.6 || 7.6 || 8.5 || 26h:1 || 6.3 || 6.5<br />
|-<br />
| 27:0 || 2.9 || - || - || - || 27h:0 || - || -<br />
|-<br />
| 27:1 || 1.8 || - || tr. || - || 27h:1 || - || -<br />
|-<br />
|colspan="8"| From: O'Brien JS, Rouser G "The fatty acid composition of brain sphingolipids: sphingomyelin, ceramide, cerebroside, and cerebroside sulfate"J Lipid Res1964; 5:339-342.PMID 5873370 Per cent of FA of each column. No PUFA, trace amount of hydroxy FA in ceramide, no hydroxy FA in sphingomyelin. The total ratio of nonhydroxy to hydroxy acids in cerebroside and sulfatide were 42:58 and 77:23, respectively (77:13 in the original paper). Human brain has a similar composition.<br />
|}<br />
<br />
==Sphingolipids in All Kingdoms==<br />
<br />
{{:Category:ScientificClassification/LBSC}}<br />
<br />
==Biosynthesis==<br />
<br />
{{Twocolumn|<br />
In Mammalia, GlcCer is synthesized by ceramide glucosyltransferase (CGlcT) at the cytosolic membrane of the Golgi apparatus, and GalCer is synthesized by ceramide galactosyltransferase (CGalT) at the lumen of the endoplasmic reticulum (ER). These enzymes do not share any sequence similarity and CGlcT possesses its transmembrane region at the N-terminal (type III) whereas CGalT possesses it at the C-terminal (type I).<ref>Sprong H, Degroote S, Nilsson T, Kawakita M, Ishida N, van der Sluijs P, van Meer G "Association of the Golgi UDP-galactose transporter with UDP-galactose:ceramide galactosyltransferase allows UDP-galactose import in the endoplasmic reticulum" Mol Biol Cell. 2003;4:3482-93 PMID 12925779</ref><br />
|<br />
哺乳動物では、ゴルジ装置の細胞質側に局在するグルコシルセラミド合成酵素(CGlcT)によって GlcCer が、小胞体の内腔側に局在するガラクトシルセラミド合成酵素(CGalT)によって GalCer が作られます。これらの酵素は配列相同性が無く、CGlcT は膜貫通領域が N 末端側(III型酵素)、CGalT は C 末端側(I型酵素)です。<br />
}}<br />
<br />
{| class="wikitable" style="text-align:center"<br />
|-<br />
! <br />
! GlcCer || GalCer<br />
|-<br />
! Enzyme<br />
| CGlcT (EC 2.4.1.80)<br />
| CGalT (EC 2.4.1.45)<br />
|-<br />
! Reaction<br />
| Ceramide + UDP-glucose &rarr; GlcCer + UDP<br />
| Ceramide + UDP-galactose &rarr; GalCer + UDP<br />
|-<br />
! Location<br />
| '''Golgi (outside)''' &rarr; flipflop &rarr; Golgi (inside)<br />
| '''ER lumen'''<br />
|}<br />
<br />
{{Twocolumn|<br />
Since all glycolipid synthesizing enzymes (except for CGlcT and CGalT) reside at the lumen of the Golgi apparatus, GlcCer must be flip-flopped from the cytosolic side to the lumen by an eyzyme called flippase.<br />
To synthesize GalCer, UDP-galactose and ceramide must transport the ER membrane. UDP-galactose transporter 2 (UGT2) is considered to be responsible.<br />
<br />
GalT can also work on glycerolipid, and synthsizes sulfated glyceroglycolipid in mammalian testis, called seminolipid.<br />
|<br />
CGlcT, CGalT 以外の糖脂質合成酵素はゴルジ装置の内腔側にあり、GlcCer はゴルジ膜の細胞質側から内腔側にフリッパーゼと呼ばれる酵素で移動(フリップフロップ)します。GalCer の場合は、UDPガラクトースとセラミドが小胞体膜を通過します。UDPガラクトーストランスポータ2 (UGT2) が関与するようです。<br />
<br />
CGalTはグリセロ脂質にも作用し、精巣の硫酸化グリセロ糖脂質であるセミノリピドも合成します。<br />
}}<br />
<br />
<references/></div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Category:LBSC&diff=117164
Category:LBSC
2023-05-18T05:11:20Z
<p>Editor: /* Galactosylceramide (GalCer) */</p>
<hr />
<div><font size="+2">Cerebroside</font><br />
{{LB/Header}}<br />
{{Hierarchy|{{PAGENAME}}}}<br />
{|<br />
|{{LBS/Cer|O-<b>Glucose</b>}} <b>GlcCer</b><br />
|{{LBS/Cer|O-<b>Galactose</b>}} <b>GalCer</b><br />
|-<br />
|colspan=2|<br />
{{Twocolumn|<br />
Monoglycosylceramides (or cerebrosides) are glycosphingolipids where a single sugar is attached to the ceramide structure. Especially, glucopyranose-attached Glucosylceramide (GlcCer) and galactopyranose-attached Galactosylceramide (GalCer) are widely observed in all kingdoms. <br />
GlcCer and GalCer are not registered in LipidBank. Instead, we summarize their distribution with bibliographic references with species information.<br />
<br />
|<br />
モノグリコシルセラミド (またはセレブロシド) はセラミドに糖が1個エステル結合したスフィンゴ糖脂質です。特にグルコース(ピラノース型)が&beta;結合したグルコシルセラミド (GlcCer) とガラクトース(ピラノース型)が&beta;結合したガラクトシルセラミド (GalCer) は生物界に広く分布します。データベース中には掲載せず、ここに解説と生物種ごとの報告例を掲載します。<br />
}}<br />
|}<br />
<br />
==Glucosylceramide (GlcCer)==<br />
<br />
{{Twocolumn|<br />
GlcCer is widely observed not only in Animal, Plant or Fungi kingdoms, but also in Protozoa Kingdom<ref>Tan RX, Chen JH. "The cerebrosides" Nat Prod Rep. 2003;20:509-34.PMID 14620845, Yu R.K. Yanagisawa M. Ariga T. Glycosphingolipid Structures,in Comprehensive Glycoscience Vol.1,pp. 73-122,doi 10.1016/B978-044451967-2/00003-9, Itonori S, Sugita M. Glycophylogenetic Aspects of Lower Animals. in Comprehensive Glycoscience Vol.3, pp. 253-84, doi 10.1016/B978-044451967-2/00050-7 (J.P. Kamerling, ed.) Elsevier, Oxford (UK). (2007)</ref>. Ceramide structures (hydrocarbon chain length, the number and position of double bonds, existence of hydroxy and other modification groups) may vary, and become complex especially in Plant and Fungi Kingdoms, and Protostomia <ref>Sphingoid base chain may terminate with an isopropyl group in spongia, annelida, echinodermata, and bacteria. Terminal isobutyl or sec-pentyl group has been found only in echinodermata. Methylated or cyclopropane-containing sphingoid base is found in spongia, echinodermata, protochordata, and fungi.</ref>.<br />
In Animal Kingdom, GlcCer is the basic structure for different derivative series such as Globo, Lacto, and Ganglio Series. In Protostomia, GlcCer is the major ceramide in its nerve tissue, e.g. shrimp brain <ref>Okamura N, Stoskopf M, Hendricks F, Kishimoto Y. "Phylogenetic dichotomy of nerve glycosphingolipids" Proc Natl Acad Sci, 1985 82:6779-6782 PMID 3863128 </ref>, and its amide-linked fatty acids do not contain hydroxy groups. GlcCer in plants contains many &alpha;-hydroxy fatty acids. In some cold-resistant plants &omega;9-unsaturated fatty acids are detected. In Mammalia (of Deuterostomia), GlcCer is major in the spleen, blood, and skin.<br />
<br />
Gaucher's disease is an inborn metabolic disorder in which GlcCer accumulates in the liver and spleen because of the deficiency of the enzyme glucocerebrosidase to dissociate glucose from the ceramide structure <ref> Brady RO, Kanfer JN, Shapiro D. "Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher's desease" Biochem Biophys Res Commun. 1965;18:221-5 PMID 14282020 </ref>.<br />
|<br />
'''GlcCer'''は系統発生的にみると動物の各組織に広く分布するだけでなく、植物界や菌界、原生生物界にも含まれます。セラミド構造(炭化水素の鎖長、二重結合の数と位置、水酸基の有無、修飾基の有無など)の組み合わせは多岐にわたり、特に植物界や菌界、旧口動物のセラミドは複雑です。動物界において、GlcCerはさまざまな糖鎖を持つ糖脂質の基本構造になり、グロボ系列、ラクト系列、ガングリオ系列などが生成されます。旧口(前口)動物の神経系にはGlcCerが多く含まれ(例えばエビ)、セラミド骨格の脂肪酸に水酸基を含みません。対して、植物は &alpha;-水酸化の脂肪酸が多く、耐冷性植物の一部からは &omega;9-不飽和の脂肪酸も見いだされます。後口動物の哺乳綱において、GlcCerは、脾臓、血液、皮膚などに多く含まれます。<br />
<br />
先天性代謝異常症であるゴーシェ (Gaucher) 病は、GlcCerを分解するグルコセレブロシダーゼが欠損し、肝臓や脾臓にGlcCerが蓄積して発症します。<br />
}}<br />
<br />
==Galactosylceramide (GalCer)==<br />
{{Twocolumn|<br />
GalCer has been observed in Eubacterial Domain, but not in Protozoa, Plant, or Fungi (except Ascomycota). It is widely observed in Animal Kingdom, but not in Ecdysozoa (cuticle-shedding animals) of Protostomia. Its ceramide structure differs widely as in GlcCer but not so complex as GlcCer in Plant and Fungi. GalCer is the basic structure for sulfatide (3-O-sulfogalactosylceramide or SM4) and Gala Series often found in Annelida (segmented worm). In Mammalia (of Deuterostomia), GalCer is major in the nerve tissue, especially myelin sheath, whose amido-linked fatty acids are hydroxylated at the C-2 position for more than 50%.<br />
<br />
Krabbe disease (globoid cell leukodystrophy) is an inborn metabolic disorder in which a small amount of psychosine (galactosylsphingosine, i.e., the lyso form of GalCer) induces demyelination because of the deficiency of the enzyme galactosylceramidase <ref>Suzuki K. "Globoid cell leukodystrophy (Krabbe's disease): update" J Child Neurol. 2003;18:595-603.PMID 14572137, Suzuki K. "Evolving concept of the pathogenesis of globoid cell leukodystrophy (Krabbe disease)" Proc Jpn Acad Ser B Phys Biol Sci 2003; 79:1-8</ref>. &alpha;-GalCer, found from Porifera (marine sponge), in which galactose is &alpha;-bonded to ceramide (not the usual &beta;-bond), uniquely binds to human or mouse NKT cells and is considered a potent anti-tumor agent.<ref>Kitamura H, Iwakabe K, Yahata T, Nishimura S, Ohta A, Ohmi Y, Sato M, Takeda K, Okumura K, Van Kaer L, Kawano T, Taniguchi M, Nishimura T. "The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells" J Exp Med. 1999; 5;189(7):1121-8. PMID 10190903 </ref> Recently, &alpha;-linked GlcCer and GalCer were reported in NKT cells in trace amount<ref>Kain L et al. <i>Immunity</i> 41(4), 543-554, 2014</ref>.<br />
|<br />
'''GalCer'''は真正細菌に存在しますが、原生生物界、植物界、菌界(子嚢菌を除く)では報告がありません。動物界に広く分布しますが旧口動物である脱皮動物には確認されていません。セラミド構造は、GlcCerと同様に多様ですが、植物や菌類のGlcCerほど複雑ではありません。GalCerはスルファチド (3-O-硫酸化ガラクトシルセラミドまたはSM4) や環形動物門に多く含まれるガラ系列の基本構造です。<br />
後口動物である哺乳綱では神経系、特にミエリン鞘にGalCerが多く含まれ、その脂肪酸の50%以上は、C2位が水酸化されています。<br />
<br />
クラッベ病(グロボイド細胞ロイコジストロフィー; GLD)はガラクトシルセラミダーゼの欠損により微量のサイコシン(ガラクトシルスフィンゴシン、つまり GalCer のリゾ体)が蓄積して脱髄(ミエリンの破壊)を起こす遺伝性疾患です。また、海綿動物門に発見された&alpha;-GalCerは、ガラクトースがセラミドに(通常の&beta;でなく)&alpha;結合しており、ヒトやマウスのナチュラルキラーT (NKT) 細胞に特異的に結合し抗腫瘍効果がみられます。&alpha;結合型の GlcCer および GalCer はNKT細胞に微量に存在します。<br />
}}<br />
<br />
<references/><br />
<br />
==Cerebrosides in Mammals==<br />
<br />
====Lipids in Heart Muscle====<br />
<br />
{| class="wikitable collapsible collapsed"<br />
|-<br />
! <br />
! Lipid (% wet weight)<br />
! Phospholipid (% dry weight)<br />
! Phosphatidylethanolamine<br/>PE (% dry weight)<br />
! Phosphatidylcholine<br/>PC (% dry weight)<br />
! Sphingomyelin (% dry weight)<br />
! '''Cerebroside''' (% dry weight)<br />
! Total cholesterol (% dry weight)<br />
|-<br />
! Human<br />
| 8.3<br />
| 6.3 - 7.5<br />
| 1.4 - 2.8<br />
| 3.3 - 5.7<br />
| 0.2 - 0.5<br />
| -<br />
| -<br />
|-<br />
! Cow<br />
| 3.1 - 19.5<br />
| 7.4 - 11.8<br />
| 5.3<br />
| 4<br />
| 0.5<br />
| 2<br />
| 0.4 (free)<br />
|-<br />
! Rat<br />
| 0.4 - 2.4<br />
| 5 - 8<br />
| 0.84 (% wet)<br />
| 2 (% wet)<br />
| 0.14 (% wet)<br />
| 1.4<br />
| 0.4 - 0.6<br />
|-<br />
|colspan="8"|生化学データブック[I] 14. 臓器・組織の成分、心臓 脂質 p1636 1981 日本生化学会編 東京化学同人 ISBN 978-4-807901-74-6 <br />
|}<br />
<br />
====Lipids in Rat Testis====<br />
{| class="wikitable collapsible collapsed"<br />
|-<br />
! Fraction<br />
! Total Lipid (mg/mg protein)<br />
! Phosphate (ug/mg protein)<br />
! Phospholipid<br/>(% total lipid)<br />
! Neutral Lipid<br/>(% total lipid)<br />
! '''Cerebroside''' (% total lipid)<br />
! Sulfated glycolipid<br/>(nmol/g total weight)<br />
|-<br />
! Total testis<br />
| 0.40<br />
| 62.88<br />
| 62.9<br />
| 34.6<br />
| 2.5<br />
| 556 &plusmn; 34<br />
|-<br />
! Golgi<br />
| 1.26<br />
| 18.49<br />
| 58.3<br />
| 39.4<br />
| 2.3<br />
| -<br />
|-<br />
! Remnant granule<br />
| 0.60<br />
| 19.67<br />
| 29.5<br />
| 68.0<br />
| 2.5<br />
| -<br />
|-<br />
! Microsome<br />
| 0.63<br />
| 53.21<br />
| 83.8<br />
| 14.5<br />
| 1.7<br />
| -<br />
|-<br />
! Lipid corpuscle<br />
| > 19<br />
| 12<br />
| 1.5<br />
| 98.5<br />
| -<br />
| -<br />
|-<br />
|colspan="7"| Keenan TW et al. "Lipid composition of subcellular fractions from rat testis"Biochim Biophys Acta 1972; 270:433-443, PMID 4340988 Suzuki A et al. "Decrease of seminolipid content in the testes of rats with vitamin A deficiency determined by high performance liquid chromatography"J Biochem 1977; 82:461-7 PMID 91479 <br />
|}<br />
<br />
====Cerebroside and Sulfatide Ratio in Animal Brain ====<br />
<br />
{| class="wikitable sortable collapsible collapsed"<br />
|-<br />
! Animal<br />
! Kerasin<br/>(GalCer with straight fatty-acyl chain)<br />
! Phrenosin<br/>(GalCer with hydroxy fatty-acyl chain)<br />
! Sulfatide<br />
|-<br />
! Human cinerea (gray matter)<br />
| 25<br />
| 52<br />
| 23<br />
|-<br />
! Human alba (white matter)<br />
| 28<br />
| 47<br />
| 25<br />
|-<br />
! Cow cinerea<br />
| 15<br />
| 56<br />
| 29<br />
|-<br />
! Cow alba<br />
| 35<br />
| 48<br />
| 17<br />
|-<br />
! Dog<br />
| 21<br />
| 57<br />
| 22<br />
|-<br />
! Cat<br />
| 21<br />
| 60<br />
| 19<br />
|-<br />
! Mouse (4 weeks)<br />
| 24<br />
| 56<br />
| 20<br />
|-<br />
! Rat (10 days)<br />
| 35<br />
| 42<br />
| 23<br />
|-<br />
! Rat (35 days)<br />
| 21<br />
| 61<br />
| 18<br />
|-<br />
! Rabbit<br />
| 13<br />
| 66<br />
| 21<br />
|-<br />
! Guinea pig<br />
| 28<br />
| 54<br />
| 18<br />
|-<br />
! Sheep<br />
| 27<br />
| 47<br />
| 26<br />
|-<br />
! Chicken<br />
| 44<br />
| 37<br />
| 19<br />
|-<br />
! Tuna<br />
| 50<br />
| 25<br />
| 25<br />
|-<br />
! Shark<br />
| 44<br />
| 24<br />
| 32<br />
|-<br />
| colspan="4" | (weight %) From: Yamakawa T, Nishimura S. "Cerebroside composition in animal brain" Jpn J Exp 1966; 36:101-2 PMID 5297247 <br />
|}<br />
<br />
====Fatty acid composition of bovine brains====<br />
<br />
{| class="wikitable sortable collapsible collapsed"<br />
|-<br />
!colspan="5"| Nonhydroxy fatty acid (adjusted GC peak %)<br />
!colspan="3"| Hydroxy fatty acid<br />
|-<br />
! fatty acid || Ceramide || Sphingomyelin || Cerebroside || Sulfatide || fatty acid || Cerebroside || Sulfatide<br />
|-<br />
|12:0<br />
|colspan="4"| - || 12h:0 || 0.4 || 0.3<br />
|-<br />
|13:0<br />
|colspan="4"| - || 13h:0 || 0.2 || 0.2<br />
|-<br />
| 14:0 || 0.6 || 0.3 || 0.2 || 0.8 || 14h:0 || 0.8 || 3.9<br />
|-<br />
| 15:0 || 0.2 || 0.1 || tr. || 0.3 || 15h:0 || tr. || 0.3<br />
|-<br />
| 16:0 || 4.5 || 5.9 || 3.5 || 4.1 || 16h:0 || 0.1 || 0.7<br />
|-<br />
| 16:1 || 0.4 || tr. || 0.1 || 0.7 || 16h:1 || tr. || 1.7<br />
|-<br />
| 17:0 || tr. || 0.3 || tr. || tr. || 17h:0 || 0.2 || 0.9<br />
|-<br />
| 18:0 || 35.2 || 40.1 || 5.8 || 3.3 || 18h:0 || 16.2 || 12.3<br />
|-<br />
| 18:1 || 2.1 || 0.7 || 2.7 || 5.2 || 18h:1 || - || -<br />
|- <br />
| 19:0 || 0.1 || 0.1 || 0.2 || 0.3 || 19h:0 || 0.4 || 0.3<br />
|-<br />
| 20:0 || 1.0 || 0.4 || 0.6 || 0.3 || 20h:0 || 0.5 || 0.7<br />
|-<br />
| 20:1 || 0.5 || tr. || 0.3 || 0.4 || 20h:1 || - || -<br />
|-<br />
| 21:0 || tr. || tr. || - || - || 21h:1 || - || -<br />
|-<br />
| 22:0 || 3.3 || 3.5 || 3.6 || 3.5 || 22h:0 || 5.8 || 7.7<br />
|-<br />
| 22:1 || 0.5 || 0.6 || 0.6 || 0.6 || 22h:1 || - || -<br />
|-<br />
| 23:0 || 3.7 || 2.8 || 5.2 || 3.1 || 23h:0 || 8.9 || 6.5<br />
|-<br />
| 23:1 || 1.0 || 1.0 || 1.2 || 0.8 || 23h:1 || - || -<br />
|-<br />
| 24:0 || 9.8 || 10.7 || 17.4 || 17.8 || 24h:0 || 30.1 || 26.0<br />
|-<br />
| 24:1 || 18.4 || 24.6 || 39.3 || 39.5 || 24h:1 || 14.6 || 16.7<br />
|-<br />
| 25:0 || 1.4 || 1.5 || 3.6 || 2.2 || 25h:0 || 7.0 || 4.5<br />
|-<br />
| 25:1 || 3.0 || 3.3 || 6.2 || 5.2 || 25h:1 || 3.0 || 2.8<br />
|-<br />
| 26:0 || 2.3 || 0.6 || 1.7 || 2.3 || 26h:0 || 3.9 || 3.8<br />
|-<br />
| 26:1 || 3.6 || 2.6 || 7.6 || 8.5 || 26h:1 || 6.3 || 6.5<br />
|-<br />
| 27:0 || 2.9 || - || - || - || 27h:0 || - || -<br />
|-<br />
| 27:1 || 1.8 || - || tr. || - || 27h:1 || - || -<br />
|-<br />
|colspan="8"| From: O'Brien JS, Rouser G "The fatty acid composition of brain sphingolipids: sphingomyelin, ceramide, cerebroside, and cerebroside sulfate"J Lipid Res1964; 5:339-342.PMID 5873370 Per cent of FA of each column. No PUFA, trace amount of hydroxy FA in ceramide, no hydroxy FA in sphingomyelin. The total ratio of nonhydroxy to hydroxy acids in cerebroside and sulfatide were 42:58 and 77:23, respectively (77:13 in the original paper). Human brain has a similar composition.<br />
|}<br />
<br />
==Sphingolipids in All Kingdoms==<br />
<br />
{{:Category:ScientificClassification/LBSC}}<br />
<br />
==Biosynthesis==<br />
<br />
{{Twocolumn|<br />
In Mammalia, GlcCer is synthesized by ceramide glucosyltransferase (CGlcT) at the cytosolic membrane of the Golgi apparatus, and GalCer is synthesized by ceramide galactosyltransferase (CGalT) at the lumen of the endoplasmic reticulum (ER). These enzymes do not share any sequence similarity and CGlcT possesses its transmembrane region at the N-terminal (type III) whereas CGalT possesses it at the C-terminal (type I).<ref>Sprong H, Degroote S, Nilsson T, Kawakita M, Ishida N, van der Sluijs P, van Meer G "Association of the Golgi UDP-galactose transporter with UDP-galactose:ceramide galactosyltransferase allows UDP-galactose import in the endoplasmic reticulum" Mol Biol Cell. 2003;4:3482-93 PMID 12925779</ref><br />
|<br />
哺乳動物では、ゴルジ装置の細胞質側に局在するグルコシルセラミド合成酵素(CGlcT)によって GlcCer が、小胞体の内腔側に局在するガラクトシルセラミド合成酵素(CGalT)によって GalCer が作られます。これらの酵素は配列相同性が無く、CGlcT は膜貫通領域が N 末端側(III型酵素)、CGalT は C 末端側(I型酵素)です。<br />
}}<br />
<br />
{| class="wikitable" style="text-align:center"<br />
|-<br />
! <br />
! GlcCer || GalCer<br />
|-<br />
! Enzyme<br />
| CGlcT (EC 2.4.1.80)<br />
| CGalT (EC 2.4.1.45)<br />
|-<br />
! Reaction<br />
| Ceramide + UDP-glucose &rarr; GlcCer + UDP<br />
| Ceramide + UDP-galactose &rarr; GalCer + UDP<br />
|-<br />
! Location<br />
| '''Golgi (outside)''' &rarr; flipflop &rarr; Golgi (inside)<br />
| '''ER lumen'''<br />
|}<br />
<br />
{{Twocolumn|<br />
Since all glycolipid synthesizing enzymes (except for CGlcT and CGalT) reside at the lumen of the Golgi apparatus, GlcCer must be flip-flopped from the cytosolic side to the lumen by an eyzyme called flippase.<br />
To synthesize GalCer, UDP-galactose and ceramide must transport the ER membrane. UDP-galactose transporter 2 (UGT2) is considered to be responsible.<br />
<br />
GalT can also work on glycerolipid, and synthsizes sulfated glyceroglycolipid in mammalian testis, called seminolipid.<br />
|<br />
CGlcT, CGalT 以外の糖脂質合成酵素はゴルジ装置の内腔側にあり、GlcCer はゴルジ膜の細胞質側から内腔側にフリッパーゼと呼ばれる酵素で移動(フリップフロップ)します。GalCer の場合は、UDPガラクトースとセラミドが小胞体膜を通過します。UDPガラクトーストランスポータ2 (UGT2) が関与するようです。<br />
<br />
CGalTはグリセロ脂質にも作用し、精巣の硫酸化グリセロ糖脂質であるセミノリピドも合成します。<br />
}}<br />
<br />
<references/></div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Category:LBSC&diff=117163
Category:LBSC
2023-05-18T05:06:37Z
<p>Editor: </p>
<hr />
<div><font size="+2">Cerebroside</font><br />
{{LB/Header}}<br />
{{Hierarchy|{{PAGENAME}}}}<br />
{|<br />
|{{LBS/Cer|O-<b>Glucose</b>}} <b>GlcCer</b><br />
|{{LBS/Cer|O-<b>Galactose</b>}} <b>GalCer</b><br />
|-<br />
|colspan=2|<br />
{{Twocolumn|<br />
Monoglycosylceramides (or cerebrosides) are glycosphingolipids where a single sugar is attached to the ceramide structure. Especially, glucopyranose-attached Glucosylceramide (GlcCer) and galactopyranose-attached Galactosylceramide (GalCer) are widely observed in all kingdoms. <br />
GlcCer and GalCer are not registered in LipidBank. Instead, we summarize their distribution with bibliographic references with species information.<br />
<br />
|<br />
モノグリコシルセラミド (またはセレブロシド) はセラミドに糖が1個エステル結合したスフィンゴ糖脂質です。特にグルコース(ピラノース型)が&beta;結合したグルコシルセラミド (GlcCer) とガラクトース(ピラノース型)が&beta;結合したガラクトシルセラミド (GalCer) は生物界に広く分布します。データベース中には掲載せず、ここに解説と生物種ごとの報告例を掲載します。<br />
}}<br />
|}<br />
<br />
==Glucosylceramide (GlcCer)==<br />
<br />
{{Twocolumn|<br />
GlcCer is widely observed not only in Animal, Plant or Fungi kingdoms, but also in Protozoa Kingdom<ref>Tan RX, Chen JH. "The cerebrosides" Nat Prod Rep. 2003;20:509-34.PMID 14620845, Yu R.K. Yanagisawa M. Ariga T. Glycosphingolipid Structures,in Comprehensive Glycoscience Vol.1,pp. 73-122,doi 10.1016/B978-044451967-2/00003-9, Itonori S, Sugita M. Glycophylogenetic Aspects of Lower Animals. in Comprehensive Glycoscience Vol.3, pp. 253-84, doi 10.1016/B978-044451967-2/00050-7 (J.P. Kamerling, ed.) Elsevier, Oxford (UK). (2007)</ref>. Ceramide structures (hydrocarbon chain length, the number and position of double bonds, existence of hydroxy and other modification groups) may vary, and become complex especially in Plant and Fungi Kingdoms, and Protostomia <ref>Sphingoid base chain may terminate with an isopropyl group in spongia, annelida, echinodermata, and bacteria. Terminal isobutyl or sec-pentyl group has been found only in echinodermata. Methylated or cyclopropane-containing sphingoid base is found in spongia, echinodermata, protochordata, and fungi.</ref>.<br />
In Animal Kingdom, GlcCer is the basic structure for different derivative series such as Globo, Lacto, and Ganglio Series. In Protostomia, GlcCer is the major ceramide in its nerve tissue, e.g. shrimp brain <ref>Okamura N, Stoskopf M, Hendricks F, Kishimoto Y. "Phylogenetic dichotomy of nerve glycosphingolipids" Proc Natl Acad Sci, 1985 82:6779-6782 PMID 3863128 </ref>, and its amide-linked fatty acids do not contain hydroxy groups. GlcCer in plants contains many &alpha;-hydroxy fatty acids. In some cold-resistant plants &omega;9-unsaturated fatty acids are detected. In Mammalia (of Deuterostomia), GlcCer is major in the spleen, blood, and skin.<br />
<br />
Gaucher's disease is an inborn metabolic disorder in which GlcCer accumulates in the liver and spleen because of the deficiency of the enzyme glucocerebrosidase to dissociate glucose from the ceramide structure <ref> Brady RO, Kanfer JN, Shapiro D. "Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher's desease" Biochem Biophys Res Commun. 1965;18:221-5 PMID 14282020 </ref>.<br />
|<br />
'''GlcCer'''は系統発生的にみると動物の各組織に広く分布するだけでなく、植物界や菌界、原生生物界にも含まれます。セラミド構造(炭化水素の鎖長、二重結合の数と位置、水酸基の有無、修飾基の有無など)の組み合わせは多岐にわたり、特に植物界や菌界、旧口動物のセラミドは複雑です。動物界において、GlcCerはさまざまな糖鎖を持つ糖脂質の基本構造になり、グロボ系列、ラクト系列、ガングリオ系列などが生成されます。旧口(前口)動物の神経系にはGlcCerが多く含まれ(例えばエビ)、セラミド骨格の脂肪酸に水酸基を含みません。対して、植物は &alpha;-水酸化の脂肪酸が多く、耐冷性植物の一部からは &omega;9-不飽和の脂肪酸も見いだされます。後口動物の哺乳綱において、GlcCerは、脾臓、血液、皮膚などに多く含まれます。<br />
<br />
先天性代謝異常症であるゴーシェ (Gaucher) 病は、GlcCerを分解するグルコセレブロシダーゼが欠損し、肝臓や脾臓にGlcCerが蓄積して発症します。<br />
}}<br />
<br />
==Galactosylceramide (GalCer)==<br />
{{Twocolumn|<br />
GalCer has been observed in Eubacterial Domain, but not in Protozoa, Plant, or Fungi (except Ascomycota). It is widely observed in Animal Kingdom, but not in Ecdysozoa (cuticle-shedding animals) of Protostomia. Its ceramide structure differs widely as in GlcCer but not so complex as GlcCer in Plant and Fungi. GalCer is the basic structure for sulfatide (3-O-sulfogalactosylceramide or SM4) and Gala Series often found in Annelida (segmented worm). In Mammalia (of Deuterostomia), GalCer is major in the nerve tissue, especially myelin sheath, whose amido-linked fatty acids are hydroxylated at the C-2 position for more than 50%.<br />
<br />
Krabbe disease (globoid cell leukodystrophy) is an inborn metabolic disorder in which a small amount of psychosine (galactosylsphingosine, i.e., the lyso form of GalCer) induces demyelination because of the deficiency of the enzyme galactosylceramidase <ref>Suzuki K. "Globoid cell leukodystrophy (Krabbe's disease): update" J Child Neurol. 2003;18:595-603.PMID 14572137, Suzuki K. "Evolving concept of the pathogenesis of globoid cell leukodystrophy (Krabbe disease)" Proc Jpn Acad Ser B Phys Biol Sci 2003; 79:1-8</ref>. &alpha;-GalCer, found from Porifera (marine sponge), in which galactose is &alpha;-bonded to ceramide (not the usual &beta;-bond), uniquely binds to human or mouse NKT cells and is considered a potent anti-tumor agent.<ref>Kitamura H, Iwakabe K, Yahata T, Nishimura S, Ohta A, Ohmi Y, Sato M, Takeda K, Okumura K, Van Kaer L, Kawano T, Taniguchi M, Nishimura T. "The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells" J Exp Med. 1999; 5;189(7):1121-8. PMID 10190903 </ref><br />
|<br />
'''GalCer'''は真正細菌に存在しますが、原生生物界、植物界、菌界(子嚢菌を除く)では報告がありません。動物界に広く分布しますが旧口動物である脱皮動物には確認されていません。セラミド構造は、GlcCerと同様に多様ですが、植物や菌類のGlcCerほど複雑ではありません。GalCerはスルファチド (3-O-硫酸化ガラクトシルセラミドまたはSM4) や環形動物門に多く含まれるガラ系列の基本構造です。<br />
後口動物である哺乳綱では神経系、特にミエリン鞘にGalCerが多く含まれ、その脂肪酸の50%以上は、C2位が水酸化されています。<br />
<br />
クラッベ病(グロボイド細胞ロイコジストロフィー; GLD)はガラクトシルセラミダーゼの欠損により微量のサイコシン(ガラクトシルスフィンゴシン、つまり GalCer のリゾ体)が蓄積して脱髄(ミエリンの破壊)を起こす遺伝性疾患です。また、海綿動物門に発見された&alpha;-GalCerは、ガラクトースがセラミドに(通常の&beta;でなく)&alpha;結合しており、ヒトやマウスのNKT細胞に特異的に結合し抗腫瘍効果がみられます。<br />
}}<br />
<br />
<references/><br />
<br />
==Cerebrosides in Mammals==<br />
<br />
====Lipids in Heart Muscle====<br />
<br />
{| class="wikitable collapsible collapsed"<br />
|-<br />
! <br />
! Lipid (% wet weight)<br />
! Phospholipid (% dry weight)<br />
! Phosphatidylethanolamine<br/>PE (% dry weight)<br />
! Phosphatidylcholine<br/>PC (% dry weight)<br />
! Sphingomyelin (% dry weight)<br />
! '''Cerebroside''' (% dry weight)<br />
! Total cholesterol (% dry weight)<br />
|-<br />
! Human<br />
| 8.3<br />
| 6.3 - 7.5<br />
| 1.4 - 2.8<br />
| 3.3 - 5.7<br />
| 0.2 - 0.5<br />
| -<br />
| -<br />
|-<br />
! Cow<br />
| 3.1 - 19.5<br />
| 7.4 - 11.8<br />
| 5.3<br />
| 4<br />
| 0.5<br />
| 2<br />
| 0.4 (free)<br />
|-<br />
! Rat<br />
| 0.4 - 2.4<br />
| 5 - 8<br />
| 0.84 (% wet)<br />
| 2 (% wet)<br />
| 0.14 (% wet)<br />
| 1.4<br />
| 0.4 - 0.6<br />
|-<br />
|colspan="8"|生化学データブック[I] 14. 臓器・組織の成分、心臓 脂質 p1636 1981 日本生化学会編 東京化学同人 ISBN 978-4-807901-74-6 <br />
|}<br />
<br />
====Lipids in Rat Testis====<br />
{| class="wikitable collapsible collapsed"<br />
|-<br />
! Fraction<br />
! Total Lipid (mg/mg protein)<br />
! Phosphate (ug/mg protein)<br />
! Phospholipid<br/>(% total lipid)<br />
! Neutral Lipid<br/>(% total lipid)<br />
! '''Cerebroside''' (% total lipid)<br />
! Sulfated glycolipid<br/>(nmol/g total weight)<br />
|-<br />
! Total testis<br />
| 0.40<br />
| 62.88<br />
| 62.9<br />
| 34.6<br />
| 2.5<br />
| 556 &plusmn; 34<br />
|-<br />
! Golgi<br />
| 1.26<br />
| 18.49<br />
| 58.3<br />
| 39.4<br />
| 2.3<br />
| -<br />
|-<br />
! Remnant granule<br />
| 0.60<br />
| 19.67<br />
| 29.5<br />
| 68.0<br />
| 2.5<br />
| -<br />
|-<br />
! Microsome<br />
| 0.63<br />
| 53.21<br />
| 83.8<br />
| 14.5<br />
| 1.7<br />
| -<br />
|-<br />
! Lipid corpuscle<br />
| > 19<br />
| 12<br />
| 1.5<br />
| 98.5<br />
| -<br />
| -<br />
|-<br />
|colspan="7"| Keenan TW et al. "Lipid composition of subcellular fractions from rat testis"Biochim Biophys Acta 1972; 270:433-443, PMID 4340988 Suzuki A et al. "Decrease of seminolipid content in the testes of rats with vitamin A deficiency determined by high performance liquid chromatography"J Biochem 1977; 82:461-7 PMID 91479 <br />
|}<br />
<br />
====Cerebroside and Sulfatide Ratio in Animal Brain ====<br />
<br />
{| class="wikitable sortable collapsible collapsed"<br />
|-<br />
! Animal<br />
! Kerasin<br/>(GalCer with straight fatty-acyl chain)<br />
! Phrenosin<br/>(GalCer with hydroxy fatty-acyl chain)<br />
! Sulfatide<br />
|-<br />
! Human cinerea (gray matter)<br />
| 25<br />
| 52<br />
| 23<br />
|-<br />
! Human alba (white matter)<br />
| 28<br />
| 47<br />
| 25<br />
|-<br />
! Cow cinerea<br />
| 15<br />
| 56<br />
| 29<br />
|-<br />
! Cow alba<br />
| 35<br />
| 48<br />
| 17<br />
|-<br />
! Dog<br />
| 21<br />
| 57<br />
| 22<br />
|-<br />
! Cat<br />
| 21<br />
| 60<br />
| 19<br />
|-<br />
! Mouse (4 weeks)<br />
| 24<br />
| 56<br />
| 20<br />
|-<br />
! Rat (10 days)<br />
| 35<br />
| 42<br />
| 23<br />
|-<br />
! Rat (35 days)<br />
| 21<br />
| 61<br />
| 18<br />
|-<br />
! Rabbit<br />
| 13<br />
| 66<br />
| 21<br />
|-<br />
! Guinea pig<br />
| 28<br />
| 54<br />
| 18<br />
|-<br />
! Sheep<br />
| 27<br />
| 47<br />
| 26<br />
|-<br />
! Chicken<br />
| 44<br />
| 37<br />
| 19<br />
|-<br />
! Tuna<br />
| 50<br />
| 25<br />
| 25<br />
|-<br />
! Shark<br />
| 44<br />
| 24<br />
| 32<br />
|-<br />
| colspan="4" | (weight %) From: Yamakawa T, Nishimura S. "Cerebroside composition in animal brain" Jpn J Exp 1966; 36:101-2 PMID 5297247 <br />
|}<br />
<br />
====Fatty acid composition of bovine brains====<br />
<br />
{| class="wikitable sortable collapsible collapsed"<br />
|-<br />
!colspan="5"| Nonhydroxy fatty acid (adjusted GC peak %)<br />
!colspan="3"| Hydroxy fatty acid<br />
|-<br />
! fatty acid || Ceramide || Sphingomyelin || Cerebroside || Sulfatide || fatty acid || Cerebroside || Sulfatide<br />
|-<br />
|12:0<br />
|colspan="4"| - || 12h:0 || 0.4 || 0.3<br />
|-<br />
|13:0<br />
|colspan="4"| - || 13h:0 || 0.2 || 0.2<br />
|-<br />
| 14:0 || 0.6 || 0.3 || 0.2 || 0.8 || 14h:0 || 0.8 || 3.9<br />
|-<br />
| 15:0 || 0.2 || 0.1 || tr. || 0.3 || 15h:0 || tr. || 0.3<br />
|-<br />
| 16:0 || 4.5 || 5.9 || 3.5 || 4.1 || 16h:0 || 0.1 || 0.7<br />
|-<br />
| 16:1 || 0.4 || tr. || 0.1 || 0.7 || 16h:1 || tr. || 1.7<br />
|-<br />
| 17:0 || tr. || 0.3 || tr. || tr. || 17h:0 || 0.2 || 0.9<br />
|-<br />
| 18:0 || 35.2 || 40.1 || 5.8 || 3.3 || 18h:0 || 16.2 || 12.3<br />
|-<br />
| 18:1 || 2.1 || 0.7 || 2.7 || 5.2 || 18h:1 || - || -<br />
|- <br />
| 19:0 || 0.1 || 0.1 || 0.2 || 0.3 || 19h:0 || 0.4 || 0.3<br />
|-<br />
| 20:0 || 1.0 || 0.4 || 0.6 || 0.3 || 20h:0 || 0.5 || 0.7<br />
|-<br />
| 20:1 || 0.5 || tr. || 0.3 || 0.4 || 20h:1 || - || -<br />
|-<br />
| 21:0 || tr. || tr. || - || - || 21h:1 || - || -<br />
|-<br />
| 22:0 || 3.3 || 3.5 || 3.6 || 3.5 || 22h:0 || 5.8 || 7.7<br />
|-<br />
| 22:1 || 0.5 || 0.6 || 0.6 || 0.6 || 22h:1 || - || -<br />
|-<br />
| 23:0 || 3.7 || 2.8 || 5.2 || 3.1 || 23h:0 || 8.9 || 6.5<br />
|-<br />
| 23:1 || 1.0 || 1.0 || 1.2 || 0.8 || 23h:1 || - || -<br />
|-<br />
| 24:0 || 9.8 || 10.7 || 17.4 || 17.8 || 24h:0 || 30.1 || 26.0<br />
|-<br />
| 24:1 || 18.4 || 24.6 || 39.3 || 39.5 || 24h:1 || 14.6 || 16.7<br />
|-<br />
| 25:0 || 1.4 || 1.5 || 3.6 || 2.2 || 25h:0 || 7.0 || 4.5<br />
|-<br />
| 25:1 || 3.0 || 3.3 || 6.2 || 5.2 || 25h:1 || 3.0 || 2.8<br />
|-<br />
| 26:0 || 2.3 || 0.6 || 1.7 || 2.3 || 26h:0 || 3.9 || 3.8<br />
|-<br />
| 26:1 || 3.6 || 2.6 || 7.6 || 8.5 || 26h:1 || 6.3 || 6.5<br />
|-<br />
| 27:0 || 2.9 || - || - || - || 27h:0 || - || -<br />
|-<br />
| 27:1 || 1.8 || - || tr. || - || 27h:1 || - || -<br />
|-<br />
|colspan="8"| From: O'Brien JS, Rouser G "The fatty acid composition of brain sphingolipids: sphingomyelin, ceramide, cerebroside, and cerebroside sulfate"J Lipid Res1964; 5:339-342.PMID 5873370 Per cent of FA of each column. No PUFA, trace amount of hydroxy FA in ceramide, no hydroxy FA in sphingomyelin. The total ratio of nonhydroxy to hydroxy acids in cerebroside and sulfatide were 42:58 and 77:23, respectively (77:13 in the original paper). Human brain has a similar composition.<br />
|}<br />
<br />
==Sphingolipids in All Kingdoms==<br />
<br />
{{:Category:ScientificClassification/LBSC}}<br />
<br />
==Biosynthesis==<br />
<br />
{{Twocolumn|<br />
In Mammalia, GlcCer is synthesized by ceramide glucosyltransferase (CGlcT) at the cytosolic membrane of the Golgi apparatus, and GalCer is synthesized by ceramide galactosyltransferase (CGalT) at the lumen of the endoplasmic reticulum (ER). These enzymes do not share any sequence similarity and CGlcT possesses its transmembrane region at the N-terminal (type III) whereas CGalT possesses it at the C-terminal (type I).<ref>Sprong H, Degroote S, Nilsson T, Kawakita M, Ishida N, van der Sluijs P, van Meer G "Association of the Golgi UDP-galactose transporter with UDP-galactose:ceramide galactosyltransferase allows UDP-galactose import in the endoplasmic reticulum" Mol Biol Cell. 2003;4:3482-93 PMID 12925779</ref><br />
|<br />
哺乳動物では、ゴルジ装置の細胞質側に局在するグルコシルセラミド合成酵素(CGlcT)によって GlcCer が、小胞体の内腔側に局在するガラクトシルセラミド合成酵素(CGalT)によって GalCer が作られます。これらの酵素は配列相同性が無く、CGlcT は膜貫通領域が N 末端側(III型酵素)、CGalT は C 末端側(I型酵素)です。<br />
}}<br />
<br />
{| class="wikitable" style="text-align:center"<br />
|-<br />
! <br />
! GlcCer || GalCer<br />
|-<br />
! Enzyme<br />
| CGlcT (EC 2.4.1.80)<br />
| CGalT (EC 2.4.1.45)<br />
|-<br />
! Reaction<br />
| Ceramide + UDP-glucose &rarr; GlcCer + UDP<br />
| Ceramide + UDP-galactose &rarr; GalCer + UDP<br />
|-<br />
! Location<br />
| '''Golgi (outside)''' &rarr; flipflop &rarr; Golgi (inside)<br />
| '''ER lumen'''<br />
|}<br />
<br />
{{Twocolumn|<br />
Since all glycolipid synthesizing enzymes (except for CGlcT and CGalT) reside at the lumen of the Golgi apparatus, GlcCer must be flip-flopped from the cytosolic side to the lumen by an eyzyme called flippase.<br />
To synthesize GalCer, UDP-galactose and ceramide must transport the ER membrane. UDP-galactose transporter 2 (UGT2) is considered to be responsible.<br />
<br />
GalT can also work on glycerolipid, and synthsizes sulfated glyceroglycolipid in mammalian testis, called seminolipid.<br />
|<br />
CGlcT, CGalT 以外の糖脂質合成酵素はゴルジ装置の内腔側にあり、GlcCer はゴルジ膜の細胞質側から内腔側にフリッパーゼと呼ばれる酵素で移動(フリップフロップ)します。GalCer の場合は、UDPガラクトースとセラミドが小胞体膜を通過します。UDPガラクトーストランスポータ2 (UGT2) が関与するようです。<br />
<br />
CGalTはグリセロ脂質にも作用し、精巣の硫酸化グリセロ糖脂質であるセミノリピドも合成します。<br />
}}<br />
<br />
<references/></div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Category:LBSC&diff=117162
Category:LBSC
2023-05-18T05:04:42Z
<p>Editor: /* Glucosylceramide (GlcCer) */</p>
<hr />
<div><font size="+2">Cerebroside</font><br />
{{LB/Header}}<br />
{{Hierarchy|{{PAGENAME}}}}<br />
{|<br />
|{{LBS/Cer|O-<b>Glucose</b>}} <b>GlcCer</b><br />
|{{LBS/Cer|O-<b>Galactose</b>}} <b>GalCer</b><br />
|-<br />
|colspan=2|<br />
{{Twocolumn|<br />
Monoglycosylceramides (or cerebrosides) are glycosphingolipids where a single sugar is attached to the ceramide structure. Especially, glucopyranose-attached Glucosylceramide (GlcCer) and galactopyranose-attached Galactosylceramide (GalCer) are widely observed in all kingdoms. Recently, &alpha;-linked GlcCer and GalCer were reported in mammalian natural killer T cells in trace amount<ref>Kain L et al. <i>Immunity</i> 41(4), 543-554, 2014</ref>.<br />
GlcCer and GalCer are not registered in LipidBank. Instead, we summarize their distribution with bibliographic references with species information.<br />
<br />
<references/><br />
|<br />
モノグリコシルセラミド (またはセレブロシド) はセラミドに糖が1個エステル結合したスフィンゴ糖脂質です。特にグルコース(ピラノース型)が&beta;結合したグルコシルセラミド (GlcCer) とガラクトース(ピラノース型)が&beta;結合したガラクトシルセラミド (GalCer) は生物界に広く分布します。データベース中には掲載せず、ここに解説と生物種ごとの報告例を掲載します。<br />
}}<br />
|}<br />
<br />
==Glucosylceramide (GlcCer)==<br />
<br />
{{Twocolumn|<br />
GlcCer is widely observed not only in Animal, Plant or Fungi kingdoms, but also in Protozoa Kingdom<ref>Tan RX, Chen JH. "The cerebrosides" Nat Prod Rep. 2003;20:509-34.PMID 14620845, Yu R.K. Yanagisawa M. Ariga T. Glycosphingolipid Structures,in Comprehensive Glycoscience Vol.1,pp. 73-122,doi 10.1016/B978-044451967-2/00003-9, Itonori S, Sugita M. Glycophylogenetic Aspects of Lower Animals. in Comprehensive Glycoscience Vol.3, pp. 253-84, doi 10.1016/B978-044451967-2/00050-7 (J.P. Kamerling, ed.) Elsevier, Oxford (UK). (2007)</ref>. Ceramide structures (hydrocarbon chain length, the number and position of double bonds, existence of hydroxy and other modification groups) may vary, and become complex especially in Plant and Fungi Kingdoms, and Protostomia <ref>Sphingoid base chain may terminate with an isopropyl group in spongia, annelida, echinodermata, and bacteria. Terminal isobutyl or sec-pentyl group has been found only in echinodermata. Methylated or cyclopropane-containing sphingoid base is found in spongia, echinodermata, protochordata, and fungi.</ref>.<br />
In Animal Kingdom, GlcCer is the basic structure for different derivative series such as Globo, Lacto, and Ganglio Series. In Protostomia, GlcCer is the major ceramide in its nerve tissue, e.g. shrimp brain <ref>Okamura N, Stoskopf M, Hendricks F, Kishimoto Y. "Phylogenetic dichotomy of nerve glycosphingolipids" Proc Natl Acad Sci, 1985 82:6779-6782 PMID 3863128 </ref>, and its amide-linked fatty acids do not contain hydroxy groups. GlcCer in plants contains many &alpha;-hydroxy fatty acids. In some cold-resistant plants &omega;9-unsaturated fatty acids are detected. In Mammalia (of Deuterostomia), GlcCer is major in the spleen, blood, and skin.<br />
<br />
Gaucher's disease is an inborn metabolic disorder in which GlcCer accumulates in the liver and spleen because of the deficiency of the enzyme glucocerebrosidase to dissociate glucose from the ceramide structure <ref> Brady RO, Kanfer JN, Shapiro D. "Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher's desease" Biochem Biophys Res Commun. 1965;18:221-5 PMID 14282020 </ref>.<br />
|<br />
'''GlcCer'''は系統発生的にみると動物の各組織に広く分布するだけでなく、植物界や菌界、原生生物界にも含まれます。セラミド構造(炭化水素の鎖長、二重結合の数と位置、水酸基の有無、修飾基の有無など)の組み合わせは多岐にわたり、特に植物界や菌界、旧口動物のセラミドは複雑です。動物界において、GlcCerはさまざまな糖鎖を持つ糖脂質の基本構造になり、グロボ系列、ラクト系列、ガングリオ系列などが生成されます。旧口(前口)動物の神経系にはGlcCerが多く含まれ(例えばエビ)、セラミド骨格の脂肪酸に水酸基を含みません。対して、植物は &alpha;-水酸化の脂肪酸が多く、耐冷性植物の一部からは &omega;9-不飽和の脂肪酸も見いだされます。後口動物の哺乳綱において、GlcCerは、脾臓、血液、皮膚などに多く含まれます。<br />
<br />
先天性代謝異常症であるゴーシェ (Gaucher) 病は、GlcCerを分解するグルコセレブロシダーゼが欠損し、肝臓や脾臓にGlcCerが蓄積して発症します。<br />
}}<br />
<br />
==Galactosylceramide (GalCer)==<br />
{{Twocolumn|<br />
GalCer has been observed in Eubacterial Domain, but not in Protozoa, Plant, or Fungi (except Ascomycota). It is widely observed in Animal Kingdom, but not in Ecdysozoa (cuticle-shedding animals) of Protostomia. Its ceramide structure differs widely as in GlcCer but not so complex as GlcCer in Plant and Fungi. GalCer is the basic structure for sulfatide (3-O-sulfogalactosylceramide or SM4) and Gala Series often found in Annelida (segmented worm). In Mammalia (of Deuterostomia), GalCer is major in the nerve tissue, especially myelin sheath, whose amido-linked fatty acids are hydroxylated at the C-2 position for more than 50%.<br />
<br />
Krabbe disease (globoid cell leukodystrophy) is an inborn metabolic disorder in which a small amount of psychosine (galactosylsphingosine, i.e., the lyso form of GalCer) induces demyelination because of the deficiency of the enzyme galactosylceramidase <ref>Suzuki K. "Globoid cell leukodystrophy (Krabbe's disease): update" J Child Neurol. 2003;18:595-603.PMID 14572137, Suzuki K. "Evolving concept of the pathogenesis of globoid cell leukodystrophy (Krabbe disease)" Proc Jpn Acad Ser B Phys Biol Sci 2003; 79:1-8</ref>. &alpha;-GalCer, found from Porifera (marine sponge), in which galactose is &alpha;-bonded to ceramide (not the usual &beta;-bond), uniquely binds to human or mouse NKT cells and is considered a potent anti-tumor agent.<ref>Kitamura H, Iwakabe K, Yahata T, Nishimura S, Ohta A, Ohmi Y, Sato M, Takeda K, Okumura K, Van Kaer L, Kawano T, Taniguchi M, Nishimura T. "The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells" J Exp Med. 1999; 5;189(7):1121-8. PMID 10190903 </ref><br />
|<br />
'''GalCer'''は真正細菌に存在しますが、原生生物界、植物界、菌界(子嚢菌を除く)では報告がありません。動物界に広く分布しますが旧口動物である脱皮動物には確認されていません。セラミド構造は、GlcCerと同様に多様ですが、植物や菌類のGlcCerほど複雑ではありません。GalCerはスルファチド (3-O-硫酸化ガラクトシルセラミドまたはSM4) や環形動物門に多く含まれるガラ系列の基本構造です。<br />
後口動物である哺乳綱では神経系、特にミエリン鞘にGalCerが多く含まれ、その脂肪酸の50%以上は、C2位が水酸化されています。<br />
<br />
クラッベ病(グロボイド細胞ロイコジストロフィー; GLD)はガラクトシルセラミダーゼの欠損により微量のサイコシン(ガラクトシルスフィンゴシン、つまり GalCer のリゾ体)が蓄積して脱髄(ミエリンの破壊)を起こす遺伝性疾患です。また、海綿動物門に発見された&alpha;-GalCerは、ガラクトースがセラミドに(通常の&beta;でなく)&alpha;結合しており、ヒトやマウスのNKT細胞に特異的に結合し抗腫瘍効果がみられます。<br />
}}<br />
<br />
<references/><br />
<br />
==Cerebrosides in Mammals==<br />
<br />
====Lipids in Heart Muscle====<br />
<br />
{| class="wikitable collapsible collapsed"<br />
|-<br />
! <br />
! Lipid (% wet weight)<br />
! Phospholipid (% dry weight)<br />
! Phosphatidylethanolamine<br/>PE (% dry weight)<br />
! Phosphatidylcholine<br/>PC (% dry weight)<br />
! Sphingomyelin (% dry weight)<br />
! '''Cerebroside''' (% dry weight)<br />
! Total cholesterol (% dry weight)<br />
|-<br />
! Human<br />
| 8.3<br />
| 6.3 - 7.5<br />
| 1.4 - 2.8<br />
| 3.3 - 5.7<br />
| 0.2 - 0.5<br />
| -<br />
| -<br />
|-<br />
! Cow<br />
| 3.1 - 19.5<br />
| 7.4 - 11.8<br />
| 5.3<br />
| 4<br />
| 0.5<br />
| 2<br />
| 0.4 (free)<br />
|-<br />
! Rat<br />
| 0.4 - 2.4<br />
| 5 - 8<br />
| 0.84 (% wet)<br />
| 2 (% wet)<br />
| 0.14 (% wet)<br />
| 1.4<br />
| 0.4 - 0.6<br />
|-<br />
|colspan="8"|生化学データブック[I] 14. 臓器・組織の成分、心臓 脂質 p1636 1981 日本生化学会編 東京化学同人 ISBN 978-4-807901-74-6 <br />
|}<br />
<br />
====Lipids in Rat Testis====<br />
{| class="wikitable collapsible collapsed"<br />
|-<br />
! Fraction<br />
! Total Lipid (mg/mg protein)<br />
! Phosphate (ug/mg protein)<br />
! Phospholipid<br/>(% total lipid)<br />
! Neutral Lipid<br/>(% total lipid)<br />
! '''Cerebroside''' (% total lipid)<br />
! Sulfated glycolipid<br/>(nmol/g total weight)<br />
|-<br />
! Total testis<br />
| 0.40<br />
| 62.88<br />
| 62.9<br />
| 34.6<br />
| 2.5<br />
| 556 &plusmn; 34<br />
|-<br />
! Golgi<br />
| 1.26<br />
| 18.49<br />
| 58.3<br />
| 39.4<br />
| 2.3<br />
| -<br />
|-<br />
! Remnant granule<br />
| 0.60<br />
| 19.67<br />
| 29.5<br />
| 68.0<br />
| 2.5<br />
| -<br />
|-<br />
! Microsome<br />
| 0.63<br />
| 53.21<br />
| 83.8<br />
| 14.5<br />
| 1.7<br />
| -<br />
|-<br />
! Lipid corpuscle<br />
| > 19<br />
| 12<br />
| 1.5<br />
| 98.5<br />
| -<br />
| -<br />
|-<br />
|colspan="7"| Keenan TW et al. "Lipid composition of subcellular fractions from rat testis"Biochim Biophys Acta 1972; 270:433-443, PMID 4340988 Suzuki A et al. "Decrease of seminolipid content in the testes of rats with vitamin A deficiency determined by high performance liquid chromatography"J Biochem 1977; 82:461-7 PMID 91479 <br />
|}<br />
<br />
====Cerebroside and Sulfatide Ratio in Animal Brain ====<br />
<br />
{| class="wikitable sortable collapsible collapsed"<br />
|-<br />
! Animal<br />
! Kerasin<br/>(GalCer with straight fatty-acyl chain)<br />
! Phrenosin<br/>(GalCer with hydroxy fatty-acyl chain)<br />
! Sulfatide<br />
|-<br />
! Human cinerea (gray matter)<br />
| 25<br />
| 52<br />
| 23<br />
|-<br />
! Human alba (white matter)<br />
| 28<br />
| 47<br />
| 25<br />
|-<br />
! Cow cinerea<br />
| 15<br />
| 56<br />
| 29<br />
|-<br />
! Cow alba<br />
| 35<br />
| 48<br />
| 17<br />
|-<br />
! Dog<br />
| 21<br />
| 57<br />
| 22<br />
|-<br />
! Cat<br />
| 21<br />
| 60<br />
| 19<br />
|-<br />
! Mouse (4 weeks)<br />
| 24<br />
| 56<br />
| 20<br />
|-<br />
! Rat (10 days)<br />
| 35<br />
| 42<br />
| 23<br />
|-<br />
! Rat (35 days)<br />
| 21<br />
| 61<br />
| 18<br />
|-<br />
! Rabbit<br />
| 13<br />
| 66<br />
| 21<br />
|-<br />
! Guinea pig<br />
| 28<br />
| 54<br />
| 18<br />
|-<br />
! Sheep<br />
| 27<br />
| 47<br />
| 26<br />
|-<br />
! Chicken<br />
| 44<br />
| 37<br />
| 19<br />
|-<br />
! Tuna<br />
| 50<br />
| 25<br />
| 25<br />
|-<br />
! Shark<br />
| 44<br />
| 24<br />
| 32<br />
|-<br />
| colspan="4" | (weight %) From: Yamakawa T, Nishimura S. "Cerebroside composition in animal brain" Jpn J Exp 1966; 36:101-2 PMID 5297247 <br />
|}<br />
<br />
====Fatty acid composition of bovine brains====<br />
<br />
{| class="wikitable sortable collapsible collapsed"<br />
|-<br />
!colspan="5"| Nonhydroxy fatty acid (adjusted GC peak %)<br />
!colspan="3"| Hydroxy fatty acid<br />
|-<br />
! fatty acid || Ceramide || Sphingomyelin || Cerebroside || Sulfatide || fatty acid || Cerebroside || Sulfatide<br />
|-<br />
|12:0<br />
|colspan="4"| - || 12h:0 || 0.4 || 0.3<br />
|-<br />
|13:0<br />
|colspan="4"| - || 13h:0 || 0.2 || 0.2<br />
|-<br />
| 14:0 || 0.6 || 0.3 || 0.2 || 0.8 || 14h:0 || 0.8 || 3.9<br />
|-<br />
| 15:0 || 0.2 || 0.1 || tr. || 0.3 || 15h:0 || tr. || 0.3<br />
|-<br />
| 16:0 || 4.5 || 5.9 || 3.5 || 4.1 || 16h:0 || 0.1 || 0.7<br />
|-<br />
| 16:1 || 0.4 || tr. || 0.1 || 0.7 || 16h:1 || tr. || 1.7<br />
|-<br />
| 17:0 || tr. || 0.3 || tr. || tr. || 17h:0 || 0.2 || 0.9<br />
|-<br />
| 18:0 || 35.2 || 40.1 || 5.8 || 3.3 || 18h:0 || 16.2 || 12.3<br />
|-<br />
| 18:1 || 2.1 || 0.7 || 2.7 || 5.2 || 18h:1 || - || -<br />
|- <br />
| 19:0 || 0.1 || 0.1 || 0.2 || 0.3 || 19h:0 || 0.4 || 0.3<br />
|-<br />
| 20:0 || 1.0 || 0.4 || 0.6 || 0.3 || 20h:0 || 0.5 || 0.7<br />
|-<br />
| 20:1 || 0.5 || tr. || 0.3 || 0.4 || 20h:1 || - || -<br />
|-<br />
| 21:0 || tr. || tr. || - || - || 21h:1 || - || -<br />
|-<br />
| 22:0 || 3.3 || 3.5 || 3.6 || 3.5 || 22h:0 || 5.8 || 7.7<br />
|-<br />
| 22:1 || 0.5 || 0.6 || 0.6 || 0.6 || 22h:1 || - || -<br />
|-<br />
| 23:0 || 3.7 || 2.8 || 5.2 || 3.1 || 23h:0 || 8.9 || 6.5<br />
|-<br />
| 23:1 || 1.0 || 1.0 || 1.2 || 0.8 || 23h:1 || - || -<br />
|-<br />
| 24:0 || 9.8 || 10.7 || 17.4 || 17.8 || 24h:0 || 30.1 || 26.0<br />
|-<br />
| 24:1 || 18.4 || 24.6 || 39.3 || 39.5 || 24h:1 || 14.6 || 16.7<br />
|-<br />
| 25:0 || 1.4 || 1.5 || 3.6 || 2.2 || 25h:0 || 7.0 || 4.5<br />
|-<br />
| 25:1 || 3.0 || 3.3 || 6.2 || 5.2 || 25h:1 || 3.0 || 2.8<br />
|-<br />
| 26:0 || 2.3 || 0.6 || 1.7 || 2.3 || 26h:0 || 3.9 || 3.8<br />
|-<br />
| 26:1 || 3.6 || 2.6 || 7.6 || 8.5 || 26h:1 || 6.3 || 6.5<br />
|-<br />
| 27:0 || 2.9 || - || - || - || 27h:0 || - || -<br />
|-<br />
| 27:1 || 1.8 || - || tr. || - || 27h:1 || - || -<br />
|-<br />
|colspan="8"| From: O'Brien JS, Rouser G "The fatty acid composition of brain sphingolipids: sphingomyelin, ceramide, cerebroside, and cerebroside sulfate"J Lipid Res1964; 5:339-342.PMID 5873370 Per cent of FA of each column. No PUFA, trace amount of hydroxy FA in ceramide, no hydroxy FA in sphingomyelin. The total ratio of nonhydroxy to hydroxy acids in cerebroside and sulfatide were 42:58 and 77:23, respectively (77:13 in the original paper). Human brain has a similar composition.<br />
|}<br />
<br />
==Sphingolipids in All Kingdoms==<br />
<br />
{{:Category:ScientificClassification/LBSC}}<br />
<br />
==Biosynthesis==<br />
<br />
{{Twocolumn|<br />
In Mammalia, GlcCer is synthesized by ceramide glucosyltransferase (CGlcT) at the cytosolic membrane of the Golgi apparatus, and GalCer is synthesized by ceramide galactosyltransferase (CGalT) at the lumen of the endoplasmic reticulum (ER). These enzymes do not share any sequence similarity and CGlcT possesses its transmembrane region at the N-terminal (type III) whereas CGalT possesses it at the C-terminal (type I).<ref>Sprong H, Degroote S, Nilsson T, Kawakita M, Ishida N, van der Sluijs P, van Meer G "Association of the Golgi UDP-galactose transporter with UDP-galactose:ceramide galactosyltransferase allows UDP-galactose import in the endoplasmic reticulum" Mol Biol Cell. 2003;4:3482-93 PMID 12925779</ref><br />
|<br />
哺乳動物では、ゴルジ装置の細胞質側に局在するグルコシルセラミド合成酵素(CGlcT)によって GlcCer が、小胞体の内腔側に局在するガラクトシルセラミド合成酵素(CGalT)によって GalCer が作られます。これらの酵素は配列相同性が無く、CGlcT は膜貫通領域が N 末端側(III型酵素)、CGalT は C 末端側(I型酵素)です。<br />
}}<br />
<br />
{| class="wikitable" style="text-align:center"<br />
|-<br />
! <br />
! GlcCer || GalCer<br />
|-<br />
! Enzyme<br />
| CGlcT (EC 2.4.1.80)<br />
| CGalT (EC 2.4.1.45)<br />
|-<br />
! Reaction<br />
| Ceramide + UDP-glucose &rarr; GlcCer + UDP<br />
| Ceramide + UDP-galactose &rarr; GalCer + UDP<br />
|-<br />
! Location<br />
| '''Golgi (outside)''' &rarr; flipflop &rarr; Golgi (inside)<br />
| '''ER lumen'''<br />
|}<br />
<br />
{{Twocolumn|<br />
Since all glycolipid synthesizing enzymes (except for CGlcT and CGalT) reside at the lumen of the Golgi apparatus, GlcCer must be flip-flopped from the cytosolic side to the lumen by an eyzyme called flippase.<br />
To synthesize GalCer, UDP-galactose and ceramide must transport the ER membrane. UDP-galactose transporter 2 (UGT2) is considered to be responsible.<br />
<br />
GalT can also work on glycerolipid, and synthsizes sulfated glyceroglycolipid in mammalian testis, called seminolipid.<br />
|<br />
CGlcT, CGalT 以外の糖脂質合成酵素はゴルジ装置の内腔側にあり、GlcCer はゴルジ膜の細胞質側から内腔側にフリッパーゼと呼ばれる酵素で移動(フリップフロップ)します。GalCer の場合は、UDPガラクトースとセラミドが小胞体膜を通過します。UDPガラクトーストランスポータ2 (UGT2) が関与するようです。<br />
<br />
CGalTはグリセロ脂質にも作用し、精巣の硫酸化グリセロ糖脂質であるセミノリピドも合成します。<br />
}}<br />
<br />
<references/></div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Category:LBSC&diff=117161
Category:LBSC
2023-05-18T05:01:02Z
<p>Editor: </p>
<hr />
<div><font size="+2">Cerebroside</font><br />
{{LB/Header}}<br />
{{Hierarchy|{{PAGENAME}}}}<br />
{|<br />
|{{LBS/Cer|O-<b>Glucose</b>}} <b>GlcCer</b><br />
|{{LBS/Cer|O-<b>Galactose</b>}} <b>GalCer</b><br />
|-<br />
|colspan=2|<br />
{{Twocolumn|<br />
Monoglycosylceramides (or cerebrosides) are glycosphingolipids where a single sugar is attached to the ceramide structure. Especially, glucopyranose-attached Glucosylceramide (GlcCer) and galactopyranose-attached Galactosylceramide (GalCer) are widely observed in all kingdoms. Recently, &alpha;-linked GlcCer and GalCer were reported in mammalian natural killer T cells in trace amount<ref>Kain L et al. <i>Immunity</i> 41(4), 543-554, 2014</ref>.<br />
GlcCer and GalCer are not registered in LipidBank. Instead, we summarize their distribution with bibliographic references with species information.<br />
<br />
<references/><br />
|<br />
モノグリコシルセラミド (またはセレブロシド) はセラミドに糖が1個エステル結合したスフィンゴ糖脂質です。特にグルコース(ピラノース型)が&beta;結合したグルコシルセラミド (GlcCer) とガラクトース(ピラノース型)が&beta;結合したガラクトシルセラミド (GalCer) は生物界に広く分布します。データベース中には掲載せず、ここに解説と生物種ごとの報告例を掲載します。<br />
}}<br />
|}<br />
<br />
==Glucosylceramide (GlcCer)==<br />
<br />
{{Twocolumn|<br />
GlcCer is widely observed not only in Animal, Plant or Fungi kingdoms, but also in Protozoa Kingdom<ref>Tan RX, Chen JH. "The cerebrosides" Nat Prod Rep. 2003;20:509-34.PMID 14620845, Yu R.K. Yanagisawa M. Ariga T. Glycosphingolipid Structures,in Comprehensive Glycoscience Vol.1,pp. 73-122,doi 10.1016/B978-044451967-2/00003-9, Itonori S, Sugita M. Glycophylogenetic Aspects of Lower Animals. in Comprehensive Glycoscience Vol.3, pp. 253-84, doi 10.1016/B978-044451967-2/00050-7 (J.P. Kamerling, ed.) Elsevier, Oxford (UK). (2007)</ref>. Ceramide structures (hydrocarbon chain length, the number and position of double bonds, existence of hydroxy and other modification groups) may vary, and become complex especially in Plant and Fungi Kingdoms, and Protostomia <ref>Sphingoid base chain may terminate with an isopropyl group in spongia, annelida, echinodermata, and bacteria. Terminal isobutyl or sec-pentyl group has been found only in echinodermata. Methylated or cyclopropane-containing sphingoid base is found in spongia, echinodermata, protochordata, and fungi.</ref>.<br />
In Animal Kingdom, GlcCer is the basic structure for different derivative series such as Globo, Lacto, and Ganglio Series. In Protostomia, GlcCer is the major ceramide in its nerve tissue, e.g. shrimp brain <ref>Okamura N, Stoskopf M, Hendricks F, Kishimoto Y. "Phylogenetic dichotomy of nerve glycosphingolipids" Proc Natl Acad Sci, 1985 82:6779-6782 PMID 3863128 </ref>, and its amide-linked fatty acids do not contain hydroxy groups. GlcCer in plants contains many &alpha;-hydroxy fatty acids. In some cold-resistant plants &omega;9-unsaturated fatty acids are detected. In Mammalia (of Deuterostomia), GlcCer is major in the spleen, blood, and skin.<br />
<br />
Gaucher's disease is an inborn metabolic disorder in which GlcCer accumulates in the liver and spleen because of the deficiency of the enzyme glucocerebrosidase to dissociate glucose from the ceramide structure <ref> Brady RO, Kanfer JN, Shapiro D. "Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher's desease" Biochem Biophys Res Commun. 1965;18:221-5 PMID 14282020 </ref>.<br />
|<br />
'''GlcCer'''は系統発生的にみると動物の各組織に広く分布するだけでなく、植物界や菌界、原生生物界にも含まれます。セラミド構造(炭化水素の鎖長、二重結合の数と位置、水酸基の有無、修飾基の有無など)の組み合わせは多岐にわたり、特に植物界や菌界、旧口動物のセラミドは複雑です。動物界において、GlcCerはさまざまな糖鎖を持つ糖脂質の基本構造になり、グロボ系列、ラクト系列、ガングリオ系列などが生成されます。旧口(前口)動物の神経系にはGlcCerが多く含まれ(例えばエビ)、セラミド骨格の脂肪酸に水酸基を含みません。対して、植物は &alpha;-水酸化の脂肪酸が多く、耐冷性植物の一部からは &omega;9-不飽和の脂肪酸も見だされています。後口動物の哺乳綱において、GlcCerは、脾臓、血液、皮膚などに多く含まれます。<br />
<br />
先天性代謝異常症であるゴーシェ (Gaucher) 病は、GlcCerを分解するグルコセレブロシダーゼが欠損し、肝臓や脾臓にGlcCerが蓄積して発症します。<br />
}}<br />
<br />
==Galactosylceramide (GalCer)==<br />
{{Twocolumn|<br />
GalCer has been observed in Eubacterial Domain, but not in Protozoa, Plant, or Fungi (except Ascomycota). It is widely observed in Animal Kingdom, but not in Ecdysozoa (cuticle-shedding animals) of Protostomia. Its ceramide structure differs widely as in GlcCer but not so complex as GlcCer in Plant and Fungi. GalCer is the basic structure for sulfatide (3-O-sulfogalactosylceramide or SM4) and Gala Series often found in Annelida (segmented worm). In Mammalia (of Deuterostomia), GalCer is major in the nerve tissue, especially myelin sheath, whose amido-linked fatty acids are hydroxylated at the C-2 position for more than 50%.<br />
<br />
Krabbe disease (globoid cell leukodystrophy) is an inborn metabolic disorder in which a small amount of psychosine (galactosylsphingosine, i.e., the lyso form of GalCer) induces demyelination because of the deficiency of the enzyme galactosylceramidase <ref>Suzuki K. "Globoid cell leukodystrophy (Krabbe's disease): update" J Child Neurol. 2003;18:595-603.PMID 14572137, Suzuki K. "Evolving concept of the pathogenesis of globoid cell leukodystrophy (Krabbe disease)" Proc Jpn Acad Ser B Phys Biol Sci 2003; 79:1-8</ref>. &alpha;-GalCer, found from Porifera (marine sponge), in which galactose is &alpha;-bonded to ceramide (not the usual &beta;-bond), uniquely binds to human or mouse NKT cells and is considered a potent anti-tumor agent.<ref>Kitamura H, Iwakabe K, Yahata T, Nishimura S, Ohta A, Ohmi Y, Sato M, Takeda K, Okumura K, Van Kaer L, Kawano T, Taniguchi M, Nishimura T. "The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells" J Exp Med. 1999; 5;189(7):1121-8. PMID 10190903 </ref><br />
|<br />
'''GalCer'''は真正細菌に存在しますが、原生生物界、植物界、菌界(子嚢菌を除く)では報告がありません。動物界に広く分布しますが旧口動物である脱皮動物には確認されていません。セラミド構造は、GlcCerと同様に多様ですが、植物や菌類のGlcCerほど複雑ではありません。GalCerはスルファチド (3-O-硫酸化ガラクトシルセラミドまたはSM4) や環形動物門に多く含まれるガラ系列の基本構造です。<br />
後口動物である哺乳綱では神経系、特にミエリン鞘にGalCerが多く含まれ、その脂肪酸の50%以上は、C2位が水酸化されています。<br />
<br />
クラッベ病(グロボイド細胞ロイコジストロフィー; GLD)はガラクトシルセラミダーゼの欠損により微量のサイコシン(ガラクトシルスフィンゴシン、つまり GalCer のリゾ体)が蓄積して脱髄(ミエリンの破壊)を起こす遺伝性疾患です。また、海綿動物門に発見された&alpha;-GalCerは、ガラクトースがセラミドに(通常の&beta;でなく)&alpha;結合しており、ヒトやマウスのNKT細胞に特異的に結合し抗腫瘍効果がみられます。<br />
}}<br />
<br />
<references/><br />
<br />
==Cerebrosides in Mammals==<br />
<br />
====Lipids in Heart Muscle====<br />
<br />
{| class="wikitable collapsible collapsed"<br />
|-<br />
! <br />
! Lipid (% wet weight)<br />
! Phospholipid (% dry weight)<br />
! Phosphatidylethanolamine<br/>PE (% dry weight)<br />
! Phosphatidylcholine<br/>PC (% dry weight)<br />
! Sphingomyelin (% dry weight)<br />
! '''Cerebroside''' (% dry weight)<br />
! Total cholesterol (% dry weight)<br />
|-<br />
! Human<br />
| 8.3<br />
| 6.3 - 7.5<br />
| 1.4 - 2.8<br />
| 3.3 - 5.7<br />
| 0.2 - 0.5<br />
| -<br />
| -<br />
|-<br />
! Cow<br />
| 3.1 - 19.5<br />
| 7.4 - 11.8<br />
| 5.3<br />
| 4<br />
| 0.5<br />
| 2<br />
| 0.4 (free)<br />
|-<br />
! Rat<br />
| 0.4 - 2.4<br />
| 5 - 8<br />
| 0.84 (% wet)<br />
| 2 (% wet)<br />
| 0.14 (% wet)<br />
| 1.4<br />
| 0.4 - 0.6<br />
|-<br />
|colspan="8"|生化学データブック[I] 14. 臓器・組織の成分、心臓 脂質 p1636 1981 日本生化学会編 東京化学同人 ISBN 978-4-807901-74-6 <br />
|}<br />
<br />
====Lipids in Rat Testis====<br />
{| class="wikitable collapsible collapsed"<br />
|-<br />
! Fraction<br />
! Total Lipid (mg/mg protein)<br />
! Phosphate (ug/mg protein)<br />
! Phospholipid<br/>(% total lipid)<br />
! Neutral Lipid<br/>(% total lipid)<br />
! '''Cerebroside''' (% total lipid)<br />
! Sulfated glycolipid<br/>(nmol/g total weight)<br />
|-<br />
! Total testis<br />
| 0.40<br />
| 62.88<br />
| 62.9<br />
| 34.6<br />
| 2.5<br />
| 556 &plusmn; 34<br />
|-<br />
! Golgi<br />
| 1.26<br />
| 18.49<br />
| 58.3<br />
| 39.4<br />
| 2.3<br />
| -<br />
|-<br />
! Remnant granule<br />
| 0.60<br />
| 19.67<br />
| 29.5<br />
| 68.0<br />
| 2.5<br />
| -<br />
|-<br />
! Microsome<br />
| 0.63<br />
| 53.21<br />
| 83.8<br />
| 14.5<br />
| 1.7<br />
| -<br />
|-<br />
! Lipid corpuscle<br />
| > 19<br />
| 12<br />
| 1.5<br />
| 98.5<br />
| -<br />
| -<br />
|-<br />
|colspan="7"| Keenan TW et al. "Lipid composition of subcellular fractions from rat testis"Biochim Biophys Acta 1972; 270:433-443, PMID 4340988 Suzuki A et al. "Decrease of seminolipid content in the testes of rats with vitamin A deficiency determined by high performance liquid chromatography"J Biochem 1977; 82:461-7 PMID 91479 <br />
|}<br />
<br />
====Cerebroside and Sulfatide Ratio in Animal Brain ====<br />
<br />
{| class="wikitable sortable collapsible collapsed"<br />
|-<br />
! Animal<br />
! Kerasin<br/>(GalCer with straight fatty-acyl chain)<br />
! Phrenosin<br/>(GalCer with hydroxy fatty-acyl chain)<br />
! Sulfatide<br />
|-<br />
! Human cinerea (gray matter)<br />
| 25<br />
| 52<br />
| 23<br />
|-<br />
! Human alba (white matter)<br />
| 28<br />
| 47<br />
| 25<br />
|-<br />
! Cow cinerea<br />
| 15<br />
| 56<br />
| 29<br />
|-<br />
! Cow alba<br />
| 35<br />
| 48<br />
| 17<br />
|-<br />
! Dog<br />
| 21<br />
| 57<br />
| 22<br />
|-<br />
! Cat<br />
| 21<br />
| 60<br />
| 19<br />
|-<br />
! Mouse (4 weeks)<br />
| 24<br />
| 56<br />
| 20<br />
|-<br />
! Rat (10 days)<br />
| 35<br />
| 42<br />
| 23<br />
|-<br />
! Rat (35 days)<br />
| 21<br />
| 61<br />
| 18<br />
|-<br />
! Rabbit<br />
| 13<br />
| 66<br />
| 21<br />
|-<br />
! Guinea pig<br />
| 28<br />
| 54<br />
| 18<br />
|-<br />
! Sheep<br />
| 27<br />
| 47<br />
| 26<br />
|-<br />
! Chicken<br />
| 44<br />
| 37<br />
| 19<br />
|-<br />
! Tuna<br />
| 50<br />
| 25<br />
| 25<br />
|-<br />
! Shark<br />
| 44<br />
| 24<br />
| 32<br />
|-<br />
| colspan="4" | (weight %) From: Yamakawa T, Nishimura S. "Cerebroside composition in animal brain" Jpn J Exp 1966; 36:101-2 PMID 5297247 <br />
|}<br />
<br />
====Fatty acid composition of bovine brains====<br />
<br />
{| class="wikitable sortable collapsible collapsed"<br />
|-<br />
!colspan="5"| Nonhydroxy fatty acid (adjusted GC peak %)<br />
!colspan="3"| Hydroxy fatty acid<br />
|-<br />
! fatty acid || Ceramide || Sphingomyelin || Cerebroside || Sulfatide || fatty acid || Cerebroside || Sulfatide<br />
|-<br />
|12:0<br />
|colspan="4"| - || 12h:0 || 0.4 || 0.3<br />
|-<br />
|13:0<br />
|colspan="4"| - || 13h:0 || 0.2 || 0.2<br />
|-<br />
| 14:0 || 0.6 || 0.3 || 0.2 || 0.8 || 14h:0 || 0.8 || 3.9<br />
|-<br />
| 15:0 || 0.2 || 0.1 || tr. || 0.3 || 15h:0 || tr. || 0.3<br />
|-<br />
| 16:0 || 4.5 || 5.9 || 3.5 || 4.1 || 16h:0 || 0.1 || 0.7<br />
|-<br />
| 16:1 || 0.4 || tr. || 0.1 || 0.7 || 16h:1 || tr. || 1.7<br />
|-<br />
| 17:0 || tr. || 0.3 || tr. || tr. || 17h:0 || 0.2 || 0.9<br />
|-<br />
| 18:0 || 35.2 || 40.1 || 5.8 || 3.3 || 18h:0 || 16.2 || 12.3<br />
|-<br />
| 18:1 || 2.1 || 0.7 || 2.7 || 5.2 || 18h:1 || - || -<br />
|- <br />
| 19:0 || 0.1 || 0.1 || 0.2 || 0.3 || 19h:0 || 0.4 || 0.3<br />
|-<br />
| 20:0 || 1.0 || 0.4 || 0.6 || 0.3 || 20h:0 || 0.5 || 0.7<br />
|-<br />
| 20:1 || 0.5 || tr. || 0.3 || 0.4 || 20h:1 || - || -<br />
|-<br />
| 21:0 || tr. || tr. || - || - || 21h:1 || - || -<br />
|-<br />
| 22:0 || 3.3 || 3.5 || 3.6 || 3.5 || 22h:0 || 5.8 || 7.7<br />
|-<br />
| 22:1 || 0.5 || 0.6 || 0.6 || 0.6 || 22h:1 || - || -<br />
|-<br />
| 23:0 || 3.7 || 2.8 || 5.2 || 3.1 || 23h:0 || 8.9 || 6.5<br />
|-<br />
| 23:1 || 1.0 || 1.0 || 1.2 || 0.8 || 23h:1 || - || -<br />
|-<br />
| 24:0 || 9.8 || 10.7 || 17.4 || 17.8 || 24h:0 || 30.1 || 26.0<br />
|-<br />
| 24:1 || 18.4 || 24.6 || 39.3 || 39.5 || 24h:1 || 14.6 || 16.7<br />
|-<br />
| 25:0 || 1.4 || 1.5 || 3.6 || 2.2 || 25h:0 || 7.0 || 4.5<br />
|-<br />
| 25:1 || 3.0 || 3.3 || 6.2 || 5.2 || 25h:1 || 3.0 || 2.8<br />
|-<br />
| 26:0 || 2.3 || 0.6 || 1.7 || 2.3 || 26h:0 || 3.9 || 3.8<br />
|-<br />
| 26:1 || 3.6 || 2.6 || 7.6 || 8.5 || 26h:1 || 6.3 || 6.5<br />
|-<br />
| 27:0 || 2.9 || - || - || - || 27h:0 || - || -<br />
|-<br />
| 27:1 || 1.8 || - || tr. || - || 27h:1 || - || -<br />
|-<br />
|colspan="8"| From: O'Brien JS, Rouser G "The fatty acid composition of brain sphingolipids: sphingomyelin, ceramide, cerebroside, and cerebroside sulfate"J Lipid Res1964; 5:339-342.PMID 5873370 Per cent of FA of each column. No PUFA, trace amount of hydroxy FA in ceramide, no hydroxy FA in sphingomyelin. The total ratio of nonhydroxy to hydroxy acids in cerebroside and sulfatide were 42:58 and 77:23, respectively (77:13 in the original paper). Human brain has a similar composition.<br />
|}<br />
<br />
==Sphingolipids in All Kingdoms==<br />
<br />
{{:Category:ScientificClassification/LBSC}}<br />
<br />
==Biosynthesis==<br />
<br />
{{Twocolumn|<br />
In Mammalia, GlcCer is synthesized by ceramide glucosyltransferase (CGlcT) at the cytosolic membrane of the Golgi apparatus, and GalCer is synthesized by ceramide galactosyltransferase (CGalT) at the lumen of the endoplasmic reticulum (ER). These enzymes do not share any sequence similarity and CGlcT possesses its transmembrane region at the N-terminal (type III) whereas CGalT possesses it at the C-terminal (type I).<ref>Sprong H, Degroote S, Nilsson T, Kawakita M, Ishida N, van der Sluijs P, van Meer G "Association of the Golgi UDP-galactose transporter with UDP-galactose:ceramide galactosyltransferase allows UDP-galactose import in the endoplasmic reticulum" Mol Biol Cell. 2003;4:3482-93 PMID 12925779</ref><br />
|<br />
哺乳動物では、ゴルジ装置の細胞質側に局在するグルコシルセラミド合成酵素(CGlcT)によって GlcCer が、小胞体の内腔側に局在するガラクトシルセラミド合成酵素(CGalT)によって GalCer が作られます。これらの酵素は配列相同性が無く、CGlcT は膜貫通領域が N 末端側(III型酵素)、CGalT は C 末端側(I型酵素)です。<br />
}}<br />
<br />
{| class="wikitable" style="text-align:center"<br />
|-<br />
! <br />
! GlcCer || GalCer<br />
|-<br />
! Enzyme<br />
| CGlcT (EC 2.4.1.80)<br />
| CGalT (EC 2.4.1.45)<br />
|-<br />
! Reaction<br />
| Ceramide + UDP-glucose &rarr; GlcCer + UDP<br />
| Ceramide + UDP-galactose &rarr; GalCer + UDP<br />
|-<br />
! Location<br />
| '''Golgi (outside)''' &rarr; flipflop &rarr; Golgi (inside)<br />
| '''ER lumen'''<br />
|}<br />
<br />
{{Twocolumn|<br />
Since all glycolipid synthesizing enzymes (except for CGlcT and CGalT) reside at the lumen of the Golgi apparatus, GlcCer must be flip-flopped from the cytosolic side to the lumen by an eyzyme called flippase.<br />
To synthesize GalCer, UDP-galactose and ceramide must transport the ER membrane. UDP-galactose transporter 2 (UGT2) is considered to be responsible.<br />
<br />
GalT can also work on glycerolipid, and synthsizes sulfated glyceroglycolipid in mammalian testis, called seminolipid.<br />
|<br />
CGlcT, CGalT 以外の糖脂質合成酵素はゴルジ装置の内腔側にあり、GlcCer はゴルジ膜の細胞質側から内腔側にフリッパーゼと呼ばれる酵素で移動(フリップフロップ)します。GalCer の場合は、UDPガラクトースとセラミドが小胞体膜を通過します。UDPガラクトーストランスポータ2 (UGT2) が関与するようです。<br />
<br />
CGalTはグリセロ脂質にも作用し、精巣の硫酸化グリセロ糖脂質であるセミノリピドも合成します。<br />
}}<br />
<br />
<references/></div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Category:LBSC&diff=117160
Category:LBSC
2023-05-18T04:54:24Z
<p>Editor: </p>
<hr />
<div><font size="+2">Cerebroside</font><br />
{{LB/Header}}<br />
{{Hierarchy|{{PAGENAME}}}}<br />
{|<br />
|{{LBS/Cer|O-<b>Glucose</b>}} <b>GlcCer</b><br />
|{{LBS/Cer|O-<b>Galactose</b>}} <b>GalCer</b><br />
|-<br />
|colspan=2|<br />
{{Twocolumn|<br />
Monoglycosylceramides (or cerebrosides) are glycosphingolipids where a single sugar is attached to the ceramide structure. Especially, glucopyranose-attached Glucosylceramide (GlcCer) and galactopyranose-attached Galactosylceramide (GalCer) are widely observed in all kingdoms. These ubiquitous molecules are not registered in LipidBank. Instead, we summarize their distribution with bibliographic references with species information.<br />
|<br />
モノグリコシルセラミド (またはセレブロシド) はセラミドに糖が1個エステル結合したスフィンゴ糖脂質です。特にグルコース(ピラノース型)が&beta;結合したグルコシルセラミド (GlcCer) とガラクトース(ピラノース型)が&beta;結合したガラクトシルセラミド (GalCer) は生物界に広く分布します。データベース中には掲載せず、ここに解説と生物種ごとの報告例を掲載します。<br />
}}<br />
|}<br />
<br />
==Glucosylceramide (GlcCer)==<br />
<br />
{{Twocolumn|<br />
GlcCer is widely observed not only in Animal, Plant or Fungi kingdoms, but also in Protozoa Kingdom<ref>Tan RX, Chen JH. "The cerebrosides" Nat Prod Rep. 2003;20:509-34.PMID 14620845, Yu R.K. Yanagisawa M. Ariga T. Glycosphingolipid Structures,in Comprehensive Glycoscience Vol.1,pp. 73-122,doi 10.1016/B978-044451967-2/00003-9, Itonori S, Sugita M. Glycophylogenetic Aspects of Lower Animals. in Comprehensive Glycoscience Vol.3, pp. 253-84, doi 10.1016/B978-044451967-2/00050-7 (J.P. Kamerling, ed.) Elsevier, Oxford (UK). (2007)</ref>. Ceramide structures (hydrocarbon chain length, the number and position of double bonds, existence of hydroxy and other modification groups) may vary, and become complex especially in Plant and Fungi Kingdoms, and Protostomia <ref>Sphingoid base chain may terminate with an isopropyl group in spongia, annelida, echinodermata, and bacteria. Terminal isobutyl or sec-pentyl group has been found only in echinodermata. Methylated or cyclopropane-containing sphingoid base is found in spongia, echinodermata, protochordata, and fungi.</ref>.<br />
In Animal Kingdom, GlcCer is the basic structure for different derivative series such as Globo, Lacto, and Ganglio Series. In Protostomia, GlcCer is the major ceramide in its nerve tissue, e.g. shrimp brain <ref>Okamura N, Stoskopf M, Hendricks F, Kishimoto Y. "Phylogenetic dichotomy of nerve glycosphingolipids" Proc Natl Acad Sci, 1985 82:6779-6782 PMID 3863128 </ref>, and its amide-linked fatty acids do not contain hydroxy groups. GlcCer in plants contains many &alpha;-hydroxy fatty acids. In some cold-resistant plants &omega;9-unsaturated fatty acids are detected. In Mammalia (of Deuterostomia), GlcCer is major in the spleen, blood, and skin.<br />
<br />
Gaucher's disease is an inborn metabolic disorder in which GlcCer accumulates in the liver and spleen because of the deficiency of the enzyme glucocerebrosidase to dissociate glucose from the ceramide structure <ref> Brady RO, Kanfer JN, Shapiro D. "Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher's desease" Biochem Biophys Res Commun. 1965;18:221-5 PMID 14282020 </ref>.<br />
|<br />
'''GlcCer'''は系統発生的にみると動物の各組織に広く分布するだけでなく、植物界や菌界、原生生物界にも含まれます。セラミド構造(炭化水素の鎖長、二重結合の数と位置、水酸基の有無、修飾基の有無など)の組み合わせは多岐にわたり、特に植物界や菌界、旧口動物のセラミドは複雑です。動物界において、GlcCerはさまざまな糖鎖を持つ糖脂質の基本構造になり、グロボ系列、ラクト系列、ガングリオ系列などが生成されます。旧口(前口)動物の神経系にはGlcCerが多く含まれ(例えばエビ)、セラミド骨格の脂肪酸に水酸基を含みません。対して、植物は &alpha;-水酸化の脂肪酸が多く、耐冷性植物の一部からは &omega;9-不飽和の脂肪酸も見だされています。後口動物の哺乳綱において、GlcCerは、脾臓、血液、皮膚などに多く含まれます。<br />
<br />
先天性代謝異常症であるゴーシェ (Gaucher) 病は、GlcCerを分解するグルコセレブロシダーゼが欠損し、肝臓や脾臓にGlcCerが蓄積して発症します。<br />
}}<br />
<br />
==Galactosylceramide (GalCer)==<br />
{{Twocolumn|<br />
GalCer has been observed in Eubacterial Domain, but not in Protozoa, Plant, or Fungi (except Ascomycota). It is widely observed in Animal Kingdom, but not in Ecdysozoa (cuticle-shedding animals) of Protostomia. Its ceramide structure differs widely as in GlcCer but not so complex as GlcCer in Plant and Fungi. GalCer is the basic structure for sulfatide (3-O-sulfogalactosylceramide or SM4) and Gala Series often found in Annelida (segmented worm). In Mammalia (of Deuterostomia), GalCer is major in the nerve tissue, especially myelin sheath, whose amido-linked fatty acids are hydroxylated at the C-2 position for more than 50%.<br />
<br />
Krabbe disease (globoid cell leukodystrophy) is an inborn metabolic disorder in which a small amount of psychosine (galactosylsphingosine, i.e., the lyso form of GalCer) induces demyelination because of the deficiency of the enzyme galactosylceramidase <ref>Suzuki K. "Globoid cell leukodystrophy (Krabbe's disease): update" J Child Neurol. 2003;18:595-603.PMID 14572137, Suzuki K. "Evolving concept of the pathogenesis of globoid cell leukodystrophy (Krabbe disease)" Proc Jpn Acad Ser B Phys Biol Sci 2003; 79:1-8</ref>. &alpha;-GalCer, found from Porifera (marine sponge), in which galactose is &alpha;-bonded to ceramide (not the usual &beta;-bond), uniquely binds to human or mouse NKT cells and is considered a potent anti-tumor agent.<ref>Kitamura H, Iwakabe K, Yahata T, Nishimura S, Ohta A, Ohmi Y, Sato M, Takeda K, Okumura K, Van Kaer L, Kawano T, Taniguchi M, Nishimura T. "The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells" J Exp Med. 1999; 5;189(7):1121-8. PMID 10190903 </ref><br />
|<br />
'''GalCer'''は真正細菌に存在しますが、原生生物界、植物界、菌界(子嚢菌を除く)では報告がありません。動物界に広く分布しますが旧口動物である脱皮動物には確認されていません。セラミド構造は、GlcCerと同様に多様ですが、植物や菌類のGlcCerほど複雑ではありません。GalCerはスルファチド (3-O-硫酸化ガラクトシルセラミドまたはSM4) や環形動物門に多く含まれるガラ系列の基本構造です。<br />
後口動物である哺乳綱では神経系、特にミエリン鞘にGalCerが多く含まれ、その脂肪酸の50%以上は、C2位が水酸化されています。<br />
<br />
クラッベ病(グロボイド細胞ロイコジストロフィー; GLD)はガラクトシルセラミダーゼの欠損により微量のサイコシン(ガラクトシルスフィンゴシン、つまり GalCer のリゾ体)が蓄積して脱髄(ミエリンの破壊)を起こす遺伝性疾患です。また、海綿動物門に発見された&alpha;-GalCerは、ガラクトースがセラミドに(通常の&beta;でなく)&alpha;結合しており、ヒトやマウスのNKT細胞に特異的に結合し抗腫瘍効果がみられます。<br />
}}<br />
<br />
<references/><br />
<br />
==Cerebrosides in Mammals==<br />
<br />
====Lipids in Heart Muscle====<br />
<br />
{| class="wikitable collapsible collapsed"<br />
|-<br />
! <br />
! Lipid (% wet weight)<br />
! Phospholipid (% dry weight)<br />
! Phosphatidylethanolamine<br/>PE (% dry weight)<br />
! Phosphatidylcholine<br/>PC (% dry weight)<br />
! Sphingomyelin (% dry weight)<br />
! '''Cerebroside''' (% dry weight)<br />
! Total cholesterol (% dry weight)<br />
|-<br />
! Human<br />
| 8.3<br />
| 6.3 - 7.5<br />
| 1.4 - 2.8<br />
| 3.3 - 5.7<br />
| 0.2 - 0.5<br />
| -<br />
| -<br />
|-<br />
! Cow<br />
| 3.1 - 19.5<br />
| 7.4 - 11.8<br />
| 5.3<br />
| 4<br />
| 0.5<br />
| 2<br />
| 0.4 (free)<br />
|-<br />
! Rat<br />
| 0.4 - 2.4<br />
| 5 - 8<br />
| 0.84 (% wet)<br />
| 2 (% wet)<br />
| 0.14 (% wet)<br />
| 1.4<br />
| 0.4 - 0.6<br />
|-<br />
|colspan="8"|生化学データブック[I] 14. 臓器・組織の成分、心臓 脂質 p1636 1981 日本生化学会編 東京化学同人 ISBN 978-4-807901-74-6 <br />
|}<br />
<br />
====Lipids in Rat Testis====<br />
{| class="wikitable collapsible collapsed"<br />
|-<br />
! Fraction<br />
! Total Lipid (mg/mg protein)<br />
! Phosphate (ug/mg protein)<br />
! Phospholipid<br/>(% total lipid)<br />
! Neutral Lipid<br/>(% total lipid)<br />
! '''Cerebroside''' (% total lipid)<br />
! Sulfated glycolipid<br/>(nmol/g total weight)<br />
|-<br />
! Total testis<br />
| 0.40<br />
| 62.88<br />
| 62.9<br />
| 34.6<br />
| 2.5<br />
| 556 &plusmn; 34<br />
|-<br />
! Golgi<br />
| 1.26<br />
| 18.49<br />
| 58.3<br />
| 39.4<br />
| 2.3<br />
| -<br />
|-<br />
! Remnant granule<br />
| 0.60<br />
| 19.67<br />
| 29.5<br />
| 68.0<br />
| 2.5<br />
| -<br />
|-<br />
! Microsome<br />
| 0.63<br />
| 53.21<br />
| 83.8<br />
| 14.5<br />
| 1.7<br />
| -<br />
|-<br />
! Lipid corpuscle<br />
| > 19<br />
| 12<br />
| 1.5<br />
| 98.5<br />
| -<br />
| -<br />
|-<br />
|colspan="7"| Keenan TW et al. "Lipid composition of subcellular fractions from rat testis"Biochim Biophys Acta 1972; 270:433-443, PMID 4340988 Suzuki A et al. "Decrease of seminolipid content in the testes of rats with vitamin A deficiency determined by high performance liquid chromatography"J Biochem 1977; 82:461-7 PMID 91479 <br />
|}<br />
<br />
====Cerebroside and Sulfatide Ratio in Animal Brain ====<br />
<br />
{| class="wikitable sortable collapsible collapsed"<br />
|-<br />
! Animal<br />
! Kerasin<br/>(GalCer with straight fatty-acyl chain)<br />
! Phrenosin<br/>(GalCer with hydroxy fatty-acyl chain)<br />
! Sulfatide<br />
|-<br />
! Human cinerea (gray matter)<br />
| 25<br />
| 52<br />
| 23<br />
|-<br />
! Human alba (white matter)<br />
| 28<br />
| 47<br />
| 25<br />
|-<br />
! Cow cinerea<br />
| 15<br />
| 56<br />
| 29<br />
|-<br />
! Cow alba<br />
| 35<br />
| 48<br />
| 17<br />
|-<br />
! Dog<br />
| 21<br />
| 57<br />
| 22<br />
|-<br />
! Cat<br />
| 21<br />
| 60<br />
| 19<br />
|-<br />
! Mouse (4 weeks)<br />
| 24<br />
| 56<br />
| 20<br />
|-<br />
! Rat (10 days)<br />
| 35<br />
| 42<br />
| 23<br />
|-<br />
! Rat (35 days)<br />
| 21<br />
| 61<br />
| 18<br />
|-<br />
! Rabbit<br />
| 13<br />
| 66<br />
| 21<br />
|-<br />
! Guinea pig<br />
| 28<br />
| 54<br />
| 18<br />
|-<br />
! Sheep<br />
| 27<br />
| 47<br />
| 26<br />
|-<br />
! Chicken<br />
| 44<br />
| 37<br />
| 19<br />
|-<br />
! Tuna<br />
| 50<br />
| 25<br />
| 25<br />
|-<br />
! Shark<br />
| 44<br />
| 24<br />
| 32<br />
|-<br />
| colspan="4" | (weight %) From: Yamakawa T, Nishimura S. "Cerebroside composition in animal brain" Jpn J Exp 1966; 36:101-2 PMID 5297247 <br />
|}<br />
<br />
====Fatty acid composition of bovine brains====<br />
<br />
{| class="wikitable sortable collapsible collapsed"<br />
|-<br />
!colspan="5"| Nonhydroxy fatty acid (adjusted GC peak %)<br />
!colspan="3"| Hydroxy fatty acid<br />
|-<br />
! fatty acid || Ceramide || Sphingomyelin || Cerebroside || Sulfatide || fatty acid || Cerebroside || Sulfatide<br />
|-<br />
|12:0<br />
|colspan="4"| - || 12h:0 || 0.4 || 0.3<br />
|-<br />
|13:0<br />
|colspan="4"| - || 13h:0 || 0.2 || 0.2<br />
|-<br />
| 14:0 || 0.6 || 0.3 || 0.2 || 0.8 || 14h:0 || 0.8 || 3.9<br />
|-<br />
| 15:0 || 0.2 || 0.1 || tr. || 0.3 || 15h:0 || tr. || 0.3<br />
|-<br />
| 16:0 || 4.5 || 5.9 || 3.5 || 4.1 || 16h:0 || 0.1 || 0.7<br />
|-<br />
| 16:1 || 0.4 || tr. || 0.1 || 0.7 || 16h:1 || tr. || 1.7<br />
|-<br />
| 17:0 || tr. || 0.3 || tr. || tr. || 17h:0 || 0.2 || 0.9<br />
|-<br />
| 18:0 || 35.2 || 40.1 || 5.8 || 3.3 || 18h:0 || 16.2 || 12.3<br />
|-<br />
| 18:1 || 2.1 || 0.7 || 2.7 || 5.2 || 18h:1 || - || -<br />
|- <br />
| 19:0 || 0.1 || 0.1 || 0.2 || 0.3 || 19h:0 || 0.4 || 0.3<br />
|-<br />
| 20:0 || 1.0 || 0.4 || 0.6 || 0.3 || 20h:0 || 0.5 || 0.7<br />
|-<br />
| 20:1 || 0.5 || tr. || 0.3 || 0.4 || 20h:1 || - || -<br />
|-<br />
| 21:0 || tr. || tr. || - || - || 21h:1 || - || -<br />
|-<br />
| 22:0 || 3.3 || 3.5 || 3.6 || 3.5 || 22h:0 || 5.8 || 7.7<br />
|-<br />
| 22:1 || 0.5 || 0.6 || 0.6 || 0.6 || 22h:1 || - || -<br />
|-<br />
| 23:0 || 3.7 || 2.8 || 5.2 || 3.1 || 23h:0 || 8.9 || 6.5<br />
|-<br />
| 23:1 || 1.0 || 1.0 || 1.2 || 0.8 || 23h:1 || - || -<br />
|-<br />
| 24:0 || 9.8 || 10.7 || 17.4 || 17.8 || 24h:0 || 30.1 || 26.0<br />
|-<br />
| 24:1 || 18.4 || 24.6 || 39.3 || 39.5 || 24h:1 || 14.6 || 16.7<br />
|-<br />
| 25:0 || 1.4 || 1.5 || 3.6 || 2.2 || 25h:0 || 7.0 || 4.5<br />
|-<br />
| 25:1 || 3.0 || 3.3 || 6.2 || 5.2 || 25h:1 || 3.0 || 2.8<br />
|-<br />
| 26:0 || 2.3 || 0.6 || 1.7 || 2.3 || 26h:0 || 3.9 || 3.8<br />
|-<br />
| 26:1 || 3.6 || 2.6 || 7.6 || 8.5 || 26h:1 || 6.3 || 6.5<br />
|-<br />
| 27:0 || 2.9 || - || - || - || 27h:0 || - || -<br />
|-<br />
| 27:1 || 1.8 || - || tr. || - || 27h:1 || - || -<br />
|-<br />
|colspan="8"| From: O'Brien JS, Rouser G "The fatty acid composition of brain sphingolipids: sphingomyelin, ceramide, cerebroside, and cerebroside sulfate"J Lipid Res1964; 5:339-342.PMID 5873370 Per cent of FA of each column. No PUFA, trace amount of hydroxy FA in ceramide, no hydroxy FA in sphingomyelin. The total ratio of nonhydroxy to hydroxy acids in cerebroside and sulfatide were 42:58 and 77:23, respectively (77:13 in the original paper). Human brain has a similar composition.<br />
|}<br />
<br />
==Sphingolipids in All Kingdoms==<br />
<br />
{{:Category:ScientificClassification/LBSC}}<br />
<br />
==Biosynthesis==<br />
<br />
{{Twocolumn|<br />
In Mammalia, GlcCer is synthesized by ceramide glucosyltransferase (CGlcT) at the cytosolic membrane of the Golgi apparatus, and GalCer is synthesized by ceramide galactosyltransferase (CGalT) at the lumen of the endoplasmic reticulum (ER). These enzymes do not share any sequence similarity and CGlcT possesses its transmembrane region at the N-terminal (type III) whereas CGalT possesses it at the C-terminal (type I).<ref>Sprong H, Degroote S, Nilsson T, Kawakita M, Ishida N, van der Sluijs P, van Meer G "Association of the Golgi UDP-galactose transporter with UDP-galactose:ceramide galactosyltransferase allows UDP-galactose import in the endoplasmic reticulum" Mol Biol Cell. 2003;4:3482-93 PMID 12925779</ref><br />
|<br />
哺乳動物では、ゴルジ装置の細胞質側に局在するグルコシルセラミド合成酵素(CGlcT)によって GlcCer が、小胞体の内腔側に局在するガラクトシルセラミド合成酵素(CGalT)によって GalCer が作られます。これらの酵素は配列相同性が無く、CGlcT は膜貫通領域が N 末端側(III型酵素)、CGalT は C 末端側(I型酵素)です。<br />
}}<br />
<br />
{| class="wikitable" style="text-align:center"<br />
|-<br />
! <br />
! GlcCer || GalCer<br />
|-<br />
! Enzyme<br />
| CGlcT (EC 2.4.1.80)<br />
| CGalT (EC 2.4.1.45)<br />
|-<br />
! Reaction<br />
| Ceramide + UDP-glucose &rarr; GlcCer + UDP<br />
| Ceramide + UDP-galactose &rarr; GalCer + UDP<br />
|-<br />
! Location<br />
| '''Golgi (outside)''' &rarr; flipflop &rarr; Golgi (inside)<br />
| '''ER lumen'''<br />
|}<br />
<br />
{{Twocolumn|<br />
Since all glycolipid synthesizing enzymes (except for CGlcT and CGalT) reside at the lumen of the Golgi apparatus, GlcCer must be flip-flopped from the cytosolic side to the lumen by an eyzyme called flippase.<br />
To synthesize GalCer, UDP-galactose and ceramide must transport the ER membrane. UDP-galactose transporter 2 (UGT2) is considered to be responsible.<br />
<br />
GalT can also work on glycerolipid, and synthsizes sulfated glyceroglycolipid in mammalian testis, called seminolipid.<br />
|<br />
CGlcT, CGalT 以外の糖脂質合成酵素はゴルジ装置の内腔側にあり、GlcCer はゴルジ膜の細胞質側から内腔側にフリッパーゼと呼ばれる酵素で移動(フリップフロップ)します。GalCer の場合は、UDPガラクトースとセラミドが小胞体膜を通過します。UDPガラクトーストランスポータ2 (UGT2) が関与するようです。<br />
<br />
CGalTはグリセロ脂質にも作用し、精巣の硫酸化グリセロ糖脂質であるセミノリピドも合成します。<br />
}}<br />
<br />
<references/></div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Category:LBSC&diff=117159
Category:LBSC
2023-05-18T04:53:13Z
<p>Editor: </p>
<hr />
<div><font size="+2">Cerebroside</font><br />
{{LB/Header}}<br />
{{Hierarchy|{{PAGENAME}}}}<br />
{|<br />
|{{LBS/Cer|O-<b>Glucose</b>}} <b>GlcCer</b><br />
|{{LBS/Cer|O-<b>Galactose</b>}} <b>GalCer</b><br />
|-<br />
|colspan=2|<br />
{{Twocolumn|<br />
Monoglycosylceramides (or cerebrosides) are glycosphingolipids where a single sugar is attached to the ceramide structure. Especially, glucopyranose-attached Glucosylceramide (GlcCer) and galactopyranose-attached Galactosylceramide (GalCer) are widely observed in all kingdoms. These ubiquitous molecules are not registered in LipidBank. Instead, we summarize their distribution with bibliographic references with species information.<br />
|<br />
モノグリコシルセラミド (またはセレブロシド) はセラミドに糖が1個エステル結合したスフィンゴ糖脂質です。特にグルコース(ピラノース型)が&eta;結合したグルコシルセラミド (GlcCer) とガラクトース(ピラノース型)が&eta;結合したガラクトシルセラミド (GalCer) は生物界に広く分布します。データベース中には掲載せず、ここに解説と生物種ごとの報告例を掲載します。<br />
}}<br />
|}<br />
<br />
==Glucosylceramide (GlcCer)==<br />
<br />
{{Twocolumn|<br />
GlcCer is widely observed not only in Animal, Plant or Fungi kingdoms, but also in Protozoa Kingdom<ref>Tan RX, Chen JH. "The cerebrosides" Nat Prod Rep. 2003;20:509-34.PMID 14620845, Yu R.K. Yanagisawa M. Ariga T. Glycosphingolipid Structures,in Comprehensive Glycoscience Vol.1,pp. 73-122,doi 10.1016/B978-044451967-2/00003-9, Itonori S, Sugita M. Glycophylogenetic Aspects of Lower Animals. in Comprehensive Glycoscience Vol.3, pp. 253-84, doi 10.1016/B978-044451967-2/00050-7 (J.P. Kamerling, ed.) Elsevier, Oxford (UK). (2007)</ref>. Ceramide structures (hydrocarbon chain length, the number and position of double bonds, existence of hydroxy and other modification groups) may vary, and become complex especially in Plant and Fungi Kingdoms, and Protostomia <ref>Sphingoid base chain may terminate with an isopropyl group in spongia, annelida, echinodermata, and bacteria. Terminal isobutyl or sec-pentyl group has been found only in echinodermata. Methylated or cyclopropane-containing sphingoid base is found in spongia, echinodermata, protochordata, and fungi.</ref>.<br />
In Animal Kingdom, GlcCer is the basic structure for different derivative series such as Globo, Lacto, and Ganglio Series. In Protostomia, GlcCer is the major ceramide in its nerve tissue, e.g. shrimp brain <ref>Okamura N, Stoskopf M, Hendricks F, Kishimoto Y. "Phylogenetic dichotomy of nerve glycosphingolipids" Proc Natl Acad Sci, 1985 82:6779-6782 PMID 3863128 </ref>, and its amide-linked fatty acids do not contain hydroxy groups. GlcCer in plants contains many &alpha;-hydroxy fatty acids. In some cold-resistant plants &omega;9-unsaturated fatty acids are detected. In Mammalia (of Deuterostomia), GlcCer is major in the spleen, blood, and skin.<br />
<br />
Gaucher's disease is an inborn metabolic disorder in which GlcCer accumulates in the liver and spleen because of the deficiency of the enzyme glucocerebrosidase to dissociate glucose from the ceramide structure <ref> Brady RO, Kanfer JN, Shapiro D. "Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher's desease" Biochem Biophys Res Commun. 1965;18:221-5 PMID 14282020 </ref>.<br />
|<br />
'''GlcCer'''は系統発生的にみると動物の各組織に広く分布するだけでなく、植物界や菌界、原生生物界にも含まれます。セラミド構造(炭化水素の鎖長、二重結合の数と位置、水酸基の有無、修飾基の有無など)の組み合わせは多岐にわたり、特に植物界や菌界、旧口動物のセラミドは複雑です。動物界において、GlcCerはさまざまな糖鎖を持つ糖脂質の基本構造になり、グロボ系列、ラクト系列、ガングリオ系列などが生成されます。旧口(前口)動物の神経系にはGlcCerが多く含まれ(例えばエビ)、セラミド骨格の脂肪酸に水酸基を含みません。対して、植物は &alpha;-水酸化の脂肪酸が多く、耐冷性植物の一部からは &omega;9-不飽和の脂肪酸も見だされています。後口動物の哺乳綱において、GlcCerは、脾臓、血液、皮膚などに多く含まれます。<br />
<br />
先天性代謝異常症であるゴーシェ (Gaucher) 病は、GlcCerを分解するグルコセレブロシダーゼが欠損し、肝臓や脾臓にGlcCerが蓄積して発症します。<br />
}}<br />
<br />
==Galactosylceramide (GalCer)==<br />
{{Twocolumn|<br />
GalCer has been observed in Eubacterial Domain, but not in Protozoa, Plant, or Fungi (except Ascomycota). It is widely observed in Animal Kingdom, but not in Ecdysozoa (cuticle-shedding animals) of Protostomia. Its ceramide structure differs widely as in GlcCer but not so complex as GlcCer in Plant and Fungi. GalCer is the basic structure for sulfatide (3-O-sulfogalactosylceramide or SM4) and Gala Series often found in Annelida (segmented worm). In Mammalia (of Deuterostomia), GalCer is major in the nerve tissue, especially myelin sheath, whose amido-linked fatty acids are hydroxylated at the C-2 position for more than 50%.<br />
<br />
Krabbe disease (globoid cell leukodystrophy) is an inborn metabolic disorder in which a small amount of psychosine (galactosylsphingosine, i.e., the lyso form of GalCer) induces demyelination because of the deficiency of the enzyme galactosylceramidase <ref>Suzuki K. "Globoid cell leukodystrophy (Krabbe's disease): update" J Child Neurol. 2003;18:595-603.PMID 14572137, Suzuki K. "Evolving concept of the pathogenesis of globoid cell leukodystrophy (Krabbe disease)" Proc Jpn Acad Ser B Phys Biol Sci 2003; 79:1-8</ref>. &alpha;-GalCer, found from Porifera (marine sponge), in which galactose is &alpha;-bonded to ceramide (not the usual &beta;-bond), uniquely binds to human or mouse NKT cells and is considered a potent anti-tumor agent.<ref>Kitamura H, Iwakabe K, Yahata T, Nishimura S, Ohta A, Ohmi Y, Sato M, Takeda K, Okumura K, Van Kaer L, Kawano T, Taniguchi M, Nishimura T. "The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells" J Exp Med. 1999; 5;189(7):1121-8. PMID 10190903 </ref><br />
|<br />
'''GalCer'''は真正細菌に存在しますが、原生生物界、植物界、菌界(子嚢菌を除く)では報告がありません。動物界に広く分布しますが旧口動物である脱皮動物には確認されていません。セラミド構造は、GlcCerと同様に多様ですが、植物や菌類のGlcCerほど複雑ではありません。GalCerはスルファチド (3-O-硫酸化ガラクトシルセラミドまたはSM4) や環形動物門に多く含まれるガラ系列の基本構造です。<br />
後口動物である哺乳綱では神経系、特にミエリン鞘にGalCerが多く含まれ、その脂肪酸の50%以上は、C2位が水酸化されています。<br />
<br />
クラッベ病(グロボイド細胞ロイコジストロフィー; GLD)はガラクトシルセラミダーゼの欠損により微量のサイコシン(ガラクトシルスフィンゴシン、つまり GalCer のリゾ体)が蓄積して脱髄(ミエリンの破壊)を起こす遺伝性疾患です。また、海綿動物門に発見された&alpha;-GalCerは、ガラクトースがセラミドに(通常の&beta;でなく)&alpha;結合しており、ヒトやマウスのNKT細胞に特異的に結合し抗腫瘍効果がみられます。<br />
}}<br />
<br />
<references/><br />
<br />
==Cerebrosides in Mammals==<br />
<br />
====Lipids in Heart Muscle====<br />
<br />
{| class="wikitable collapsible collapsed"<br />
|-<br />
! <br />
! Lipid (% wet weight)<br />
! Phospholipid (% dry weight)<br />
! Phosphatidylethanolamine<br/>PE (% dry weight)<br />
! Phosphatidylcholine<br/>PC (% dry weight)<br />
! Sphingomyelin (% dry weight)<br />
! '''Cerebroside''' (% dry weight)<br />
! Total cholesterol (% dry weight)<br />
|-<br />
! Human<br />
| 8.3<br />
| 6.3 - 7.5<br />
| 1.4 - 2.8<br />
| 3.3 - 5.7<br />
| 0.2 - 0.5<br />
| -<br />
| -<br />
|-<br />
! Cow<br />
| 3.1 - 19.5<br />
| 7.4 - 11.8<br />
| 5.3<br />
| 4<br />
| 0.5<br />
| 2<br />
| 0.4 (free)<br />
|-<br />
! Rat<br />
| 0.4 - 2.4<br />
| 5 - 8<br />
| 0.84 (% wet)<br />
| 2 (% wet)<br />
| 0.14 (% wet)<br />
| 1.4<br />
| 0.4 - 0.6<br />
|-<br />
|colspan="8"|生化学データブック[I] 14. 臓器・組織の成分、心臓 脂質 p1636 1981 日本生化学会編 東京化学同人 ISBN 978-4-807901-74-6 <br />
|}<br />
<br />
====Lipids in Rat Testis====<br />
{| class="wikitable collapsible collapsed"<br />
|-<br />
! Fraction<br />
! Total Lipid (mg/mg protein)<br />
! Phosphate (ug/mg protein)<br />
! Phospholipid<br/>(% total lipid)<br />
! Neutral Lipid<br/>(% total lipid)<br />
! '''Cerebroside''' (% total lipid)<br />
! Sulfated glycolipid<br/>(nmol/g total weight)<br />
|-<br />
! Total testis<br />
| 0.40<br />
| 62.88<br />
| 62.9<br />
| 34.6<br />
| 2.5<br />
| 556 &plusmn; 34<br />
|-<br />
! Golgi<br />
| 1.26<br />
| 18.49<br />
| 58.3<br />
| 39.4<br />
| 2.3<br />
| -<br />
|-<br />
! Remnant granule<br />
| 0.60<br />
| 19.67<br />
| 29.5<br />
| 68.0<br />
| 2.5<br />
| -<br />
|-<br />
! Microsome<br />
| 0.63<br />
| 53.21<br />
| 83.8<br />
| 14.5<br />
| 1.7<br />
| -<br />
|-<br />
! Lipid corpuscle<br />
| > 19<br />
| 12<br />
| 1.5<br />
| 98.5<br />
| -<br />
| -<br />
|-<br />
|colspan="7"| Keenan TW et al. "Lipid composition of subcellular fractions from rat testis"Biochim Biophys Acta 1972; 270:433-443, PMID 4340988 Suzuki A et al. "Decrease of seminolipid content in the testes of rats with vitamin A deficiency determined by high performance liquid chromatography"J Biochem 1977; 82:461-7 PMID 91479 <br />
|}<br />
<br />
====Cerebroside and Sulfatide Ratio in Animal Brain ====<br />
<br />
{| class="wikitable sortable collapsible collapsed"<br />
|-<br />
! Animal<br />
! Kerasin<br/>(GalCer with straight fatty-acyl chain)<br />
! Phrenosin<br/>(GalCer with hydroxy fatty-acyl chain)<br />
! Sulfatide<br />
|-<br />
! Human cinerea (gray matter)<br />
| 25<br />
| 52<br />
| 23<br />
|-<br />
! Human alba (white matter)<br />
| 28<br />
| 47<br />
| 25<br />
|-<br />
! Cow cinerea<br />
| 15<br />
| 56<br />
| 29<br />
|-<br />
! Cow alba<br />
| 35<br />
| 48<br />
| 17<br />
|-<br />
! Dog<br />
| 21<br />
| 57<br />
| 22<br />
|-<br />
! Cat<br />
| 21<br />
| 60<br />
| 19<br />
|-<br />
! Mouse (4 weeks)<br />
| 24<br />
| 56<br />
| 20<br />
|-<br />
! Rat (10 days)<br />
| 35<br />
| 42<br />
| 23<br />
|-<br />
! Rat (35 days)<br />
| 21<br />
| 61<br />
| 18<br />
|-<br />
! Rabbit<br />
| 13<br />
| 66<br />
| 21<br />
|-<br />
! Guinea pig<br />
| 28<br />
| 54<br />
| 18<br />
|-<br />
! Sheep<br />
| 27<br />
| 47<br />
| 26<br />
|-<br />
! Chicken<br />
| 44<br />
| 37<br />
| 19<br />
|-<br />
! Tuna<br />
| 50<br />
| 25<br />
| 25<br />
|-<br />
! Shark<br />
| 44<br />
| 24<br />
| 32<br />
|-<br />
| colspan="4" | (weight %) From: Yamakawa T, Nishimura S. "Cerebroside composition in animal brain" Jpn J Exp 1966; 36:101-2 PMID 5297247 <br />
|}<br />
<br />
====Fatty acid composition of bovine brains====<br />
<br />
{| class="wikitable sortable collapsible collapsed"<br />
|-<br />
!colspan="5"| Nonhydroxy fatty acid (adjusted GC peak %)<br />
!colspan="3"| Hydroxy fatty acid<br />
|-<br />
! fatty acid || Ceramide || Sphingomyelin || Cerebroside || Sulfatide || fatty acid || Cerebroside || Sulfatide<br />
|-<br />
|12:0<br />
|colspan="4"| - || 12h:0 || 0.4 || 0.3<br />
|-<br />
|13:0<br />
|colspan="4"| - || 13h:0 || 0.2 || 0.2<br />
|-<br />
| 14:0 || 0.6 || 0.3 || 0.2 || 0.8 || 14h:0 || 0.8 || 3.9<br />
|-<br />
| 15:0 || 0.2 || 0.1 || tr. || 0.3 || 15h:0 || tr. || 0.3<br />
|-<br />
| 16:0 || 4.5 || 5.9 || 3.5 || 4.1 || 16h:0 || 0.1 || 0.7<br />
|-<br />
| 16:1 || 0.4 || tr. || 0.1 || 0.7 || 16h:1 || tr. || 1.7<br />
|-<br />
| 17:0 || tr. || 0.3 || tr. || tr. || 17h:0 || 0.2 || 0.9<br />
|-<br />
| 18:0 || 35.2 || 40.1 || 5.8 || 3.3 || 18h:0 || 16.2 || 12.3<br />
|-<br />
| 18:1 || 2.1 || 0.7 || 2.7 || 5.2 || 18h:1 || - || -<br />
|- <br />
| 19:0 || 0.1 || 0.1 || 0.2 || 0.3 || 19h:0 || 0.4 || 0.3<br />
|-<br />
| 20:0 || 1.0 || 0.4 || 0.6 || 0.3 || 20h:0 || 0.5 || 0.7<br />
|-<br />
| 20:1 || 0.5 || tr. || 0.3 || 0.4 || 20h:1 || - || -<br />
|-<br />
| 21:0 || tr. || tr. || - || - || 21h:1 || - || -<br />
|-<br />
| 22:0 || 3.3 || 3.5 || 3.6 || 3.5 || 22h:0 || 5.8 || 7.7<br />
|-<br />
| 22:1 || 0.5 || 0.6 || 0.6 || 0.6 || 22h:1 || - || -<br />
|-<br />
| 23:0 || 3.7 || 2.8 || 5.2 || 3.1 || 23h:0 || 8.9 || 6.5<br />
|-<br />
| 23:1 || 1.0 || 1.0 || 1.2 || 0.8 || 23h:1 || - || -<br />
|-<br />
| 24:0 || 9.8 || 10.7 || 17.4 || 17.8 || 24h:0 || 30.1 || 26.0<br />
|-<br />
| 24:1 || 18.4 || 24.6 || 39.3 || 39.5 || 24h:1 || 14.6 || 16.7<br />
|-<br />
| 25:0 || 1.4 || 1.5 || 3.6 || 2.2 || 25h:0 || 7.0 || 4.5<br />
|-<br />
| 25:1 || 3.0 || 3.3 || 6.2 || 5.2 || 25h:1 || 3.0 || 2.8<br />
|-<br />
| 26:0 || 2.3 || 0.6 || 1.7 || 2.3 || 26h:0 || 3.9 || 3.8<br />
|-<br />
| 26:1 || 3.6 || 2.6 || 7.6 || 8.5 || 26h:1 || 6.3 || 6.5<br />
|-<br />
| 27:0 || 2.9 || - || - || - || 27h:0 || - || -<br />
|-<br />
| 27:1 || 1.8 || - || tr. || - || 27h:1 || - || -<br />
|-<br />
|colspan="8"| From: O'Brien JS, Rouser G "The fatty acid composition of brain sphingolipids: sphingomyelin, ceramide, cerebroside, and cerebroside sulfate"J Lipid Res1964; 5:339-342.PMID 5873370 Per cent of FA of each column. No PUFA, trace amount of hydroxy FA in ceramide, no hydroxy FA in sphingomyelin. The total ratio of nonhydroxy to hydroxy acids in cerebroside and sulfatide were 42:58 and 77:23, respectively (77:13 in the original paper). Human brain has a similar composition.<br />
|}<br />
<br />
==Sphingolipids in All Kingdoms==<br />
<br />
{{:Category:ScientificClassification/LBSC}}<br />
<br />
==Biosynthesis==<br />
<br />
{{Twocolumn|<br />
In Mammalia, GlcCer is synthesized by ceramide glucosyltransferase (CGlcT) at the cytosolic membrane of the Golgi apparatus, and GalCer is synthesized by ceramide galactosyltransferase (CGalT) at the lumen of the endoplasmic reticulum (ER). These enzymes do not share any sequence similarity and CGlcT possesses its transmembrane region at the N-terminal (type III) whereas CGalT possesses it at the C-terminal (type I).<ref>Sprong H, Degroote S, Nilsson T, Kawakita M, Ishida N, van der Sluijs P, van Meer G "Association of the Golgi UDP-galactose transporter with UDP-galactose:ceramide galactosyltransferase allows UDP-galactose import in the endoplasmic reticulum" Mol Biol Cell. 2003;4:3482-93 PMID 12925779</ref><br />
|<br />
哺乳動物では、ゴルジ装置の細胞質側に局在するグルコシルセラミド合成酵素(CGlcT)によって GlcCer が、小胞体の内腔側に局在するガラクトシルセラミド合成酵素(CGalT)によって GalCer が作られます。これらの酵素は配列相同性が無く、CGlcT は膜貫通領域が N 末端側(III型酵素)、CGalT は C 末端側(I型酵素)です。<br />
}}<br />
<br />
{| class="wikitable" style="text-align:center"<br />
|-<br />
! <br />
! GlcCer || GalCer<br />
|-<br />
! Enzyme<br />
| CGlcT (EC 2.4.1.80)<br />
| CGalT (EC 2.4.1.45)<br />
|-<br />
! Reaction<br />
| Ceramide + UDP-glucose &rarr; GlcCer + UDP<br />
| Ceramide + UDP-galactose &rarr; GalCer + UDP<br />
|-<br />
! Location<br />
| '''Golgi (outside)''' &rarr; flipflop &rarr; Golgi (inside)<br />
| '''ER lumen'''<br />
|}<br />
<br />
{{Twocolumn|<br />
Since all glycolipid synthesizing enzymes (except for CGlcT and CGalT) reside at the lumen of the Golgi apparatus, GlcCer must be flip-flopped from the cytosolic side to the lumen by an eyzyme called flippase.<br />
To synthesize GalCer, UDP-galactose and ceramide must transport the ER membrane. UDP-galactose transporter 2 (UGT2) is considered to be responsible.<br />
<br />
GalT can also work on glycerolipid, and synthsizes sulfated glyceroglycolipid in mammalian testis, called seminolipid.<br />
|<br />
CGlcT, CGalT 以外の糖脂質合成酵素はゴルジ装置の内腔側にあり、GlcCer はゴルジ膜の細胞質側から内腔側にフリッパーゼと呼ばれる酵素で移動(フリップフロップ)します。GalCer の場合は、UDPガラクトースとセラミドが小胞体膜を通過します。UDPガラクトーストランスポータ2 (UGT2) が関与するようです。<br />
<br />
CGalTはグリセロ脂質にも作用し、精巣の硫酸化グリセロ糖脂質であるセミノリピドも合成します。<br />
}}<br />
<br />
<references/></div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Category:LBS&diff=117158
Category:LBS
2023-05-18T02:39:53Z
<p>Editor: /* {{Bilingual|スフィンゴリン脂質1文字目|First (s1) Digit for Phosphosphingolipid}} */</p>
<hr />
<div>{{Huge|{{Bilingual|スフィンゴ脂質|Sphingolipid}}}}<br />
{{LB/Header}}<br />
{{Hierarchy|{{PAGENAME}}}}<br />
{| style="float:left"<br />
| __TOC__<br />
|}<br />
=={{Bilingual|概要|Class Overview}}==<br />
<br />
{{Twocolumn|<br />
Three Sphingolipid categories (LBS) exist in this database. <br />
|このデータベースではスフィンゴ脂質を以下に分けています。<br />
}}<br />
<br />
<center><br />
{| <br />
|-<br />
| style="vertical-align:top" width="33%"|<br />
[[:Category:LBSB| '''Ceramide''']]<br/>{{LBS/Cer|OH}}<br/><small>セラミド</small><br />
| style="vertical-align:top" width="33%"|<br />
'''Glycosphingolipid'''<br/>{{LBS/Cer|O-(sugar)}}<br/><small>スフィンゴ糖脂質</small><br />
| style="vertical-align:top" width="33%"|<br />
[[:Category:LBSP| '''Phosphosphingolipid''']]<br/>{{LBS/Cer|O-(phosphate)}}<br/><small>スフィンゴリン脂質</small><br />
|-<br />
|<br />
*[[:Category:LBSB|Long-chain base and ceramide]]<br />
|<br />
*[[:Category:LBSC|Cerebroside <small>(monohexosyl ceramides)</small>]]<br />
*[[:Category:LBSG|Acidic glycosphingolipid]]<br />
|<br />
*[[:Category:LBSP|Sphingomyelin, CPE, CAEP and GIPC]]<br />
|}<br />
</center><br />
<br />
<center><br />
{| class="wikitable"<br />
|<big><br />
[[:Category:LBS/Search|{{Bilingual|スフィンゴ脂質検索画面にいく|Go to Sphingolipid search.}}]]<br />
</big><br />
|}<br />
</center><br />
<br />
==={{Bilingual|スフィンゴ脂質の歴史|History of Sphingolipids}}===<br />
{{Twocolumn|<br />
Sphingolipids were first isolated from brain by J.L.W. Thudichum (1829-1901) as lipids of unknown function and structure.<ref>Thudichum J.L.W.?"A Treatise on the Chemical Constitution of the Balliere" Tindall and Cox, London,?1884</ref> The basic structure is a long-chain base (long-chain amino-alcohol) whose amino-group is acylated with a long-chain fatty acid. This hydrophobic structure is called ceramides.<br />
Sphingolipid consists of phospho-sphingolipid and glyco-sphingolipid, whose ceramide structure is bonded with phosphate and (oligo)saccharides, respectively. Phosphosphingolipid includes sphingomyelin, and glycosphingolipid, cerebrosides and gangliosides. Both are abundant in neural tissues.<ref>Gault CR,?Obeid LM,?Hannun YA "An overview of sphingolipid synthesis to breakdown" Adv Exp Med Biol.?2010;688:1-23. PMID 20919643</ref><br />
|<br />
スフィンゴ脂質は J.L.W. Thudichum (1829-1901) により機能や構造未知の脂質として脳から見いだされました。基本骨格は長鎖塩基 (長鎖アミノアルコール) のアミノ基が長鎖脂肪酸とアミド結合したもので、セラミドと呼ばれます。<br />
スフィンゴ脂質はセラミドにリン酸が結合したスフィンゴリン脂質と糖が結合したスフィンゴ糖脂質に分けられます。スフィンゴリン脂質にはスフィンゴミエリンが、スフィンゴ糖脂質にはセレブロシドやガングリオシドなどが含まれ、いずれも神経系に多く存在します。<br />
}}<br />
<br />
<references/><br />
<br />
=={{Bilingual|スフィンゴ脂質|Sphingolipid}}==<br />
<br />
==={{Bilingual|表記法|Notation}}===<br />
{| class="wikitable collapsible collapsed" style="width:80%"<br />
!colspan="4" align="center" style="background:lightgray"| Symbol Abbreviations (e.g. Glc = glucose)<br />
|-<br />
!colspan="4" align="center" style="background:lightgray"| Backbones<br />
{{#repeatnum:LBS/AbbrevRow|1|<br />
Cer && ceramide && セラミド && <br />
Sph && sphingosine && スフィンゴシン && <br />
}}<br />
|-<br />
!colspan="4" align="center" style="background:lightgray"| Sugars<br />
{{#repeatnum:LBS/AbbrevRow|1|<br />
Glc && glucose && グルコース && C6H12O6 && <br />
Gal && galactose && ガラクトース && C6H12O6 && <br />
GlcNAc && ''N''-acetyl-glucosamine && ''N''-アセチルグルコサミン && C8H15NO6 <br />
GalNAc && ''N''-acetyl-galactosamine && ''N''-アセチルガラクトサミン && C8H15NO6<br />
GlcN && glucosamine && グルコサミン && C6H13NO5<br />
GalN && galactosamine && ガラクトサミン && C6H13NO5<br />
GlcA && glucuronic acid && グルクロン酸 && C6H10O7<br />
GalA && galacturonic acid && ガラクツロン酸 && C6H10O7 && <br />
Man && mannose && マンノース && C6H12O6 && 18950<br />
Rha && rhamnose (= 6-deoxy-mannose) && ラムノース (6-デオキシマンノース) && C6H12O5 && 19233<br />
Ins && inositol && イノシトール && C6H12O6 && 892<br />
Fuc && fucose (= 6-deoxy-galactose) && フコース (6-デオキシガラクトース) && C6H12O5 && 17106<br />
Ara && arabinose && アラビノース && C5H10O5 && 5460291<br />
Xyl && xylose && キシロース && C5H10O5 && 135191<br />
NeuNH && (deacetyl) neuraminic acid<br/>(pyruvate + mannosamine) && ノイラミン酸<br/>(ピルビン酸+マンノサミン) && C9H17N1O8 && 513472<br />
NeuAc && ''N''-acetyl-neuraminic acid && ''N''-アセチルノイラミン酸 && C11H19NO9 && 439197<br />
NeuGc && ''N''-glycolyl-neuraminic acid && ''N''-グリコリルノイラミン酸 && C11H19NO10 && 123802<br />
Kdn && 2-keto-3-deoxy-D-glycero-<br/>D-galacto-nononic acid && デアミノノイラミン酸 && C9H16O9 && 13991616<br />
}}<br />
|-<br />
!colspan="4" align="center" style="background:lightgray"| Modifiers<br />
{{#repeatnum:LBS/AbbrevRow|1|<br />
AEPn && aminoethylphosphonic acid, or<br/>(2-aminoethyl)hydroxyphosphoryl- && アミノエチルホスホン酸(C-P結合)<br />
MAEPn && ''N''-methyl aminoethylphosphonic acid, or<br/>(''N''-methyl-2-aminoethyl) hydroxyphosphoryl- && AEPnの''N''-メチル体(C-P結合)<br />
EtnP && phosphoethanolamine (PEA), or<br/>2-aminoethanolphospho- && ホスホエタノールアミン<br />
PC && Phosphocholine && ホスホコリン<br />
Butenyl && Butenyl && ブテニル基<br />
Me && Methyl && メチル基<br />
Et && Ethyl && エチル基<br />
}}<br />
|}<br />
<br />
==={{Bilingual|分類体系|Page/ID-Code Design}}===<br />
{{Twocolumn|<br />
Major series of phosphosphingolipids are determined by molecules bound to their phosphates, and the series of glycosphingolipids are determined by oligosaccharides bound to their ceramides. The IUPAC series of glycosphingolipids (1977) were based on the order and bonding patterns of four sugars rooting at the long-chain base. Our series, however, are based on three sugars. Two original series, Echino and Schisto, are also added.<br />
|スフィンゴリン脂質はリン酸に結合する分子や糖の種類、スフィンゴ糖脂質はセラミドに結合する糖鎖により系列を作成しています。1977年にIUPACが提唱したスフィンゴ糖脂質の系列は、長鎖塩基に結合する四糖の並びと結合を基準にしています。ここではより広い糖鎖の系列を検索できるよう、三糖を基準に分類しています。また新たにEchinoとSchistoの系列を加えています。<br />
}}<br />
<br />
{|<br />
|<br />
<table border=1><br />
<tr><br />
<td style="background-color:yellowgreen;" width=20px align="center"><big>L</big><br />
<td style="background-color:yellowgreen;" width=20px align="center"><big>B</big><br />
<td style="background-color:yellowgreen;" width=20px align="center"><big>S</big><br />
<td style="background-color:green;" width=20px align="center"><big>''G/P''</big><br />
<td style="background-color:Blue; color:white" width=20px align="center"><big>''s1''</big><br />
<td style="background-color:Blue; color:white" width=20px align="center"><big>''s2''</big><br />
<td style="background-color:tomato; color:white" width=20px align="center"><big>''n1''</big><br />
<td style="background-color:tomato; color:white" width=20px align="center"><big>''n2''</big><br />
<td style="background-color:firebrick; color:white" width=20px align="center"><big>''y''</big><br />
<td style="background-color:white;" width=20px align="center"><big>''c1''</big><br />
<td style="background-color:white;" width=20px align="center"><big>''c2''</big><br />
</tr><br />
</table><br />
| &nbsp;<br />
|<br />
{| class="wikitable"<br />
! '''G/P''' || '''G''' (glyco) || '''P''' (phospho) <br />
|-<br />
! '''s1, s2''' <br />
|colspan="3"| structure code as explained below<br />
|-<br />
! '''n1, n2''' <br />
|colspan="2"| number of sugars (2 digits)<br />
|-<br />
! '''y'''<br />
|colspan="2"| number of sialic acids (1 digit)<br />
|-<br />
! '''c1, c2'''<br />
|colspan="2"| serial numbers<br />
|}<br />
|}<br />
<br />
==={{Bilingual|スフィンゴ糖脂質1文字目|First (s1) Digit for Glycosphingolipid}}===<br />
<span id="SphingolipidClass"></span><br />
{| class="wikitable" style="text-align:right; background-color:white"<br />
! First sugar || Code || Root sequence<br />
! colspan=2 | Major Series <br />
|-<br />
! Cerebroside <br />
| colspan="3" style="text-align:left" | '''For GalCer and GlcCer, visit [[:Category:LBSC|this page]].'''<br />
|-<br />
! starting with<br/><big>Galactose</big><br />
| {{#volatile:ListMol/LBStitle|<b>G1</b>|LBSG1}} <br /> ({{#volatile:ClassMatrix|{{#countTitle:LBSG1}} items|LBSG1.....|7|8|9|9|Number_of_Sugars|Number_of_Sialic_acids}})<br />
|style="text-align:right"| '''Gal'''-Cer<br />
|<br />
{| style="width:100%;"<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Gala / Neogala|Mainchain.*Gala1-4?6?Galb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|Gala1-4/6Galb1-Cer}} <br />
|-<br />
|style="border:0;text-align:left"|{{#volatile:ListMol/LBS|Spirometo|Mainchain.*Galb1-4Glcb1-3Galb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|Galb1-4Glcb1-3Galb1-Cer}}<br />
|}<br />
|-<br />
! rowspan="8" | starting with<br/><big>Glucose</big><br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>G2</b>|LBSG2}} <br /> ({{#volatile:ClassMatrix|{{#countTitle:LBSG2}} items|LBSG2.....|7|8|9|9|Number_of_Sugars|Number_of_Sialic_acids}})<br />
|style="text-align:right"| '''GalNAc<sub>&beta;</sub>'''-Gal<sub>&beta;</sub>-Glc<sub>&beta;</sub>-Cer<br />
|<br />
{| style="width:100%"<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Ganglio|Mainchain.*GalNAcb1-4Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GalNAcb1-4Galb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Isoganglio|Mainchain.*GalNAcb1-3Galb1-4Glcb1-Cer}}<ref name="iso">In IUPAC, "iso" refers to a change from position 4 to position 3.</ref><br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GalNAcb1-3Galb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Lactoganglio|Structure.*GlcNAcb1-3\(.*GalNAcb1-4\)Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GlcNAcb1-3(GalNAcb1-4)Galb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|a-series|Structure.*\(?NeuAca2-3\)?Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GalNAcb1-4(NeuAca2-3)Galb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|b-series|Structure.*\(?NeuAca2-8NeuAca2-3\)?Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GalNAcb1-4(NeuAca2-8NeuAca2-3)Galb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|c-series|Structure.*\(?NeuAca2-8NeuAca2-8NeuAca2-3\)?Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GalNAcb1-4(NeuAca2-8NeuAca2-8NeuAca2-3)Galb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|&alpha;-series|Structure.*\(?NeuAca2-6\)?GalNAcb1-4Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|...(NeuAca2-6)GalNAcb1-4Galb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|&beta;-series|Structure.*\(?NeuAca2-8NeuAca2-6\)?GalNAcb1-4Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|...(NeuAca2-8NeuAca2-6)GalNAcb1-4Galb1-4Glcb1-Cer}}<br />
|}<br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>G3</b>|LBSG3}} <br /> ({{#volatile:ClassMatrix|{{#countTitle:LBSG3}} items|LBSG3.....|7|8|9|9|Number_of_Sugars|Number_of_Sialic_acids}})<br />
|style="text-align:right"| '''GlcNAc<sub>&beta;</sub>'''-Gal<sub>&beta;</sub>-Glc<sub>&beta;</sub>-Cer<br />
|<br />
{| style="width:100%"<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Lacto|Mainchain.*Galb1-3GlcNAcb1-3Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|Galb1-3GlcNAcb1-3Galb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Neolacto|Mainchain.*Gal.1-4GlcNAcb1-3Galb1-4Glcb1-Cer}}<ref name="neo">In IUPAC, "neo" refers to a change from position 3 to position 4.</ref><br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|Galb1-4GlcNAcb1-3Galb1-4Glcb1-Cer}}<br />
|}<br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>G4</b>|LBSG4}} <br /> ({{#volatile:ClassMatrix|{{#countTitle:LBSG4}} items|LBSG4.....|7|8|9|9|Number_of_Sugars|Number_of_Sialic_acids}})<br />
|style="text-align:right"| '''Gal<sub>&alpha;</sub>'''-Gal<sub>&beta;</sub>-Glc<sub>&beta;</sub>-Cer<br />
|<br />
{| style="width:100%"<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Globo|Mainchain.*Gala1-4Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|Gala1-4Galb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Isoglobo|Mainchain.*Gala1-3Galb1-4Glcb1-Cer}}<ref name="iso"/><br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|Gala1-3Galb1-4Glcb1-Cer}}<br />
|}<br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>G5</b>|LBSG5}} <br /> ({{#volatile:ClassMatrix|{{#countTitle:LBSG5}} items|LBSG5.....|7|8|9|9|Number_of_Sugars|Number_of_Sialic_acids}})<br />
|style="text-align:right"| Gal-Glc-Cer<br/>(Other than G2&sim;G4)<br />
|<br />
{| style="width:100%"<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Muco|Mainchain.*Galb1-4Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|Galb1-4Galb1-4Glcb1-Cer}}<br />
|}<br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>G6</b>|LBSG6}} <br /> ({{#volatile:ClassMatrix|{{#countTitle:LBSG6}} items|LBSG6.....|7|8|9|9|Number_of_Sugars|Number_of_Sialic_acids}})<br />
|style="text-align:right"| '''Man'''-Glc<sub>&beta;</sub>-Cer<br />
|<br />
{| style="width:100%"<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Arthro|Mainchain.*GlcNAcb1-3Manb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GlcNAcb1-3Manb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Mollu|Mainchain.*Mana1-3Manb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|Mana1-3Manb1-4Glcb1-Cer}}<br />
|}<br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>G7</b>|LBSG7}} <br /> ({{#volatile:ClassMatrix|{{#countTitle:LBSG7}} items|LBSG7.....|7|8|9|9|Number_of_Sugars|Number_of_Sialic_acids}})<br />
|style="text-align:right"| '''NeuAc'''/'''NeuGc'''-Glc<sub>&beta;</sub>-Cer<br />
|<br />
{| style="width:100%"<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Echino|Mainchain.*Neu(A~G)c.2-6Glcb1-Cer}}<br />
|style="border:0;text-align:right"| <font color=purple>'''NeuGc'''</font> or {{#invoke:LBS|FormatSugar|NeuAca2-6Glcb1-Cer}}<br />
|}<br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>G8</b>|LBSG8}} <br /> ({{#volatile:ClassMatrix|{{#countTitle:LBSG8}} items|LBSG8.....|7|8|9|9|Number_of_Sugars|Number_of_Sialic_acids}})<br />
|style="text-align:right"| '''GalNAc'''-Glc-Cer<br />
|<br />
{| style="width:100%"<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Schisto|Mainchain.*GalNAc.1-4Glc.1-Cer}}<ref>Makaaru CK, Damian RT, Smith DF, Cummings RD. "The human blood fluke Schistosoma mansoni synthesizes a novel type of glycosphingolipid" J Biol Chem 1992 267:2251-2257 PMID 1733932</ref><br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GalNAcb1-4Glcb1-Cer}}<br />
|}<br />
|-<br />
! starting with<br/><big>Other Sugars</big><br />
| {{#volatile:ListMol/LBStitle|<b>G</b>(<b>A</b>&sim;<b>R</b>)|LBSG(A~B~C~D~E~F~G~H~J~K~M~N~O~P~Q~R)}}<br />
|colspan="2"| Symbols follow the Sugar-digit table.<br />
|}<br />
<references/><br />
<br />
==={{Bilingual|スフィンゴリン脂質1文字目|First (s1) Digit for Phosphosphingolipid}}===<br />
{| class="wikitable" style="text-align:right; background-color:white"<br />
! First sugar || Code || Root sequence <br />
!colspan="2"| Major Series<br />
|-<br />
! No Sugar Attached<br />
| '''P1''' ([[:Category:LBSP|LBSP]])<br />
| R-P-Cer<br />
| Sphingomyelin and Ceramide phosphoetanolamine<br/>(Visit [[:Category:LBSP|this page]].)<br />
|-<br />
! rowspan="4" | starting with<br/><big>Inositol</big><br />
| {{#volatile:ListMol/LBStitle|<b>P2</b>|LBSP2}} <br /> ({{#countTitle:LBSP2}} items)<br />
| style="text-align:right"| '''GlcN'''<sub>&alpha;/&beta;1&minus;2/6</sub>Ins<sub>1</sub>-P-Cer<br />
|<br />
{|style="width:100%"<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Protozoa & Fungi-specific|Mainchain.*GlcN.1-.Ins-P-Cer}}<br />
| style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GlcNa/b1-2/6Ins1-P-Cer}}<br />
|}<br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>P3</b>|LBSP3}} <br /> ({{#countTitle:LBSP3}} items) <br />
|style="text-align:right"| '''GlcA'''<sub>&alpha;/&beta;1&minus;2/6</sub>Ins<sub>1</sub>-P-Cer<br />
|<br />
{|style="width:100%"<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Plant-specific|Mainchain.*GlcA.1-.Ins-P-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GlcAa/b1-2/6Ins1-P-Cer}}<br />
|}<br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>P4</b>|LBSP4}} <br /> ({{#countTitle:LBSP4}} items)<br />
| style="text-align:right"| '''Man'''<sub>&alpha;/&beta;1&minus;2/6</sub>Ins<sub>1</sub>-P-Cer<br />
|<br />
{| style="width:100%"<br />
| style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Fungi-specific|Mainchain.*Man.1-.Ins-P-Cer}}<br />
| style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|Mana/b1-2/6Ins1-P-Cer}}<br />
|}<br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>P5</b>|LBSP5}} <br /> ({{#countTitle:LBSP5}} items)<br />
| style="text-align:right"| Gal, Glc, and Others<br />
| style="text-align:right"| {{#invoke:LBS|FormatSugar|X-Ins1-P-Cer}}<br />
|}<br />
<br />
==={{Bilingual|コード2文字目|Second (s2) Digit}}===<br />
<span id="SphingolipidSugar"></span><br />
{{Bilingual|クリックすると一覧が出ます。記号の略称については|Click to see the full list. For abbreviations, see}} [[#Notation]].<br />
<br />
{| <br />
|-<br />
| valign="top"|<br />
{| class="wikitable"<br />
|-<br />
! Code || Structure<br />
|-<br />
! '''A'''<br />
| Glc [[File:LBS-Monomer-Glc.png]]<br />
|-<br />
! '''B'''<br />
| Gal [[File:LBS-Monomer-Gal.png]]<br />
|-<br />
! '''C'''<br />
| GlcNAc [[File:LBS-Monomer-GlcNAc.png]]<br />
|-<br />
! '''D'''<br />
| GalNAc [[File:LBS-Monomer-GalNAc.png]]<br />
|-<br />
! '''E'''<br />
| GlcN [[File:LBS-Monomer-GlcN.png]]<br />
|-<br />
! '''F'''<br />
| GalN [[File:LBS-Monomer-GalN.png]]<br />
|-<br />
! '''G'''<br />
| GlcA [[File:LBS-Monomer-GlcA.png]]<br />
|-<br />
! '''H'''<br />
| GalA [[File:LBS-Monomer-GalA.png]]<br />
|-<br />
! '''I'''<br />
| not used<br />
|}<br />
|valign="top"|<br />
{| class="wikitable"<br />
|-<br />
! Code || Structure<br />
|-<br />
! '''J'''<br />
| {{#volatile:ListMol/LBS|Mannose|Structure.*Man}} [[File:LBS-Monomer-Man.png]]<br />
|-<br />
! '''K'''<br />
| {{#volatile:ListMol/LBS|Rhamnose|Structure.*Rha}} [[File:LBS-Monomer-Rha.png]]<br />
|-<br />
! '''L'''<br />
| {{#volatile:ListMol/LBS|Inositol|Structure.*Ins(Me)?-P-[^Cer]}} <br />
|-<br />
! '''M'''<br />
| Fucose ({{#volatile:ListMol/LBS| 1|Structure[^F]+Fuc[^F]+$}}, {{#volatile:ListMol/LBS|2|Structure([^F]+Fuc){2}[^F]+$}}, {{#volatile:ListMol/LBS|>3|Structure([^F]+Fuc){3} }}) [[File:LBS-Monomer-Fuc.png]]<br />
|-<br />
! '''N'''<br />
| {{#volatile:ListMol/LBS|Arabinose|Structure.*Ara}} [[File:LBS-Monomer-Ara.png]]<br />
|-<br />
! '''O'''<br />
| {{#volatile:ListMol/LBS|Xylose|Structure.*Xyl}} [[File:LBS-Monomer-Xyl.png]]<br />
|-<br />
! '''P'''<br />
| {{#volatile:ListMol/LBS|NeuAc / NeuNH|Structure.*(NeuAc~NeuNH)}} [[File:LBS-Monomer-NeuAc.png]]<br />
|-<br />
! '''Q'''<br />
| {{#volatile:ListMol/LBS|NeuGc|Structure.*(NeuGc)}} [[File:LBS-Monomer-NeuGc.png]]<br />
|-<br />
! '''R'''<br />
| {{#volatile:ListMol/LBS|Kdn|Structure.*(KDN)}} [[File:LBS-Monomer-KDN.png]]<br />
|}<br />
|valign="top"|<br />
{| class="wikitable"<br />
|-<br />
! Code || Structure<br />
|-<br />
! '''S'''<br />
| {{#volatile:ListMol/LBS|Phosphate (except GIPC)|Structure.*(Phospho)}} [[File:LBS-Monomer-P.png]]<br />
|-<br />
! '''T'''<br />
| {{#volatile:ListMol/LBS|(M)AEPn|Structure.*(AEPn)}}, {{#volatile:ListMol/LBS|EtnP|Structure.*(EtnP)}}, {{#volatile:ListMol/LBS|PC|Structure.*(PC)}} [[File:LBS-Monomer-AEPn.png]]<br />
|-<br />
! '''U'''<br />
| {{#volatile:ListMol/LBS|Sulfate|Structure.*Sulfo}} [[File:LBS-Monomer-S.png]]<br />
|-<br />
! '''V'''<br />
| acyl/alkyl/alkenyl chain [[File:LBS-Monomer-Alkyl.png]]<br />
|}<br />
<br />
=={{Bilingual|生合成|Biosynthesis}}==<br />
{{Twocolumn|<br />
Sphingosine is synthesized from decarboxylating condensation of palmitoyl CoA with serine on the ER membrane. It is a 18-carbon amino alcohol (16 carbons from palmitic acid and 2 from serine) with one unsaturated bond (trans-form) at the C-4 position (2-amino-4-octadecene-1,3-diol). ([[:Category:LBS/Biosynthesis|more details]])<br />
|<br />
スフィンゴシンはパルミトイルCoAがアミノ酸セリンと脱炭酸縮合して生成します。炭素を18個含むアミノアルコール(16個がパルミチン酸、2個がセリン由来)でトランス型の不飽和結合をC-4に1つ含みます。([[:Category:LBS/Biosynthesis|詳細はこちら]])<br />
}}<br />
<br />
<br />
<!---<br />
{|<br />
|valign="top"|<br />
{| class="wikitable" style="text-align:center"<br />
!width="5%"| code<br />
!colspan="2"| Galactose<br />
|-<br />
| '''0''' <br />
|colspan="2"| no sugar<br />
|-<br />
| '''1''' <br />
|rowspan="3"| <b>Galactose</b><br/>(&alpha; form)<br />
| {{#invoke:LBS|FormatSugar|Gala1-3 ...}}<br />
|-<br />
| '''2''' || {{#invoke:LBS|FormatSugar|Gala1-4 ...}}<br />
|-<br />
| '''3''' || {{#invoke:LBS|FormatSugar|Gala1-6 ...}}<br />
|-<br />
| '''4'''<br />
|rowspan="3"| <b>Galactose</b><br/>(&beta; form)<br />
| {{#invoke:LBS|FormatSugar|Galb1-3 ...}}<br />
|-<br />
| '''5''' || {{#invoke:LBS|FormatSugar|Galb1-4 ...}}<br />
|-<br />
| '''6''' || {{#invoke:LBS|FormatSugar|Galb1-6 ...}}<br />
|}<br />
|valign="top"|<br />
{| class="wikitable" style="text-align:center"<br />
!width="5%"| code<br />
!colspan="2"| ''N''-Acetylated Sugars<br />
|-<br />
|-<br />
| '''7''' <br />
|rowspan="3"| <b>''N''-Acetyl Galactosamine</b><br/>(&beta; form)<br />
| {{#invoke:LBS|FormatSugar|GalNAcb1-3 ...}}<br />
|-<br />
| '''8''' || {{#invoke:LBS|FormatSugar|GalNAcb1-4 ...}}<br />
|-<br />
| '''9''' || {{#invoke:LBS|FormatSugar|GalNAcb1-6 ...}}<br />
|-<br />
| '''A''' <br />
|rowspan="3"| <b>''N''-Acetyl Glucosamine</b><br/>(&beta; form)<br />
| {{#invoke:LBS|FormatSugar|GlcNAcb1-3 ...}}<br />
|-<br />
| '''B'''<br />
| {{#invoke:LBS|FormatSugar|GlcNAcb1-4 ...}}<br />
|-<br />
| '''C'''<br />
| {{#invoke:LBS|FormatSugar|GlcNAcb1-6 ...}}<br />
|}<br />
|}<br />
<br />
<br />
{|<br />
|valign="top"|<br />
{| class="wikitable" style="text-align:center"<br />
!width="5%"| code<br />
!colspan="2"| Galactose & Glucose<br />
|-<br />
| '''D''' <br />
|rowspan="2"| <b>Aminated Sugars</b><br/>(Except for Code 7&sim;C)<br />
| {{#invoke:LBS|FormatSugar|GalNAc, GalN}}<br />
|-<br />
| '''E''' || {{#invoke:LBS|FormatSugar|GlcNAc, GlcN}}<br />
|-<br />
| '''F''' <br />
| <b>Galactose</b><br/>(Except Code 1&sim;6)<br />
| <span style="color:gold"><b>Gal</b></span><br />
|-<br />
| '''G''' <br />
| <b>Glucose</b><br />
| <span style="color:blue"><b>Glc</b></span><br />
|}<br />
|valign="top"|<br />
{| class="wikitable" style="text-align:center"<br />
!width="5%"| code<br />
! Other Sugars<br />
|-<br />
| '''J''' || Inositol (<span style="color:"><b>Ins</b></span>)<br />
|-<br />
| '''K''' || Fucose (<span style="color:red"><b>Fuc</b></span>)<br />
|-<br />
| '''L''' || Pentose sugars<br/>(<span style="color:DarkOrange"><b>Ara, Xyl</b></span>)<br />
|-<br />
| '''M''' || Mannose and Rhamnose (= 6-deoxymannose)<br/>(<span style="color:green"><b>Man, Rha</b></span>)<br />
|-<br />
| '''N''' || Sialic acids<br/>(<b><span style="color:Purple">NeuAc, NeuNH</span>, <span style="color:gray">NeuGc</span>, <span style="color:Green">Kdn</span></b>)<br />
|}<br />
|}<br />
<br />
{|<br />
|valign="top"|<br />
{| class="wikitable" style="text-align:center"<br />
!width="5%"| code<br />
!colspan="2"| Modifiers<br />
|-<br />
| '''P''' || Phosphate (<b>HPO4</b>), Sulphate (<b>HSO4</b>),<br/>and Phosphocholine (<b>PC</b>)<br />
|-<br />
| '''Q''' || Aminoethylphosphates<br/><b>AEPn, MAEPn, MAEPr, EtnP</b><br />
|-<br />
| '''R''' || Alkyl and acyl groups<br/><b>OAc, Methyl, Butenyl</b><br />
|}<br />
|valign="top"|<br />
{| class="wikitable" style="text-align:center"<br />
!width="5%"| code<br />
!colspan="2"| Abbreviations<br />
|-<br />
| '''Y''' || {{#invoke:LBS|FormatSugar|GlcNAcb1-3Manb1-4Glcb1-1Cer}}<br />
|-<br />
| '''Z''' || {{#invoke:LBS|FormatSugar|Galb1-4Glcb1-1bCer}}<br />
|}<br />
|}<br />
<br />
<br />
<br />
==={{Bilingual|よく知られたパターン|Common Patterns}}===<br />
<br />
{| class="wikitable"<br />
! Common Name || Records || Sequence<br />
|-<br />
|colspan="3" style="background:#efefef; text-align:center"| By GalCer Synthase (EC 2.4.1.62)<br />
{{#repeat:LBS/AbbrevTable/Row|1|<br />
Gala_(Ga) Gala1-4/6Galb1-Cer LBSF%5b23%5d.<br />
Spirometo_(Sp) Galb1-4Glcb1-3Galb1-Cer LBSFG5<br />
}}<br />
|-<br />
|colspan="3" style="background:#efefef; text-align:center"| By GlcCer Synthase (EC 2.4.1.80)<br />
{{#repeat:LBS/AbbrevTable/Row|1|<br />
Ganglio_(Gg) GalNAcb1-4Galb1-4Glcb1-Cer LBSZ8.<br />
Isoganglio_(iGg) GalNAcb1-3Galb1-4Glcb1-Cer LBSZ7.<br />
Globo_(Gb) Gala1-4Galb1-4Glcb1-Cer LBSZ2.<br />
Isoglobo_(iGb) Gala1-3Galb1-4Glcb1-Cer LBSZ1.<br />
Lacto_(Lc) Galb1-3GlcNAcb1-3Galb1-4Glcb1-Cer LBSZD4<br />
NeoLacto_(nLc) Galb1-4GlcNAcb1-3Galb1-4Glcb1-Cer LBSZA5<br />
Muco_(Mc) Galb1-4Galb1-4Glcb1-Cer LBSZ5.<br />
}}<br />
|-<br />
|colspan="3" style="background:#efefef; text-align:center"| With Mannose<br />
{{#repeat:LBS/AbbrevTable/Row|1|<br />
Arthro_(At) GlcNAcb1-3Manb1-4Glcb1-Cer LBSY<br />
Mollu_(Mu) Mana1-3Manb1-4Glcb1-Cer LBSGMM<br />
}}<br />
|}<br />
<br />
==={{Bilingual|分類|Classification}}===<br />
===={{Bilingual|糖の個数|By the Number of Sugars}}====<br />
<br />
{| class="wikitable" border="1" cellpadding="2" cellspacing="1" margin: 1em 1em 1em 1em"<br />
|+ Table 1. Classification by the Number of Sugars<br />
! # of sugars || {{Bilingual|脊椎動物 (V)|'''V'''ertebrate}} ({{#expr:{{#countTitle:LBS.....V}}+{{#countTitle:LBS.....N}}}} items) || {{Bilingual|無脊椎動物 (I)|'''I'''nvertebrate}} ({{#expr:{{#countTitle:LBS.....I}}+{{#countTitle:LBS.....N}}}} items)<br />
|- valign="top"<br />
| 1 || {{MapLink|ListMol|LBS...01V|LBS...01V}} || {{MapLink|ListMol|LBS...01I|LBS...01I}}<br />
|-<br />
| 2 || {{MapLink|ListMol|LBS...02V|LBS...02V}} || {{MapLink|ListMol|LBS...02I|LBS...02I}}<br />
|-<br />
| 3 || {{MapLink|ListMol|LBS...03V|LBS...03V}} || {{MapLink|ListMol|LBS...03I|LBS...03I}}<br />
|-<br />
| 4 || {{MapLink|ListMol|LBS...04V|LBS...04V}} || {{MapLink|ListMol|LBS...04I|LBS...04I}}<br />
|-<br />
| 5 || {{MapLink|ListMol|LBS...05V|LBS...05V}} || {{MapLink|ListMol|LBS...05I|LBS...05I}}<br />
|-<br />
| 6 || {{MapLink|ListMol|LBS...06V|LBS...06V}} || {{MapLink|ListMol|LBS...06I|LBS...06I}}<br />
|-<br />
| 7 || {{MapLink|ListMol|LBS...07V|LBS...07V}} || {{MapLink|ListMol|LBS...07I|LBS...07I}}<br />
|-<br />
| 8 || {{MapLink|ListMol|LBS...08V|LBS...08V}} || {{MapLink|ListMol|LBS...08I|LBS...08I}}<br />
|-<br />
| 9 || {{MapLink|ListMol|LBS...09V|LBS...09V}} || {{MapLink|ListMol|LBS...09I|LBS...09I}}<br />
|-<br />
| 10-19 || {{MapLink|ListMol|LBS...1.V|LBS...1.<VN>}} || {{MapLink|ListMol|LBS...1.I|LBS...1.<IN>}}<br />
|-<br />
| 20-29 || {{MapLink|ListMol|LBS...2.V|LBS...2.<VN>}} || {{MapLink|ListMol|LBS...2.I|LBS...2.<IN>}}<br />
|}<br />
<br />
===={{Bilingual|シアル酸の個数|By the Number of Sialic acids}}====<br />
<br />
{| class="wikitable" border="1" cellpadding="2" cellspacing="1" margin: 1em 1em 1em 1em"<br />
|+ Table 2. Classification by the Number of Sialic acids<br />
! # of sialic acids || {{Bilingual|脊椎動物 (V)|'''V'''ertebrate}} ({{#expr:{{#countTitle:LBS.....V}}+{{#countTitle:LBS.....N}}}} items) || {{Bilingual|無脊椎動物 (I)|'''I'''nvertebrate}} ({{#expr:{{#countTitle:LBS.....I}}+{{#countTitle:LBS.....N}}}} items)<br />
|- valign="top"<br />
| 1 || {{MapLink|ListMol|LBS.....V1|LBS.....V1}} || {{MapLink|ListMol|LBS.....I1|LBS.....I1}}<br />
|-<br />
| 2 || {{MapLink|ListMol|LBS.....V2|LBS.....V2}} || {{MapLink|ListMol|LBS.....I2|LBS.....I2}}<br />
|-<br />
| 3 || {{MapLink|ListMol|LBS.....V3|LBS.....V3}} || {{MapLink|ListMol|LBS.....I3|LBS.....I3}}<br />
|-<br />
| 4 || {{MapLink|ListMol|LBS.....V4|LBS.....V4}} || {{MapLink|ListMol|LBS.....I4|LBS.....I4}}<br />
|-<br />
| 5 || {{MapLink|ListMol|LBS.....V5|LBS.....V5}} || {{MapLink|ListMol|LBS.....I5|LBS.....I5}}<br />
|-<br />
| 6 || {{MapLink|ListMol|LBS.....V6|LBS.....V6}} || {{MapLink|ListMol|LBS.....I6|LBS.....I6}}<br />
|-<br />
| 7 || {{MapLink|ListMol|LBS.....V7|LBS.....V7}} || {{MapLink|ListMol|LBS.....I7|LBS.....I7}}<br />
|-<br />
| 8 || {{MapLink|ListMol|LBS.....V8|LBS.....V8}} || {{MapLink|ListMol|LBS.....I8|LBS.....I8}}<br />
|}<br />
<br />
---></div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Category:LBS&diff=117157
Category:LBS
2023-05-18T02:38:29Z
<p>Editor: /* {{Bilingual|スフィンゴリン脂質1文字目|First (s1) Digit for Phosphosphingolipid}} */</p>
<hr />
<div>{{Huge|{{Bilingual|スフィンゴ脂質|Sphingolipid}}}}<br />
{{LB/Header}}<br />
{{Hierarchy|{{PAGENAME}}}}<br />
{| style="float:left"<br />
| __TOC__<br />
|}<br />
=={{Bilingual|概要|Class Overview}}==<br />
<br />
{{Twocolumn|<br />
Three Sphingolipid categories (LBS) exist in this database. <br />
|このデータベースではスフィンゴ脂質を以下に分けています。<br />
}}<br />
<br />
<center><br />
{| <br />
|-<br />
| style="vertical-align:top" width="33%"|<br />
[[:Category:LBSB| '''Ceramide''']]<br/>{{LBS/Cer|OH}}<br/><small>セラミド</small><br />
| style="vertical-align:top" width="33%"|<br />
'''Glycosphingolipid'''<br/>{{LBS/Cer|O-(sugar)}}<br/><small>スフィンゴ糖脂質</small><br />
| style="vertical-align:top" width="33%"|<br />
[[:Category:LBSP| '''Phosphosphingolipid''']]<br/>{{LBS/Cer|O-(phosphate)}}<br/><small>スフィンゴリン脂質</small><br />
|-<br />
|<br />
*[[:Category:LBSB|Long-chain base and ceramide]]<br />
|<br />
*[[:Category:LBSC|Cerebroside <small>(monohexosyl ceramides)</small>]]<br />
*[[:Category:LBSG|Acidic glycosphingolipid]]<br />
|<br />
*[[:Category:LBSP|Sphingomyelin, CPE, CAEP and GIPC]]<br />
|}<br />
</center><br />
<br />
<center><br />
{| class="wikitable"<br />
|<big><br />
[[:Category:LBS/Search|{{Bilingual|スフィンゴ脂質検索画面にいく|Go to Sphingolipid search.}}]]<br />
</big><br />
|}<br />
</center><br />
<br />
==={{Bilingual|スフィンゴ脂質の歴史|History of Sphingolipids}}===<br />
{{Twocolumn|<br />
Sphingolipids were first isolated from brain by J.L.W. Thudichum (1829-1901) as lipids of unknown function and structure.<ref>Thudichum J.L.W.?"A Treatise on the Chemical Constitution of the Balliere" Tindall and Cox, London,?1884</ref> The basic structure is a long-chain base (long-chain amino-alcohol) whose amino-group is acylated with a long-chain fatty acid. This hydrophobic structure is called ceramides.<br />
Sphingolipid consists of phospho-sphingolipid and glyco-sphingolipid, whose ceramide structure is bonded with phosphate and (oligo)saccharides, respectively. Phosphosphingolipid includes sphingomyelin, and glycosphingolipid, cerebrosides and gangliosides. Both are abundant in neural tissues.<ref>Gault CR,?Obeid LM,?Hannun YA "An overview of sphingolipid synthesis to breakdown" Adv Exp Med Biol.?2010;688:1-23. PMID 20919643</ref><br />
|<br />
スフィンゴ脂質は J.L.W. Thudichum (1829-1901) により機能や構造未知の脂質として脳から見いだされました。基本骨格は長鎖塩基 (長鎖アミノアルコール) のアミノ基が長鎖脂肪酸とアミド結合したもので、セラミドと呼ばれます。<br />
スフィンゴ脂質はセラミドにリン酸が結合したスフィンゴリン脂質と糖が結合したスフィンゴ糖脂質に分けられます。スフィンゴリン脂質にはスフィンゴミエリンが、スフィンゴ糖脂質にはセレブロシドやガングリオシドなどが含まれ、いずれも神経系に多く存在します。<br />
}}<br />
<br />
<references/><br />
<br />
=={{Bilingual|スフィンゴ脂質|Sphingolipid}}==<br />
<br />
==={{Bilingual|表記法|Notation}}===<br />
{| class="wikitable collapsible collapsed" style="width:80%"<br />
!colspan="4" align="center" style="background:lightgray"| Symbol Abbreviations (e.g. Glc = glucose)<br />
|-<br />
!colspan="4" align="center" style="background:lightgray"| Backbones<br />
{{#repeatnum:LBS/AbbrevRow|1|<br />
Cer && ceramide && セラミド && <br />
Sph && sphingosine && スフィンゴシン && <br />
}}<br />
|-<br />
!colspan="4" align="center" style="background:lightgray"| Sugars<br />
{{#repeatnum:LBS/AbbrevRow|1|<br />
Glc && glucose && グルコース && C6H12O6 && <br />
Gal && galactose && ガラクトース && C6H12O6 && <br />
GlcNAc && ''N''-acetyl-glucosamine && ''N''-アセチルグルコサミン && C8H15NO6 <br />
GalNAc && ''N''-acetyl-galactosamine && ''N''-アセチルガラクトサミン && C8H15NO6<br />
GlcN && glucosamine && グルコサミン && C6H13NO5<br />
GalN && galactosamine && ガラクトサミン && C6H13NO5<br />
GlcA && glucuronic acid && グルクロン酸 && C6H10O7<br />
GalA && galacturonic acid && ガラクツロン酸 && C6H10O7 && <br />
Man && mannose && マンノース && C6H12O6 && 18950<br />
Rha && rhamnose (= 6-deoxy-mannose) && ラムノース (6-デオキシマンノース) && C6H12O5 && 19233<br />
Ins && inositol && イノシトール && C6H12O6 && 892<br />
Fuc && fucose (= 6-deoxy-galactose) && フコース (6-デオキシガラクトース) && C6H12O5 && 17106<br />
Ara && arabinose && アラビノース && C5H10O5 && 5460291<br />
Xyl && xylose && キシロース && C5H10O5 && 135191<br />
NeuNH && (deacetyl) neuraminic acid<br/>(pyruvate + mannosamine) && ノイラミン酸<br/>(ピルビン酸+マンノサミン) && C9H17N1O8 && 513472<br />
NeuAc && ''N''-acetyl-neuraminic acid && ''N''-アセチルノイラミン酸 && C11H19NO9 && 439197<br />
NeuGc && ''N''-glycolyl-neuraminic acid && ''N''-グリコリルノイラミン酸 && C11H19NO10 && 123802<br />
Kdn && 2-keto-3-deoxy-D-glycero-<br/>D-galacto-nononic acid && デアミノノイラミン酸 && C9H16O9 && 13991616<br />
}}<br />
|-<br />
!colspan="4" align="center" style="background:lightgray"| Modifiers<br />
{{#repeatnum:LBS/AbbrevRow|1|<br />
AEPn && aminoethylphosphonic acid, or<br/>(2-aminoethyl)hydroxyphosphoryl- && アミノエチルホスホン酸(C-P結合)<br />
MAEPn && ''N''-methyl aminoethylphosphonic acid, or<br/>(''N''-methyl-2-aminoethyl) hydroxyphosphoryl- && AEPnの''N''-メチル体(C-P結合)<br />
EtnP && phosphoethanolamine (PEA), or<br/>2-aminoethanolphospho- && ホスホエタノールアミン<br />
PC && Phosphocholine && ホスホコリン<br />
Butenyl && Butenyl && ブテニル基<br />
Me && Methyl && メチル基<br />
Et && Ethyl && エチル基<br />
}}<br />
|}<br />
<br />
==={{Bilingual|分類体系|Page/ID-Code Design}}===<br />
{{Twocolumn|<br />
Major series of phosphosphingolipids are determined by molecules bound to their phosphates, and the series of glycosphingolipids are determined by oligosaccharides bound to their ceramides. The IUPAC series of glycosphingolipids (1977) were based on the order and bonding patterns of four sugars rooting at the long-chain base. Our series, however, are based on three sugars. Two original series, Echino and Schisto, are also added.<br />
|スフィンゴリン脂質はリン酸に結合する分子や糖の種類、スフィンゴ糖脂質はセラミドに結合する糖鎖により系列を作成しています。1977年にIUPACが提唱したスフィンゴ糖脂質の系列は、長鎖塩基に結合する四糖の並びと結合を基準にしています。ここではより広い糖鎖の系列を検索できるよう、三糖を基準に分類しています。また新たにEchinoとSchistoの系列を加えています。<br />
}}<br />
<br />
{|<br />
|<br />
<table border=1><br />
<tr><br />
<td style="background-color:yellowgreen;" width=20px align="center"><big>L</big><br />
<td style="background-color:yellowgreen;" width=20px align="center"><big>B</big><br />
<td style="background-color:yellowgreen;" width=20px align="center"><big>S</big><br />
<td style="background-color:green;" width=20px align="center"><big>''G/P''</big><br />
<td style="background-color:Blue; color:white" width=20px align="center"><big>''s1''</big><br />
<td style="background-color:Blue; color:white" width=20px align="center"><big>''s2''</big><br />
<td style="background-color:tomato; color:white" width=20px align="center"><big>''n1''</big><br />
<td style="background-color:tomato; color:white" width=20px align="center"><big>''n2''</big><br />
<td style="background-color:firebrick; color:white" width=20px align="center"><big>''y''</big><br />
<td style="background-color:white;" width=20px align="center"><big>''c1''</big><br />
<td style="background-color:white;" width=20px align="center"><big>''c2''</big><br />
</tr><br />
</table><br />
| &nbsp;<br />
|<br />
{| class="wikitable"<br />
! '''G/P''' || '''G''' (glyco) || '''P''' (phospho) <br />
|-<br />
! '''s1, s2''' <br />
|colspan="3"| structure code as explained below<br />
|-<br />
! '''n1, n2''' <br />
|colspan="2"| number of sugars (2 digits)<br />
|-<br />
! '''y'''<br />
|colspan="2"| number of sialic acids (1 digit)<br />
|-<br />
! '''c1, c2'''<br />
|colspan="2"| serial numbers<br />
|}<br />
|}<br />
<br />
==={{Bilingual|スフィンゴ糖脂質1文字目|First (s1) Digit for Glycosphingolipid}}===<br />
<span id="SphingolipidClass"></span><br />
{| class="wikitable" style="text-align:right; background-color:white"<br />
! First sugar || Code || Root sequence<br />
! colspan=2 | Major Series <br />
|-<br />
! Cerebroside <br />
| colspan="3" style="text-align:left" | '''For GalCer and GlcCer, visit [[:Category:LBSC|this page]].'''<br />
|-<br />
! starting with<br/><big>Galactose</big><br />
| {{#volatile:ListMol/LBStitle|<b>G1</b>|LBSG1}} <br /> ({{#volatile:ClassMatrix|{{#countTitle:LBSG1}} items|LBSG1.....|7|8|9|9|Number_of_Sugars|Number_of_Sialic_acids}})<br />
|style="text-align:right"| '''Gal'''-Cer<br />
|<br />
{| style="width:100%;"<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Gala / Neogala|Mainchain.*Gala1-4?6?Galb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|Gala1-4/6Galb1-Cer}} <br />
|-<br />
|style="border:0;text-align:left"|{{#volatile:ListMol/LBS|Spirometo|Mainchain.*Galb1-4Glcb1-3Galb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|Galb1-4Glcb1-3Galb1-Cer}}<br />
|}<br />
|-<br />
! rowspan="8" | starting with<br/><big>Glucose</big><br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>G2</b>|LBSG2}} <br /> ({{#volatile:ClassMatrix|{{#countTitle:LBSG2}} items|LBSG2.....|7|8|9|9|Number_of_Sugars|Number_of_Sialic_acids}})<br />
|style="text-align:right"| '''GalNAc<sub>&beta;</sub>'''-Gal<sub>&beta;</sub>-Glc<sub>&beta;</sub>-Cer<br />
|<br />
{| style="width:100%"<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Ganglio|Mainchain.*GalNAcb1-4Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GalNAcb1-4Galb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Isoganglio|Mainchain.*GalNAcb1-3Galb1-4Glcb1-Cer}}<ref name="iso">In IUPAC, "iso" refers to a change from position 4 to position 3.</ref><br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GalNAcb1-3Galb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Lactoganglio|Structure.*GlcNAcb1-3\(.*GalNAcb1-4\)Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GlcNAcb1-3(GalNAcb1-4)Galb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|a-series|Structure.*\(?NeuAca2-3\)?Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GalNAcb1-4(NeuAca2-3)Galb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|b-series|Structure.*\(?NeuAca2-8NeuAca2-3\)?Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GalNAcb1-4(NeuAca2-8NeuAca2-3)Galb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|c-series|Structure.*\(?NeuAca2-8NeuAca2-8NeuAca2-3\)?Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GalNAcb1-4(NeuAca2-8NeuAca2-8NeuAca2-3)Galb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|&alpha;-series|Structure.*\(?NeuAca2-6\)?GalNAcb1-4Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|...(NeuAca2-6)GalNAcb1-4Galb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|&beta;-series|Structure.*\(?NeuAca2-8NeuAca2-6\)?GalNAcb1-4Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|...(NeuAca2-8NeuAca2-6)GalNAcb1-4Galb1-4Glcb1-Cer}}<br />
|}<br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>G3</b>|LBSG3}} <br /> ({{#volatile:ClassMatrix|{{#countTitle:LBSG3}} items|LBSG3.....|7|8|9|9|Number_of_Sugars|Number_of_Sialic_acids}})<br />
|style="text-align:right"| '''GlcNAc<sub>&beta;</sub>'''-Gal<sub>&beta;</sub>-Glc<sub>&beta;</sub>-Cer<br />
|<br />
{| style="width:100%"<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Lacto|Mainchain.*Galb1-3GlcNAcb1-3Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|Galb1-3GlcNAcb1-3Galb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Neolacto|Mainchain.*Gal.1-4GlcNAcb1-3Galb1-4Glcb1-Cer}}<ref name="neo">In IUPAC, "neo" refers to a change from position 3 to position 4.</ref><br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|Galb1-4GlcNAcb1-3Galb1-4Glcb1-Cer}}<br />
|}<br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>G4</b>|LBSG4}} <br /> ({{#volatile:ClassMatrix|{{#countTitle:LBSG4}} items|LBSG4.....|7|8|9|9|Number_of_Sugars|Number_of_Sialic_acids}})<br />
|style="text-align:right"| '''Gal<sub>&alpha;</sub>'''-Gal<sub>&beta;</sub>-Glc<sub>&beta;</sub>-Cer<br />
|<br />
{| style="width:100%"<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Globo|Mainchain.*Gala1-4Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|Gala1-4Galb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Isoglobo|Mainchain.*Gala1-3Galb1-4Glcb1-Cer}}<ref name="iso"/><br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|Gala1-3Galb1-4Glcb1-Cer}}<br />
|}<br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>G5</b>|LBSG5}} <br /> ({{#volatile:ClassMatrix|{{#countTitle:LBSG5}} items|LBSG5.....|7|8|9|9|Number_of_Sugars|Number_of_Sialic_acids}})<br />
|style="text-align:right"| Gal-Glc-Cer<br/>(Other than G2&sim;G4)<br />
|<br />
{| style="width:100%"<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Muco|Mainchain.*Galb1-4Galb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|Galb1-4Galb1-4Glcb1-Cer}}<br />
|}<br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>G6</b>|LBSG6}} <br /> ({{#volatile:ClassMatrix|{{#countTitle:LBSG6}} items|LBSG6.....|7|8|9|9|Number_of_Sugars|Number_of_Sialic_acids}})<br />
|style="text-align:right"| '''Man'''-Glc<sub>&beta;</sub>-Cer<br />
|<br />
{| style="width:100%"<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Arthro|Mainchain.*GlcNAcb1-3Manb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GlcNAcb1-3Manb1-4Glcb1-Cer}}<br />
|-<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Mollu|Mainchain.*Mana1-3Manb1-4Glcb1-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|Mana1-3Manb1-4Glcb1-Cer}}<br />
|}<br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>G7</b>|LBSG7}} <br /> ({{#volatile:ClassMatrix|{{#countTitle:LBSG7}} items|LBSG7.....|7|8|9|9|Number_of_Sugars|Number_of_Sialic_acids}})<br />
|style="text-align:right"| '''NeuAc'''/'''NeuGc'''-Glc<sub>&beta;</sub>-Cer<br />
|<br />
{| style="width:100%"<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Echino|Mainchain.*Neu(A~G)c.2-6Glcb1-Cer}}<br />
|style="border:0;text-align:right"| <font color=purple>'''NeuGc'''</font> or {{#invoke:LBS|FormatSugar|NeuAca2-6Glcb1-Cer}}<br />
|}<br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>G8</b>|LBSG8}} <br /> ({{#volatile:ClassMatrix|{{#countTitle:LBSG8}} items|LBSG8.....|7|8|9|9|Number_of_Sugars|Number_of_Sialic_acids}})<br />
|style="text-align:right"| '''GalNAc'''-Glc-Cer<br />
|<br />
{| style="width:100%"<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Schisto|Mainchain.*GalNAc.1-4Glc.1-Cer}}<ref>Makaaru CK, Damian RT, Smith DF, Cummings RD. "The human blood fluke Schistosoma mansoni synthesizes a novel type of glycosphingolipid" J Biol Chem 1992 267:2251-2257 PMID 1733932</ref><br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GalNAcb1-4Glcb1-Cer}}<br />
|}<br />
|-<br />
! starting with<br/><big>Other Sugars</big><br />
| {{#volatile:ListMol/LBStitle|<b>G</b>(<b>A</b>&sim;<b>R</b>)|LBSG(A~B~C~D~E~F~G~H~J~K~M~N~O~P~Q~R)}}<br />
|colspan="2"| Symbols follow the Sugar-digit table.<br />
|}<br />
<references/><br />
<br />
==={{Bilingual|スフィンゴリン脂質1文字目|First (s1) Digit for Phosphosphingolipid}}===<br />
{| class="wikitable" style="text-align:right; background-color:white"<br />
! First sugar || Code || Root sequence <br />
!colspan="2"| Major Series<br />
|-<br />
! No Sugar Attached<br />
| '''P1''' ([[:Category:LBSP|LBSP]])<br />
| R-P-Cer<br />
| Sphingomyelin and Ceramide phosphoetanolamine<br/>(Visit [[:Category:LBSP|this page]].)<br />
|-<br />
! rowspan="4" | starting with<br/><big>Inositol</big><br />
| {{#volatile:ListMol/LBStitle|<b>P2</b>|LBSP2}} <br /> ({{#countTitle:LBSP2}} items)<br />
| style="text-align:right"| '''GlcN'''<sub>&alpha;/&beta;1&minus;2/6</sub>Ins<sub>1</sub>-P-Cer<br />
|<br />
{|style="width:100%"<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Protozoa & Fungi-specific|Mainchain.*GlcN.1-.Ins-P-Cer}}<br />
| style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GlcNa/b1-2/6Ins1-P-Cer}}<br />
|}<br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>P3</b>|LBSP3}} <br /> ({{#countTitle:LBSP3}} items) <br />
|style="text-align:right"| '''GlcA'''<sub>&alpha;/&beta;1&minus;2/6</sub>Ins<sub>1</sub>-P-Cer<br />
|<br />
{|style="width:100%"<br />
|style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Plant-specific|Mainchain.*GlcA.1-.Ins-P-Cer}}<br />
|style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|GlcAa/b1-2/6Ins1-P-Cer}}<br />
|}<br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>P4</b>|LBSP4}} <br /> ({{#countTitle:LBSP4}} items)<br />
| style="text-align:right"| '''Man'''<sub>&alpha;/&beta;1&minus;2/6</sub>Ins<sub>1</sub>-P-Cer<br />
|<br />
{| style="width:100%"<br />
| style="border:0;text-align:left"| {{#volatile:ListMol/LBS|Fungi-specific|Mainchain.*Man.1-.Ins-P-Cer}}<br />
| style="border:0;text-align:right"| {{#invoke:LBS|FormatSugar|Mana/b1-2/6Ins1-P-Cer}}<br />
|}<br />
|-<br />
| {{#volatile:ListMol/LBStitle|<b>P5</b>|LBSP5}} <br /> ({{#countTitle:LBSP5}} items)<br />
| style="text-align:right"| Gal, Glc, and Others<br />
| style="text-align:right"| {{#invoke:LBS|FormatSugar|Ins1-P-Cer}}<br />
|}<br />
<br />
==={{Bilingual|コード2文字目|Second (s2) Digit}}===<br />
<span id="SphingolipidSugar"></span><br />
{{Bilingual|クリックすると一覧が出ます。記号の略称については|Click to see the full list. For abbreviations, see}} [[#Notation]].<br />
<br />
{| <br />
|-<br />
| valign="top"|<br />
{| class="wikitable"<br />
|-<br />
! Code || Structure<br />
|-<br />
! '''A'''<br />
| Glc [[File:LBS-Monomer-Glc.png]]<br />
|-<br />
! '''B'''<br />
| Gal [[File:LBS-Monomer-Gal.png]]<br />
|-<br />
! '''C'''<br />
| GlcNAc [[File:LBS-Monomer-GlcNAc.png]]<br />
|-<br />
! '''D'''<br />
| GalNAc [[File:LBS-Monomer-GalNAc.png]]<br />
|-<br />
! '''E'''<br />
| GlcN [[File:LBS-Monomer-GlcN.png]]<br />
|-<br />
! '''F'''<br />
| GalN [[File:LBS-Monomer-GalN.png]]<br />
|-<br />
! '''G'''<br />
| GlcA [[File:LBS-Monomer-GlcA.png]]<br />
|-<br />
! '''H'''<br />
| GalA [[File:LBS-Monomer-GalA.png]]<br />
|-<br />
! '''I'''<br />
| not used<br />
|}<br />
|valign="top"|<br />
{| class="wikitable"<br />
|-<br />
! Code || Structure<br />
|-<br />
! '''J'''<br />
| {{#volatile:ListMol/LBS|Mannose|Structure.*Man}} [[File:LBS-Monomer-Man.png]]<br />
|-<br />
! '''K'''<br />
| {{#volatile:ListMol/LBS|Rhamnose|Structure.*Rha}} [[File:LBS-Monomer-Rha.png]]<br />
|-<br />
! '''L'''<br />
| {{#volatile:ListMol/LBS|Inositol|Structure.*Ins(Me)?-P-[^Cer]}} <br />
|-<br />
! '''M'''<br />
| Fucose ({{#volatile:ListMol/LBS| 1|Structure[^F]+Fuc[^F]+$}}, {{#volatile:ListMol/LBS|2|Structure([^F]+Fuc){2}[^F]+$}}, {{#volatile:ListMol/LBS|>3|Structure([^F]+Fuc){3} }}) [[File:LBS-Monomer-Fuc.png]]<br />
|-<br />
! '''N'''<br />
| {{#volatile:ListMol/LBS|Arabinose|Structure.*Ara}} [[File:LBS-Monomer-Ara.png]]<br />
|-<br />
! '''O'''<br />
| {{#volatile:ListMol/LBS|Xylose|Structure.*Xyl}} [[File:LBS-Monomer-Xyl.png]]<br />
|-<br />
! '''P'''<br />
| {{#volatile:ListMol/LBS|NeuAc / NeuNH|Structure.*(NeuAc~NeuNH)}} [[File:LBS-Monomer-NeuAc.png]]<br />
|-<br />
! '''Q'''<br />
| {{#volatile:ListMol/LBS|NeuGc|Structure.*(NeuGc)}} [[File:LBS-Monomer-NeuGc.png]]<br />
|-<br />
! '''R'''<br />
| {{#volatile:ListMol/LBS|Kdn|Structure.*(KDN)}} [[File:LBS-Monomer-KDN.png]]<br />
|}<br />
|valign="top"|<br />
{| class="wikitable"<br />
|-<br />
! Code || Structure<br />
|-<br />
! '''S'''<br />
| {{#volatile:ListMol/LBS|Phosphate (except GIPC)|Structure.*(Phospho)}} [[File:LBS-Monomer-P.png]]<br />
|-<br />
! '''T'''<br />
| {{#volatile:ListMol/LBS|(M)AEPn|Structure.*(AEPn)}}, {{#volatile:ListMol/LBS|EtnP|Structure.*(EtnP)}}, {{#volatile:ListMol/LBS|PC|Structure.*(PC)}} [[File:LBS-Monomer-AEPn.png]]<br />
|-<br />
! '''U'''<br />
| {{#volatile:ListMol/LBS|Sulfate|Structure.*Sulfo}} [[File:LBS-Monomer-S.png]]<br />
|-<br />
! '''V'''<br />
| acyl/alkyl/alkenyl chain [[File:LBS-Monomer-Alkyl.png]]<br />
|}<br />
<br />
=={{Bilingual|生合成|Biosynthesis}}==<br />
{{Twocolumn|<br />
Sphingosine is synthesized from decarboxylating condensation of palmitoyl CoA with serine on the ER membrane. It is a 18-carbon amino alcohol (16 carbons from palmitic acid and 2 from serine) with one unsaturated bond (trans-form) at the C-4 position (2-amino-4-octadecene-1,3-diol). ([[:Category:LBS/Biosynthesis|more details]])<br />
|<br />
スフィンゴシンはパルミトイルCoAがアミノ酸セリンと脱炭酸縮合して生成します。炭素を18個含むアミノアルコール(16個がパルミチン酸、2個がセリン由来)でトランス型の不飽和結合をC-4に1つ含みます。([[:Category:LBS/Biosynthesis|詳細はこちら]])<br />
}}<br />
<br />
<br />
<!---<br />
{|<br />
|valign="top"|<br />
{| class="wikitable" style="text-align:center"<br />
!width="5%"| code<br />
!colspan="2"| Galactose<br />
|-<br />
| '''0''' <br />
|colspan="2"| no sugar<br />
|-<br />
| '''1''' <br />
|rowspan="3"| <b>Galactose</b><br/>(&alpha; form)<br />
| {{#invoke:LBS|FormatSugar|Gala1-3 ...}}<br />
|-<br />
| '''2''' || {{#invoke:LBS|FormatSugar|Gala1-4 ...}}<br />
|-<br />
| '''3''' || {{#invoke:LBS|FormatSugar|Gala1-6 ...}}<br />
|-<br />
| '''4'''<br />
|rowspan="3"| <b>Galactose</b><br/>(&beta; form)<br />
| {{#invoke:LBS|FormatSugar|Galb1-3 ...}}<br />
|-<br />
| '''5''' || {{#invoke:LBS|FormatSugar|Galb1-4 ...}}<br />
|-<br />
| '''6''' || {{#invoke:LBS|FormatSugar|Galb1-6 ...}}<br />
|}<br />
|valign="top"|<br />
{| class="wikitable" style="text-align:center"<br />
!width="5%"| code<br />
!colspan="2"| ''N''-Acetylated Sugars<br />
|-<br />
|-<br />
| '''7''' <br />
|rowspan="3"| <b>''N''-Acetyl Galactosamine</b><br/>(&beta; form)<br />
| {{#invoke:LBS|FormatSugar|GalNAcb1-3 ...}}<br />
|-<br />
| '''8''' || {{#invoke:LBS|FormatSugar|GalNAcb1-4 ...}}<br />
|-<br />
| '''9''' || {{#invoke:LBS|FormatSugar|GalNAcb1-6 ...}}<br />
|-<br />
| '''A''' <br />
|rowspan="3"| <b>''N''-Acetyl Glucosamine</b><br/>(&beta; form)<br />
| {{#invoke:LBS|FormatSugar|GlcNAcb1-3 ...}}<br />
|-<br />
| '''B'''<br />
| {{#invoke:LBS|FormatSugar|GlcNAcb1-4 ...}}<br />
|-<br />
| '''C'''<br />
| {{#invoke:LBS|FormatSugar|GlcNAcb1-6 ...}}<br />
|}<br />
|}<br />
<br />
<br />
{|<br />
|valign="top"|<br />
{| class="wikitable" style="text-align:center"<br />
!width="5%"| code<br />
!colspan="2"| Galactose & Glucose<br />
|-<br />
| '''D''' <br />
|rowspan="2"| <b>Aminated Sugars</b><br/>(Except for Code 7&sim;C)<br />
| {{#invoke:LBS|FormatSugar|GalNAc, GalN}}<br />
|-<br />
| '''E''' || {{#invoke:LBS|FormatSugar|GlcNAc, GlcN}}<br />
|-<br />
| '''F''' <br />
| <b>Galactose</b><br/>(Except Code 1&sim;6)<br />
| <span style="color:gold"><b>Gal</b></span><br />
|-<br />
| '''G''' <br />
| <b>Glucose</b><br />
| <span style="color:blue"><b>Glc</b></span><br />
|}<br />
|valign="top"|<br />
{| class="wikitable" style="text-align:center"<br />
!width="5%"| code<br />
! Other Sugars<br />
|-<br />
| '''J''' || Inositol (<span style="color:"><b>Ins</b></span>)<br />
|-<br />
| '''K''' || Fucose (<span style="color:red"><b>Fuc</b></span>)<br />
|-<br />
| '''L''' || Pentose sugars<br/>(<span style="color:DarkOrange"><b>Ara, Xyl</b></span>)<br />
|-<br />
| '''M''' || Mannose and Rhamnose (= 6-deoxymannose)<br/>(<span style="color:green"><b>Man, Rha</b></span>)<br />
|-<br />
| '''N''' || Sialic acids<br/>(<b><span style="color:Purple">NeuAc, NeuNH</span>, <span style="color:gray">NeuGc</span>, <span style="color:Green">Kdn</span></b>)<br />
|}<br />
|}<br />
<br />
{|<br />
|valign="top"|<br />
{| class="wikitable" style="text-align:center"<br />
!width="5%"| code<br />
!colspan="2"| Modifiers<br />
|-<br />
| '''P''' || Phosphate (<b>HPO4</b>), Sulphate (<b>HSO4</b>),<br/>and Phosphocholine (<b>PC</b>)<br />
|-<br />
| '''Q''' || Aminoethylphosphates<br/><b>AEPn, MAEPn, MAEPr, EtnP</b><br />
|-<br />
| '''R''' || Alkyl and acyl groups<br/><b>OAc, Methyl, Butenyl</b><br />
|}<br />
|valign="top"|<br />
{| class="wikitable" style="text-align:center"<br />
!width="5%"| code<br />
!colspan="2"| Abbreviations<br />
|-<br />
| '''Y''' || {{#invoke:LBS|FormatSugar|GlcNAcb1-3Manb1-4Glcb1-1Cer}}<br />
|-<br />
| '''Z''' || {{#invoke:LBS|FormatSugar|Galb1-4Glcb1-1bCer}}<br />
|}<br />
|}<br />
<br />
<br />
<br />
==={{Bilingual|よく知られたパターン|Common Patterns}}===<br />
<br />
{| class="wikitable"<br />
! Common Name || Records || Sequence<br />
|-<br />
|colspan="3" style="background:#efefef; text-align:center"| By GalCer Synthase (EC 2.4.1.62)<br />
{{#repeat:LBS/AbbrevTable/Row|1|<br />
Gala_(Ga) Gala1-4/6Galb1-Cer LBSF%5b23%5d.<br />
Spirometo_(Sp) Galb1-4Glcb1-3Galb1-Cer LBSFG5<br />
}}<br />
|-<br />
|colspan="3" style="background:#efefef; text-align:center"| By GlcCer Synthase (EC 2.4.1.80)<br />
{{#repeat:LBS/AbbrevTable/Row|1|<br />
Ganglio_(Gg) GalNAcb1-4Galb1-4Glcb1-Cer LBSZ8.<br />
Isoganglio_(iGg) GalNAcb1-3Galb1-4Glcb1-Cer LBSZ7.<br />
Globo_(Gb) Gala1-4Galb1-4Glcb1-Cer LBSZ2.<br />
Isoglobo_(iGb) Gala1-3Galb1-4Glcb1-Cer LBSZ1.<br />
Lacto_(Lc) Galb1-3GlcNAcb1-3Galb1-4Glcb1-Cer LBSZD4<br />
NeoLacto_(nLc) Galb1-4GlcNAcb1-3Galb1-4Glcb1-Cer LBSZA5<br />
Muco_(Mc) Galb1-4Galb1-4Glcb1-Cer LBSZ5.<br />
}}<br />
|-<br />
|colspan="3" style="background:#efefef; text-align:center"| With Mannose<br />
{{#repeat:LBS/AbbrevTable/Row|1|<br />
Arthro_(At) GlcNAcb1-3Manb1-4Glcb1-Cer LBSY<br />
Mollu_(Mu) Mana1-3Manb1-4Glcb1-Cer LBSGMM<br />
}}<br />
|}<br />
<br />
==={{Bilingual|分類|Classification}}===<br />
===={{Bilingual|糖の個数|By the Number of Sugars}}====<br />
<br />
{| class="wikitable" border="1" cellpadding="2" cellspacing="1" margin: 1em 1em 1em 1em"<br />
|+ Table 1. Classification by the Number of Sugars<br />
! # of sugars || {{Bilingual|脊椎動物 (V)|'''V'''ertebrate}} ({{#expr:{{#countTitle:LBS.....V}}+{{#countTitle:LBS.....N}}}} items) || {{Bilingual|無脊椎動物 (I)|'''I'''nvertebrate}} ({{#expr:{{#countTitle:LBS.....I}}+{{#countTitle:LBS.....N}}}} items)<br />
|- valign="top"<br />
| 1 || {{MapLink|ListMol|LBS...01V|LBS...01V}} || {{MapLink|ListMol|LBS...01I|LBS...01I}}<br />
|-<br />
| 2 || {{MapLink|ListMol|LBS...02V|LBS...02V}} || {{MapLink|ListMol|LBS...02I|LBS...02I}}<br />
|-<br />
| 3 || {{MapLink|ListMol|LBS...03V|LBS...03V}} || {{MapLink|ListMol|LBS...03I|LBS...03I}}<br />
|-<br />
| 4 || {{MapLink|ListMol|LBS...04V|LBS...04V}} || {{MapLink|ListMol|LBS...04I|LBS...04I}}<br />
|-<br />
| 5 || {{MapLink|ListMol|LBS...05V|LBS...05V}} || {{MapLink|ListMol|LBS...05I|LBS...05I}}<br />
|-<br />
| 6 || {{MapLink|ListMol|LBS...06V|LBS...06V}} || {{MapLink|ListMol|LBS...06I|LBS...06I}}<br />
|-<br />
| 7 || {{MapLink|ListMol|LBS...07V|LBS...07V}} || {{MapLink|ListMol|LBS...07I|LBS...07I}}<br />
|-<br />
| 8 || {{MapLink|ListMol|LBS...08V|LBS...08V}} || {{MapLink|ListMol|LBS...08I|LBS...08I}}<br />
|-<br />
| 9 || {{MapLink|ListMol|LBS...09V|LBS...09V}} || {{MapLink|ListMol|LBS...09I|LBS...09I}}<br />
|-<br />
| 10-19 || {{MapLink|ListMol|LBS...1.V|LBS...1.<VN>}} || {{MapLink|ListMol|LBS...1.I|LBS...1.<IN>}}<br />
|-<br />
| 20-29 || {{MapLink|ListMol|LBS...2.V|LBS...2.<VN>}} || {{MapLink|ListMol|LBS...2.I|LBS...2.<IN>}}<br />
|}<br />
<br />
===={{Bilingual|シアル酸の個数|By the Number of Sialic acids}}====<br />
<br />
{| class="wikitable" border="1" cellpadding="2" cellspacing="1" margin: 1em 1em 1em 1em"<br />
|+ Table 2. Classification by the Number of Sialic acids<br />
! # of sialic acids || {{Bilingual|脊椎動物 (V)|'''V'''ertebrate}} ({{#expr:{{#countTitle:LBS.....V}}+{{#countTitle:LBS.....N}}}} items) || {{Bilingual|無脊椎動物 (I)|'''I'''nvertebrate}} ({{#expr:{{#countTitle:LBS.....I}}+{{#countTitle:LBS.....N}}}} items)<br />
|- valign="top"<br />
| 1 || {{MapLink|ListMol|LBS.....V1|LBS.....V1}} || {{MapLink|ListMol|LBS.....I1|LBS.....I1}}<br />
|-<br />
| 2 || {{MapLink|ListMol|LBS.....V2|LBS.....V2}} || {{MapLink|ListMol|LBS.....I2|LBS.....I2}}<br />
|-<br />
| 3 || {{MapLink|ListMol|LBS.....V3|LBS.....V3}} || {{MapLink|ListMol|LBS.....I3|LBS.....I3}}<br />
|-<br />
| 4 || {{MapLink|ListMol|LBS.....V4|LBS.....V4}} || {{MapLink|ListMol|LBS.....I4|LBS.....I4}}<br />
|-<br />
| 5 || {{MapLink|ListMol|LBS.....V5|LBS.....V5}} || {{MapLink|ListMol|LBS.....I5|LBS.....I5}}<br />
|-<br />
| 6 || {{MapLink|ListMol|LBS.....V6|LBS.....V6}} || {{MapLink|ListMol|LBS.....I6|LBS.....I6}}<br />
|-<br />
| 7 || {{MapLink|ListMol|LBS.....V7|LBS.....V7}} || {{MapLink|ListMol|LBS.....I7|LBS.....I7}}<br />
|-<br />
| 8 || {{MapLink|ListMol|LBS.....V8|LBS.....V8}} || {{MapLink|ListMol|LBS.....I8|LBS.....I8}}<br />
|}<br />
<br />
---></div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Template:Metabolite&diff=117156
Template:Metabolite
2023-02-13T04:46:32Z
<p>Editor: </p>
<hr />
<div><noinclude><br />
=代謝物のテンプレート=<br />
;引数リスト<br />
;;リンクテーブル用<br />
<br />
{{{LipidBank}}}<br />
{{{CAS}}}<br />
{{{KEGG}}}<br />
{{{KNApSAcK}}}<br />
<br />
;;構造テーブル用<br />
{{{Common Name}}}<br />
{{{SysName}}}<br />
{{{Symbol}}}<br />
{{{Melting Point}}}<br />
{{{Boiling Point}}}<br />
{{{Density}}}<br />
{{{Optical}}}<br />
{{{Refractive}}}<br />
{{{Solubility}}}<br />
{{{Mass Spectra}}}<br />
{{{UV Spectra}}}<br />
{{{IR Spectra}}}<br />
{{{NMR Spectra}}}<br />
{{{Other Spectra}}}<br />
{{{Chromatograms}}}<br />
{{{Source}}}<br />
{{{Chemical Synthesis}}}<br />
{{{Metabolism}}}<br />
{{{Biological Activity}}}<br />
{{{Note}}}<br />
{{{Genetic Information}}}<br />
<br />
<!-- Special:CreateNewMetabolite用<br />
名前&&必須(blank or other)&&デフォルト値&タイプ(line, file, text)&&説明<br />
<br />
{{{LipidBank&&&&&&line&&LipidBank ID}}}<br />
{{{CAS&&&&&&line&&CAS ID}}}<br />
{{{KEGG&&&&&&line&&KEGG ID}}}<br />
{{{KNApSAcK&&&&&&line&&KNApSAcK ID}}}<br />
{{{Common Name&&&&&&text&&Concatenate name by &rsquo;&amp;&amp;&rsquo;}}}<br />
{{{SysName&&&&&&line&&Systematic name}}}<br />
{{{Symbol&&&&&&line&&}}}<br />
{{{Melting Point&&&&&&line&&}}}<br />
{{{Boiling Point&&&&&&line&&}}}<br />
{{{Density&&&&&&line&&}}}<br />
{{{Optical&&&&&&line&&}}}<br />
{{{Refractive&&&&&&line&&}}}<br />
{{{Solubility&&&&&&line&&}}}<br />
{{{Mass Spectra&&&&&&line&&}}}<br />
{{{UV Spectra&&&&&&line&&}}}<br />
{{{IR Spectra&&&&&&line&&}}}<br />
{{{NMR Spectra&&&&&&line&&}}}<br />
{{{Chromatograms&&&&&&line&&}}}<br />
{{{IUPAC Name&&&&&&line&&}}}<br />
{{{Genetic Information&&&&&&line&&}}}<br />
{{{Note&&&&&&line&&}}}<br />
--><br />
</noinclude><includeonly><br />
{{#if:{{{IUPAC Name|}}}|= {{{IUPAC Name|}}} =}}<br />
<!--{{Hierarchy|{{PAGENAME}}}}--><br />
<div><br />
{| class="wikitable nowraplinks" border="1" cellpadding="2" cellspacing="1" style="background-color: #f8f8e0; float: right; clear: none; margin: 1em 1em 1em 1em; text-align:center"<br />
|-<br />
! colspan="2" style="background-color: #eeee99" | IDs and Links<br />
|- class{{{LipidBank|}}}="hiddenStructure"<br />
| [https://lipidbank.jp/ LipidBank]<br />
| [https://lipidbank.jp/{{#substring:{{{LipidBank|}}}|0|3}}.html#{{{LipidBank|}}} {{{LipidBank|}}}]<br />
|- class{{{LipidMaps|}}}="hiddenStructure"<br />
| [https://lipidmaps.org/ LipidMaps]<br />
| [https://www.lipidmaps.org/databases/lmsd/{{{LipidMaps|}}} {{{LipidMaps|}}}]<br />
|- class{{{CAS|}}}="hiddenStructure"<br />
| [[CAS|CAS]]<br />
| {{{CAS|}}}<br />
|- class{{{KEGG|}}}="hiddenStructure"<br />
| [https://www.genome.ad.jp/kegg/ KEGG]<br />
| [https://www.genome.jp/dbget-bin/www_bget?compound+{{{KEGG}}} {{{KEGG}}}]<br />
|- class{{{KNApSAcK|}}}="hiddenStructure"<br />
| [http://kanaya.naist.jp/KNApSAcK/ KNApSAcK]<br />
| [http://kanaya.naist.jp/knapsack_jsp/information.jsp?sname=C_ID&word={{{KNApSAcK|}}} {{{KNApSAcK}}}]<br />
|- class{{#ifexistfile:/data/cdx/{{#substring:{{PAGENAME}}|0|4}}/{{PAGENAME}}.cdx}}="hiddenStructure"<br />
| {{#ifexistfile:/data/cdx/{{#substring:{{PAGENAME}}|0|4}}/{{PAGENAME}}.cdx}}<br />
|- class{{#ifexists:Mol:{{PAGENAME}}|true|}}="hiddenStructure"<br />
| mol || [[Mol:{{PAGENAME}}|{{PAGENAME}}]]<!-- {{#ifexistfile:/data/mol/{{#substring:{{PAGENAME}}|0|4}}/{{PAGENAME}}.mol}} --><br />
|}<br />
<br />
{| class="wikitable" border="1" cellpadding="2" cellspacing="1" style="width:70%; background-color: #f8f8e0; margin: 1em 1em 1em 1em"<br />
! colspan="2" style="background-color: #eeee99" | {{FormatName|1= {{#cadr:{{{Common Name|}}}|&&}} }}<br />
|-<br />
| colspan="2" align="center" | {{#ifexists:Image:{{PAGENAME}}.png|[[Image:{{PAGENAME}}.png]]|{{#ifexists:Image:{{{LipidBank}}}.png|[[Image:{{{LipidBank}}}.png]]|{{#ifexists:Image:{{#nth:{{{LipidBank}}}|0|,}}.png|}}}}}}<br />
|-<br />
! colspan="2" style="background-color: #eeee99" | Structural Information<br />
|-<br />
| style="width: 20%;" | {{#volatile:ShowField|Systematic Name|SysName||{{#substring:{{PAGENAME}}|0|3}}}}<br />
| style="width: 80%;" | {{FormatName|1= {{{SysName|}}} }}<br />
|- style="li: margin-bottom: 2px"<br />
| style="width: 20%;" | {{#volatile:ShowField|Common Name|Common||{{#substring:{{PAGENAME}}|0|3}}}}<br />
| style="width: 80%;" |<noinclude>ここを改行しておかないと<p>タグで区切られてしまう</noinclude><br />
{{Metabolite/NameList|{{{Common Name|}}}}}<br />
|- class{{{Symbol|}}}="hiddenStructure"<br />
| style="width: 20%;" | {{#volatile:ShowField|Symbol|Symbol||{{#substring:{{PAGENAME}}|0|3}}}}<br />
| style="width: 80%;" | {{{Symbol|}}}<br />
|-<br />
| style="width: 20%;" | Formula<br />
| style="width: 80%;" | {{#replace:{{#SearchLine:FORMULA|Mol|{{PAGENAME}}}}|.*FORMULA||}}<br />
|-<br />
| style="width: 20%;" | Exact Mass<br />
| style="width: 80%;" | {{#replace:{{#SearchLine:EXACTMASS|Mol|{{PAGENAME}}}}|.*EXACTMASS||}}<br />
|-<br />
| style="width: 20%;" | Average Mass<br />
| style="width: 80%;" | {{#replace:{{#SearchLine:AVERAGEMASS|Mol|{{PAGENAME}}}}|.*AVERAGEMASS||}}<br />
|-<br />
| style="width: 20%;" | [[SMILES|SMILES]]<br />
| style="width: 80%;" | <tt>{{#replace:{{#SearchLine:SMILES|Mol|{{PAGENAME}}}}|.*SMILES||}}</tt><br />
|-<br />
! colspan="2" <!---{{#if:{{{Melting Point|}}}{{{Boiling Point|}}}{{{Density|}}}{{{Optical|}}}{{{Refractive|}}}{{{Solubility|}}}{{{Source|}}}{{{Chemical Synthesis|}}}{{{Metabolism|}}}{{{Biological Activity|}}}{{{Genetic Information|}}}{{{Note|}}}||class="hiddenStructure"}}---> style="background-color: #eeee99" | Physicochemical Information<br />
|- class{{#substring:{{{Melting Point|}}}|0|1}}="hiddenStructure"<br />
| style="width: 20%;" | {{#volatile:ShowField|Melting Point|Melting||{{#substring:{{PAGENAME}}|0|3}}}}<br />
| style="width: 80%;" | {{{Melting Point|}}}<br />
|- class{{#substring:{{{Boiling Point|}}}|0|1}}="hiddenStructure"<br />
| style="width: 20%;" | {{#volatile:ShowField|Boiling Point|Boiling||{{#substring:{{PAGENAME}}|0|3}}}}<br />
| style="width: 80%;" | {{{Boiling Point|}}}<br />
|- class{{#substring:{{{Density|}}}|0|1}}="hiddenStructure"<br />
| style="width: 20%;" | {{#volatile:ShowField|Density|Density||{{#substring:{{PAGENAME}}|0|3}}}}<br />
| style="width: 80%;" | {{#if:{{{Density|}}}|{{FormatName|1= {{{Density}}} }} }}<br />
|- class{{#substring:{{{Optical|}}}|0|1}}="hiddenStructure"<br />
| style="width: 20%;" | {{#volatile:ShowField|Optical Rotation|Optical||{{#substring:{{PAGENAME}}|0|3}}}}<br />
| style="width: 80%;" | {{#if:{{{Optical|}}}|{{FormatName|1= {{{Optical}}} }} }}<br />
|- class{{#substring:{{{Refractive|}}}|0|1}}="hiddenStructure"<br />
| style="width: 20%;" | {{#volatile:ShowField|Refractive Index|Refractive||{{#substring:{{PAGENAME}}|0|3}}}}<br />
| style="width: 80%;" | {{#if:{{{Refractive|}}}|{{FormatName|1= {{{Refractive|}}} }} }}<br />
|- class{{#substring:{{{Solubility|}}}|0|1}}="hiddenStructure"<br />
| style="width: 20%;" | {{#volatile:ShowField|Solubility|Solubility||{{#substring:{{PAGENAME}}|0|3}}}}<br />
| style="width: 80%;" | {{#if:{{{Solubility|}}}|{{FormatName|1={{{Solubility}}} }} }}<br />
|- class{{#substring:{{{Source|}}}|0|1}}="hiddenStructure"<br />
| style="width: 20%;" | {{#volatile:ShowField|Source|Source||{{#substring:{{PAGENAME}}|0|3}}}}<br />
| style="width: 80%;" | {{{Source|}}}<br />
|- class{{#substring:{{{Chemical Synthesis|}}}|0|1}}="hiddenStructure"<br />
| style="width: 20%;" | {{#volatile:ShowField|Chemical Synthesis|Chemical_Synthesis||{{#substring:{{PAGENAME}}|0|3}}}}<br />
| style="width: 80%;" | {{{Chemical Synthesis|}}}<br />
|- class{{#substring:{{{Metabolism|}}}|0|1}}="hiddenStructure"<br />
| style="width: 20%;" | {{#volatile:ShowField|Metabolism|Metabolism||{{#substring:{{PAGENAME}}|0|3}}}}<br />
| style="width: 80%;" | {{{Metabolism|}}}<br />
|- class{{#substring:{{{Biological Activity|}}}|0|1}}="hiddenStructure"<br />
| style="width: 20%;" | {{#volatile:ShowField|Biological Activity|Biological_Activity||{{#substring:{{PAGENAME}}|0|3}}}}<br />
| style="width: 80%;" | {{{Biological Activity|}}}<br />
|- class{{#substring:{{{Genetic Information|}}}|0|1}}="hiddenStructure"<br />
| style="width: 20%;" | {{#volatile:ShowField|Genetic Information|Genetic_Information||{{#substring:{{PAGENAME}}|0|3}}}}<br />
| style="width: 80%;" | {{{Genetic Information|}}}<br />
|- class{{#substring:{{{Note|}}}|0|1}}="hiddenStructure"<br />
| style="width: 20%;" | {{#volatile:ShowField|Note|Note||{{#substring:{{PAGENAME}}|0|3}}}}<br />
| style="width: 80%;" | {{{Note|}}}<br />
|-<br />
! colspan="2" {{#if:{{{Mass Spectra|}}}{{{UV Spectra|}}}{{{IR Spectra|}}}{{{NMR Spectra|}}}{{{Other Spectra|}}}{{{Chromatograms|}}}||class="hiddenStructure"}} style="background-color: #eeee99" | Spectral Information<br />
|- class{{#substring:{{{Mass Spectra|}}}|0|1}}="hiddenStructure"<br />
| style="width: 20%;" | [[Mass|Mass Spectra]]<br />
| style="width: 80%;" | {{#if:{{{Mass Spectra|}}}|{{FormatName| {{{Mass Spectra}}} }} }}<br />
|- class{{#substring:{{{UV Spectra|}}}|0|1}}="hiddenStructure"<br />
| style="width: 20%;" | [[UV|UV Spectra]]<br />
| style="width: 80%;" | {{#if:{{{UV Spectra|}}}|{{FormatName| {{{UV Spectra}}} }} }}<br />
|- class{{#substring:{{{IR Spectra|}}}|0|1}}="hiddenStructure"<br />
| style="width: 20%;" | [[IR|IR Spectra]]<br />
| style="width: 80%;" | {{#if:{{{IR Spectra|}}}|{{FormatName| {{{IR Spectra}}} }} }}<br />
|- class{{#substring:{{{NMR Spectra|}}}|0|1}}="hiddenStructure"<br />
| style="width: 20%;" | [[NMR|NMR Spectra]]<br />
| style="width: 80%;" | {{#if:{{{NMR Spectra|}}}|{{FormatName| {{{NMR Spectra}}} }} }}<br />
|- class{{#substring:{{{Other Spectra|}}}|0|1}}="hiddenStructure"<br />
| style="width: 20%;" | [[Other|Other Spectra]]<br />
| style="width: 80%;" | {{#if:{{{Other Spectra|}}}|{{FormatName| {{{Other Spectra}}} }} }}<br />
|- class{{#substring:{{{Chromatograms|}}}|0|1}}="hiddenStructure"<br />
| style="width: 20%;" | [[Chromato|Chromatograms]]<br />
| style="width: 80%;" | {{#if:{{{Chromatograms|}}}|{{FormatName| {{{Chromatograms}}} }} }}<br />
|-<br />
|}<br />
</div><br />
{{#ifeq: {{#substring:{{PAGENAME}}|0|2}}|LB|<br />
{{#def:species| {{#SearchLine:&&{{PAGENAME}}|Reference}} }}<br />
{{#if:{{#var:species}}| {{RelationTable| {{#var:species}} }} }}<br />
}}<br />
</includeonly></div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Module:Toyama&diff=117155
Module:Toyama
2023-02-08T06:29:28Z
<p>Editor: </p>
<hr />
<div>local getArgs = require('Module:Arguments').getArgs;<br />
local defArgs = require('Module:Arguments').defaultArgs;<br />
local toyama = {};<br />
<br />
function toyama.func1( frame )<br />
local args = defArgs(getArgs(frame), 1, "");<br />
local arg = args[1];<br />
local text = ""<br />
<br />
for line in arg:gmatch("[%S ]+") do<br />
text = text .. line<br />
end<br />
<br />
return text<br />
end<br />
<br />
<br />
function toyama.vbar( frame )<br />
local args = defArgs(getArgs(frame), 1, "");<br />
local arg = args[1];<br />
local text = ""<br />
<br />
local label = ""<br />
local data = ""<br />
for i,j in arg:gmatch("&&([%S ]+)&&([-.0-9]+)") do<br />
label = label .. "," .. i<br />
data = data .. "," .. j<br />
end<br />
label = string.sub(label,1)<br />
data = string.sub(data,1)<br />
text = text .. "label=" .. label .. ";data=" .. string.sub(data,2)<br />
<br />
return text<br />
end<br />
<br />
return toyama</div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Lipidbank_wiki:Status2v1.39&diff=117154
Lipidbank wiki:Status2v1.39
2023-02-03T07:38:29Z
<p>Editor: </p>
<hr />
<div>動作していないがリストにないページや、対応済みとなっているが表示や動作がおかしいページがあれば、「mediawiki ver1.39への対応状況」やテーブルの「コメント」欄に追記してください。<br />
<br />
wikiの書き方に慣れていなければ、この下の「コメント(自由記述)」に追記してください。<br />
<br />
==コメント(自由記述)==<br />
<br />
<br />
==mediawiki ver1.39への対応状況==<br />
<br />
* 2023/02/03 lipidbankに関する機能は全て対応(Suwa)<br />
* 2023/01/31 要チェックリストを追加(Suwa)、Category:LBGAを再修正(Suwa)、全Volatileの修正が完了(Suwa)<br />
* 2023/01/30 全Cateogryの修正が完了(Suwa)<br />
* 2023/01/26 Cateogry:LBGAを修正(Suwa)<br />
* 2023/01/25 このページを作成(Suwa)<br />
<br />
==対応状況==<br />
<br />
* 現在、<strong>84/84</strong>(うち10件保留)が完了。<br />
* テーブルヘッダの「対応」セルをクリックして並べ替えることで、対応済み項目だけまとめて表示可能。<br />
{{#def:c|1}}<br />
{| class="wikitable sortable"<br />
|-<br />
! 番号 || ページ || 対応 || 対応内容 || コメント<br />
|-<br />
| {{#var:c}} || [[:Category:LBS/Search]] || 2023/01/25対応 ||・HTMLForm extensionをv1.39に対応<br />・javascriptが動くよう修正<br />・Volatile機能をHTMLFormだけで実現<br />・luaがmediawikiにバンドルされたので、そのluaで動くよう修正<br />・Persistは動かないので、AllChainsへのページリンクだけ表示<br />・Template:LBS/FormatSugarのluaをModule:LBSに移して使用(Template:LBS/FormatSugarは不要)<br />・defTempが使えないため、Template:GetIconを追加・<del><span style="color: red">「Search from Structure」のリンク先(Volatile:ListMol/LBS)にてアイコンが表示されていない問題は未対応<br />・Search from Structureで「&lt;sub&gt;」がそのまま表示されている。</span></del><hr />(追加)Module:LBS, Template:GetIcon<br />(廃止)Template:LBS/FormatSugar || (Category:LBS/Searchのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[:Category:LBA]] || 不要 || [[:Category:LBGA]]へのリダイレクトのため || (Category:LBAのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[:Category:LBS]] || 2023/01/30対応 ||・luaをModule:LBSにFomatSugar()として移動<br />・volatileの修正<br/ >・volatileの機能修正により、引数をencodeが不要に || (Category:LBSのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[:Category:LBGAD]] || 2023/01/30対応 ||・Template:ListMolを修正<br />・Template:FormatNameのluaをModule:Commonに移動<br /><hr />(追加)Module:Common || (Category:LBGADのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[:Category:LBGAC]] || 2023/01/30対応 ||・luaをModule:LBGAにGroupTable()として移動 || (Category:LBGACのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[:Category:LBGA]] || 2023/01/26対応<br />2023/01/31追加修正 ||・luaプログラムをModule:LBGAに切り分け<br />・<del><span style="color: red">「Species-Structure Relationship」テーブルのリンク先(Volatile:ListMolByReference)は未対応</span></del><br />・volatileの書き方を修正<hr />(追加)Module:LBGA|| (Category:LBGAのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[:Category:LBGAA]] || 2023/01/30対応 ||・volatileの書き方を修正 || (Category:LBGAAのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[:Category:LBG]] || 2023/01/30対応 ||・volatileの書き方を修正<br />・Template:MapLinkを修正 || (Category:LBGのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[:Category:LBF]] || 2023/01/30対応 ||・volatileの書き方を修正 || (Category:LBFのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:AuthorSummary]] || 2023/01/30対応<br />2023/02/03グラフ対応 ||・luaをModule:AuthorSummaryへ移動<br />・<del><span style="color:red">グラフ表示はどう対応するか検討</span></del>・グラフ表示は一旦jpgraphで実装<hr />(追加)Module:AuthorSummary || (Volatile:AuthorSummaryのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ClassMatrix]] || 2023/01/30対応 ||・luaをModule:ClassMatrixへ移動<br />・Template:ClassMatrix/CreateRowのvolatileの書き方を修正<hr />(追加)Module:ClassMatrix || (11のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:JAS/Genes]] || 2023/01/31対応 ||・volatileの書き方を修正<br />・luaをModule:JASに移動<hr />(追加)Module:JAS || (12のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ListField]] || 2023/01/30対応<br /><span style="color:red">動作未確認</span> ||・luaをModule/ListFieldに移動<br />・volatileの書き方を修正<br />(ただし、どこからも呼び出されてないので動作検証できず)<hr />(追加)Module:ListField || (13のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ListMol/LBS]] || 2023/01/30対応 || ・<nowiki>{{{1}}}を{{#get:1}}に変更</nowiki><br />・<del><span style="color:red">アイコン画像が表示されるよう対応予定</span></del>|| (14のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ListMol/LBStitle]] || 2023/01/30対応 ||・volatileの書き方を修正 || (15のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ListMolByField]] || 2023/01/30対応<br /><span style="color:red">動作未確認</span> ||・volatileの書き方を修正<br />(ただし、どこからも呼び出されてないので動作検証できず) || (16のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ListMolByReference]] || 2023/01/30対応 ||・luaをModule:CommonにListMolByReference()として移動 || (17のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ListPage]] || 2023/01/30対応 ||・volatileの書き方を修正 || (18のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ListRef]] || 2023/01/30対応 ||・volatileの書き方を修正 || (19のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ListRefOfID]] || 2023/01/31対応 ||・luaをModule:ListRefOfIDに移動<hr />(追加)Module:ListRefOfID || (20のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ListStructures]] || 不要 || || (21のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ShowField]] || 2023/01/30対応<br />2023/02/01修正 ||・<del>他の修正に連動して完了</del><br />・volatileの書き方を修正 || (22のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:StructureSearch]] || 2023/01/30対応<br /><span style="color:red">動作未確認</span> ||・volatileの書き方を修正 || (23のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:VolatileTest]] || 不要 || || (24のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:AdvancedLBSSearch.js]] || 未使用のため保留 || || (25のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:CalculateMass.js]] || 未使用のため保留 || || (26のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:Common.css]] || 2023/01/25対応 || ・volatileリンクの見た目のスタイルを追加 || (27のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:Common.js]] || 2023/01/25対応 || ・現在の構成で動作するよう修正 || (28のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:GlycosphingolipidMassCalculator.js]] || 2023/01/25対応 || ・クラス化して、現在の構成で動作するよう修正 || (29のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:GlyphEditor.js]] || 2023/02/01対応 ||・javascriptを修正(MediaWiki:Common.js, MediaWiki:GlyphEditor.js, Template:GlyphEditor, StructureSearch) || (30のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:GoogleAPI.js]] || 未使用のため保留 || || (31のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:JBrowse.js]] || 保留 ||・未使用のため || (32のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:LBSSearch.js]] || 2023/01/25対応 || ・クラス化して、現在の構成で動くよう修正 || (33のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:Lipoquality.js]] || 保留 || || (34のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:LipoqualityChart.js]] || 保留 || || (35のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:LipoqualityCommon.js]] || 保留 || || (36のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:LipoqualityGet.js]] || 保留 || || (37のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:LipoqualitySearch.js]] || 保留 || || (38のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:PathwayEditor.js]] || 2023/02/03対応 ||・MediaWiki:PathwayEditorHandler.jsの修正にて完了 || (39のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:PathwayEditorHandler.js]] || 2023/02/03対応 ||・javascriptを修正(MediaWiki:Common.js)<br />・PathwayMap名前空間が無かったため、PathwayMap名前空間を作成し、そこに移動 || (40のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:MapLink]] || 2023/01/30対応 ||・volatileの書き方を修正 || (Template:MapLinのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:LBGA/GroupTable]] || 2023/01/30対応 ||・luaをModule:LBGAへ移動 || (Template:LBGA/GroupTableのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Glycolipid/distribution]] || 2023/01/30対応 ||・defTempが使えないため、Template:GetIconを作成<hr />(追加)Template:GetIcon|| (Template:Glycolipid/distributionのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:FormatName]] || 2023/01/30対応 ||・luaをModule:Commonに移動 || (Template:FormatNameのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:ClassMatrix/CreateRow]] || 2023/01/30対応 ||・volatileの書き方を修正 || (Template:ClassMatrix/CreateRowのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:JournalTitle/TableRow3]] || 2023/01/30対応 ||・volatileの書き方を修正 || (Template:JournalTitle/TableRow3のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:JAS/MutationStat]] || 2023/01/31対応 ||・luaをModule:JASへ移動 || (Template:JAS/MutationStatのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:JAS/AllMutation]] || 2023/01/31対応 ||・luaをModule:JASへ移動 || (Template:JAS/AllMutationのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:AuthorSummary]] || 2023/01/31対応 ||・volatileの書き方を修正 || (Template:AuthorSummaryのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Index:LBGA]] || 2023/02/02対応 ||・defTempをTemplate:VolatileLinkに移動<hr />(追加)Template:VolatileLink || (Index:LBGAのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[JAS:Home]] || 2023/02/01対応 ||・template:JAS/GeneList/Rowの修正により完了 || (JAS:Homeのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:ClassMatrix]] || 2023/01/31対応 ||・luaをModule:ClassMatrixから使用(ただし、初期のテンプレートで、今は使われていないと思われる) || (Template:ClassMatrixのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:CountryTable]] || 未使用のため保留 || || (Template:CountryTableのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Glycolipid]] || 2023/02/01対応 ||・volatileの書き方を修正<br />・<span style="color: red"><nowiki>{{#googleapi:}}が各ページに書き込まれているので、あとでダミーを作って非表示にする</nowiki></span> || (Template:Glycolipidのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:JAS/GeneList/LinkPage]] || 2023/02/01対応 ||・volatileの書き方を修正 || (Template:JAS/GeneList/LinkPageのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:ListAllChains]] || ・2023/02/01対応 ||・luaをModule:ListAllChainsに移動<hr />(追加)Module:ListAllChains || (Template:ListAllChainsのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:ListPage]] ||・2023/02/01対応 ||・volatileの書き方を修正 || (Template:ListPageのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Map/Glycerophospholipid]] || 不要 ||・Template:Map/Glycerophospholipid/Expressionの対応により完了 || (Template:Map/Glycerophospholipidのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Map/Glycerophospholipid/Expression]] || 2023/02/02対応 ||・luaでmaxを取得した物を{{#max:}}に変更 || (Template:Map/Glycerophospholipid/Expressionのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Map/Glycerophospholipid/GetValues]] || 不要 ||・Template:Map/Glycerophospholipid/Expressionの対応により完了 || (Template:Map/Glycerophospholipid/GetValuesのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Metabolite]] || 2023/02/02対応 ||・volatileの書き方を修正 || (Template:Metaboliteのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Reference/AuthorLink]] || 2023/02/02対応 ||・volatileの書き方を修正(ただし、未使用) || (Template:Reference/AuthorLinkのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:RelationTable]] || 2023/02/01対応 ||・defTempをテンプレートページに移動<hr />(追加)Template:RelationTable/Row2, Template:RelationTable/Row3 || (Template:RelationTableのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:TableRow3]] || 2023/02/02対応 ||・volatileの書き方を修正 || (Template:TableRow3のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:TableRow3/Country]] || 2023/02/02対応 ||・volatileの書き方を修正(ただし、未使用) || (Template:TableRow3/Countryのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:TableRow6/author]] || 2023/02/02対応 ||・volatileの書き方を修正(ただし、未使用) || (Template:TableRow6/authorのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:TableRow6/authorSub]] || 2023/02/02対応 ||・volatileの書き方を修正(ただし、未使用) || (Template:TableRow6/authorSubのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Taguchi/LinkItem]] || 2023/02/02対応 ||・volatileの書き方を修正 || (Template:Taguchi/LinkItemのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Taguchi/LinkItems]] || 不要 || Template:Taguchi/LinkItemの修正にて完了 || (Template:Taguchi/LinkItemsのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Toyama/Matrix]] || 2023/02/02対応<br /> ||・luaをModule:Toayamに移動<hr />(追加)Module:Toyama || (Template:Toyama/Matrixのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:LBS/FormatSugar]] || 2023/02/01対応 ||・luaをModule:LBSから呼び出すよう修正 || (Template:LBS/FormatSugarのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Glycolipid/OldLBLink]] || 2023/02/01対応 ||・httpをhttpsに変更</br />・cgi-binで各ページに飛ばしていたが、現在はカテゴリ毎に一ページになったため、ページへジャンプするよう修正 || (Template:Glycolipid/OldLBLinkのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:GlyphEditor]] || 2023/01/31対応 ||・javascriptの呼び出し方を変更 || (Template:GlyphEditorのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:ListRefOfID]] || 2023/02/02対応 ||・Volatile:ListRefOfIDと同じ || (Template:ListRefOfIDのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:FL digit56]] || 保留 ||・フラボノイド用機能のため || (Template:FL digit56のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:FL digit56with78]] || 保留 ||・フラボノイド用機能のため || (Template:FL digit56with78のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:FL digit78]] || 保留 ||・フラボノイド用機能のため || (Template:FL digit78のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:LBFA digit910Table/Row]] || 不要 ||・リダイレクトページのため || (Template:LBFA digit910Table/Rowのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:LBF digit910Table]] || 2023/02/02対応 ||・luaをModule:LBFDigitに移動<hr />(追加)Module:LBFDigit || (Template:LBF digit910Tableのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:LBF digit910Table/Row]] || 2023/02/02対応 ||・未使用のため動作未確認 || (Template:LBF digit910Table/Rowのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Index/author]] || 2023/02/03対応 ||・luaをModule:Indexに移動<hr />(追加)Module:Index || (Template:Index/authorのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Index/formula]] || 2023/02/03対応 ||・luaをModule:Indexに移動 || (Template:Index/formulaのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Index/mass]] || 2023/02/03対応 ||・luaをModule:Indexに移動 || (Template:Index/massのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Index/name]] || 2023/02/03対応 ||・luaをModule:Indexに移動 || (Template:Index/nameのコメントはここに記述)<br />
|}<br />
<br />
==要対応==<br />
# <del>[[Template:JCBL/Header]]</del><br />
<br />
==要確認==<br />
# [[Template:Index/persist]]<br />
# <del>[[Template:Percent2Color]]</del><br />
# <del>[[Template:Search/Checkbox]]</del><br />
<br />
==要チェック==<br />
# Lipoquality名前空間<br />
<br />
==未使用(済)==<br />
# [[Template:LBS/AbbrevTable/Row]](LBS/FormatSugarを呼び出してる)<br />
# [[Template:EditButton]]<br />
# [[Template:EditButton/CheckList]]<br />
# [[Template:LambdaTest]]<br />
<br />
==修正の必要はないが、エラーで表示できない(済)==<br />
<br />
# [[Template:List Description/Body]]<br />
# [[Template:List Description/SetAnchor]]<br />
# [[Template:List Image/Body]]<br />
# [[Template:List Image/NameList]]<br />
# [[Template:List Links]]<br />
# [[Template:Metabolite/NameList]]<br />
# [[Template:Metabolite/SpeciesLink]]<br />
# [[Template:Reference/RefAbbrev]]<br />
# [[Template:RelationTable/GetNames]]<br />
# [[Template:TreeClass/ListSpecies]]<br />
<br />
表示しようとするとErrorが表示され、編集しようとするとEdit conflictが発生。削除も出来ない。<br />
<br />
Error<br />
<br />
There is currently no text in this page.<br />
You can search for this page title in other pages, search the related logs, or create this page.<br />
<br />
Edit conflict: Template:List Description/Body<br />
<br />
Someone else has changed this page since you started editing it.<br />
The upper text area contains the page text as it currently exists.<br />
Your changes are shown in the lower text area.<br />
You will have to merge your changes into the existing text.<br />
Only the text in the upper text area will be published when you press "Save changes".<br />
<br />
原因は、reivsionテーブルのrev_actor(編集者)が、あり得ない0になっていることが原因と思われる(actorテーブルを見ると、IDは1からとなっている)。<br />
rev_id: 100<br />
rev_page: 100<br />
rev_comment_id: 0<br />
rev_actor: 0 <- ここ<br />
rev_timestamp: 20080203000000<br />
rev_minor_edit: 1<br />
rev_deleted: 0<br />
rev_len: 10<br />
rev_parent_id: 0<br />
<br />
actor=0は、おそらく別環境からimportした際に、当環境に存在しないユーザが編集したページで発生している様子(該当ページはどうやらmetabolomics.jpからimportした)。<br />
本番環境、テスト環境両方で発生しており、おそらくかなり古いバージョンからアップデートした場合に、mediawikiが整合性をとれない構造になっているのではないかと思われる。<br />
<br />
<br />
解決策としては、rev_actorを存在するアカウントIDに書き換えることで対応可能(ただし、コードから独自に見つけた解決策なので、他にエラーが発生しないか様子を見る必要がある)。<br />
<br />
update revision set rev_actor = 2 where rev_actor = 0;<br />
<br />
==開発用メモ==<br />
* volatileは以下のように記述方法を変更<br />
- リンク元での書き方<br />
[[volatile:volatileページ|引数群|リンク表示名}}<br />
↓<br />
<nowiki>{{#volatile:volatileページ|リンク表示名|引数1|引数2|...|引数N}}</nowiki><br />
<br />
<nowiki>e.g. {{#volatile:ListMol/LBS|Blood group A|Structure=GalNAca1-3\(Fuca1-2\)Galb1-3GlcNAcb1-3}}</nowiki><br />
- リンク先での書き方<br />
{{{1}}}<br />
↓<br />
<nowiki>{{#get:1}}</nowiki><br />
<br />
* luaについて<br />
- luaがmediawikiにバンドルされたので、すぐに使える状態になっている。<br />
<br />
- スクリプトはModule名前空間に記述する<br />
<br />
- Module名前空間のコンテンツモデルを「Scribunto」に変更する必要がある。<br />
<br />
- 基本構文は以下の通り(一番目の引数を返すだけの関数)<br />
local getArgs = require('Module:Arguments').getArgs; -- 引数を受け取るための機能呼び出し<br />
local defArgs = require('Module:Arguments').defaultArgs; -- 引数のnil確認からデフォルト引数の処理を行う<br />
local lbs = {}; -- lbsとしているが、この名前は何でも良い。<br />
<br />
function lbs.FormatSugar( frame ) -- 関数を定義<br />
local args = defArgs(getArgs(frame), 1, ""); -- 引数を取得(defArgs(getArgs(frame), 必要な引数の個数, 引数1のデフォルト値, 引数2のデフォルト値, ..., 引数Nのデフォルト値)<br />
<br />
return args[1] -- 出力したい文字列を返す<br />
end<br />
<br />
return lbs; -- 関数定義したモジュールを返す<br />
<br />
- 呼び出し方は以下の通り<br />
<nowiki>{{#invoke:Module名前空間のページ|関数名|引数1|引数2|...|引数3}}</nowiki><br />
<br />
<nowiki>e.g. {{#invoke:LBS|FormatSugar|GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb1-3-R}}</nowiki></div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Lipidbank_wiki:Status2v1.39&diff=117153
Lipidbank wiki:Status2v1.39
2023-02-03T07:37:30Z
<p>Editor: </p>
<hr />
<div>動作していないがリストにないページや、対応済みとなっているが表示や動作がおかしいページがあれば、「mediawiki ver1.39への対応状況」やテーブルの「コメント」欄に追記してください。<br />
<br />
wikiの書き方に慣れていなければ、この下の「コメント(自由記述)」に追記してください。<br />
<br />
==コメント(自由記述)==<br />
<br />
<br />
==mediawiki ver1.39への対応状況==<br />
<br />
* 2023/01/31 要チェックリストを追加(Suwa)、Category:LBGAを再修正(Suwa)、全Volatileの修正が完了(Suwa)<br />
* 2023/01/30 全Cateogryの修正が完了(Suwa)<br />
* 2023/01/26 Cateogry:LBGAを修正(Suwa)<br />
* 2023/01/25 このページを作成(Suwa)<br />
<br />
==対応状況==<br />
<br />
* 現在、<strong>84/84</strong>(うち10件保留)が完了。<br />
* テーブルヘッダの「対応」セルをクリックして並べ替えることで、対応済み項目だけまとめて表示可能。<br />
{{#def:c|1}}<br />
{| class="wikitable sortable"<br />
|-<br />
! 番号 || ページ || 対応 || 対応内容 || コメント<br />
|-<br />
| {{#var:c}} || [[:Category:LBS/Search]] || 2023/01/25対応 ||・HTMLForm extensionをv1.39に対応<br />・javascriptが動くよう修正<br />・Volatile機能をHTMLFormだけで実現<br />・luaがmediawikiにバンドルされたので、そのluaで動くよう修正<br />・Persistは動かないので、AllChainsへのページリンクだけ表示<br />・Template:LBS/FormatSugarのluaをModule:LBSに移して使用(Template:LBS/FormatSugarは不要)<br />・defTempが使えないため、Template:GetIconを追加・<del><span style="color: red">「Search from Structure」のリンク先(Volatile:ListMol/LBS)にてアイコンが表示されていない問題は未対応<br />・Search from Structureで「&lt;sub&gt;」がそのまま表示されている。</span></del><hr />(追加)Module:LBS, Template:GetIcon<br />(廃止)Template:LBS/FormatSugar || (Category:LBS/Searchのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[:Category:LBA]] || 不要 || [[:Category:LBGA]]へのリダイレクトのため || (Category:LBAのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[:Category:LBS]] || 2023/01/30対応 ||・luaをModule:LBSにFomatSugar()として移動<br />・volatileの修正<br/ >・volatileの機能修正により、引数をencodeが不要に || (Category:LBSのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[:Category:LBGAD]] || 2023/01/30対応 ||・Template:ListMolを修正<br />・Template:FormatNameのluaをModule:Commonに移動<br /><hr />(追加)Module:Common || (Category:LBGADのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[:Category:LBGAC]] || 2023/01/30対応 ||・luaをModule:LBGAにGroupTable()として移動 || (Category:LBGACのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[:Category:LBGA]] || 2023/01/26対応<br />2023/01/31追加修正 ||・luaプログラムをModule:LBGAに切り分け<br />・<del><span style="color: red">「Species-Structure Relationship」テーブルのリンク先(Volatile:ListMolByReference)は未対応</span></del><br />・volatileの書き方を修正<hr />(追加)Module:LBGA|| (Category:LBGAのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[:Category:LBGAA]] || 2023/01/30対応 ||・volatileの書き方を修正 || (Category:LBGAAのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[:Category:LBG]] || 2023/01/30対応 ||・volatileの書き方を修正<br />・Template:MapLinkを修正 || (Category:LBGのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[:Category:LBF]] || 2023/01/30対応 ||・volatileの書き方を修正 || (Category:LBFのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:AuthorSummary]] || 2023/01/30対応<br />2023/02/03グラフ対応 ||・luaをModule:AuthorSummaryへ移動<br />・<del><span style="color:red">グラフ表示はどう対応するか検討</span></del>・グラフ表示は一旦jpgraphで実装<hr />(追加)Module:AuthorSummary || (Volatile:AuthorSummaryのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ClassMatrix]] || 2023/01/30対応 ||・luaをModule:ClassMatrixへ移動<br />・Template:ClassMatrix/CreateRowのvolatileの書き方を修正<hr />(追加)Module:ClassMatrix || (11のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:JAS/Genes]] || 2023/01/31対応 ||・volatileの書き方を修正<br />・luaをModule:JASに移動<hr />(追加)Module:JAS || (12のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ListField]] || 2023/01/30対応<br /><span style="color:red">動作未確認</span> ||・luaをModule/ListFieldに移動<br />・volatileの書き方を修正<br />(ただし、どこからも呼び出されてないので動作検証できず)<hr />(追加)Module:ListField || (13のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ListMol/LBS]] || 2023/01/30対応 || ・<nowiki>{{{1}}}を{{#get:1}}に変更</nowiki><br />・<del><span style="color:red">アイコン画像が表示されるよう対応予定</span></del>|| (14のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ListMol/LBStitle]] || 2023/01/30対応 ||・volatileの書き方を修正 || (15のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ListMolByField]] || 2023/01/30対応<br /><span style="color:red">動作未確認</span> ||・volatileの書き方を修正<br />(ただし、どこからも呼び出されてないので動作検証できず) || (16のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ListMolByReference]] || 2023/01/30対応 ||・luaをModule:CommonにListMolByReference()として移動 || (17のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ListPage]] || 2023/01/30対応 ||・volatileの書き方を修正 || (18のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ListRef]] || 2023/01/30対応 ||・volatileの書き方を修正 || (19のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ListRefOfID]] || 2023/01/31対応 ||・luaをModule:ListRefOfIDに移動<hr />(追加)Module:ListRefOfID || (20のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ListStructures]] || 不要 || || (21のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ShowField]] || 2023/01/30対応<br />2023/02/01修正 ||・<del>他の修正に連動して完了</del><br />・volatileの書き方を修正 || (22のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:StructureSearch]] || 2023/01/30対応<br /><span style="color:red">動作未確認</span> ||・volatileの書き方を修正 || (23のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:VolatileTest]] || 不要 || || (24のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:AdvancedLBSSearch.js]] || 未使用のため保留 || || (25のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:CalculateMass.js]] || 未使用のため保留 || || (26のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:Common.css]] || 2023/01/25対応 || ・volatileリンクの見た目のスタイルを追加 || (27のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:Common.js]] || 2023/01/25対応 || ・現在の構成で動作するよう修正 || (28のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:GlycosphingolipidMassCalculator.js]] || 2023/01/25対応 || ・クラス化して、現在の構成で動作するよう修正 || (29のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:GlyphEditor.js]] || 2023/02/01対応 ||・javascriptを修正(MediaWiki:Common.js, MediaWiki:GlyphEditor.js, Template:GlyphEditor, StructureSearch) || (30のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:GoogleAPI.js]] || 未使用のため保留 || || (31のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:JBrowse.js]] || 保留 ||・未使用のため || (32のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:LBSSearch.js]] || 2023/01/25対応 || ・クラス化して、現在の構成で動くよう修正 || (33のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:Lipoquality.js]] || 保留 || || (34のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:LipoqualityChart.js]] || 保留 || || (35のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:LipoqualityCommon.js]] || 保留 || || (36のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:LipoqualityGet.js]] || 保留 || || (37のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:LipoqualitySearch.js]] || 保留 || || (38のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:PathwayEditor.js]] || 2023/02/03対応 ||・MediaWiki:PathwayEditorHandler.jsの修正にて完了 || (39のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:PathwayEditorHandler.js]] || 2023/02/03対応 ||・javascriptを修正(MediaWiki:Common.js)<br />・PathwayMap名前空間が無かったため、PathwayMap名前空間を作成し、そこに移動 || (40のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:MapLink]] || 2023/01/30対応 ||・volatileの書き方を修正 || (Template:MapLinのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:LBGA/GroupTable]] || 2023/01/30対応 ||・luaをModule:LBGAへ移動 || (Template:LBGA/GroupTableのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Glycolipid/distribution]] || 2023/01/30対応 ||・defTempが使えないため、Template:GetIconを作成<hr />(追加)Template:GetIcon|| (Template:Glycolipid/distributionのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:FormatName]] || 2023/01/30対応 ||・luaをModule:Commonに移動 || (Template:FormatNameのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:ClassMatrix/CreateRow]] || 2023/01/30対応 ||・volatileの書き方を修正 || (Template:ClassMatrix/CreateRowのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:JournalTitle/TableRow3]] || 2023/01/30対応 ||・volatileの書き方を修正 || (Template:JournalTitle/TableRow3のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:JAS/MutationStat]] || 2023/01/31対応 ||・luaをModule:JASへ移動 || (Template:JAS/MutationStatのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:JAS/AllMutation]] || 2023/01/31対応 ||・luaをModule:JASへ移動 || (Template:JAS/AllMutationのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:AuthorSummary]] || 2023/01/31対応 ||・volatileの書き方を修正 || (Template:AuthorSummaryのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Index:LBGA]] || 2023/02/02対応 ||・defTempをTemplate:VolatileLinkに移動<hr />(追加)Template:VolatileLink || (Index:LBGAのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[JAS:Home]] || 2023/02/01対応 ||・template:JAS/GeneList/Rowの修正により完了 || (JAS:Homeのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:ClassMatrix]] || 2023/01/31対応 ||・luaをModule:ClassMatrixから使用(ただし、初期のテンプレートで、今は使われていないと思われる) || (Template:ClassMatrixのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:CountryTable]] || 未使用のため保留 || || (Template:CountryTableのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Glycolipid]] || 2023/02/01対応 ||・volatileの書き方を修正<br />・<span style="color: red"><nowiki>{{#googleapi:}}が各ページに書き込まれているので、あとでダミーを作って非表示にする</nowiki></span> || (Template:Glycolipidのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:JAS/GeneList/LinkPage]] || 2023/02/01対応 ||・volatileの書き方を修正 || (Template:JAS/GeneList/LinkPageのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:ListAllChains]] || ・2023/02/01対応 ||・luaをModule:ListAllChainsに移動<hr />(追加)Module:ListAllChains || (Template:ListAllChainsのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:ListPage]] ||・2023/02/01対応 ||・volatileの書き方を修正 || (Template:ListPageのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Map/Glycerophospholipid]] || 不要 ||・Template:Map/Glycerophospholipid/Expressionの対応により完了 || (Template:Map/Glycerophospholipidのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Map/Glycerophospholipid/Expression]] || 2023/02/02対応 ||・luaでmaxを取得した物を{{#max:}}に変更 || (Template:Map/Glycerophospholipid/Expressionのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Map/Glycerophospholipid/GetValues]] || 不要 ||・Template:Map/Glycerophospholipid/Expressionの対応により完了 || (Template:Map/Glycerophospholipid/GetValuesのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Metabolite]] || 2023/02/02対応 ||・volatileの書き方を修正 || (Template:Metaboliteのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Reference/AuthorLink]] || 2023/02/02対応 ||・volatileの書き方を修正(ただし、未使用) || (Template:Reference/AuthorLinkのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:RelationTable]] || 2023/02/01対応 ||・defTempをテンプレートページに移動<hr />(追加)Template:RelationTable/Row2, Template:RelationTable/Row3 || (Template:RelationTableのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:TableRow3]] || 2023/02/02対応 ||・volatileの書き方を修正 || (Template:TableRow3のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:TableRow3/Country]] || 2023/02/02対応 ||・volatileの書き方を修正(ただし、未使用) || (Template:TableRow3/Countryのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:TableRow6/author]] || 2023/02/02対応 ||・volatileの書き方を修正(ただし、未使用) || (Template:TableRow6/authorのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:TableRow6/authorSub]] || 2023/02/02対応 ||・volatileの書き方を修正(ただし、未使用) || (Template:TableRow6/authorSubのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Taguchi/LinkItem]] || 2023/02/02対応 ||・volatileの書き方を修正 || (Template:Taguchi/LinkItemのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Taguchi/LinkItems]] || 不要 || Template:Taguchi/LinkItemの修正にて完了 || (Template:Taguchi/LinkItemsのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Toyama/Matrix]] || 2023/02/02対応<br /> ||・luaをModule:Toayamに移動<hr />(追加)Module:Toyama || (Template:Toyama/Matrixのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:LBS/FormatSugar]] || 2023/02/01対応 ||・luaをModule:LBSから呼び出すよう修正 || (Template:LBS/FormatSugarのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Glycolipid/OldLBLink]] || 2023/02/01対応 ||・httpをhttpsに変更</br />・cgi-binで各ページに飛ばしていたが、現在はカテゴリ毎に一ページになったため、ページへジャンプするよう修正 || (Template:Glycolipid/OldLBLinkのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:GlyphEditor]] || 2023/01/31対応 ||・javascriptの呼び出し方を変更 || (Template:GlyphEditorのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:ListRefOfID]] || 2023/02/02対応 ||・Volatile:ListRefOfIDと同じ || (Template:ListRefOfIDのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:FL digit56]] || 保留 ||・フラボノイド用機能のため || (Template:FL digit56のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:FL digit56with78]] || 保留 ||・フラボノイド用機能のため || (Template:FL digit56with78のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:FL digit78]] || 保留 ||・フラボノイド用機能のため || (Template:FL digit78のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:LBFA digit910Table/Row]] || 不要 ||・リダイレクトページのため || (Template:LBFA digit910Table/Rowのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:LBF digit910Table]] || 2023/02/02対応 ||・luaをModule:LBFDigitに移動<hr />(追加)Module:LBFDigit || (Template:LBF digit910Tableのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:LBF digit910Table/Row]] || 2023/02/02対応 ||・未使用のため動作未確認 || (Template:LBF digit910Table/Rowのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Index/author]] || 2023/02/03対応 ||・luaをModule:Indexに移動<hr />(追加)Module:Index || (Template:Index/authorのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Index/formula]] || 2023/02/03対応 ||・luaをModule:Indexに移動 || (Template:Index/formulaのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Index/mass]] || 2023/02/03対応 ||・luaをModule:Indexに移動 || (Template:Index/massのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Index/name]] || 2023/02/03対応 ||・luaをModule:Indexに移動 || (Template:Index/nameのコメントはここに記述)<br />
|}<br />
<br />
==要対応==<br />
# <del>[[Template:JCBL/Header]]</del><br />
<br />
==要確認==<br />
# [[Template:Index/persist]]<br />
# <del>[[Template:Percent2Color]]</del><br />
# <del>[[Template:Search/Checkbox]]</del><br />
<br />
==要チェック==<br />
# Lipoquality名前空間<br />
<br />
==未使用(済)==<br />
# [[Template:LBS/AbbrevTable/Row]](LBS/FormatSugarを呼び出してる)<br />
# [[Template:EditButton]]<br />
# [[Template:EditButton/CheckList]]<br />
# [[Template:LambdaTest]]<br />
<br />
==修正の必要はないが、エラーで表示できない(済)==<br />
<br />
# [[Template:List Description/Body]]<br />
# [[Template:List Description/SetAnchor]]<br />
# [[Template:List Image/Body]]<br />
# [[Template:List Image/NameList]]<br />
# [[Template:List Links]]<br />
# [[Template:Metabolite/NameList]]<br />
# [[Template:Metabolite/SpeciesLink]]<br />
# [[Template:Reference/RefAbbrev]]<br />
# [[Template:RelationTable/GetNames]]<br />
# [[Template:TreeClass/ListSpecies]]<br />
<br />
表示しようとするとErrorが表示され、編集しようとするとEdit conflictが発生。削除も出来ない。<br />
<br />
Error<br />
<br />
There is currently no text in this page.<br />
You can search for this page title in other pages, search the related logs, or create this page.<br />
<br />
Edit conflict: Template:List Description/Body<br />
<br />
Someone else has changed this page since you started editing it.<br />
The upper text area contains the page text as it currently exists.<br />
Your changes are shown in the lower text area.<br />
You will have to merge your changes into the existing text.<br />
Only the text in the upper text area will be published when you press "Save changes".<br />
<br />
原因は、reivsionテーブルのrev_actor(編集者)が、あり得ない0になっていることが原因と思われる(actorテーブルを見ると、IDは1からとなっている)。<br />
rev_id: 100<br />
rev_page: 100<br />
rev_comment_id: 0<br />
rev_actor: 0 <- ここ<br />
rev_timestamp: 20080203000000<br />
rev_minor_edit: 1<br />
rev_deleted: 0<br />
rev_len: 10<br />
rev_parent_id: 0<br />
<br />
actor=0は、おそらく別環境からimportした際に、当環境に存在しないユーザが編集したページで発生している様子(該当ページはどうやらmetabolomics.jpからimportした)。<br />
本番環境、テスト環境両方で発生しており、おそらくかなり古いバージョンからアップデートした場合に、mediawikiが整合性をとれない構造になっているのではないかと思われる。<br />
<br />
<br />
解決策としては、rev_actorを存在するアカウントIDに書き換えることで対応可能(ただし、コードから独自に見つけた解決策なので、他にエラーが発生しないか様子を見る必要がある)。<br />
<br />
update revision set rev_actor = 2 where rev_actor = 0;<br />
<br />
==開発用メモ==<br />
* volatileは以下のように記述方法を変更<br />
- リンク元での書き方<br />
[[volatile:volatileページ|引数群|リンク表示名}}<br />
↓<br />
<nowiki>{{#volatile:volatileページ|リンク表示名|引数1|引数2|...|引数N}}</nowiki><br />
<br />
<nowiki>e.g. {{#volatile:ListMol/LBS|Blood group A|Structure=GalNAca1-3\(Fuca1-2\)Galb1-3GlcNAcb1-3}}</nowiki><br />
- リンク先での書き方<br />
{{{1}}}<br />
↓<br />
<nowiki>{{#get:1}}</nowiki><br />
<br />
* luaについて<br />
- luaがmediawikiにバンドルされたので、すぐに使える状態になっている。<br />
<br />
- スクリプトはModule名前空間に記述する<br />
<br />
- Module名前空間のコンテンツモデルを「Scribunto」に変更する必要がある。<br />
<br />
- 基本構文は以下の通り(一番目の引数を返すだけの関数)<br />
local getArgs = require('Module:Arguments').getArgs; -- 引数を受け取るための機能呼び出し<br />
local defArgs = require('Module:Arguments').defaultArgs; -- 引数のnil確認からデフォルト引数の処理を行う<br />
local lbs = {}; -- lbsとしているが、この名前は何でも良い。<br />
<br />
function lbs.FormatSugar( frame ) -- 関数を定義<br />
local args = defArgs(getArgs(frame), 1, ""); -- 引数を取得(defArgs(getArgs(frame), 必要な引数の個数, 引数1のデフォルト値, 引数2のデフォルト値, ..., 引数Nのデフォルト値)<br />
<br />
return args[1] -- 出力したい文字列を返す<br />
end<br />
<br />
return lbs; -- 関数定義したモジュールを返す<br />
<br />
- 呼び出し方は以下の通り<br />
<nowiki>{{#invoke:Module名前空間のページ|関数名|引数1|引数2|...|引数3}}</nowiki><br />
<br />
<nowiki>e.g. {{#invoke:LBS|FormatSugar|GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb1-3-R}}</nowiki></div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Lipidbank_wiki:Status2v1.39&diff=117152
Lipidbank wiki:Status2v1.39
2023-02-03T07:31:25Z
<p>Editor: </p>
<hr />
<div>動作していないがリストにないページや、対応済みとなっているが表示や動作がおかしいページがあれば、「mediawiki ver1.39への対応状況」やテーブルの「コメント」欄に追記してください。<br />
<br />
wikiの書き方に慣れていなければ、この下の「コメント(自由記述)」に追記してください。<br />
<br />
==コメント(自由記述)==<br />
<br />
<br />
==mediawiki ver1.39への対応状況==<br />
<br />
* 2023/01/31 要チェックリストを追加(Suwa)、Category:LBGAを再修正(Suwa)、全Volatileの修正が完了(Suwa)<br />
* 2023/01/30 全Cateogryの修正が完了(Suwa)<br />
* 2023/01/26 Cateogry:LBGAを修正(Suwa)<br />
* 2023/01/25 このページを作成(Suwa)<br />
<br />
==対応状況==<br />
<br />
* 現在、<strong>83/84</strong>(うち9件保留)が完了。<br />
* テーブルヘッダの「対応」セルをクリックして並べ替えることで、対応済み項目だけまとめて表示可能。<br />
{{#def:c|1}}<br />
{| class="wikitable sortable"<br />
|-<br />
! 番号 || ページ || 対応 || 対応内容 || コメント<br />
|-<br />
| {{#var:c}} || [[:Category:LBS/Search]] || 2023/01/25対応 ||・HTMLForm extensionをv1.39に対応<br />・javascriptが動くよう修正<br />・Volatile機能をHTMLFormだけで実現<br />・luaがmediawikiにバンドルされたので、そのluaで動くよう修正<br />・Persistは動かないので、AllChainsへのページリンクだけ表示<br />・Template:LBS/FormatSugarのluaをModule:LBSに移して使用(Template:LBS/FormatSugarは不要)<br />・defTempが使えないため、Template:GetIconを追加・<del><span style="color: red">「Search from Structure」のリンク先(Volatile:ListMol/LBS)にてアイコンが表示されていない問題は未対応<br />・Search from Structureで「&lt;sub&gt;」がそのまま表示されている。</span></del><hr />(追加)Module:LBS, Template:GetIcon<br />(廃止)Template:LBS/FormatSugar || (Category:LBS/Searchのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[:Category:LBA]] || 不要 || [[:Category:LBGA]]へのリダイレクトのため || (Category:LBAのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[:Category:LBS]] || 2023/01/30対応 ||・luaをModule:LBSにFomatSugar()として移動<br />・volatileの修正<br/ >・volatileの機能修正により、引数をencodeが不要に || (Category:LBSのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[:Category:LBGAD]] || 2023/01/30対応 ||・Template:ListMolを修正<br />・Template:FormatNameのluaをModule:Commonに移動<br /><hr />(追加)Module:Common || (Category:LBGADのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[:Category:LBGAC]] || 2023/01/30対応 ||・luaをModule:LBGAにGroupTable()として移動 || (Category:LBGACのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[:Category:LBGA]] || 2023/01/26対応<br />2023/01/31追加修正 ||・luaプログラムをModule:LBGAに切り分け<br />・<del><span style="color: red">「Species-Structure Relationship」テーブルのリンク先(Volatile:ListMolByReference)は未対応</span></del><br />・volatileの書き方を修正<hr />(追加)Module:LBGA|| (Category:LBGAのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[:Category:LBGAA]] || 2023/01/30対応 ||・volatileの書き方を修正 || (Category:LBGAAのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[:Category:LBG]] || 2023/01/30対応 ||・volatileの書き方を修正<br />・Template:MapLinkを修正 || (Category:LBGのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[:Category:LBF]] || 2023/01/30対応 ||・volatileの書き方を修正 || (Category:LBFのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:AuthorSummary]] || 2023/01/30対応<br />2023/02/03グラフ対応 ||・luaをModule:AuthorSummaryへ移動<br />・<del><span style="color:red">グラフ表示はどう対応するか検討</span></del>・グラフ表示は一旦jpgraphで実装<hr />(追加)Module:AuthorSummary || (Volatile:AuthorSummaryのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ClassMatrix]] || 2023/01/30対応 ||・luaをModule:ClassMatrixへ移動<br />・Template:ClassMatrix/CreateRowのvolatileの書き方を修正<hr />(追加)Module:ClassMatrix || (11のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:JAS/Genes]] || 2023/01/31対応 ||・volatileの書き方を修正<br />・luaをModule:JASに移動<hr />(追加)Module:JAS || (12のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ListField]] || 2023/01/30対応<br /><span style="color:red">動作未確認</span> ||・luaをModule/ListFieldに移動<br />・volatileの書き方を修正<br />(ただし、どこからも呼び出されてないので動作検証できず)<hr />(追加)Module:ListField || (13のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ListMol/LBS]] || 2023/01/30対応 || ・<nowiki>{{{1}}}を{{#get:1}}に変更</nowiki><br />・<del><span style="color:red">アイコン画像が表示されるよう対応予定</span></del>|| (14のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ListMol/LBStitle]] || 2023/01/30対応 ||・volatileの書き方を修正 || (15のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ListMolByField]] || 2023/01/30対応<br /><span style="color:red">動作未確認</span> ||・volatileの書き方を修正<br />(ただし、どこからも呼び出されてないので動作検証できず) || (16のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ListMolByReference]] || 2023/01/30対応 ||・luaをModule:CommonにListMolByReference()として移動 || (17のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ListPage]] || 2023/01/30対応 ||・volatileの書き方を修正 || (18のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ListRef]] || 2023/01/30対応 ||・volatileの書き方を修正 || (19のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ListRefOfID]] || 2023/01/31対応 ||・luaをModule:ListRefOfIDに移動<hr />(追加)Module:ListRefOfID || (20のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ListStructures]] || 不要 || || (21のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ShowField]] || 2023/01/30対応<br />2023/02/01修正 ||・<del>他の修正に連動して完了</del><br />・volatileの書き方を修正 || (22のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:StructureSearch]] || 2023/01/30対応<br /><span style="color:red">動作未確認</span> ||・volatileの書き方を修正 || (23のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:VolatileTest]] || 不要 || || (24のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:AdvancedLBSSearch.js]] || 未使用のため保留 || || (25のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:CalculateMass.js]] || 未使用のため保留 || || (26のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:Common.css]] || 2023/01/25対応 || ・volatileリンクの見た目のスタイルを追加 || (27のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:Common.js]] || 2023/01/25対応 || ・現在の構成で動作するよう修正 || (28のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:GlycosphingolipidMassCalculator.js]] || 2023/01/25対応 || ・クラス化して、現在の構成で動作するよう修正 || (29のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:GlyphEditor.js]] || 2023/02/01対応 ||・javascriptを修正(MediaWiki:Common.js, MediaWiki:GlyphEditor.js, Template:GlyphEditor, StructureSearch) || (30のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:GoogleAPI.js]] || 未使用のため保留 || || (31のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:JBrowse.js]] || || || (32のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:LBSSearch.js]] || 2023/01/25対応 || ・クラス化して、現在の構成で動くよう修正 || (33のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:Lipoquality.js]] || 保留 || || (34のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:LipoqualityChart.js]] || 保留 || || (35のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:LipoqualityCommon.js]] || 保留 || || (36のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:LipoqualityGet.js]] || 保留 || || (37のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:LipoqualitySearch.js]] || 保留 || || (38のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:PathwayEditor.js]] || 2023/02/03対応 ||・MediaWiki:PathwayEditorHandler.jsの修正にて完了 || (39のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:PathwayEditorHandler.js]] || 2023/02/03対応 ||・javascriptを修正(MediaWiki:Common.js)<br />・PathwayMap名前空間が無かったため、PathwayMap名前空間を作成し、そこに移動 || (40のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:MapLink]] || 2023/01/30対応 ||・volatileの書き方を修正 || (Template:MapLinのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:LBGA/GroupTable]] || 2023/01/30対応 ||・luaをModule:LBGAへ移動 || (Template:LBGA/GroupTableのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Glycolipid/distribution]] || 2023/01/30対応 ||・defTempが使えないため、Template:GetIconを作成<hr />(追加)Template:GetIcon|| (Template:Glycolipid/distributionのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:FormatName]] || 2023/01/30対応 ||・luaをModule:Commonに移動 || (Template:FormatNameのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:ClassMatrix/CreateRow]] || 2023/01/30対応 ||・volatileの書き方を修正 || (Template:ClassMatrix/CreateRowのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:JournalTitle/TableRow3]] || 2023/01/30対応 ||・volatileの書き方を修正 || (Template:JournalTitle/TableRow3のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:JAS/MutationStat]] || 2023/01/31対応 ||・luaをModule:JASへ移動 || (Template:JAS/MutationStatのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:JAS/AllMutation]] || 2023/01/31対応 ||・luaをModule:JASへ移動 || (Template:JAS/AllMutationのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:AuthorSummary]] || 2023/01/31対応 ||・volatileの書き方を修正 || (Template:AuthorSummaryのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Index:LBGA]] || 2023/02/02対応 ||・defTempをTemplate:VolatileLinkに移動<hr />(追加)Template:VolatileLink || (Index:LBGAのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[JAS:Home]] || 2023/02/01対応 ||・template:JAS/GeneList/Rowの修正により完了 || (JAS:Homeのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:ClassMatrix]] || 2023/01/31対応 ||・luaをModule:ClassMatrixから使用(ただし、初期のテンプレートで、今は使われていないと思われる) || (Template:ClassMatrixのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:CountryTable]] || 未使用のため保留 || || (Template:CountryTableのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Glycolipid]] || 2023/02/01対応 ||・volatileの書き方を修正<br />・<span style="color: red"><nowiki>{{#googleapi:}}が各ページに書き込まれているので、あとでダミーを作って非表示にする</nowiki></span> || (Template:Glycolipidのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:JAS/GeneList/LinkPage]] || 2023/02/01対応 ||・volatileの書き方を修正 || (Template:JAS/GeneList/LinkPageのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:ListAllChains]] || ・2023/02/01対応 ||・luaをModule:ListAllChainsに移動<hr />(追加)Module:ListAllChains || (Template:ListAllChainsのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:ListPage]] ||・2023/02/01対応 ||・volatileの書き方を修正 || (Template:ListPageのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Map/Glycerophospholipid]] || 不要 ||・Template:Map/Glycerophospholipid/Expressionの対応により完了 || (Template:Map/Glycerophospholipidのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Map/Glycerophospholipid/Expression]] || 2023/02/02対応 ||・luaでmaxを取得した物を{{#max:}}に変更 || (Template:Map/Glycerophospholipid/Expressionのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Map/Glycerophospholipid/GetValues]] || 不要 ||・Template:Map/Glycerophospholipid/Expressionの対応により完了 || (Template:Map/Glycerophospholipid/GetValuesのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Metabolite]] || 2023/02/02対応 ||・volatileの書き方を修正 || (Template:Metaboliteのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Reference/AuthorLink]] || 2023/02/02対応 ||・volatileの書き方を修正(ただし、未使用) || (Template:Reference/AuthorLinkのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:RelationTable]] || 2023/02/01対応 ||・defTempをテンプレートページに移動<hr />(追加)Template:RelationTable/Row2, Template:RelationTable/Row3 || (Template:RelationTableのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:TableRow3]] || 2023/02/02対応 ||・volatileの書き方を修正 || (Template:TableRow3のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:TableRow3/Country]] || 2023/02/02対応 ||・volatileの書き方を修正(ただし、未使用) || (Template:TableRow3/Countryのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:TableRow6/author]] || 2023/02/02対応 ||・volatileの書き方を修正(ただし、未使用) || (Template:TableRow6/authorのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:TableRow6/authorSub]] || 2023/02/02対応 ||・volatileの書き方を修正(ただし、未使用) || (Template:TableRow6/authorSubのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Taguchi/LinkItem]] || 2023/02/02対応 ||・volatileの書き方を修正 || (Template:Taguchi/LinkItemのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Taguchi/LinkItems]] || 不要 || Template:Taguchi/LinkItemの修正にて完了 || (Template:Taguchi/LinkItemsのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Toyama/Matrix]] || 2023/02/02対応<br /> ||・luaをModule:Toayamに移動<hr />(追加)Module:Toyama || (Template:Toyama/Matrixのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:LBS/FormatSugar]] || 2023/02/01対応 ||・luaをModule:LBSから呼び出すよう修正 || (Template:LBS/FormatSugarのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Glycolipid/OldLBLink]] || 2023/02/01対応 ||・httpをhttpsに変更</br />・cgi-binで各ページに飛ばしていたが、現在はカテゴリ毎に一ページになったため、ページへジャンプするよう修正 || (Template:Glycolipid/OldLBLinkのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:GlyphEditor]] || 2023/01/31対応 ||・javascriptの呼び出し方を変更 || (Template:GlyphEditorのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:ListRefOfID]] || 2023/02/02対応 ||・Volatile:ListRefOfIDと同じ || (Template:ListRefOfIDのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:FL digit56]] || 保留 ||・フラボノイド用機能のため || (Template:FL digit56のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:FL digit56with78]] || 保留 ||・フラボノイド用機能のため || (Template:FL digit56with78のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:FL digit78]] || 保留 ||・フラボノイド用機能のため || (Template:FL digit78のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:LBFA digit910Table/Row]] || 不要 ||・リダイレクトページのため || (Template:LBFA digit910Table/Rowのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:LBF digit910Table]] || 2023/02/02対応 ||・luaをModule:LBFDigitに移動<hr />(追加)Module:LBFDigit || (Template:LBF digit910Tableのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:LBF digit910Table/Row]] || 2023/02/02対応 ||・未使用のため動作未確認 || (Template:LBF digit910Table/Rowのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Index/author]] || 2023/02/03対応 ||・luaをModule:Indexに移動<hr />(追加)Module:Index || (Template:Index/authorのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Index/formula]] || 2023/02/03対応 ||・luaをModule:Indexに移動 || (Template:Index/formulaのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Index/mass]] || 2023/02/03対応 ||・luaをModule:Indexに移動 || (Template:Index/massのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Index/name]] || 2023/02/03対応 ||・luaをModule:Indexに移動 || (Template:Index/nameのコメントはここに記述)<br />
|}<br />
<br />
==要対応==<br />
# <del>[[Template:JCBL/Header]]</del><br />
<br />
==要確認==<br />
# [[Template:Index/persist]]<br />
# <del>[[Template:Percent2Color]]</del><br />
# <del>[[Template:Search/Checkbox]]</del><br />
<br />
==要チェック==<br />
# Lipoquality名前空間<br />
<br />
==未使用(済)==<br />
# [[Template:LBS/AbbrevTable/Row]](LBS/FormatSugarを呼び出してる)<br />
# [[Template:EditButton]]<br />
# [[Template:EditButton/CheckList]]<br />
# [[Template:LambdaTest]]<br />
<br />
==修正の必要はないが、エラーで表示できない(済)==<br />
<br />
# [[Template:List Description/Body]]<br />
# [[Template:List Description/SetAnchor]]<br />
# [[Template:List Image/Body]]<br />
# [[Template:List Image/NameList]]<br />
# [[Template:List Links]]<br />
# [[Template:Metabolite/NameList]]<br />
# [[Template:Metabolite/SpeciesLink]]<br />
# [[Template:Reference/RefAbbrev]]<br />
# [[Template:RelationTable/GetNames]]<br />
# [[Template:TreeClass/ListSpecies]]<br />
<br />
表示しようとするとErrorが表示され、編集しようとするとEdit conflictが発生。削除も出来ない。<br />
<br />
Error<br />
<br />
There is currently no text in this page.<br />
You can search for this page title in other pages, search the related logs, or create this page.<br />
<br />
Edit conflict: Template:List Description/Body<br />
<br />
Someone else has changed this page since you started editing it.<br />
The upper text area contains the page text as it currently exists.<br />
Your changes are shown in the lower text area.<br />
You will have to merge your changes into the existing text.<br />
Only the text in the upper text area will be published when you press "Save changes".<br />
<br />
原因は、reivsionテーブルのrev_actor(編集者)が、あり得ない0になっていることが原因と思われる(actorテーブルを見ると、IDは1からとなっている)。<br />
rev_id: 100<br />
rev_page: 100<br />
rev_comment_id: 0<br />
rev_actor: 0 <- ここ<br />
rev_timestamp: 20080203000000<br />
rev_minor_edit: 1<br />
rev_deleted: 0<br />
rev_len: 10<br />
rev_parent_id: 0<br />
<br />
actor=0は、おそらく別環境からimportした際に、当環境に存在しないユーザが編集したページで発生している様子(該当ページはどうやらmetabolomics.jpからimportした)。<br />
本番環境、テスト環境両方で発生しており、おそらくかなり古いバージョンからアップデートした場合に、mediawikiが整合性をとれない構造になっているのではないかと思われる。<br />
<br />
<br />
解決策としては、rev_actorを存在するアカウントIDに書き換えることで対応可能(ただし、コードから独自に見つけた解決策なので、他にエラーが発生しないか様子を見る必要がある)。<br />
<br />
update revision set rev_actor = 2 where rev_actor = 0;<br />
<br />
==開発用メモ==<br />
* volatileは以下のように記述方法を変更<br />
- リンク元での書き方<br />
[[volatile:volatileページ|引数群|リンク表示名}}<br />
↓<br />
<nowiki>{{#volatile:volatileページ|リンク表示名|引数1|引数2|...|引数N}}</nowiki><br />
<br />
<nowiki>e.g. {{#volatile:ListMol/LBS|Blood group A|Structure=GalNAca1-3\(Fuca1-2\)Galb1-3GlcNAcb1-3}}</nowiki><br />
- リンク先での書き方<br />
{{{1}}}<br />
↓<br />
<nowiki>{{#get:1}}</nowiki><br />
<br />
* luaについて<br />
- luaがmediawikiにバンドルされたので、すぐに使える状態になっている。<br />
<br />
- スクリプトはModule名前空間に記述する<br />
<br />
- Module名前空間のコンテンツモデルを「Scribunto」に変更する必要がある。<br />
<br />
- 基本構文は以下の通り(一番目の引数を返すだけの関数)<br />
local getArgs = require('Module:Arguments').getArgs; -- 引数を受け取るための機能呼び出し<br />
local defArgs = require('Module:Arguments').defaultArgs; -- 引数のnil確認からデフォルト引数の処理を行う<br />
local lbs = {}; -- lbsとしているが、この名前は何でも良い。<br />
<br />
function lbs.FormatSugar( frame ) -- 関数を定義<br />
local args = defArgs(getArgs(frame), 1, ""); -- 引数を取得(defArgs(getArgs(frame), 必要な引数の個数, 引数1のデフォルト値, 引数2のデフォルト値, ..., 引数Nのデフォルト値)<br />
<br />
return args[1] -- 出力したい文字列を返す<br />
end<br />
<br />
return lbs; -- 関数定義したモジュールを返す<br />
<br />
- 呼び出し方は以下の通り<br />
<nowiki>{{#invoke:Module名前空間のページ|関数名|引数1|引数2|...|引数3}}</nowiki><br />
<br />
<nowiki>e.g. {{#invoke:LBS|FormatSugar|GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb1-3-R}}</nowiki></div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Template:ReferencePDF&diff=117151
Template:ReferencePDF
2023-02-03T05:51:57Z
<p>Editor: </p>
<hr />
<div>{{#def:url|{{#nth:{{{1|}}}|6|,}}}}<br />
{{#if:{{#var:url}}|{{#def:filename|{{#replace:{{{1|}}}|,{{#var:url}}|}}}}|{{#def:filename|{{{1|}}}}}}}<br />
<br />
{{#if:{{{1|}}}|{{#bar:}}-{{#cr:}}{{#bar:}} {{#nth:{{{1}}}|1|,}} {{#bar:}}{{#bar:}} {{#nth:{{{1}}}|2|,}} {{#bar:}}{{#bar:}} {{#nth:{{{1}}}|3|,}} {{#bar:}}{{#bar:}} {{#nth:{{{1}}}|4|,}} {{#bar:}}{{#bar:}} {{#nth:{{{1}}}|5|,}} {{#bar:}}{{#bar:}} {{#if:{{#var:url}}|[https://jcbl.jp/{{#var:url}}/{{#replace:{{#var:filename}}|&#160;|%20}}.pdf {{#var:filename}}.pdf]|[[File:{{{1}}}.pdf|alt=pdf]]}} {{#bar:}}{{#bar:}} {{{2|}}} {{#cr:}} }}{{#cr:}}</div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Lipidbank_wiki:Status2v1.39&diff=117150
Lipidbank wiki:Status2v1.39
2023-02-03T05:43:57Z
<p>Editor: </p>
<hr />
<div>動作していないがリストにないページや、対応済みとなっているが表示や動作がおかしいページがあれば、「mediawiki ver1.39への対応状況」やテーブルの「コメント」欄に追記してください。<br />
<br />
wikiの書き方に慣れていなければ、この下の「コメント(自由記述)」に追記してください。<br />
<br />
==コメント(自由記述)==<br />
<br />
<br />
==mediawiki ver1.39への対応状況==<br />
<br />
* 2023/01/31 要チェックリストを追加(Suwa)、Category:LBGAを再修正(Suwa)、全Volatileの修正が完了(Suwa)<br />
* 2023/01/30 全Cateogryの修正が完了(Suwa)<br />
* 2023/01/26 Cateogry:LBGAを修正(Suwa)<br />
* 2023/01/25 このページを作成(Suwa)<br />
<br />
==対応状況==<br />
<br />
* 現在、<strong>84/84</strong>(うち10件保留)が完了。<br />
* テーブルヘッダの「対応」セルをクリックして並べ替えることで、対応済み項目だけまとめて表示可能。<br />
{{#def:c|1}}<br />
{| class="wikitable sortable"<br />
|-<br />
! 番号 || ページ || 対応 || 対応内容 || コメント<br />
|-<br />
| {{#var:c}} || [[:Category:LBS/Search]] || 2023/01/25対応 ||・HTMLForm extensionをv1.39に対応<br />・javascriptが動くよう修正<br />・Volatile機能をHTMLFormだけで実現<br />・luaがmediawikiにバンドルされたので、そのluaで動くよう修正<br />・Persistは動かないので、AllChainsへのページリンクだけ表示<br />・Template:LBS/FormatSugarのluaをModule:LBSに移して使用(Template:LBS/FormatSugarは不要)<br />・defTempが使えないため、Template:GetIconを追加・<del><span style="color: red">「Search from Structure」のリンク先(Volatile:ListMol/LBS)にてアイコンが表示されていない問題は未対応<br />・Search from Structureで「&lt;sub&gt;」がそのまま表示されている。</span></del><hr />(追加)Module:LBS, Template:GetIcon<br />(廃止)Template:LBS/FormatSugar || (Category:LBS/Searchのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[:Category:LBA]] || 不要 || [[:Category:LBGA]]へのリダイレクトのため || (Category:LBAのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[:Category:LBS]] || 2023/01/30対応 ||・luaをModule:LBSにFomatSugar()として移動<br />・volatileの修正<br/ >・volatileの機能修正により、引数をencodeが不要に || (Category:LBSのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[:Category:LBGAD]] || 2023/01/30対応 ||・Template:ListMolを修正<br />・Template:FormatNameのluaをModule:Commonに移動<br /><hr />(追加)Module:Common || (Category:LBGADのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[:Category:LBGAC]] || 2023/01/30対応 ||・luaをModule:LBGAにGroupTable()として移動 || (Category:LBGACのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[:Category:LBGA]] || 2023/01/26対応<br />2023/01/31追加修正 ||・luaプログラムをModule:LBGAに切り分け<br />・<del><span style="color: red">「Species-Structure Relationship」テーブルのリンク先(Volatile:ListMolByReference)は未対応</span></del><br />・volatileの書き方を修正<hr />(追加)Module:LBGA|| (Category:LBGAのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[:Category:LBGAA]] || 2023/01/30対応 ||・volatileの書き方を修正 || (Category:LBGAAのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[:Category:LBG]] || 2023/01/30対応 ||・volatileの書き方を修正<br />・Template:MapLinkを修正 || (Category:LBGのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[:Category:LBF]] || 2023/01/30対応 ||・volatileの書き方を修正 || (Category:LBFのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:AuthorSummary]] || 2023/01/30対応<br />(グラフのみ保留) ||・luaをModule:AuthorSummaryへ移動<br />・<span style="color:red">グラフ表示はどう対応するか検討</span><hr />(追加)Module:AuthorSummary || (Volatile:AuthorSummaryのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ClassMatrix]] || 2023/01/30対応 ||・luaをModule:ClassMatrixへ移動<br />・Template:ClassMatrix/CreateRowのvolatileの書き方を修正<hr />(追加)Module:ClassMatrix || (11のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:JAS/Genes]] || 2023/01/31対応 ||・volatileの書き方を修正<br />・luaをModule:JASに移動<hr />(追加)Module:JAS || (12のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ListField]] || 2023/01/30対応<br /><span style="color:red">動作未確認</span> ||・luaをModule/ListFieldに移動<br />・volatileの書き方を修正<br />(ただし、どこからも呼び出されてないので動作検証できず)<hr />(追加)Module:ListField || (13のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ListMol/LBS]] || 2023/01/30対応 || ・<nowiki>{{{1}}}を{{#get:1}}に変更</nowiki><br />・<del><span style="color:red">アイコン画像が表示されるよう対応予定</span></del>|| (14のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ListMol/LBStitle]] || 2023/01/30対応 ||・volatileの書き方を修正 || (15のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ListMolByField]] || 2023/01/30対応<br /><span style="color:red">動作未確認</span> ||・volatileの書き方を修正<br />(ただし、どこからも呼び出されてないので動作検証できず) || (16のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ListMolByReference]] || 2023/01/30対応 ||・luaをModule:CommonにListMolByReference()として移動 || (17のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ListPage]] || 2023/01/30対応 ||・volatileの書き方を修正 || (18のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ListRef]] || 2023/01/30対応 ||・volatileの書き方を修正 || (19のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ListRefOfID]] || 2023/01/31対応 ||・luaをModule:ListRefOfIDに移動<hr />(追加)Module:ListRefOfID || (20のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ListStructures]] || 不要 || || (21のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:ShowField]] || 2023/01/30対応<br />2023/02/01修正 ||・<del>他の修正に連動して完了</del><br />・volatileの書き方を修正 || (22のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:StructureSearch]] || 2023/01/30対応<br /><span style="color:red">動作未確認</span> ||・volatileの書き方を修正 || (23のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Volatile:VolatileTest]] || 不要 || || (24のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:AdvancedLBSSearch.js]] || 未使用のため保留 || || (25のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:CalculateMass.js]] || 未使用のため保留 || || (26のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:Common.css]] || 2023/01/25対応 || ・volatileリンクの見た目のスタイルを追加 || (27のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:Common.js]] || 2023/01/25対応 || ・現在の構成で動作するよう修正 || (28のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:GlycosphingolipidMassCalculator.js]] || 2023/01/25対応 || ・クラス化して、現在の構成で動作するよう修正 || (29のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:GlyphEditor.js]] || 2023/02/01対応 ||・javascriptを修正(MediaWiki:Common.js, MediaWiki:GlyphEditor.js, Template:GlyphEditor, StructureSearch) || (30のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:GoogleAPI.js]] || 未使用のため保留 || || (31のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:JBrowse.js]] || || || (32のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:LBSSearch.js]] || 2023/01/25対応 || ・クラス化して、現在の構成で動くよう修正 || (33のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:Lipoquality.js]] || 保留 || || (34のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:LipoqualityChart.js]] || 保留 || || (35のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:LipoqualityCommon.js]] || 保留 || || (36のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:LipoqualityGet.js]] || 保留 || || (37のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:LipoqualitySearch.js]] || 保留 || || (38のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:PathwayEditor.js]] || 2023/02/03対応 ||・MediaWiki:PathwayEditorHandler.jsの修正にて完了 || (39のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[MediaWiki:PathwayEditorHandler.js]] || 2023/02/03対応 ||・javascriptを修正(MediaWiki:Common.js)<br />・PathwayMap名前空間が無かったため、PathwayMap名前空間を作成し、そこに移動 || (40のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:MapLink]] || 2023/01/30対応 ||・volatileの書き方を修正 || (Template:MapLinのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:LBGA/GroupTable]] || 2023/01/30対応 ||・luaをModule:LBGAへ移動 || (Template:LBGA/GroupTableのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Glycolipid/distribution]] || 2023/01/30対応 ||・defTempが使えないため、Template:GetIconを作成<hr />(追加)Template:GetIcon|| (Template:Glycolipid/distributionのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:FormatName]] || 2023/01/30対応 ||・luaをModule:Commonに移動 || (Template:FormatNameのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:ClassMatrix/CreateRow]] || 2023/01/30対応 ||・volatileの書き方を修正 || (Template:ClassMatrix/CreateRowのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:JournalTitle/TableRow3]] || 2023/01/30対応 ||・volatileの書き方を修正 || (Template:JournalTitle/TableRow3のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:JAS/MutationStat]] || 2023/01/31対応 ||・luaをModule:JASへ移動 || (Template:JAS/MutationStatのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:JAS/AllMutation]] || 2023/01/31対応 ||・luaをModule:JASへ移動 || (Template:JAS/AllMutationのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:AuthorSummary]] || 2023/01/31対応 ||・volatileの書き方を修正 || (Template:AuthorSummaryのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Index:LBGA]] || 2023/02/02対応 ||・defTempをTemplate:VolatileLinkに移動<hr />(追加)Template:VolatileLink || (Index:LBGAのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[JAS:Home]] || 2023/02/01対応 ||・template:JAS/GeneList/Rowの修正により完了 || (JAS:Homeのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:ClassMatrix]] || 2023/01/31対応 ||・luaをModule:ClassMatrixから使用(ただし、初期のテンプレートで、今は使われていないと思われる) || (Template:ClassMatrixのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:CountryTable]] || 未使用のため保留 || || (Template:CountryTableのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Glycolipid]] || 2023/02/01対応 ||・volatileの書き方を修正<br />・<span style="color: red"><nowiki>{{#googleapi:}}が各ページに書き込まれているので、あとでダミーを作って非表示にする</nowiki></span> || (Template:Glycolipidのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:JAS/GeneList/LinkPage]] || 2023/02/01対応 ||・volatileの書き方を修正 || (Template:JAS/GeneList/LinkPageのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:ListAllChains]] || ・2023/02/01対応 ||・luaをModule:ListAllChainsに移動<hr />(追加)Module:ListAllChains || (Template:ListAllChainsのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:ListPage]] ||・2023/02/01対応 ||・volatileの書き方を修正 || (Template:ListPageのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Map/Glycerophospholipid]] || 不要 ||・Template:Map/Glycerophospholipid/Expressionの対応により完了 || (Template:Map/Glycerophospholipidのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Map/Glycerophospholipid/Expression]] || 2023/02/02対応 ||・luaでmaxを取得した物を{{#max:}}に変更 || (Template:Map/Glycerophospholipid/Expressionのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Map/Glycerophospholipid/GetValues]] || 不要 ||・Template:Map/Glycerophospholipid/Expressionの対応により完了 || (Template:Map/Glycerophospholipid/GetValuesのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Metabolite]] || 2023/02/02対応 ||・volatileの書き方を修正 || (Template:Metaboliteのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Reference/AuthorLink]] || 2023/02/02対応 ||・volatileの書き方を修正(ただし、未使用) || (Template:Reference/AuthorLinkのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:RelationTable]] || 2023/02/01対応 ||・defTempをテンプレートページに移動<hr />(追加)Template:RelationTable/Row2, Template:RelationTable/Row3 || (Template:RelationTableのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:TableRow3]] || 2023/02/02対応 ||・volatileの書き方を修正 || (Template:TableRow3のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:TableRow3/Country]] || 2023/02/02対応 ||・volatileの書き方を修正(ただし、未使用) || (Template:TableRow3/Countryのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:TableRow6/author]] || 2023/02/02対応 ||・volatileの書き方を修正(ただし、未使用) || (Template:TableRow6/authorのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:TableRow6/authorSub]] || 2023/02/02対応 ||・volatileの書き方を修正(ただし、未使用) || (Template:TableRow6/authorSubのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Taguchi/LinkItem]] || 2023/02/02対応 ||・volatileの書き方を修正 || (Template:Taguchi/LinkItemのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Taguchi/LinkItems]] || 不要 || Template:Taguchi/LinkItemの修正にて完了 || (Template:Taguchi/LinkItemsのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Toyama/Matrix]] || 2023/02/02対応<br />(グラフのみ保留) ||・luaをModule:Toayamに移動<hr />(追加)Module:Toyama || (Template:Toyama/Matrixのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:LBS/FormatSugar]] || 2023/02/01対応 ||・luaをModule:LBSから呼び出すよう修正 || (Template:LBS/FormatSugarのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Glycolipid/OldLBLink]] || 2023/02/01対応 ||・httpをhttpsに変更</br />・cgi-binで各ページに飛ばしていたが、現在はカテゴリ毎に一ページになったため、ページへジャンプするよう修正 || (Template:Glycolipid/OldLBLinkのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:GlyphEditor]] || 2023/01/31対応 ||・javascriptの呼び出し方を変更 || (Template:GlyphEditorのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:ListRefOfID]] || 2023/02/02対応 ||・Volatile:ListRefOfIDと同じ || (Template:ListRefOfIDのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:FL digit56]] || 保留 ||・フラボノイド用機能のため || (Template:FL digit56のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:FL digit56with78]] || 保留 ||・フラボノイド用機能のため || (Template:FL digit56with78のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:FL digit78]] || 保留 ||・フラボノイド用機能のため || (Template:FL digit78のコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:LBFA digit910Table/Row]] || 不要 ||・リダイレクトページのため || (Template:LBFA digit910Table/Rowのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:LBF digit910Table]] || 2023/02/02対応 ||・luaをModule:LBFDigitに移動<hr />(追加)Module:LBFDigit || (Template:LBF digit910Tableのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:LBF digit910Table/Row]] || 2023/02/02対応 ||・未使用のため動作未確認 || (Template:LBF digit910Table/Rowのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Index/author]] || 2023/02/03対応 ||・luaをModule:Indexに移動<hr />(追加)Module:Index || (Template:Index/authorのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Index/formula]] || 2023/02/03対応 ||・luaをModule:Indexに移動 || (Template:Index/formulaのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Index/mass]] || 2023/02/03対応 ||・luaをModule:Indexに移動 || (Template:Index/massのコメントはここに記述)<br />
|-{{#def:c|{{#expr:{{#var:c}}+1}}}}<br />
| {{#var:c}} || [[Template:Index/name]] || 2023/02/03対応 ||・luaをModule:Indexに移動 || (Template:Index/nameのコメントはここに記述)<br />
|}<br />
<br />
==要対応==<br />
# <del>[[Template:JCBL/Header]]</del><br />
<br />
==要確認==<br />
# [[Template:Index/persist]]<br />
# <del>[[Template:Percent2Color]]</del><br />
# <del>[[Template:Search/Checkbox]]</del><br />
<br />
==要チェック==<br />
# Lipoquality名前空間<br />
<br />
==未使用(済)==<br />
# [[Template:LBS/AbbrevTable/Row]](LBS/FormatSugarを呼び出してる)<br />
# [[Template:EditButton]]<br />
# [[Template:EditButton/CheckList]]<br />
# [[Template:LambdaTest]]<br />
<br />
==修正の必要はないが、エラーで表示できない(済)==<br />
<br />
# [[Template:List Description/Body]]<br />
# [[Template:List Description/SetAnchor]]<br />
# [[Template:List Image/Body]]<br />
# [[Template:List Image/NameList]]<br />
# [[Template:List Links]]<br />
# [[Template:Metabolite/NameList]]<br />
# [[Template:Metabolite/SpeciesLink]]<br />
# [[Template:Reference/RefAbbrev]]<br />
# [[Template:RelationTable/GetNames]]<br />
# [[Template:TreeClass/ListSpecies]]<br />
<br />
表示しようとするとErrorが表示され、編集しようとするとEdit conflictが発生。削除も出来ない。<br />
<br />
Error<br />
<br />
There is currently no text in this page.<br />
You can search for this page title in other pages, search the related logs, or create this page.<br />
<br />
Edit conflict: Template:List Description/Body<br />
<br />
Someone else has changed this page since you started editing it.<br />
The upper text area contains the page text as it currently exists.<br />
Your changes are shown in the lower text area.<br />
You will have to merge your changes into the existing text.<br />
Only the text in the upper text area will be published when you press "Save changes".<br />
<br />
原因は、reivsionテーブルのrev_actor(編集者)が、あり得ない0になっていることが原因と思われる(actorテーブルを見ると、IDは1からとなっている)。<br />
rev_id: 100<br />
rev_page: 100<br />
rev_comment_id: 0<br />
rev_actor: 0 <- ここ<br />
rev_timestamp: 20080203000000<br />
rev_minor_edit: 1<br />
rev_deleted: 0<br />
rev_len: 10<br />
rev_parent_id: 0<br />
<br />
actor=0は、おそらく別環境からimportした際に、当環境に存在しないユーザが編集したページで発生している様子(該当ページはどうやらmetabolomics.jpからimportした)。<br />
本番環境、テスト環境両方で発生しており、おそらくかなり古いバージョンからアップデートした場合に、mediawikiが整合性をとれない構造になっているのではないかと思われる。<br />
<br />
<br />
解決策としては、rev_actorを存在するアカウントIDに書き換えることで対応可能(ただし、コードから独自に見つけた解決策なので、他にエラーが発生しないか様子を見る必要がある)。<br />
<br />
update revision set rev_actor = 2 where rev_actor = 0;<br />
<br />
==開発用メモ==<br />
* volatileは以下のように記述方法を変更<br />
- リンク元での書き方<br />
[[volatile:volatileページ|引数群|リンク表示名}}<br />
↓<br />
<nowiki>{{#volatile:volatileページ|リンク表示名|引数1|引数2|...|引数N}}</nowiki><br />
<br />
<nowiki>e.g. {{#volatile:ListMol/LBS|Blood group A|Structure=GalNAca1-3\(Fuca1-2\)Galb1-3GlcNAcb1-3}}</nowiki><br />
- リンク先での書き方<br />
{{{1}}}<br />
↓<br />
<nowiki>{{#get:1}}</nowiki><br />
<br />
* luaについて<br />
- luaがmediawikiにバンドルされたので、すぐに使える状態になっている。<br />
<br />
- スクリプトはModule名前空間に記述する<br />
<br />
- Module名前空間のコンテンツモデルを「Scribunto」に変更する必要がある。<br />
<br />
- 基本構文は以下の通り(一番目の引数を返すだけの関数)<br />
local getArgs = require('Module:Arguments').getArgs; -- 引数を受け取るための機能呼び出し<br />
local defArgs = require('Module:Arguments').defaultArgs; -- 引数のnil確認からデフォルト引数の処理を行う<br />
local lbs = {}; -- lbsとしているが、この名前は何でも良い。<br />
<br />
function lbs.FormatSugar( frame ) -- 関数を定義<br />
local args = defArgs(getArgs(frame), 1, ""); -- 引数を取得(defArgs(getArgs(frame), 必要な引数の個数, 引数1のデフォルト値, 引数2のデフォルト値, ..., 引数Nのデフォルト値)<br />
<br />
return args[1] -- 出力したい文字列を返す<br />
end<br />
<br />
return lbs; -- 関数定義したモジュールを返す<br />
<br />
- 呼び出し方は以下の通り<br />
<nowiki>{{#invoke:Module名前空間のページ|関数名|引数1|引数2|...|引数3}}</nowiki><br />
<br />
<nowiki>e.g. {{#invoke:LBS|FormatSugar|GalNAca1-3(Fuca1-2)Galb1-3GlcNAcb1-3-R}}</nowiki></div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Template:Index/mass&diff=117149
Template:Index/mass
2023-02-03T05:41:56Z
<p>Editor: </p>
<hr />
<div><noinclude>質量のインデクス: {{{1}}} 最小値(デフォルト0) {{{2}}} 最大値(デフォルト1万) {{{3}}} 検索ページタイトル {{{4}}} true/nil EXTMASS と AVGMASSの選択</noinclude><br />
This page is automatically generated using [[Help:Contents|''Persist'' function]] (Last updated: {{REVISIONTIMESTAMP}}).<br><br />
<br />
{| width=100%<br />
|-<br />
|align=left| {{Index/persist|{{#if:{{{4|}}}|exact mass|average mass}}|{{#expr:{{{1|0}}}-{{{2|0}}}+{{{1|0}}}}}|{{{1|0}}}|Index/mass|{{{3}}}|{{{4|}}}}}<br />
|align=center| [[Index:{{{3}}}|<big>Back to Index</big>]]<br />
|align=right| {{Index/persist|{{#if:{{{4|}}}|exact mass|average mass}}|{{{2|0}}}|{{#expr:{{{2|0}}}+{{{2|0}}}-{{{1|0}}}}}|Index/mass|{{{3}}}|{{{4|}}}}}<br />
|}<br />
<hr><br />
<br />
{| class="wikitable" style="width=100%; margin: 1em auto; border-width:0px 0px 0px 0px;"<br />
|- style="background:#ccf"<br />
{{#repeat:IndexTable|1|<br />
{{#invoke:Index|MassIndexTable|{{#if:{{{4|}}}| {{#extmass:{{{3|FL1C99}}}}}| {{#avemass:{{{3|FL1C99}}}}} }}|{{{1}}}|{{{2}}}}}<br />
}}<br />
|}</div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Template:Index/name&diff=117148
Template:Index/name
2023-02-03T05:41:50Z
<p>Editor: </p>
<hr />
<div><noinclude>名前のインデクス {{{1}}} 値(文字列) {{{2}}} ページタイトル (FL/LB/..)</noinclude><br />
This page is automatically generated using [[Help:Contents|''Persist'' function]] (Last updated: {{REVISIONTIMESTAMP}}).<br><br />
<br />
<small>Note: words of less than 4 letters are excluded from the index.</small> <br />
{| width=100%<br />
|-<br />
|align=left| {{#persist:FLindex/name {{PrevLetter|{{{1}}}}}|go to Index {{PrevLetter|{{{1}}}}}|Index/name|2|{{PrevLetter|{{{1}}}}};FL}}<br />
|align=center| [[Index:{{{2}}}|<big>Back to Index</big>]]<br />
|align=right| {{#persist:FLindex/name {{PrevLetter|{{{1}}}}}|go to Index {{NextLetter|{{{1}}}}}|Index/name|2|{{NextLetter|{{{1}}}}};FL}}<br />
|}<br />
<hr><br />
{{#invoke:Index|Name|{{{1}}} {{#SearchLine:Common Name=||{{{2}}}%}}<br />
}}<br />
[[#top]]</div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Template:Index/formula&diff=117147
Template:Index/formula
2023-02-03T05:41:36Z
<p>Editor: </p>
<hr />
<div><noinclude>名前のインデクス {{{1}}} 原子 {{{2}}} 数 {{{3}}} ページタイトル {{{4}}} タイトル候補リスト(&&区切り)</noinclude><br />
This page is automatically generated using [[Help:Contents|''Persist'' function]] (Last updated: {{REVISIONTIMESTAMP}}).<br><br />
<br />
{| width=100%<br />
|-<br />
|align=left|<br />
{{#repeat:Index/persist|6|{{#cdr:<br />
{{#invoke:Index|FormulaFunc1|{{{4}}} }} |%}}|%}}<br />
|align=center| [[Index:{{{3}}}|<big>Back to Index</big>]]<br />
|align=right|<br />
{{#repeat:Index/persist|6|{{#cdr:<br />
{{#invoke:Index|FormulaFunc2|{{{4}}} }} |%}}|%}}<br />
|}<br />
<hr><br />
{| class="wikitable" style="width=100%; margin: 1em auto; border-width:0px 0px 0px 0px;"<br />
|- style="background:#ccf"<br />
{{#repeat:IndexTable|1|<br />
{{#invoke:Index|FormulaIndexTable|{{#formula:{{{3|FL1C99}}}}}|{{{1|C}}}|{{{2|20}}}}}<br />
}}<br />
|}</div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Template:Index/author&diff=117146
Template:Index/author
2023-02-03T05:41:28Z
<p>Editor: </p>
<hr />
<div><noinclude>著者名のインデクス {{{1}}} 値(文字列) {{{2}}} ページタイトル (FL/LB/..)</noinclude><br />
This page is automatically generated using [[Help:Contents|''Persist'' function]] (Last updated: {{REVISIONTIMESTAMP}}).<br/><br />
<br />
{| width=100%<br />
|-<br />
|align=left| {{#persist:FLindex/author {{PrevLetter|{{{1}}}}}|go to Index {{PrevLetter|{{{1}}}}}|Index/author|2|{{PrevLetter|{{{1}}}}};FL Author}}<br />
|align=center| [[Index:{{{2}}}|<big>Back to Index</big>]]<br />
|align=right| {{#persist:FLindex/author {{NextLetter|{{{1}}}}}|go to Index {{NextLetter|{{{1}}}}}|Index/author|2|{{NextLetter|{{{1}}}}};FL Author}}<br />
|}<br />
<hr><br />
<br />
{| class="wikitable sortable"<br />
! Author || #articles || earliest<br/>paper || latest<br/>paper || peak<br/>year || major<br/>coauthors<br />
{{#repeat:TableRow6/author|6|<br />
{{#cdr:<br />
{{#invoke:Index|Author| {{{1|Z}}} {{#SearchTitle:.*|Reference}}}}<br />
|&&}}<br />
|&&}}<br />
|}<br />
<br />
[[#top]]</div>
Editor
https://lipidbank.jp/mediawiki/index.php?title=Module:Index&diff=117145
Module:Index
2023-02-03T05:41:18Z
<p>Editor: Created page with "local getArgs = require('Module:Arguments').getArgs; local defArgs = require('Module:Arguments').defaultArgs; local index = {}; function index.Author( frame ) local args = defArgs(getArgs(frame), 1, ""); local arg = args[1]; local key = arg:match("%w+"); local H = {}; local I = {}; for line in arg:gmatch("(%S+)") do for names, ja, yr in string.gmatch(line,"([%a:_']+),([%w\._]+),([%d]+),") do for name in string.gmatch(names,"([%a_']+)") do if (st..."</p>
<hr />
<div>local getArgs = require('Module:Arguments').getArgs;<br />
local defArgs = require('Module:Arguments').defaultArgs;<br />
local index = {};<br />
<br />
function index.Author( frame )<br />
local args = defArgs(getArgs(frame), 1, "");<br />
local arg = args[1];<br />
<br />
local key = arg:match("%w+");<br />
local H = {};<br />
local I = {};<br />
for line in arg:gmatch("(%S+)") do<br />
for names, ja, yr in string.gmatch(line,"([%a:_']+),([%w\._]+),([%d]+),") do<br />
for name in string.gmatch(names,"([%a_']+)") do<br />
if (string.sub(name,0,1) == key) then<br />
if (H[name] == nil) then<br />
tmp = {};<br />
tmp[line] = tonumber(yr);<br />
H[name] = tmp;<br />
table.insert(I, name);<br />
else<br />
tmp = H[name];<br />
tmp[line] = tonumber(yr);<br />
end<br />
end<br />
end<br />
end<br />
end<br />
table.sort(I);<br />
local ret = "";<br />
for i=1,table.getn(I) do<br />
local author = I[i];<br />
local tmp = H[author];<br />
local count = 0;<br />
local peakDist = {};<br />
local coAu = {};<br />
local earliest = 3000;<br />
local latest = 0;<br />
for k,v in pairs(tmp) do<br />
--check earliest and latest publications<br />
if (earliest > v) then earliest = v; end<br />
if (latest < v) then latest = v; end<br />
count = count + 1;<br />
for i=v-2,v+2 do<br />
if (peakDist[i] == nil) <br />
then peakDist[i] = 3-math.abs(v-i);<br />
else peakDist[i] = peakDist[i] + 3-math.abs(v-i);<br />
end<br />
end<br />
--check major coauthors<br />
for names, ja, yr in string.gmatch(k,"([%a:_']+),([%w\._]+),([%d]+),") do<br />
for name in string.gmatch(names,"([%a_']+)") do<br />
if (name ~= author) then <br />
if (coAu[name] == nil) then<br />
coAu[name] = 1;<br />
else<br />
coAu[name] = coAu[name] + 1;<br />
end<br />
end<br />
end<br />
end <br />
end<br />
local peak = 0;<br />
local peakY = 0;<br />
for k,v in pairs(peakDist) do<br />
if (v > peak) then peakY = k; peak = v; end<br />
end<br />
local auL = "";<br />
if (count > 4) then<br />
for k,v in pairs(coAu) do<br />
if (v >= 3) then <br />
if (auL == "") then<br />
auL = k; else auL = auL .. ":" .. k; end<br />
end<br />
end<br />
end<br />
ret = ret .. "&&" .. author .. <br />
"&&" .. count .. "&&" .. earliest .. "&&" .. latest ..<br />
"&&" .. peakY .. "&&" .. auL .. "\n";<br />
end<br />
return ret;<br />
end<br />
<br />
function index.FormulaFunc1( frame )<br />
local args = defArgs(getArgs(frame), 4, "", "", "", "");<br />
local arg = args[1];<br />
local arg1 = args[2];<br />
local arg2 = tonumber(args[3])-1;<br />
local arg4 = args[4];<br />
<br />
local output = "";<br />
for id in arg:gmatch("&&(%w+)") do<br />
output = output.."%formula%" .. arg1 .. "%" .. arg2 .. "%Index/formula%"..id.."%" .. arg4;<br />
end<br />
return output;<br />
end<br />
<br />
function index.FormulaFunc2( frame )<br />
local args = defArgs(getArgs(frame), 4, "", "", "", "");<br />
local arg = args[1];<br />
local arg1 = args[2];<br />
local arg2 = tonumber(args[3])+1;<br />
local arg4 = args[4];<br />
<br />
local id;<br />
local output = "";<br />
for id in arg:gmatch("&&(%w+)") do<br />
output = output.."%formula%" .. arg1 .. "%" .. arg2 .. "%Index/formula%"..id.."%" .. arg4;<br />
end<br />
return output;<br />
end<br />
<br />
function index.FormulaIndexTable( frame )<br />
local args = defArgs(getArgs(frame), 3, "", "C", "20");<br />
local arg = args[1];<br />
local arg1 = args[2];<br />
local arg2 = args[3];<br />
<br />
local id, formula;<br />
local pat = arg1 .. arg2;<br />
local hash = {};<br />
local idx = {};<br />
for id, formula in arg:gmatch("&&(%w+)&&([%a%d]+)") do<br />
if (formula.match(formula, pat) ~= null) then<br />
if (hash[formula] == null)<br />
then hash[formula] = id;<br />
table.insert(idx, formula);<br />
else hash[formula] = hash[formula].."&&"..id;<br />
end<br />
end<br />
end<br />
table.sort(idx);<br />
local output = "";<br />
for id, val in pairs(idx) do<br />
output = output .. val .."&&".. hash[val] .. "\n";<br />
end<br />
return output;<br />
end<br />
<br />
function index.MassIndexTable( frame )<br />
local args = defArgs(getArgs(frame), 3, "", "0", "2000");<br />
local arg = args[1];<br />
local arg1 = args[2];<br />
local arg2 = args[3];<br />
<br />
local id, ms, msd;<br />
local min = arg1;<br />
local max = arg2;<br />
local hash = {};<br />
local idx = {};<br />
for id, ms in arg:gmatch("&&(%w+)&&([%d\.]+)") do<br />
msd = tonumber(ms); ---質量の最小と最大の間に入る部分のみ考慮<br />
if ((msd >= min) and (msd <= max)) then<br />
if (hash[msd] == null)<br />
then hash[msd] = id;<br />
table.insert(idx, msd);<br />
else hash[msd] = hash[msd].."&&"..id;<br />
end<br />
end<br />
end<br />
table.sort(idx);<br />
local output = "";<br />
for id, val in pairs(idx) do<br />
output = output .. val .."&&".. hash[val] .. "\n";<br />
end<br />
return output;<br />
end<br />
<br />
function index.Name( frame )<br />
local args = defArgs(getArgs(frame), 1, "");<br />
local arg = args[1];<br />
<br />
local key = arg:match("%w+");<br />
local H = {};<br />
local I = {};<br />
for id, name in arg:gmatch("&&(%w+).Common Name=&&(%S+)") do<br />
name = string.lower(name);<br />
for term in string.gmatch(name,"(%a+)") do<br />
if ((string.len(term) > 3) and<br />
(string.sub(term,0,1) == key)) then<br />
if (H[term] == nil) then<br />
H[term] = id; table.insert(I, term);<br />
else<br />
H[term] = H[term] .. ";" .. id;<br />
end<br />
end<br />
end<br />
end<br />
table.sort(I);<br />
local ret = "";<br />
for i=1,table.getn(I) do<br />
local k = I[i];<br />
ret = ret .. "* '''" .. k;<br />
for id in string.gmatch(H[k],"%w+") do<br />
ret = ret .. "'''&nbsp;&nbsp; [[" .. id .."]] &nbsp; ";<br />
end<br />
ret = ret .. "\n";<br />
end<br />
return ret;<br />
end<br />
<br />
return index</div>
Editor